Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12401611,FIO(2),"After intubation of the trachea, the lungs of the patients were ventilated to normocapnia with an oxygen-air mixture (FIO(2) = 0.33).",Changes of propofol concentration in cerebrospinal fluid during continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401611/),,0.33,394,DB00813,Fentanyl
,12401611,concentration,The CSF propofol concentration at 180 min (21.4 +/- 14.0 ng/mL) was not significantly different from the concentration at 150 min.,Changes of propofol concentration in cerebrospinal fluid during continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401611/),[ng] / [ml],21.4,395,DB00813,Fentanyl
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],6.7,925,DB00813,Fentanyl
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],18.1,926,DB00813,Fentanyl
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],16.9,927,DB00813,Fentanyl
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],13.1,928,DB00813,Fentanyl
,2959170,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[l] / [kg],4.15,929,DB00813,Fentanyl
,2959170,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[l] / [kg],2.73,930,DB00813,Fentanyl
,2959170,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[l] / [kg],2.75,931,DB00813,Fentanyl
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,783,932,DB00813,Fentanyl
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,214,933,DB00813,Fentanyl
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,140,934,DB00813,Fentanyl
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,209,935,DB00813,Fentanyl
,32861508,V1,"The V1, V2, V3, Cl, Q1, and Q2 of a 70 kg subject were 10.1, 26.5, 206 L, 0.704, 2.38, and 1.49 L min-1, respectively.",An allometric pharmacokinetic model and minimum effective analgesic concentration of fentanyl in patients undergoing major abdominal surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32861508/),l,10.1,995,DB00813,Fentanyl
,32861508,Q2,"The V1, V2, V3, Cl, Q1, and Q2 of a 70 kg subject were 10.1, 26.5, 206 L, 0.704, 2.38, and 1.49 L min-1, respectively.",An allometric pharmacokinetic model and minimum effective analgesic concentration of fentanyl in patients undergoing major abdominal surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32861508/),[l] / [min],2.38,996,DB00813,Fentanyl
,32861508,Q2,"The V1, V2, V3, Cl, Q1, and Q2 of a 70 kg subject were 10.1, 26.5, 206 L, 0.704, 2.38, and 1.49 L min-1, respectively.",An allometric pharmacokinetic model and minimum effective analgesic concentration of fentanyl in patients undergoing major abdominal surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32861508/),[l] / [min],1.49,997,DB00813,Fentanyl
,32861508,MEC,"In the MEAC study (n=30), the median (inter-quartile range) MEC and MEAC were 0.72 (0.58-1.05) ng ml-1, and 0.99 (0.76-1.28) ng ml-1, respectively.",An allometric pharmacokinetic model and minimum effective analgesic concentration of fentanyl in patients undergoing major abdominal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32861508/),[ng] / [ml],0.72,998,DB00813,Fentanyl
,32861508,MEAC,"In the MEAC study (n=30), the median (inter-quartile range) MEC and MEAC were 0.72 (0.58-1.05) ng ml-1, and 0.99 (0.76-1.28) ng ml-1, respectively.",An allometric pharmacokinetic model and minimum effective analgesic concentration of fentanyl in patients undergoing major abdominal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32861508/),[ng] / [ml],0.99,999,DB00813,Fentanyl
,2968186,distribution (alpha),"A biexponential equation provided the best fit of the sufentanil concentration data with mean +/- SEM distribution (alpha) and elimination (beta) half-lives of 2.9 +/- 1.3 and 176 +/- 87 minutes, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),min,2.9,1227,DB00813,Fentanyl
,2968186,elimination (beta) half-lives,"A biexponential equation provided the best fit of the sufentanil concentration data with mean +/- SEM distribution (alpha) and elimination (beta) half-lives of 2.9 +/- 1.3 and 176 +/- 87 minutes, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),min,176,1228,DB00813,Fentanyl
,2968186,Vc,"The mean Vc and Vd beta values were 0.15 +/- 0.05 L.kg-1 and 0.85 +/- 0.16 L.kg-1, respectively; plasma drug clearance was 11.5 +/- 3.7 ml.kg-1.min-1.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),[l] / [kg],0.15,1229,DB00813,Fentanyl
,2968186,Vd beta,"The mean Vc and Vd beta values were 0.15 +/- 0.05 L.kg-1 and 0.85 +/- 0.16 L.kg-1, respectively; plasma drug clearance was 11.5 +/- 3.7 ml.kg-1.min-1.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),[l] / [kg],0.85,1230,DB00813,Fentanyl
,2968186,plasma drug clearance,"The mean Vc and Vd beta values were 0.15 +/- 0.05 L.kg-1 and 0.85 +/- 0.16 L.kg-1, respectively; plasma drug clearance was 11.5 +/- 3.7 ml.kg-1.min-1.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),[ml] / [kg·min],11.5,1231,DB00813,Fentanyl
,2968186,K10,"Mean values for K10, K12 and K21 were 0.15 +/- 0.06.min-1, 0.4 +/- 0.14.min-1 and 0.1 +/- 0.04.min-1, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),,0.15,1232,DB00813,Fentanyl
,2968186,K12,"Mean values for K10, K12 and K21 were 0.15 +/- 0.06.min-1, 0.4 +/- 0.14.min-1 and 0.1 +/- 0.04.min-1, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),1/[min],0.4,1233,DB00813,Fentanyl
,2968186,K21,"Mean values for K10, K12 and K21 were 0.15 +/- 0.06.min-1, 0.4 +/- 0.14.min-1 and 0.1 +/- 0.04.min-1, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),1/[min],0.1,1234,DB00813,Fentanyl
,9512844,gamma,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,6.0,1964,DB00813,Fentanyl
,9512844,IC50,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,2.1,1965,DB00813,Fentanyl
,9512844,t1/2Keo,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,2.1,1966,DB00813,Fentanyl
,9477048,apparent elimination half-life,"Except for the 200-microg dose, the apparent elimination half-life remained relatively constant (358-386 min).",Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9477048/),min,358-386,1969,DB00813,Fentanyl
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,30,3433,DB00813,Fentanyl
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,54,3434,DB00813,Fentanyl
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,67,3435,DB00813,Fentanyl
,16950210,micro,"Relative to heroin-dependent volunteers maintained on BUP placebo, whole-brain microOR availability was 30%, 54%, 67%, and 82% at 4, 28, 52, and 76 hours after BUP.",Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16950210/),%,82,3436,DB00813,Fentanyl
,3425871,Elimination half-life,Elimination half-life ranged from 0.72 to 15.06 h.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,0.72 to 15.06,3654,DB00813,Fentanyl
,3425871,Cl,Cl ranged from 2.5 to 12.8 ml/min per kilogram.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),[ml] / [kg·min],2.5 to 12.8,3655,DB00813,Fentanyl
,3425871,t1/2el,Four patients (= 9%) had a t1/2el of 7-15 h; in 16 cases we found secondary concentration peaks.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,7-15,3656,DB00813,Fentanyl
up to,3425871,half-life,"In accordance with others, we found some patients with a half-life of up to 15 h, which might reflect the influence of the anesthesia itself.",[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,15,3657,DB00813,Fentanyl
,24365989,Urinary excretion rates,"Urinary excretion rates of fentanyl and norfentanyl were 4.4% and 71%, respectively, and no significant differences were observed between the CYP3A5 genotypes.",Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365989/),%,4.4,4196,DB00813,Fentanyl
,24365989,Urinary excretion rates,"Urinary excretion rates of fentanyl and norfentanyl were 4.4% and 71%, respectively, and no significant differences were observed between the CYP3A5 genotypes.",Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365989/),%,71,4197,DB00813,Fentanyl
,24365989,Renal clearance ratios,"Renal clearance ratios of fentanyl and norfentanyl to creatinine were 0.34 and 3.4, respectively.",Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365989/),,0.34,4198,DB00813,Fentanyl
,24365989,Renal clearance ratios,"Renal clearance ratios of fentanyl and norfentanyl to creatinine were 0.34 and 3.4, respectively.",Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365989/),,3.4,4199,DB00813,Fentanyl
,24365989,Free fractions,"Free fractions of fentanyl and norfentanyl in human plasma were 4.9% and 95%, respectively.",Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365989/),%,4.9,4200,DB00813,Fentanyl
,24365989,Free fractions,"Free fractions of fentanyl and norfentanyl in human plasma were 4.9% and 95%, respectively.",Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365989/),%,95,4201,DB00813,Fentanyl
,25880448,Ce50,"The overall calculated propofol Ce50 and Ce95 were 3.8 μg·ml(-1) (95% CI: 3.1-4.4 μg·ml(-1) ) and 6.1 μg·ml(-1) (95% CI: 4.6-7.6 μg·ml(-1) ), respectively.",Propofol concentration to induce general anesthesia in children aged 3-11 years with the Kataria effect-site model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880448/),[μg] / [ml],3.8,4687,DB00813,Fentanyl
,25880448,Ce95,"The overall calculated propofol Ce50 and Ce95 were 3.8 μg·ml(-1) (95% CI: 3.1-4.4 μg·ml(-1) ) and 6.1 μg·ml(-1) (95% CI: 4.6-7.6 μg·ml(-1) ), respectively.",Propofol concentration to induce general anesthesia in children aged 3-11 years with the Kataria effect-site model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880448/),[μg] / [ml],6.1,4688,DB00813,Fentanyl
,3927954,duration of adequate analgesia,"Maximum pain relief developed within 10-15 min and the average duration of adequate analgesia was 78 min with the lower dose and 45 min with the higher dose, but this difference was not statistically significant.",Clinical assessment and plasma pharmacokinetics associated with intramuscular or extradural alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3927954/),min,78,5386,DB00813,Fentanyl
,3927954,duration of adequate analgesia,"Maximum pain relief developed within 10-15 min and the average duration of adequate analgesia was 78 min with the lower dose and 45 min with the higher dose, but this difference was not statistically significant.",Clinical assessment and plasma pharmacokinetics associated with intramuscular or extradural alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3927954/),min,45,5387,DB00813,Fentanyl
,7762853,clearance,"The clearance of mirfentanil was high (5.8-7.2 L/min), and the volume of distribution large (247-348 L).",Pharmacokinetic/dynamic assessment in drug development: application to the investigational opioid mirfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7762853/),[l] / [min],5.8-7.2,6056,DB00813,Fentanyl
,7762853,volume of distribution,"The clearance of mirfentanil was high (5.8-7.2 L/min), and the volume of distribution large (247-348 L).",Pharmacokinetic/dynamic assessment in drug development: application to the investigational opioid mirfentanil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7762853/),l,247-348,6057,DB00813,Fentanyl
,15581380,half-time,"By virtue of these distinctive pharmacokinetic properties, the context-sensitive half-time (i.e. the time required for the drug's plasma concentration to decrease by 50% after cessation of an infusion) of remifentanil remains consistently short (3.2 minutes), even following an infusion of long duration (> or =8 hours).",Remifentanil update: clinical science and utility. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15581380/),min,3.2,6722,DB00813,Fentanyl
<,25061702,plasma concentrations,"During the fentanyl CRI, mean ± SD plasma fentanyl concentration decreased from 4.41 ± 1.86 ng/mL to 2.99 ± 1.28 ng/mL and was correlated with antinociception; plasma concentrations < 1.33 ± 0.30 ng/mL were not associated with antinociception.",Pharmacokinetics and pharmacodynamics of a constant rate infusion of fentanyl (5 μg/kg/h) in awake cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25061702/),ng,1.33,7182,DB00813,Fentanyl
,25149986,EC50,The EC50 of 2.80 mg/L and the biophase distribution rate constant of 3.33 min(-1) were found for a typical patient.,Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25149986/),[mg] / [l],2.80,8027,DB00813,Fentanyl
,25149986,biophase distribution rate constant,The EC50 of 2.80 mg/L and the biophase distribution rate constant of 3.33 min(-1) were found for a typical patient.,Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25149986/),1/[min],3.33,8028,DB00813,Fentanyl
,1923912,total-body clearance,"Noncompartmental pharmacokinetic analysis of the data revealed the following estimates (mean +/- SD): total-body clearance 3.24 +/- 2.23 ml/kg/minute, volume of distribution 0.54 +/- 0.21 L/kg, and elimination half-life 4.14 +/- 2.58 hours.",The disposition of alfentanil in neonates with respiratory distress. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923912/),[ml] / [kg·min],3.24,8481,DB00813,Fentanyl
,1923912,volume of distribution,"Noncompartmental pharmacokinetic analysis of the data revealed the following estimates (mean +/- SD): total-body clearance 3.24 +/- 2.23 ml/kg/minute, volume of distribution 0.54 +/- 0.21 L/kg, and elimination half-life 4.14 +/- 2.58 hours.",The disposition of alfentanil in neonates with respiratory distress. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923912/),[l] / [kg],0.54,8482,DB00813,Fentanyl
,1923912,elimination half-life,"Noncompartmental pharmacokinetic analysis of the data revealed the following estimates (mean +/- SD): total-body clearance 3.24 +/- 2.23 ml/kg/minute, volume of distribution 0.54 +/- 0.21 L/kg, and elimination half-life 4.14 +/- 2.58 hours.",The disposition of alfentanil in neonates with respiratory distress. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1923912/),h,4.14,8483,DB00813,Fentanyl
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB00813,Fentanyl
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB00813,Fentanyl
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB00813,Fentanyl
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB00813,Fentanyl
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB00813,Fentanyl
,7229112,terminal half-times,"The terminal half-times were 750 and 853 minutes, respectively.",Fentanyl pharmacokinetics in awake volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229112/),min,750,9453,DB00813,Fentanyl
,7229112,terminal half-times,"The terminal half-times were 750 and 853 minutes, respectively.",Fentanyl pharmacokinetics in awake volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229112/),min,853,9454,DB00813,Fentanyl
,11452708,total body clearance,"NPEM-derived parameters were a total body clearance of 2.12 +/- 0.28 L/kg/h, distributional clearance of 8.43 +/- 4.58 L/kg/h, central volume of distribution of 1.22 +/- 0.21 L/kg, and peripheral volume of distribution of 1.81 +/- 1.47 L/kg.",Population pharmacokinetics of fentanyl in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452708/),[l] / [h·kg],2.12,9552,DB00813,Fentanyl
,11452708,distributional clearance,"NPEM-derived parameters were a total body clearance of 2.12 +/- 0.28 L/kg/h, distributional clearance of 8.43 +/- 4.58 L/kg/h, central volume of distribution of 1.22 +/- 0.21 L/kg, and peripheral volume of distribution of 1.81 +/- 1.47 L/kg.",Population pharmacokinetics of fentanyl in healthy volunteers. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452708/),[l] / [h·kg],8.43,9553,DB00813,Fentanyl
,11452708,central volume of distribution,"NPEM-derived parameters were a total body clearance of 2.12 +/- 0.28 L/kg/h, distributional clearance of 8.43 +/- 4.58 L/kg/h, central volume of distribution of 1.22 +/- 0.21 L/kg, and peripheral volume of distribution of 1.81 +/- 1.47 L/kg.",Population pharmacokinetics of fentanyl in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452708/),[l] / [kg],1.22,9554,DB00813,Fentanyl
,11452708,peripheral volume of distribution,"NPEM-derived parameters were a total body clearance of 2.12 +/- 0.28 L/kg/h, distributional clearance of 8.43 +/- 4.58 L/kg/h, central volume of distribution of 1.22 +/- 0.21 L/kg, and peripheral volume of distribution of 1.81 +/- 1.47 L/kg.",Population pharmacokinetics of fentanyl in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452708/),[l] / [kg],1.81,9555,DB00813,Fentanyl
,8424303,delta CBF/delta PaCO2,The cerebrovascular reactivity to hypocapnia (delta CBF/delta PaCO2) was maintained throughout the experimental period and amounted to (95% confidence interval) 9.1 (7.1-11.1) ml x 100 g-1 x min-1 x kPa-1 within the PaCO2 range 3.3-6.3 kPa.,"Cerebral haemodynamic and electrocortical CO2 reactivity in pigs anaesthetized with fentanyl, nitrous oxide and pancuronium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424303/),[100·ml] / [g·kpa·min],9.1,11556,DB00813,Fentanyl
,21389904,C(max),"This postmortem concentration is approximately 3-fold the C(max) determined during antemortem pharmacokinetic analysis, 4 ng/mL, which was achieved 24 hours after the application of the second 50-μg/h Durogesic pain patch.",Postmortem redistribution of fentanyl in the rabbit blood. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21389904/),[ng] / [ml],4,11906,DB00813,Fentanyl
,33604895,clearance (CL,"The fentanyl PK was adequately described by a weight-based allometry model with the power of 0.75 for clearance (CL=89.8 L/hr/70 kg) and distributional CL, and 1 for volumes of distribution.","Analysis of fentanyl pharmacokinetics, and its sedative effects and tolerance in critically ill children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33604895/),[l] / [70·h·kg],89.8,12659,DB00813,Fentanyl
,33604895,CL,"In infants <6.6 months, age was an additional factor for CL (31.4 L/h/70 kg) to account for age-related maturation.","Analysis of fentanyl pharmacokinetics, and its sedative effects and tolerance in critically ill children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33604895/),[l] / [70·h·kg],31.4,12660,DB00813,Fentanyl
,33604895,plasma concentration,"Seven of twelve nonparalyzed patients achieved goal sedation, defined as >80% of SBS scores ≤0 per 24 h, on the first day of fentanyl infusion with a median plasma concentration of 1.29 ng/ml (interquartile range: 0.78-2.05).","Analysis of fentanyl pharmacokinetics, and its sedative effects and tolerance in critically ill children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33604895/),[ng] / [ml],1.29,12661,DB00813,Fentanyl
,3264670,elimination half-life,"The calculated pharmacokinetic parameters were: elimination half-life = 41.7 +/- 20 min, clearance = 2.14 +/- 0.55 l.min-1 and equilibrium distribution volume = 43.4 +/- 15.2 l.","[The course of blood concentrations of propofol administered at a constant rate, combined with fentanyl]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264670/),min,41.7,14109,DB00813,Fentanyl
,3264670,clearance,"The calculated pharmacokinetic parameters were: elimination half-life = 41.7 +/- 20 min, clearance = 2.14 +/- 0.55 l.min-1 and equilibrium distribution volume = 43.4 +/- 15.2 l.","[The course of blood concentrations of propofol administered at a constant rate, combined with fentanyl]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264670/),[l] / [min],2.14,14110,DB00813,Fentanyl
,3264670,equilibrium distribution volume,"The calculated pharmacokinetic parameters were: elimination half-life = 41.7 +/- 20 min, clearance = 2.14 +/- 0.55 l.min-1 and equilibrium distribution volume = 43.4 +/- 15.2 l.","[The course of blood concentrations of propofol administered at a constant rate, combined with fentanyl]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264670/),l,43.4,14111,DB00813,Fentanyl
,9134513,elimination half-life,"Mean elimination half-life was 9.5 +/- 2.6 hours (range 5.7 to 12.7 hours), and volume of distribution at steady state was 17 +/- 9 L/kg (range 10.1 to 30.3 L/kg).",Pharmacokinetics of continuous infusion fentanyl in newborns. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134513/),h,9.5,14676,DB00813,Fentanyl
,9134513,volume of distribution at steady state,"Mean elimination half-life was 9.5 +/- 2.6 hours (range 5.7 to 12.7 hours), and volume of distribution at steady state was 17 +/- 9 L/kg (range 10.1 to 30.3 L/kg).",Pharmacokinetics of continuous infusion fentanyl in newborns. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134513/),[l] / [kg],17,14677,DB00813,Fentanyl
,9134513,TBC,Mean TBC was 1154 +/- 494 ml/kg/hr (range 565 to 2000 ml/kg/hr).,Pharmacokinetics of continuous infusion fentanyl in newborns. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9134513/),[ml] / [h·kg],1154,14678,DB00813,Fentanyl
,18467078,k1e,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.038,14909,DB00813,Fentanyl
,18467078,keo,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.043,14910,DB00813,Fentanyl
,18467078,k1e,"Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1).",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.04 to 0.47,14911,DB00813,Fentanyl
,18467078,EC50,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),[ng] / [ml],1.2-451,14912,DB00813,Fentanyl
,18467078,alpha,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),μv,18-109,14913,DB00813,Fentanyl
,17192502,time to maximum concentration (tmax),"Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (tmax) was 52.2 and 49.8 minutes, respectively.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),min,52.2,15845,DB00813,Fentanyl
,17192502,time to maximum concentration (tmax),"Following single- and multiple-dose administration of fentanyl buccal tablet, the median time to maximum concentration (tmax) was 52.2 and 49.8 minutes, respectively.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),min,49.8,15846,DB00813,Fentanyl
,17192502,Peak plasma concentration of fentanyl (Cmax),Peak plasma concentration of fentanyl (Cmax) was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen.,Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),[ng] / [ml],0.88,15847,DB00813,Fentanyl
,17192502,Peak plasma concentration of fentanyl (Cmax),Peak plasma concentration of fentanyl (Cmax) was 0.88 ng/mL for the single-dose regimen and 1.77 ng/mL for the multiple-dose regimen.,Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),[ng] / [ml],1.77,15848,DB00813,Fentanyl
,17192502,half-life,"Steady state was reached within 5 days, consistent with the observed median half-life of approximately 22 hours following multiple doses.",Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192502/),h,22,15849,DB00813,Fentanyl
,1503284,Elimination half-life,"Elimination half-life in group M was 3.22 +/- 1.96 h, and total plasma clearance 8.54 +/- 2.8 ml.kg-1.min-1.",[Pharmacokinetics of methohexital given by constant rate intravenous infusion]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503284/),h,3.22,15910,DB00813,Fentanyl
,1503284,total plasma clearance,"Elimination half-life in group M was 3.22 +/- 1.96 h, and total plasma clearance 8.54 +/- 2.8 ml.kg-1.min-1.",[Pharmacokinetics of methohexital given by constant rate intravenous infusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503284/),[ml] / [kg·min],8.54,15911,DB00813,Fentanyl
,1503284,plasma concentrations,"At that time, plasma concentrations were respectively 3.12 +/- 0.99 mg.l-1 (group MF) and 5.71 +/- 2.09 mg.l-1 (group M), (p less than 0.05).",[Pharmacokinetics of methohexital given by constant rate intravenous infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503284/),[mg] / [l],3.12,15912,DB00813,Fentanyl
,1503284,plasma concentrations,"At that time, plasma concentrations were respectively 3.12 +/- 0.99 mg.l-1 (group MF) and 5.71 +/- 2.09 mg.l-1 (group M), (p less than 0.05).",[Pharmacokinetics of methohexital given by constant rate intravenous infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503284/),[mg] / [l],5.71,15913,DB00813,Fentanyl
,31794512,Clearance,"Clearance (l/min) before and after St. John's wort (1.13 ± 0.29 and 1.24 ± 0.26, respectively) or placebo (0.96 ± 0.28 and 1.12 ± 0.27, respectively) were not different.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[l] / [min],1.13,16971,DB00813,Fentanyl
,31794512,Clearance,"Clearance (l/min) before and after St. John's wort (1.13 ± 0.29 and 1.24 ± 0.26, respectively) or placebo (0.96 ± 0.28 and 1.12 ± 0.27, respectively) were not different.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[l] / [min],1.24,16972,DB00813,Fentanyl
,31794512,Clearance,"Clearance (l/min) before and after St. John's wort (1.13 ± 0.29 and 1.24 ± 0.26, respectively) or placebo (0.96 ± 0.28 and 1.12 ± 0.27, respectively) were not different.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[l] / [min],0.96,16973,DB00813,Fentanyl
,31794512,Clearance,"Clearance (l/min) before and after St. John's wort (1.13 ± 0.29 and 1.24 ± 0.26, respectively) or placebo (0.96 ± 0.28 and 1.12 ± 0.27, respectively) were not different.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[l] / [min],1.12,16974,DB00813,Fentanyl
,31794512,EC50,EC50 (ng/ml) was 1.1 ± 0.7 and 1.4 ± 0.9 before and after St. John's wort versus 1.2 ± 0.8 and 1.4 ± 1.7 before and after placebo.,"Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[ng] / [ml],1.1,16975,DB00813,Fentanyl
,31794512,EC50,EC50 (ng/ml) was 1.1 ± 0.7 and 1.4 ± 0.9 before and after St. John's wort versus 1.2 ± 0.8 and 1.4 ± 1.7 before and after placebo.,"Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[ng] / [ml],1.4,16976,DB00813,Fentanyl
,31794512,EC50,EC50 (ng/ml) was 1.1 ± 0.7 and 1.4 ± 0.9 before and after St. John's wort versus 1.2 ± 0.8 and 1.4 ± 1.7 before and after placebo.,"Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[ng] / [ml],1.2,16977,DB00813,Fentanyl
,31794512,EC50,EC50 (ng/ml) was 1.1 ± 0.7 and 1.4 ± 0.9 before and after St. John's wort versus 1.2 ± 0.8 and 1.4 ± 1.7 before and after placebo.,"Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),[ng] / [ml],1.4,16978,DB00813,Fentanyl
,31794512,"T½,ke0","Effect site equilibration time, T½,ke0 (min), was 12.8 ± 5.3 and 11.3 ± 6.4 before and after St. John's wort versus 11.4 ± 6.4 and 11.1 ± 5.6 before and after placebo.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),min,12.8,16979,DB00813,Fentanyl
,31794512,"T½,ke0","Effect site equilibration time, T½,ke0 (min), was 12.8 ± 5.3 and 11.3 ± 6.4 before and after St. John's wort versus 11.4 ± 6.4 and 11.1 ± 5.6 before and after placebo.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),min,11.3,16980,DB00813,Fentanyl
,31794512,"T½,ke0","Effect site equilibration time, T½,ke0 (min), was 12.8 ± 5.3 and 11.3 ± 6.4 before and after St. John's wort versus 11.4 ± 6.4 and 11.1 ± 5.6 before and after placebo.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),min,11.4,16981,DB00813,Fentanyl
,31794512,"T½,ke0","Effect site equilibration time, T½,ke0 (min), was 12.8 ± 5.3 and 11.3 ± 6.4 before and after St. John's wort versus 11.4 ± 6.4 and 11.1 ± 5.6 before and after placebo.","Influence of St. John's Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31794512/),min,11.1,16982,DB00813,Fentanyl
,10475315,time to onset of relief,Median time to onset of relief was approximately 5 min for all groups.,The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10475315/),min,5,17298,DB00813,Fentanyl
>,23100195,octanol:water partition coefficient,"It is a full agonist at μ-opioid receptors and possesses physicochemical properties, in particular a high lipophilicity (octanol:water partition coefficient >700), which allow it to cross quickly between plasma and central nervous target sites (transfer half-life of 4.7-6.6 min).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),,700,18089,DB00813,Fentanyl
,23100195,transfer half-life,"It is a full agonist at μ-opioid receptors and possesses physicochemical properties, in particular a high lipophilicity (octanol:water partition coefficient >700), which allow it to cross quickly between plasma and central nervous target sites (transfer half-life of 4.7-6.6 min).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,4.7-6.6,18090,DB00813,Fentanyl
,23100195,bioavailability,"It undergoes first-pass metabolism via cytochrome P450 3A (bioavailability ~30 % after rapid swallowing), which can be circumvented by non-intravenous formulations (bioavailability 50-90 % for oral transmucosal or intranasal formulations).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),%,30,18091,DB00813,Fentanyl
,23100195,bioavailability,"It undergoes first-pass metabolism via cytochrome P450 3A (bioavailability ~30 % after rapid swallowing), which can be circumvented by non-intravenous formulations (bioavailability 50-90 % for oral transmucosal or intranasal formulations).",Pharmacokinetics of non-intravenous formulations of fentanyl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),%,50-90,18092,DB00813,Fentanyl
,23100195,time to reach maximum fentanyl plasma concentrations,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,20,18093,DB00813,Fentanyl
,23100195,time to reach maximum fentanyl plasma concentrations,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,12,18094,DB00813,Fentanyl
,23100195,time to onset of analgesia,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,5,18095,DB00813,Fentanyl
,23100195,time to onset of analgesia,"Oral transmucosal and intranasal routes provide fast delivery (time to reach maximum fentanyl plasma concentrations 20 min [range 20-180 min] and 12 min [range 12-21 min], respectively) suitable for rapid onset of analgesia in acute pain conditions with time to onset of analgesia of 5 or 2 min, respectively.",Pharmacokinetics of non-intravenous formulations of fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100195/),min,2,18096,DB00813,Fentanyl
,7978415,plasma concentrations,"Based on simulated infusions using the pharmacokinetic modeling program IV-SIM, we administered fentanyl or placebo to nine healthy volunteers (aged 21-45 yr) by continuous i.v. infusion, targeting plasma concentrations of 1, 1.5, and 2.5 ng/mL in succession.",Impaired memory and behavioral performance with fentanyl at low plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978415/),,1,18132,DB00813,Fentanyl
,21672126,E'Iso,During the second phase anaesthesia was induced in a similar manner and E'Iso was set at 0.75 × MAC for each individual.,Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),Mac,0.75,18308,DB00813,Fentanyl
,21672126,target plasma concentrations,Fentanyl was infused IV to achieve target plasma concentrations between 8 and 32 ng mL(-1).,Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],8 and 32,18309,DB00813,Fentanyl
,21672126,plasma concentrations,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],0,18310,DB00813,Fentanyl
,21672126,plasma concentrations,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],8.51,18311,DB00813,Fentanyl
,21672126,plasma concentrations,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],14.85,18312,DB00813,Fentanyl
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],14.85,18313,DB00813,Fentanyl
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),[ng] / [ml],29.25,18314,DB00813,Fentanyl
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,2.05,18315,DB00813,Fentanyl
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,1.42,18316,DB00813,Fentanyl
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,1.14,18317,DB00813,Fentanyl
,21672126,MACs,"Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively.",Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21672126/),%,0.93,18318,DB00813,Fentanyl
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,176,19818,DB00813,Fentanyl
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,516,19819,DB00813,Fentanyl
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,27.1,19820,DB00813,Fentanyl
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,42.5,19821,DB00813,Fentanyl
,2394062,total duration of neuromuscular blockade,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,51.8,19822,DB00813,Fentanyl
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,9.6,19823,DB00813,Fentanyl
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,64.1,19824,DB00813,Fentanyl
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,16.7,19825,DB00813,Fentanyl
,33811491,absorption rate constant,"The absorption rate constant was 0.136 h-1 (between subject variability (BSV), 46%), lag time 0.66 h (BSV 51%), apparent volume of distribution 6.28 L (BSV 30%), and apparent clearance 16.3 L.h-1 (BSV 54%).",Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811491/),1/[h],0.136,20303,DB00813,Fentanyl
,33811491,lag time,"The absorption rate constant was 0.136 h-1 (between subject variability (BSV), 46%), lag time 0.66 h (BSV 51%), apparent volume of distribution 6.28 L (BSV 30%), and apparent clearance 16.3 L.h-1 (BSV 54%).",Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811491/),h,0.66,20304,DB00813,Fentanyl
,33811491,apparent volume of distribution,"The absorption rate constant was 0.136 h-1 (between subject variability (BSV), 46%), lag time 0.66 h (BSV 51%), apparent volume of distribution 6.28 L (BSV 30%), and apparent clearance 16.3 L.h-1 (BSV 54%).",Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811491/),l,6.28,20305,DB00813,Fentanyl
,33811491,apparent clearance,"The absorption rate constant was 0.136 h-1 (between subject variability (BSV), 46%), lag time 0.66 h (BSV 51%), apparent volume of distribution 6.28 L (BSV 30%), and apparent clearance 16.3 L.h-1 (BSV 54%).",Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33811491/),[l] / [h],16.3,20306,DB00813,Fentanyl
,8857120,bioavailability,The bioavailability of i.t. fentanyl was 71%.,Intratracheal administration of fentanyl: pharmacokinetics and local tissue effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8857120/),%,71,21262,DB00813,Fentanyl
,23780500,terminal,"Compared with the results of group 2, the ECC procedure reduced the terminal or gamma half-life from 36.35 ± 6.37 h to 23.25 ± 2.75 h in group 1.",Pharmacokinetic assessment of sufentanil in cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780500/),h,36.35,22004,DB00813,Fentanyl
,23780500,gamma half-life,"Compared with the results of group 2, the ECC procedure reduced the terminal or gamma half-life from 36.35 ± 6.37 h to 23.25 ± 2.75 h in group 1.",Pharmacokinetic assessment of sufentanil in cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780500/),h,23.25,22005,DB00813,Fentanyl
,24333052,minute ventilation,Simulated data were analyzed to determine if plasma fentanyl concentrations producing a 50% decrease in minute ventilation (6.1 ng/mL) were achieved.,Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333052/),[ng] / [ml],6.1,22116,DB00813,Fentanyl
,24333052,Maximum plasma fentanyl concentrations,"Maximum plasma fentanyl concentrations were 1.8 ng/mL and 3.4 ng/mL for the normal and ritonavir simulations, respectively, and did not reach concentrations associated with 50% decrease in minute ventilation.",Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333052/),[ng] / [ml],1.8,22117,DB00813,Fentanyl
,24333052,Maximum plasma fentanyl concentrations,"Maximum plasma fentanyl concentrations were 1.8 ng/mL and 3.4 ng/mL for the normal and ritonavir simulations, respectively, and did not reach concentrations associated with 50% decrease in minute ventilation.",Effect of ritonavir-induced cytochrome P450 3A4 inhibition on plasma fentanyl concentrations during patient-controlled epidural labor analgesia: a pharmacokinetic simulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333052/),[ng] / [ml],3.4,22118,DB00813,Fentanyl
,22731772,mean absorption lag time (t(lag) ),Fentanyl was rapidly detected following application with a mean absorption lag time (t(lag) ) of 0.333 h in the 1.3 mg/kg group and 0 in the other two groups.,"Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),h,0.333,22149,DB00813,Fentanyl
,22731772,mean absorption lag time (t(lag) ),Fentanyl was rapidly detected following application with a mean absorption lag time (t(lag) ) of 0.333 h in the 1.3 mg/kg group and 0 in the other two groups.,"Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),,0,22150,DB00813,Fentanyl
,22731772,C(max),"The mean C(max) increased with dose and were 2.28, 2.67, and 4.71 ng/mL in the 1.3, 2.6 and 5.2 mg/kg dose groups, respectively.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),[ng] / [ml],2.28,22151,DB00813,Fentanyl
,22731772,C(max),"The mean C(max) increased with dose and were 2.28, 2.67, and 4.71 ng/mL in the 1.3, 2.6 and 5.2 mg/kg dose groups, respectively.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),[ng] / [ml],2.67,22152,DB00813,Fentanyl
,22731772,C(max),"The mean C(max) increased with dose and were 2.28, 2.67, and 4.71 ng/mL in the 1.3, 2.6 and 5.2 mg/kg dose groups, respectively.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),[ng] / [ml],4.71,22153,DB00813,Fentanyl
,22731772,terminal half-lives,"Mean terminal half-lives were 53.7, 69.6, and 103 h in the 1.3, 2.6, and 5.2 mg/kg dose groups, respectively.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),h,53.7,22154,DB00813,Fentanyl
,22731772,terminal half-lives,"Mean terminal half-lives were 53.7, 69.6, and 103 h in the 1.3, 2.6, and 5.2 mg/kg dose groups, respectively.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),h,69.6,22155,DB00813,Fentanyl
,22731772,terminal half-lives,"Mean terminal half-lives were 53.7, 69.6, and 103 h in the 1.3, 2.6, and 5.2 mg/kg dose groups, respectively.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),h,103,22156,DB00813,Fentanyl
,22731772,AUC(0-LLOQ),"The mean AUC(0-LLOQ) from lowest to highest dose groups were 157, 268, and 645 ng·h/mL and were dose proportional with a R(2) value of 0.9818.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),[h·ng] / [ml],157,22157,DB00813,Fentanyl
,22731772,AUC(0-LLOQ),"The mean AUC(0-LLOQ) from lowest to highest dose groups were 157, 268, and 645 ng·h/mL and were dose proportional with a R(2) value of 0.9818.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),[h·ng] / [ml],268,22158,DB00813,Fentanyl
,22731772,AUC(0-LLOQ),"The mean AUC(0-LLOQ) from lowest to highest dose groups were 157, 268, and 645 ng·h/mL and were dose proportional with a R(2) value of 0.9818.","Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731772/),[h·ng] / [ml],645,22159,DB00813,Fentanyl
,20079167,effect-site concentration,"Sufentanil was administered with a specific TCI system incorporating the population pharmacokinetic data of sufentanil previously reported, using a target effect-site concentration of sufentanil 4 or 6 ng/ml.",Clinical evaluation of target controlled infusion system for sufentanil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),ng,4,23308,DB00813,Fentanyl
,20079167,TCI duration,Sufentanil TCI duration was 30 minutes.,Clinical evaluation of target controlled infusion system for sufentanil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),min,30,23309,DB00813,Fentanyl
,20079167,Time to eye opening,Time to eye opening and extubation were (5.6 + or - 1.7) minutes when TCI set to 4 ng/ml and (7.2 + or - 2.3) minutes when set to 6 ng/ml.,Clinical evaluation of target controlled infusion system for sufentanil administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),min,5.6,23310,DB00813,Fentanyl
,20079167,extubation,Time to eye opening and extubation were (5.6 + or - 1.7) minutes when TCI set to 4 ng/ml and (7.2 + or - 2.3) minutes when set to 6 ng/ml.,Clinical evaluation of target controlled infusion system for sufentanil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),min,7.2,23311,DB00813,Fentanyl
,8061260,clearance,"The set of Scott et al with the lowest clearance (2.4 mL/kg/min) shows the best accuracy (MDAPE: 19.5%) and precision (P10: -40%, P90: 16%).",Predictive accuracy of alfentanil infusion in coronary artery surgery: a prebypass study in middle-aged and elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061260/),[ml] / [kg·min],2.4,24143,DB00813,Fentanyl
,17472504,plasma concentration,"Methadone plasma concentration increased from 2 to 245 ng/mL, and fentanyl plasma concentration decreased from 15 to 8 ng/mL, 25 hours after.",Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472504/),[ng] / [ml],2,24539,DB00813,Fentanyl
,17472504,plasma concentration,"Methadone plasma concentration increased from 2 to 245 ng/mL, and fentanyl plasma concentration decreased from 15 to 8 ng/mL, 25 hours after.",Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472504/),ng,15,24540,DB00813,Fentanyl
,14531255,EPECs,The EPECs at awakening were 1.5 +/- 0.2 micrograms.,[Effect of body fat percentage on estimated propofol concentrations at awakening from anesthesia using target controlled infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531255/),μg,1.5,24830,DB00813,Fentanyl
,15701707,k(eo),"The k(eo) was 0.024 min(-1) [95% confidence interval (CI): 0.018-0.030 min(-1)] and 0.123 min(-1) (95% CI: 0.095-0.151 min(-1)) for buprenorphine and fentanyl, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),1/[min],0.024,25962,DB00813,Fentanyl
,15701707,k(eo),"The k(eo) was 0.024 min(-1) [95% confidence interval (CI): 0.018-0.030 min(-1)] and 0.123 min(-1) (95% CI: 0.095-0.151 min(-1)) for buprenorphine and fentanyl, respectively.",Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),1/[min],0.123,25963,DB00813,Fentanyl
,15701707,k(off),The k(off) was 0.073 min(-1) (95% CI: 0.042-0.104 min(-1)) and k(on) was 0.023 ml/ng/min (95% CI: 0.013-0.033 ml/ng/min).,Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),1/[min],0.073,25964,DB00813,Fentanyl
,15701707,k(on),The k(off) was 0.073 min(-1) (95% CI: 0.042-0.104 min(-1)) and k(on) was 0.023 ml/ng/min (95% CI: 0.013-0.033 ml/ng/min).,Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701707/),[ml] / [min·ng],0.023,25965,DB00813,Fentanyl
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],150,26130,DB00813,Fentanyl
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],300,26131,DB00813,Fentanyl
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],600,26132,DB00813,Fentanyl
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),,40,26133,DB00813,Fentanyl
,7631949,volume of distribution at steady-state,"The mean (+/- SD) volume of distribution at steady-state and clearance of fentanyl after the intravenous administration were comparable to previous studies: 435 +/- 1821 and 0.584 +/- 0.209 l.min-1, respectively.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),[l] / [min],435,26294,DB00813,Fentanyl
,7631949,clearance,"The mean (+/- SD) volume of distribution at steady-state and clearance of fentanyl after the intravenous administration were comparable to previous studies: 435 +/- 1821 and 0.584 +/- 0.209 l.min-1, respectively.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),[l] / [min],0.584,26295,DB00813,Fentanyl
,7631949,peak Cfen,The mean (+/- SD) peak Cfen was significantly greater for the intravenous administration compared to the aerosol mixture of free and liposome-encapsulated fentanyl (4.67 +/- 1.87 vs. 1.15 +/- 0.36 ng.ml-1).,Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),[ng] / [ml],4.67,26296,DB00813,Fentanyl
,7631949,peak Cfen,The mean (+/- SD) peak Cfen was significantly greater for the intravenous administration compared to the aerosol mixture of free and liposome-encapsulated fentanyl (4.67 +/- 1.87 vs. 1.15 +/- 0.36 ng.ml-1).,Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),[ng] / [ml],1.15,26297,DB00813,Fentanyl
,7631949,CfenS,"However, CfenS at 8 and 24 h after aerosol administration were greater compared to intravenous (0.25 +/- 0.14 and 0.12 +/- 0.16 ng.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),ng,0.25,26298,DB00813,Fentanyl
,7631949,CfenS,"However, CfenS at 8 and 24 h after aerosol administration were greater compared to intravenous (0.25 +/- 0.14 and 0.12 +/- 0.16 ng.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),ng,0.12,26299,DB00813,Fentanyl
,7631949,peak absorption rate,"The peak absorption rate, time to peak absorption, and bioavailability after inhalation were 7.02 (+/- 2.34) micrograms.min, -1(16) (+/- 8.0) min, and 0.12 (+/- 0.11), respectively.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),min·μg,7.02,26300,DB00813,Fentanyl
,7631949,time to peak absorption,"The peak absorption rate, time to peak absorption, and bioavailability after inhalation were 7.02 (+/- 2.34) micrograms.min, -1(16) (+/- 8.0) min, and 0.12 (+/- 0.11), respectively.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),min,-1,26301,DB00813,Fentanyl
,7631949,bioavailability,"The peak absorption rate, time to peak absorption, and bioavailability after inhalation were 7.02 (+/- 2.34) micrograms.min, -1(16) (+/- 8.0) min, and 0.12 (+/- 0.11), respectively.",Pharmacokinetics of inhaled liposome-encapsulated fentanyl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631949/),,0.12,26302,DB00813,Fentanyl
,8319480,volume of distribution at steady state,"After the use of fentanyl by long-term infusion, the volume of distribution at steady state was increased 15.2 L/kg (range 5.1 to 30.5) and the terminal elimination half-life was prolonged 21.1 hrs (range 11.2 to 36.0) compared with previous studies.",Pharmacokinetics of continuous infusions of fentanyl in critically ill children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8319480/),[l] / [kg],15.2,26635,DB00813,Fentanyl
,8319480,terminal elimination half-life,"After the use of fentanyl by long-term infusion, the volume of distribution at steady state was increased 15.2 L/kg (range 5.1 to 30.5) and the terminal elimination half-life was prolonged 21.1 hrs (range 11.2 to 36.0) compared with previous studies.",Pharmacokinetics of continuous infusions of fentanyl in critically ill children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8319480/),h,21.1,26636,DB00813,Fentanyl
,18405786,T(max),"Mean T(max) values were 12.8 and 6.0 minutes (P<0.001), times to onset of analgesia were 7 and 2 minutes (P<0.001), and durations of effect were 56 and 59 minutes after i.n. and i.v. administration (P=NS), respectively.","Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405786/),min,12.8,26804,DB00813,Fentanyl
,18405786,T(max),"Mean T(max) values were 12.8 and 6.0 minutes (P<0.001), times to onset of analgesia were 7 and 2 minutes (P<0.001), and durations of effect were 56 and 59 minutes after i.n. and i.v. administration (P=NS), respectively.","Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405786/),min,6.0,26805,DB00813,Fentanyl
,18405786,times to onset of analgesia,"Mean T(max) values were 12.8 and 6.0 minutes (P<0.001), times to onset of analgesia were 7 and 2 minutes (P<0.001), and durations of effect were 56 and 59 minutes after i.n. and i.v. administration (P=NS), respectively.","Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405786/),min,7,26806,DB00813,Fentanyl
,18405786,times to onset of analgesia,"Mean T(max) values were 12.8 and 6.0 minutes (P<0.001), times to onset of analgesia were 7 and 2 minutes (P<0.001), and durations of effect were 56 and 59 minutes after i.n. and i.v. administration (P=NS), respectively.","Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405786/),min,2,26807,DB00813,Fentanyl
,18405786,durations of effect,"Mean T(max) values were 12.8 and 6.0 minutes (P<0.001), times to onset of analgesia were 7 and 2 minutes (P<0.001), and durations of effect were 56 and 59 minutes after i.n. and i.v. administration (P=NS), respectively.","Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405786/),min,56,26808,DB00813,Fentanyl
,18405786,durations of effect,"Mean T(max) values were 12.8 and 6.0 minutes (P<0.001), times to onset of analgesia were 7 and 2 minutes (P<0.001), and durations of effect were 56 and 59 minutes after i.n. and i.v. administration (P=NS), respectively.","Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405786/),min,59,26809,DB00813,Fentanyl
,33453066,time to maximum plasma concentration,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),h,10,27444,DB00813,Fentanyl
,33453066,maximum plasma concentration,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),h,14.3,27445,DB00813,Fentanyl
,33453066,maximum plasma concentration,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),h,10.3,27446,DB00813,Fentanyl
,33453066,maximum plasma concentration,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[ng] / [ml],2.07,27447,DB00813,Fentanyl
,33453066,maximum plasma concentration,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[ng] / [ml],1.55,27448,DB00813,Fentanyl
,33453066,maximum plasma concentration,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[h·ng] / [ml],46.6,27449,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),h,10.3,27450,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[ng] / [ml],2.07,27451,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[ng] / [ml],1.55,27452,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[ng] / [ml],2.07,27453,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[h·ng] / [ml],46.6,27454,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[h·ng] / [ml],44.6,27455,DB00813,Fentanyl
,33453066,area under the curve extrapolated to infinity,"The time to maximum plasma concentration, maximum plasma concentration and area under the curve extrapolated to infinity were 10 ± 3.79, 14.3 ± 5.13 and 10.3 ± 4.8 hours; 2.07 ± 0.74, 1.55 ± 0.53 and 2.07 ± 0.72 ng/mL; and 46.6 ± 9.3, 44.6 ± 6.0 and 46.2 ± 7.68 ng hours/mL for TXA, TXM and TXT respectively.",The pharmacokinetics of a fentanyl matrix patch applied at three different anatomical locations in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33453066/),[h·ng] / [ml],46.2,27456,DB00813,Fentanyl
,9009935,V1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,4.98,28910,DB00813,Fentanyl
,9009935,V2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,9.01,28911,DB00813,Fentanyl
,9009935,V3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,6.54,28912,DB00813,Fentanyl
,9009935,Cl1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],2.46,28913,DB00813,Fentanyl
,9009935,Cl2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],1.69,28914,DB00813,Fentanyl
,9009935,Cl3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],0.065,28915,DB00813,Fentanyl
,9009935,Ke0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),1/[min],0.516,28916,DB00813,Fentanyl
,9009935,E0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,20,28917,DB00813,Fentanyl
,9009935,Emax,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,5.62,28918,DB00813,Fentanyl
,9009935,EC50,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[ng] / [ml],11.2,28919,DB00813,Fentanyl
,9009935,gamma,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),,2.51,28920,DB00813,Fentanyl
,1540461,elimination half-lives,"Pharmacokinetic variables were similar in uraemic and control patients; mean elimination half-lives were 1638 (SD 340) min and 1714 (842) min, respectively.",Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540461/),min,1638,28932,DB00813,Fentanyl
,1540461,elimination half-lives,"Pharmacokinetic variables were similar in uraemic and control patients; mean elimination half-lives were 1638 (SD 340) min and 1714 (842) min, respectively.",Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540461/),min,1714,28933,DB00813,Fentanyl
,10582751,heart rate,Mean heart rate of all dogs varied from 52 to 140 beats/min during the infusion.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[beats] / [min],52 to 140,28977,DB00813,Fentanyl
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,26,28978,DB00813,Fentanyl
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,30,28979,DB00813,Fentanyl
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,59,28980,DB00813,Fentanyl
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,105,28981,DB00813,Fentanyl
,10582751,Mean residence time (MRTinf),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,104.7,28982,DB00813,Fentanyl
,10582751,body clearance (Clb),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ml] / [kg·min],53.35,28983,DB00813,Fentanyl
,10582751,volume of distribution at steady state (Vdss),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[l] / [kg],3.27,28984,DB00813,Fentanyl
,10582751,Plasma concentration,Plasma concentration of fentanyl for seven dogs during the infusion varied from 1.22 to 4.54 ng/mL.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ng] / [ml],1.22 to 4.54,28985,DB00813,Fentanyl
,10582751,MRTinf,MRTinf for fentanyl was 111.3 +/- 5.7 minutes.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,111.3,28986,DB00813,Fentanyl
,10582751,body clearance,Mean body clearance was 29.1 +/- 2.2 mL/kg/min and Vdss was 2.21 +/- 0.19 L/kg.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ml] / [kg·min],29.1,28987,DB00813,Fentanyl
,10582751,Vdss,Mean body clearance was 29.1 +/- 2.2 mL/kg/min and Vdss was 2.21 +/- 0.19 L/kg.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[l] / [kg],2.21,28988,DB00813,Fentanyl
,14508328,bioavailability,Release rate estimated in vivo was similar to that measured in vitro; bioavailability did not differ from 100%.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),%,100,29506,DB00813,Fentanyl
,14508328,Absorption half-life,Absorption half-life was 16.2 h.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),h,16.2,29507,DB00813,Fentanyl
>,14508328,half-life,The rate at which sufentanil was absorbed from the subcutaneous space (half-life > 16 h) was markedly slower than reported with subcutaneous or intramuscular administration of large volumes of dilute opioids; this slow absorption dampens potential changes in Cp if release rate is perturbed.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),h,16,29508,DB00813,Fentanyl
,19501972,volumes of distribution,"The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L, 153 L vs. 301 L, respectively) compared to the non-burned.",Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19501972/),l,27.9,29545,DB00813,Fentanyl
,19501972,volumes of distribution,"The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L, 153 L vs. 301 L, respectively) compared to the non-burned.",Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19501972/),l,63.4,29546,DB00813,Fentanyl
,19501972,volumes of distribution,"The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L, 153 L vs. 301 L, respectively) compared to the non-burned.",Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19501972/),l,64.7,29547,DB00813,Fentanyl
,19501972,volumes of distribution,"The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L, 153 L vs. 301 L, respectively) compared to the non-burned.",Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19501972/),l,92.9,29548,DB00813,Fentanyl
,19501972,volumes of distribution,"The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L, 153 L vs. 301 L, respectively) compared to the non-burned.",Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19501972/),l,153,29549,DB00813,Fentanyl
,19501972,volumes of distribution,"The volumes of distribution were considerably expanded in all three compartments (27.9 L vs. 63.4 L, 64.7 L vs. 92.9 L, 153 L vs. 301 L, respectively) compared to the non-burned.",Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: burns vs. non-burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19501972/),l,301,29550,DB00813,Fentanyl
,2521279,elimination half life,The average (+/- SD) elimination half life was 3.5 +/- 0.9 hrs in controls and did not differ in cirrhotics: 4.1 +/- 0.6 hrs.,Sufentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),h,3.5,29718,DB00813,Fentanyl
,2521279,elimination half life,The average (+/- SD) elimination half life was 3.5 +/- 0.9 hrs in controls and did not differ in cirrhotics: 4.1 +/- 0.6 hrs.,Sufentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),h,4.1,29719,DB00813,Fentanyl
,2521279,plasma clearance,The plasma clearance did not differ between the two groups: 11.3 +/- 2.5 ml.min-1.kg-1 in controls and 10.8 +/- 4.6 ml.min-1.kg-1 in cirrhotic patients.,Sufentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),[ml] / [kg·min],11.3,29720,DB00813,Fentanyl
,2521279,plasma clearance,The plasma clearance did not differ between the two groups: 11.3 +/- 2.5 ml.min-1.kg-1 in controls and 10.8 +/- 4.6 ml.min-1.kg-1 in cirrhotic patients.,Sufentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),[ml] / [kg·min],10.8,29721,DB00813,Fentanyl
,2521279,free fraction,The sufentanil free fraction was also similar in controls (8.3 +/- 1.5%) and in cirrhotic patients (9.6 +/- 1.8%).,Sufentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),%,8.3,29722,DB00813,Fentanyl
,2521279,free fraction,The sufentanil free fraction was also similar in controls (8.3 +/- 1.5%) and in cirrhotic patients (9.6 +/- 1.8%).,Sufentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),%,9.6,29723,DB00813,Fentanyl
,9657668,achieved,Plasma fentanyl achieved steady state levels by 30 min of infusion both in the systemic (202.7 +/- 39.1 ng/ml) and sagittal sinus vein (136.7 +/- 20.7 ng/ml).,Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657668/),[ng] / [ml],202.7,30380,DB00813,Fentanyl
,9657668,steady state levels,Plasma fentanyl achieved steady state levels by 30 min of infusion both in the systemic (202.7 +/- 39.1 ng/ml) and sagittal sinus vein (136.7 +/- 20.7 ng/ml).,Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657668/),[ng] / [ml],202.7,30381,DB00813,Fentanyl
,9657668,steady state levels,Plasma fentanyl achieved steady state levels by 30 min of infusion both in the systemic (202.7 +/- 39.1 ng/ml) and sagittal sinus vein (136.7 +/- 20.7 ng/ml).,Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657668/),[ng] / [ml],136.7,30382,DB00813,Fentanyl
,9657668,clearance,"Mean clearance was estimated as 56.2 +/- 13.7 ml/kg/h (range 43.5-76.9 ml/kg/h), mean volume of distribution at steady state was 1.29 +/- 0.6 liters/kg (range 0.78-2.15 liters/kg) and the mean half-life was 15.7 +/- 5.7 h (range 9.4-22.5 h).",Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657668/),[ml] / [h·kg],56.2,30383,DB00813,Fentanyl
,9657668,volume of distribution at steady state,"Mean clearance was estimated as 56.2 +/- 13.7 ml/kg/h (range 43.5-76.9 ml/kg/h), mean volume of distribution at steady state was 1.29 +/- 0.6 liters/kg (range 0.78-2.15 liters/kg) and the mean half-life was 15.7 +/- 5.7 h (range 9.4-22.5 h).",Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657668/),[l] / [kg],1.29,30384,DB00813,Fentanyl
,9657668,half-life,"Mean clearance was estimated as 56.2 +/- 13.7 ml/kg/h (range 43.5-76.9 ml/kg/h), mean volume of distribution at steady state was 1.29 +/- 0.6 liters/kg (range 0.78-2.15 liters/kg) and the mean half-life was 15.7 +/- 5.7 h (range 9.4-22.5 h).",Pharmacodynamic effects and pharmacokinetic profile of continuous infusion fentanyl in newborn piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657668/),h,15.7,30385,DB00813,Fentanyl
,2950809,elimination half-lives,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),min,53,31781,DB00813,Fentanyl
,2950809,elimination half-lives,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),min,55,31782,DB00813,Fentanyl
,2950809,clearance,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[ml] / [kg·min],27.5,31783,DB00813,Fentanyl
,2950809,clearance,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[ml] / [kg·min],18.1,31784,DB00813,Fentanyl
,2950809,volumes of distribution,"However, the volumes of distribution were significantly smaller in group 1 compared with group 2 (1.6 +/- 0.46 vs 3.0 +/- 1.3 L/kg).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[l] / [kg],1.6,31785,DB00813,Fentanyl
,2950809,volumes of distribution,"However, the volumes of distribution were significantly smaller in group 1 compared with group 2 (1.6 +/- 0.46 vs 3.0 +/- 1.3 L/kg).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[l] / [kg],3.0,31786,DB00813,Fentanyl
,2950809,elimination half-life,"In infants younger than 10 months who were surface-cooled (group 3) elimination half-life was longer (120 +/- 36 min) and volume of distribution larger (3.7 +/- 1.1 L/kg), but clearance rate was similar (21.5 +/- 5.0 ml X kg-1 X min-1) compared with age- and weight-matched infants (group 1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),min,120,31787,DB00813,Fentanyl
,2950809,volume of distribution,"In infants younger than 10 months who were surface-cooled (group 3) elimination half-life was longer (120 +/- 36 min) and volume of distribution larger (3.7 +/- 1.1 L/kg), but clearance rate was similar (21.5 +/- 5.0 ml X kg-1 X min-1) compared with age- and weight-matched infants (group 1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[l] / [kg],3.7,31788,DB00813,Fentanyl
,2950809,clearance rate,"In infants younger than 10 months who were surface-cooled (group 3) elimination half-life was longer (120 +/- 36 min) and volume of distribution larger (3.7 +/- 1.1 L/kg), but clearance rate was similar (21.5 +/- 5.0 ml X kg-1 X min-1) compared with age- and weight-matched infants (group 1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[ml] / [kg·min],21.5,31789,DB00813,Fentanyl
,10381758,steady-state plasma concentrations,The continuous administration of dobutamine (steady-state plasma concentrations: 217 +/- 118 ng.,Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381758/),ng,217,32054,DB00813,Fentanyl
,10381758,plasma levels,"In parallel, dobutamine plasma levels increased significantly (275 +/- 165 ng. ml-1; p <.05).",Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381758/),[ng] / [ml],275,32055,DB00813,Fentanyl
,30721546,concentrations,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),[ng] / [ml],0.18,32621,DB00813,Fentanyl
,30721546,concentrations,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),[ng] / [ml],0.15,32622,DB00813,Fentanyl
,30721546,concentrations,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),[ng] / [ml],0.57,32623,DB00813,Fentanyl
,30721546,concentrations,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),[ng] / [ml],0.37,32624,DB00813,Fentanyl
,30721546,concentrations,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),[ng] / [ml],0.35,32625,DB00813,Fentanyl
,30721546,half-lives,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),h,1.6 to 20.5,32626,DB00813,Fentanyl
,30721546,half-lives,"The median fentanyl concentrations were 0.18, 0.15, 0.15 and 0.57, 0.37, 0.35 ng/mL at 15-31 minutes, two and four hours and the half-lives were 1.6 to 20.5 or 4.1 to 32.6 hours for the low- and high-dose groups, respectively.",Individual variations in fentanyl pharmacokinetics and pharmacodynamics in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721546/),h,4.1 to 32.6,32627,DB00813,Fentanyl
,7486179,V1,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg],19.2,32722,DB00813,Fentanyl
,7486179,V2,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg],99,32723,DB00813,Fentanyl
,7486179,V3,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg],2344,32724,DB00813,Fentanyl
,7486179,Cl1,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg·min],2.5,32725,DB00813,Fentanyl
,7486179,Cl2,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg·min],38,32726,DB00813,Fentanyl
,7486179,Cl3,Parameters for the simple three-compartment model are: V1 = 19.2 ml.kg-1; V2 = 99 ml.kg-1; V3 = 2344 ml.kg-1; Cl1 = 2.5 ml.kg-1.min-1; Cl2 = 38 ml.kg-1.min-1; and Cl3 = 15 ml.kg-1.min-1.,Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486179/),[ml] / [kg·min],15,32727,DB00813,Fentanyl
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,0.7-1.0,32863,DB00813,Fentanyl
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,2.8-4.0,32864,DB00813,Fentanyl
,9029316,limit of detection,"Using 1-ml plasma samples, the estimated limit of detection of fentanyl was 20 pg/ml.",Determination of subnanogram concentrations of fentanyl in plasma by gas chromatography-mass spectrometry: comparison with standard radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029316/),[pg] / [ml],20,33732,DB00813,Fentanyl
,9265933,half-life,The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min).,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),min,16.8,34917,DB00813,Fentanyl
,9265933,T1/2 (keo)),The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min).,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),min,16.8,34918,DB00813,Fentanyl
,9265933,steady-state plasma concentration,The steady-state plasma concentration required to produce 50% of maximum analgesia (EC50) was 12.1 ng/ml (range: 2.9-29.8 ng/ml) and correlated with initial pain intensity.,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),[ng] / [ml],12.1,34919,DB00813,Fentanyl
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35144,DB00813,Fentanyl
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35145,DB00813,Fentanyl
,10392320,plasma drug concentrations,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],6.6,35146,DB00813,Fentanyl
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],3.9,35147,DB00813,Fentanyl
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],4.2,35148,DB00813,Fentanyl
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],6.6,35149,DB00813,Fentanyl
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],7.9,35150,DB00813,Fentanyl
,10392320,clearances,"There were no significant interday differences in plasma drug concentrations or clearances (3.9 +/- 1.4, 3.9 +/- 1.7, and 4.2 +/- 1.7 ml/kg/min for alfentanil, respectively, and 6.6 +/- 2.0, 7.9 +/- 2.4, and 7.9 +/- 2.5 ml/kg/min for midazolam, respectively, on days 1, 13, and 21 [mean +/- SD]).",Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392320/),[ml] / [kg·min],7.9,35151,DB00813,Fentanyl
,10201688,CO,The CO of individual pigs varied from 1.33 to 6.44 l/min.,Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201688/),[l] / [min],1.33 to 6.44,35223,DB00813,Fentanyl
,32650192,time for,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,7.3,35406,DB00813,Fentanyl
,32650192,time for,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,13.3,35407,DB00813,Fentanyl
,32650192,clearance,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,7.3,35408,DB00813,Fentanyl
,32650192,clearance,"The mean (SD) time for fentanyl and norfentanyl clearance was 7.3 (4.9) and 13.3 (6.9) days, respectively.",Protracted renal clearance of fentanyl in persons with opioid use disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32650192/),d,13.3,35409,DB00813,Fentanyl
,26288466,t peaks,The mean t peaks were measured as 44 ± 22 s and 227 ± 91 s by heart rate and by mean blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),s,44,35512,DB00813,Fentanyl
,26288466,t peaks,The mean t peaks were measured as 44 ± 22 s and 227 ± 91 s by heart rate and by mean blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),s,227,35513,DB00813,Fentanyl
,26288466,ke0,The estimated ke0 were 5.16/min and 0.49/min by heart rate and blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),1/[min],5.16,35514,DB00813,Fentanyl
,26288466,ke0,The estimated ke0 were 5.16/min and 0.49/min by heart rate and blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),1/[min],0.49,35515,DB00813,Fentanyl
>,8466061,Spo2,No subject developing rigidity required neuromuscular blockade to allow positive pressure ventilation and adequate oxygenation (Spo2 > 90%).,"Fentanyl-induced rigidity and unconsciousness in human volunteers. Incidence, duration, and plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466061/),%,90,37296,DB00813,Fentanyl
,3081598,serum clearance,"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),[ml] / [kg·min],5.2,37375,DB00813,Fentanyl
,3081598,volume of distribution at steady state (Vss),"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),[l] / [kg],0.47,37376,DB00813,Fentanyl
,3081598,elimination half-life,"The mean +/- SD alfentanil serum clearance, volume of distribution at steady state (Vss), and elimination half-life were 5.2 +/- 2.0 mL/min/kg, 0.47 +/- 0.1 L/kg, and 97 +/- 52 minutes, respectively.",The pharmacokinetics of alfentanil in gynecologic surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),min,97,37377,DB00813,Fentanyl
,3081598,fraction of alfentanil unbound in serum (fu),The mean fraction of alfentanil unbound in serum (fu) was 0.18 +/- 0.08.,The pharmacokinetics of alfentanil in gynecologic surgical patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081598/),,0.18,37378,DB00813,Fentanyl
,8825188,steady state,"Approximately 40 min (steady state achieved) after initiation of remifentanil infusions at the same rates as described above, and while infusions were still in progress, blood was collected from the series of catheters.","The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825188/),min,40,38334,DB00813,Fentanyl
,8825188,systemic clearance,"There were no differences in systemic clearance (approximately 45 ml/kg/min), volume of distribution at steady state, mean residence time, dose-normalized normalized concentration at steady state, or dose-normalized AUC between the doses administered to conscious dogs; the t1/2 alpha was 3-5 min.","The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825188/),[ml] / [kg·min],45,38335,DB00813,Fentanyl
,8825188,t1/2 alpha,"There were no differences in systemic clearance (approximately 45 ml/kg/min), volume of distribution at steady state, mean residence time, dose-normalized normalized concentration at steady state, or dose-normalized AUC between the doses administered to conscious dogs; the t1/2 alpha was 3-5 min.","The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8825188/),min,3-5,38336,DB00813,Fentanyl
,30965021,limits of detection,"The method was validated following SWGTOX guidelines, and both analytes displayed limits of detection and quantification at 7.5 and 15 pg/mL, respectively.","Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30965021/),[pg] / [ml],7.5,38968,DB00813,Fentanyl
,30965021,limits of detection,"The method was validated following SWGTOX guidelines, and both analytes displayed limits of detection and quantification at 7.5 and 15 pg/mL, respectively.","Evidence for nonlinear accumulation of the ultrapotent fentanyl analog, carfentanil, after systemic administration to male rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30965021/),[pg] / [ml],15,38969,DB00813,Fentanyl
,7482686,initial distribution phase t1/2 pi,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,2.22,39406,DB00813,Fentanyl
,7482686,intermediate distribution phase t1/2 alpha,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,42.9,39407,DB00813,Fentanyl
,7482686,elimination phase t1/2 beta,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,370,39408,DB00813,Fentanyl
,7482686,clearance,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[l] / [min],1.31,39409,DB00813,Fentanyl
,7482686,blood concentration,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),mg,2.2,39410,DB00813,Fentanyl
,7482686,apparent Css,The mean calculated apparent Css was 3.9 (1.5) mg/L.,Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[mg] / [l],3.9,39411,DB00813,Fentanyl
,6131992,terminal elimination half-life,The terminal elimination half-life was 88 min for alfentanil and 140 min for sufentanil.,Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),min,88,39734,DB00813,Fentanyl
,6131992,terminal elimination half-life,The terminal elimination half-life was 88 min for alfentanil and 140 min for sufentanil.,Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),min,140,39735,DB00813,Fentanyl
,6131992,plasma,"Six hours after a therapeutic dose, plasma levels were in the order of 3 and 0.3 ng ml-1 for alfentanil and sufentanil respectively.",Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),ng,0.3,39736,DB00813,Fentanyl
,9807977,basal,Serum fentanyl concentrations sufficient for analgesia (1-3 ng/mL) were attained in treatments using the E-TRANS (fentanyl) system with basal current of 100 microA for 26 hours.,"Fentanyl delivery from an electrotransport system: delivery is a function of total current, not duration of current. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9807977/),,100,39804,DB00813,Fentanyl
,30085853,apparent volume of the central compartment,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],222,40661,DB00813,Fentanyl
,30085853,apparent volume of the central compartment,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],"5,108",40662,DB00813,Fentanyl
,30085853,volume of distribution at steady state,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],987,40663,DB00813,Fentanyl
,30085853,volume of distribution at steady state,"Median apparent volume of the central compartment and volume of distribution at steady state were 222 mL/kg and 987 mL/kg, respectively, for the red-tailed hawks and 5,108 mL/kg and 13,079 mL/kg, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg],"13,079",40664,DB00813,Fentanyl
,30085853,clearance,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg·min],8.9,40665,DB00813,Fentanyl
,30085853,clearance,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),[ml] / [kg·min],198.8,40666,DB00813,Fentanyl
,30085853,elimination half-life,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),min,90.22,40667,DB00813,Fentanyl
,30085853,elimination half-life,"Median clearance and elimination half-life were 8.9 mL/min/kg and 90.22 minutes, respectively, for the red-tailed hawks and 198.8 mL/min/kg and 51.18 minutes, respectively, for the Hispaniolan Amazon parrots.",Pharmacokinetics of fentanyl after intravenous administration in isoflurane-anesthetized red-tailed hawks (Buteo jamaicensis) and Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085853/),min,51.18,40668,DB00813,Fentanyl
,2503375,clearance,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[ml] / [kg·min],5.2,41034,DB00813,Fentanyl
,2503375,volume of distribution,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),[1] / [kg],0.63,41035,DB00813,Fentanyl
,2503375,elimination half-life,"Values for pharmacokinetic parameters of alfentanil were as follows: clearance, 5.2 +/- 2.0 ml kg-1 min-1; volume of distribution, 0.63 +/- 0.20 1 kg-1; and elimination half-life, 96.9 +/- 52.5 min.",A comparison of enflurane with alfentanil anaesthesia for gynaecological surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503375/),min,96.9,41036,DB00813,Fentanyl
,31010456,AUC0-inf,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[h·ng] / [ml],115,41289,DB00813,Fentanyl
,31010456,AUC0-inf,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[h·ng] / [ml],462,41290,DB00813,Fentanyl
,31010456,AUC0-inf,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[h·ng] / [ml],778,41291,DB00813,Fentanyl
,31010456,plasma half-lifes,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),h,22,41292,DB00813,Fentanyl
,31010456,plasma half-lifes,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),h,77,41293,DB00813,Fentanyl
,31010456,plasma half-lifes,"The AUC0-inf for fentanyl and the low and high dose buprenorphine patches were 115 ± 14, 462 ± 74, and 778 ± 344 ng× h/mL, and the plasma half-lifes were 22 ± 4, 77 ± 27, and 42 ± 11 h, respectively.",Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),h,42,41294,DB00813,Fentanyl
,31010456,Minimal therapeutic concentrations,Minimal therapeutic concentrations for fentanyl (0.2 ng/mL) and buprenorphine (0.1 ng/mL) were achieved in all macaques within 8 h of fentanyl and 24 h of buprenorphine TDP application.,Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[ng] / [ml],0.2,41295,DB00813,Fentanyl
,31010456,Minimal therapeutic concentrations,Minimal therapeutic concentrations for fentanyl (0.2 ng/mL) and buprenorphine (0.1 ng/mL) were achieved in all macaques within 8 h of fentanyl and 24 h of buprenorphine TDP application.,Evaluation of Analgesic Patches in Cynomolgus Macaques (Macaca fascicularis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31010456/),[ng] / [ml],0.1,41296,DB00813,Fentanyl
,7653804,elimination half-life of alfentanil (t1/2 beta),"However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups.",The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653804/),min,134,41869,DB00813,Fentanyl
,7653804,elimination half-life of alfentanil (t1/2 beta),"However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups.",The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653804/),min,143,41870,DB00813,Fentanyl
,7653804,elimination half-life of alfentanil (t1/2 beta),"However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups.",The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653804/),min,111,41871,DB00813,Fentanyl
,27468018,maximum plasma concentration,Mean maximum plasma concentration was 228.8 ng/ml at 4 hr.,PHARMACOKINETIC EVALUATION OF A LONG-ACTING FENTANYL SOLUTION AFTER TRANSDERMAL ADMINISTRATION IN HELMETED GUINEAFOWL (NUMIDA MELEAGRIS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468018/),[ng] / [ml],228.8,42396,DB00813,Fentanyl
,27468018,plasma terminal half-life,The mean plasma terminal half-life was 33.2 hr.,PHARMACOKINETIC EVALUATION OF A LONG-ACTING FENTANYL SOLUTION AFTER TRANSDERMAL ADMINISTRATION IN HELMETED GUINEAFOWL (NUMIDA MELEAGRIS). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468018/),h,33.2,42397,DB00813,Fentanyl
,27468018,mean plasma concentration,At 168 hr the mean plasma concentration was 1.3 ng/ml.,PHARMACOKINETIC EVALUATION OF A LONG-ACTING FENTANYL SOLUTION AFTER TRANSDERMAL ADMINISTRATION IN HELMETED GUINEAFOWL (NUMIDA MELEAGRIS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27468018/),[ng] / [ml],1.3,42398,DB00813,Fentanyl
,8750122,central compartment distribution volume (V1),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,31.2,43540,DB00813,Fentanyl
,8750122,steady-state distribution volume (Vdss),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,499,43541,DB00813,Fentanyl
,8750122,total clearance (Cltot),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),[ml] / [min],1001,43542,DB00813,Fentanyl
,8750122,redistribution half-life (t1/2 gamma),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,90,43543,DB00813,Fentanyl
,8750122,elimination half-life (t1/2 beta),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,558,43544,DB00813,Fentanyl
,8750122,V1,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,31.9,43545,DB00813,Fentanyl
,8750122,Vdss,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,124,43546,DB00813,Fentanyl
,8750122,Cltot,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),[ml] / [min],345,43547,DB00813,Fentanyl
,8750122,t1/2 gamma,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,36,43548,DB00813,Fentanyl
,8750122,t1/2 beta,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,275,43549,DB00813,Fentanyl
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],42.3,44250,DB00813,Fentanyl
,9422901,volume of the central compartment,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],55.2,44251,DB00813,Fentanyl
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],168.4,44252,DB00813,Fentanyl
,9422901,volume of distribution at steady state,"The mean volume of the central compartment and volume of distribution at steady state were 42.3 (SD 11.8) ml kg-1 and 168.4 (31.5) ml kg-1, respectively, in control patients, and significantly greater (55.2 (13.4) ml kg-1 and 225.9 (53.3) ml kg-1) in the haemodilution patients (P < 0.05).",Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),[ml] / [kg],225.9,44253,DB00813,Fentanyl
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,50.3,44254,DB00813,Fentanyl
,9422901,elimination half-life,The elimination half-life was 50.3 (11.5) min in control patients and significantly greater (68.2 (15.1) min) in the haemodilution patients (P < 0.05).,Pharmacokinetics of vecuronium during acute isovolaemic haemodilution. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422901/),min,68.2,44255,DB00813,Fentanyl
,30145048,terminal half-life,"The terminal half-life was 3.31 (2.93-4.41) hours for F3 and 3.67 (3.39-4.32) hours for F5 (median, range).",Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145048/),h,3.31,44470,DB00813,Fentanyl
,30145048,terminal half-life,"The terminal half-life was 3.31 (2.93-4.41) hours for F3 and 3.67 (3.39-4.32) hours for F5 (median, range).",Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145048/),h,3.67,44471,DB00813,Fentanyl
,30145048,Systemic clearance,"Systemic clearance for treatments F3 and F5 was 1.95 (1.46-2.44) and 2.25 (1.98-2.47) L hour-1 kg-1 (median, range), respectively.",Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145048/),[l] / [h·kg],1.95,44472,DB00813,Fentanyl
,30145048,Systemic clearance,"Systemic clearance for treatments F3 and F5 was 1.95 (1.46-2.44) and 2.25 (1.98-2.47) L hour-1 kg-1 (median, range), respectively.",Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145048/),[l] / [h·kg],2.25,44473,DB00813,Fentanyl
<,30145048,Plasma concentrations,Plasma concentrations <1.84 ng mL-1 were not associated with a significant increase in TT.,Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145048/),[ng] / [ml],1.84,44474,DB00813,Fentanyl
,8424509,maximum concentration (Cmax),"Sufentanil appeared rapidly in lumbar CSF, reaching a maximum concentration (Cmax) of 57 ng/mL at 6.5 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],57,44567,DB00813,Fentanyl
,8424509,Cmax,"In cisternal CSF, a Cmax of 1.2 ng/mL was reached at 21 min, and Cmax in plasma was 0.35 ng/mL at 6 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],1.2,44568,DB00813,Fentanyl
,8424509,Cmax,"In cisternal CSF, a Cmax of 1.2 ng/mL was reached at 21 min, and Cmax in plasma was 0.35 ng/mL at 6 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],0.35,44569,DB00813,Fentanyl
,8034201,area under the curve from 0 to 60 h (AUC0-60),"The mean patch duration (PD) in elderly subjects was 11.7 +/- 4.9 h, yielding a mean area under the curve from 0 to 60 h (AUC0-60) of 20.4 +/- 10.3 ng h/ml versus a mean AUC0-60 of 21.0 +/- 10.4 ng h/ml in young subjects.",Transdermal fentanyl disposition in elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034201/),[h·ng] / [ml],20.4,45671,DB00813,Fentanyl
,8034201,AUC0-60,"The mean patch duration (PD) in elderly subjects was 11.7 +/- 4.9 h, yielding a mean area under the curve from 0 to 60 h (AUC0-60) of 20.4 +/- 10.3 ng h/ml versus a mean AUC0-60 of 21.0 +/- 10.4 ng h/ml in young subjects.",Transdermal fentanyl disposition in elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034201/),[h·ng] / [ml],21.0,45672,DB00813,Fentanyl
,8034201,AUC0-60,"Correcting AUC0-60 for PD (AUC0-60/PD) gave a mean value of 2.05 +/- 1.10 ng/ml for elderly subjects, which was significantly greater than the AUC0-60/PD of 0.88 +/- 0.44 ng/ml in young subjects (p = 0.034, Student's t test).",Transdermal fentanyl disposition in elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034201/),[ng] / [ml],2.05,45673,DB00813,Fentanyl
,8034201,AUC0-60/PD,"Correcting AUC0-60 for PD (AUC0-60/PD) gave a mean value of 2.05 +/- 1.10 ng/ml for elderly subjects, which was significantly greater than the AUC0-60/PD of 0.88 +/- 0.44 ng/ml in young subjects (p = 0.034, Student's t test).",Transdermal fentanyl disposition in elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034201/),[ng] / [ml],2.05,45674,DB00813,Fentanyl
,8034201,AUC0-60/PD,"Correcting AUC0-60 for PD (AUC0-60/PD) gave a mean value of 2.05 +/- 1.10 ng/ml for elderly subjects, which was significantly greater than the AUC0-60/PD of 0.88 +/- 0.44 ng/ml in young subjects (p = 0.034, Student's t test).",Transdermal fentanyl disposition in elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8034201/),[ng] / [ml],0.88,45675,DB00813,Fentanyl
,7437210,half-life,This was followed by a slower elimination phase with a half-life of about 2 h.,Infusion model for fentanyl based on pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437210/),h,2,45701,DB00813,Fentanyl
,7437210,total volume of distribution,The total volume of distribution of 80 litre exceeded the body weight only slightly.,Infusion model for fentanyl based on pharmacokinetic analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437210/),l,80,45702,DB00813,Fentanyl
,7437210,total plasma clearance,The total plasma clearance was 500ml min-1.,Infusion model for fentanyl based on pharmacokinetic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437210/),[ml] / [min],500,45703,DB00813,Fentanyl
,9049575,clearance,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ml] / [kg·min],11.6,45783,DB00813,Fentanyl
,9049575,clearance,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ml] / [kg·min],13.3,45784,DB00813,Fentanyl
,9049575,clearance,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ml] / [kg·min],14.3,45785,DB00813,Fentanyl
,9049575,steady-state volume of distribution,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[l] / [kg],0.220,45786,DB00813,Fentanyl
,9049575,steady-state volume of distribution,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[l] / [kg],0.255,45787,DB00813,Fentanyl
,9049575,steady-state volume of distribution,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[l] / [kg],0.331,45788,DB00813,Fentanyl
,9049575,mean residence time,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,18.8,45789,DB00813,Fentanyl
,9049575,mean residence time,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,13.3,45790,DB00813,Fentanyl
,9049575,mean residence time,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,14.3,45791,DB00813,Fentanyl
,9049575,Cmax,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ng] / [ml],421,45792,DB00813,Fentanyl
,9049575,Cmax,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ng] / [ml],125,45793,DB00813,Fentanyl
,9049575,Cmax,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ng] / [ml],53,45794,DB00813,Fentanyl
,9049575,AUC,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,0 to 3,45795,DB00813,Fentanyl
,9049575,Times to reach peak haemodynamic effect,"Times to reach peak haemodynamic effect ranged from 4.3 to 4.9 min for group I, from 4.6 to 6.1 min for group II, and from 9.9 to 11.3 for group III.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,4.3 to 4.9,45796,DB00813,Fentanyl
,9049575,Times to reach peak haemodynamic effect,"Times to reach peak haemodynamic effect ranged from 4.3 to 4.9 min for group I, from 4.6 to 6.1 min for group II, and from 9.9 to 11.3 for group III.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,4.6 to 6.1,45797,DB00813,Fentanyl
,9049575,Times to reach peak haemodynamic effect,"Times to reach peak haemodynamic effect ranged from 4.3 to 4.9 min for group I, from 4.6 to 6.1 min for group II, and from 9.9 to 11.3 for group III.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),,9.9 to 11.3,45798,DB00813,Fentanyl
,12081155,apparent distribution volumes,"The apparent distribution volumes of patients A and B were 1.43 and 1.62 l/kg, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),[l] / [kg],1.43,46489,DB00813,Fentanyl
,12081155,apparent distribution volumes,"The apparent distribution volumes of patients A and B were 1.43 and 1.62 l/kg, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),[l] / [kg],1.62,46490,DB00813,Fentanyl
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),min,13.3,46491,DB00813,Fentanyl
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),min,17.4,46492,DB00813,Fentanyl
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),h,10.1,46493,DB00813,Fentanyl
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),h,10.5,46494,DB00813,Fentanyl
,7149300,terminal elimination half-life,"This was reflected by a prolonged terminal elimination half-life in the elderly compared with the younger patients (945 versus 265 minutes, respectively, p less than 0.005).",Age and fentanyl pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149300/),min,945,47455,DB00813,Fentanyl
,7149300,terminal elimination half-life,"This was reflected by a prolonged terminal elimination half-life in the elderly compared with the younger patients (945 versus 265 minutes, respectively, p less than 0.005).",Age and fentanyl pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149300/),min,265,47456,DB00813,Fentanyl
,7149300,drug clearance,"However, drug clearance was markedly decreased in the elderly (265 versus 991 ml/min, p less than 0.005).",Age and fentanyl pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149300/),[ml] / [min],265,47457,DB00813,Fentanyl
,7149300,drug clearance,"However, drug clearance was markedly decreased in the elderly (265 versus 991 ml/min, p less than 0.005).",Age and fentanyl pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149300/),[ml] / [min],991,47458,DB00813,Fentanyl
,24824135,MRT,"Elimination of sufentanil following epidural administration was very slow, with MRT = 28.25 [18.36-44.75] h and t1/2 MRT = 19.57 [12.72-31.01] h.",Pharmacokinetics of sufentanil administered with 0.2% ropivacaine as a continuous epidural infusion for postoperative pain relief in infants. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824135/),h,28.25,47575,DB00813,Fentanyl
,24824135,t1/2 MRT,"Elimination of sufentanil following epidural administration was very slow, with MRT = 28.25 [18.36-44.75] h and t1/2 MRT = 19.57 [12.72-31.01] h.",Pharmacokinetics of sufentanil administered with 0.2% ropivacaine as a continuous epidural infusion for postoperative pain relief in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824135/),h,19.57,47576,DB00813,Fentanyl
,3099599,volume of distribution at steady state,The volume of distribution at steady state was greater (P less than 0.02) in patients with renal failure (405 +/- 86 ml/kg) than in patients with normal renal function (281 +/- 97 ml/kg).,Pharmacokinetics of alfentanil in chronic renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),[ml] / [kg],405,47779,DB00813,Fentanyl
,3099599,volume of distribution at steady state,The volume of distribution at steady state was greater (P less than 0.02) in patients with renal failure (405 +/- 86 ml/kg) than in patients with normal renal function (281 +/- 97 ml/kg).,Pharmacokinetics of alfentanil in chronic renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),[ml] / [kg],281,47780,DB00813,Fentanyl
,3099599,plasma free fraction,Patients with renal failure had a higher (P less than 0.01) alfentanil plasma free fraction (0.19 +/- 0.06) than patients with normal renal function (0.11 +/- 0.03).,Pharmacokinetics of alfentanil in chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),,0.19,47781,DB00813,Fentanyl
,3099599,plasma free fraction,Patients with renal failure had a higher (P less than 0.01) alfentanil plasma free fraction (0.19 +/- 0.06) than patients with normal renal function (0.11 +/- 0.03).,Pharmacokinetics of alfentanil in chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099599/),,0.11,47782,DB00813,Fentanyl
,1466226,concentration,The predicted median alfentanil concentration (289(256-363) ng ml-1) was significantly lower than the measured median plasma concentration of 368(168-666) ng ml-1).,Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466226/),[ng] / [ml],289,47783,DB00813,Fentanyl
,1466226,plasma concentration,The predicted median alfentanil concentration (289(256-363) ng ml-1) was significantly lower than the measured median plasma concentration of 368(168-666) ng ml-1).,Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466226/),[ng] / [ml],368,47784,DB00813,Fentanyl
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],7.73,48497,DB00813,Fentanyl
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],4.54,48498,DB00813,Fentanyl
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],3.26,48499,DB00813,Fentanyl
,3377944,concentration,"Fentanyl concentration, per microgram kg-1 administered, was higher in elderly than in young patients at 2 min (7.73 +/- 3.14 v. 4.54 +/- 1.83 ng ml-1 (mean +/- SD), respectively) and at 4 min after the start of infusion (3.26 +/- 1.44 v. 1.78 +/- 0.72 ng ml-1, respectively).",Pharmacokinetics of fentanyl in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[ng] / [ml],1.78,48500,DB00813,Fentanyl
,3377944,Volume of distribution at steady-state (VDss),Volume of distribution at steady-state (VDss) was smaller in elderly patients (1.36 +/- 0.44 v. 2.27 +/- 0.82 litre kg-1).,Pharmacokinetics of fentanyl in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[l] / [kg],1.36,48501,DB00813,Fentanyl
,3377944,Volume of distribution at steady-state (VDss),Volume of distribution at steady-state (VDss) was smaller in elderly patients (1.36 +/- 0.44 v. 2.27 +/- 0.82 litre kg-1).,Pharmacokinetics of fentanyl in the elderly. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377944/),[l] / [kg],2.27,48502,DB00813,Fentanyl
,10631438,sedation score,The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period.,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,1,48719,DB00813,Fentanyl
,10631438,sedation score,The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period.,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,2 and 3,48720,DB00813,Fentanyl
,10631438,plasma concentrations,"At the same time, propofol plasma concentrations increased from 0.7 +/- 0.3 microgram/ml to 1.8 +/- 1.3 micrograms/ml.","[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),[μg] / [ml],0.,48721,DB00813,Fentanyl
,10631438,plasma concentrations,"At the same time, propofol plasma concentrations increased from 0.7 +/- 0.3 microgram/ml to 1.8 +/- 1.3 micrograms/ml.","[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,1,48722,DB00813,Fentanyl
,10631438,clearance,Alfentanil clearance was found to be reduced with four patients having extremely small clearance values (33 +/- 3 ml/min).,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),[ml] / [min],33,48723,DB00813,Fentanyl
,3499160,T1/2 alpha,"The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min).",Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),min,3,49295,DB00813,Fentanyl
,3499160,T1/2 beta,"The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min).",Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),min,45,49296,DB00813,Fentanyl
,3499160,total body clearance,The total body clearance of propofol was rapid (1.91 litre min-1).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),[l] / [min],1.91,49297,DB00813,Fentanyl
,3499160,Vss,Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),l,305,49298,DB00813,Fentanyl
,3499160,V gamma,Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),l,722,49299,DB00813,Fentanyl
,2147593,initial volume of distribution,The initial volume of distribution was significantly smaller in the elderly patients (310 +/- 109 ml.kg-1 vs 491 +/- 112 ml.kg-1 mean +/- SD).,Pharmacokinetics of sufentanil in the elderly surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[ml] / [kg],310,49463,DB00813,Fentanyl
,2147593,initial volume of distribution,The initial volume of distribution was significantly smaller in the elderly patients (310 +/- 109 ml.kg-1 vs 491 +/- 112 ml.kg-1 mean +/- SD).,Pharmacokinetics of sufentanil in the elderly surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[ml] / [kg],491,49464,DB00813,Fentanyl
greater,2147593,rate of ventilation,Six of seven elderly patients required administration of naloxone at the termination of surgery to achieve an adequate rate of ventilation (greater than eight breaths.min-1) while only one younger patient required antagonism of ventilatory depression.,Pharmacokinetics of sufentanil in the elderly surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[breaths] / [min],eight,49465,DB00813,Fentanyl
,9100179,constant rate,"kg-1, 5 min before induction of anesthesia, and infused at a constant rate of 0.5 microgram.",Predictive accuracy of continuous propofol infusions in neurosurgical patients: comparison of pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9100179/),μg,0.5,50314,DB00813,Fentanyl
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,5,50874,DB00813,Fentanyl
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,8,50875,DB00813,Fentanyl
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,14,50876,DB00813,Fentanyl
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,20,50877,DB00813,Fentanyl
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,3.4,51558,DB00813,Fentanyl
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,2.5,51559,DB00813,Fentanyl
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,25.5,51560,DB00813,Fentanyl
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,21.5,51561,DB00813,Fentanyl
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],126,51562,DB00813,Fentanyl
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],108,51563,DB00813,Fentanyl
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],5.0,51564,DB00813,Fentanyl
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],4.6,51565,DB00813,Fentanyl
,8659778,time to onset,"These differences are not associated with changes in recovery profile after a single bolus dose, although the mean time to onset was approximately 1 min longer in elderly patients.",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,1,51566,DB00813,Fentanyl
,11353518,peak concentration,The peak concentration in the others ranged from 0.38 to 0.71 ng/ml.,Evaluation of a transdermal fentanyl system in yucatan miniature pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353518/),[ng] / [ml],0.38 to 0.71,52105,DB00813,Fentanyl
,2522289,Total drug clearance,Total drug clearance was 15.0 +/- 3.2 ml.min-1.kg-1.,Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522289/),[ml] / [kg·min],15.0,52484,DB00813,Fentanyl
,2522289,volume of distribution at steady-state (Vdss),The volume of distribution at steady-state (Vdss) was 8.7 +/- 4.5 l.kg-1.,Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522289/),[l] / [kg],8.7,52485,DB00813,Fentanyl
,2522289,elimination half-time,"In general surgical patients, the mean elimination half-time of sufentanil has been reported to be 2.7 h.",Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522289/),h,2.7,52486,DB00813,Fentanyl
,32192089,Plasma levels,"Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80).",The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192089/),[ng] / [ml],4.6,52599,DB00813,Fentanyl
,32192089,Plasma levels,"Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80).",The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192089/),[ng] / [ml],16.8,52600,DB00813,Fentanyl
,32192089,Plasma levels,"Plasma levels were 4.6 ng/mL, 16.8 ng/mL, and 43.4 ng/mL for the three IM doses, and a significant correlation between percent RO and plasma NLX level was observed (r = 0.80).",The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32192089/),[ng] / [ml],43.4,52601,DB00813,Fentanyl
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,52,52850,DB00813,Fentanyl
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,126,52851,DB00813,Fentanyl
,2048708,elimination half-time (t beta 1/2),Midazolam elimination half-time (t beta 1/2) was significantly shorter in group II than in groups III and I (52 min vs 126 min and 139 min; p less than 0.05).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),min,139,52852,DB00813,Fentanyl
,2048708,initial midazolam,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52853,DB00813,Fentanyl
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],655,52854,DB00813,Fentanyl
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],323,52855,DB00813,Fentanyl
,2048708,mean concentrations,The measured initial midazolam mean concentrations in group II were twice those in groups III and I (655 ng/ml vs 323 ng/ml and 332 ng/ml).,[The effect of a thigh tourniquet on the pharmacokinetics of midazolam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2048708/),[ng] / [ml],332,52856,DB00813,Fentanyl
,3919613,half-time,With fentanyl a significantly greater time lag was present (half-time = 6.4 +/- 1.3 min; mean +/- SD) than with alfentanil (half-time = 1.1 +/- 0.3 min).,EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),min,6.4,53033,DB00813,Fentanyl
,3919613,half-time,With fentanyl a significantly greater time lag was present (half-time = 6.4 +/- 1.3 min; mean +/- SD) than with alfentanil (half-time = 1.1 +/- 0.3 min).,EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),min,1.1,53034,DB00813,Fentanyl
,3919613,steady-state serum concentration,"The steady-state serum concentration that caused one-half of the maximal EEG slowing was 6.9 +/- 1.5 ng/ml for fentanyl, compared with 520 +/- 163 ng/ml for alfentanil.",EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),[ng] / [ml],6.9,53035,DB00813,Fentanyl
,3919613,steady-state serum concentration,"The steady-state serum concentration that caused one-half of the maximal EEG slowing was 6.9 +/- 1.5 ng/ml for fentanyl, compared with 520 +/- 163 ng/ml for alfentanil.",EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919613/),[ng] / [ml],520,53036,DB00813,Fentanyl
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],2.8,53268,DB00813,Fentanyl
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],5.3,53269,DB00813,Fentanyl
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],0.42,53270,DB00813,Fentanyl
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,280,53271,DB00813,Fentanyl
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,120,53272,DB00813,Fentanyl
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,1030,53273,DB00813,Fentanyl
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],4.2,53274,DB00813,Fentanyl
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],8.8,53275,DB00813,Fentanyl
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],1.2,53276,DB00813,Fentanyl
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,62,53277,DB00813,Fentanyl
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,34,53278,DB00813,Fentanyl
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,211,53279,DB00813,Fentanyl
,2051573,I (,"Two hours following the end of the ketamine infusion, plasma ketamine levels decreased to 14% of the control value (0.81 micrograms.ml-1), while metabolite I (K1) was still about 1.8 micrograms.","[A clinical study on total intravenous anesthesia with droperidol, fentanyl and ketamine--2. Pharmacokinetics following the end of continuous ketamine infusion]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051573/),μg,1.8,54434,DB00813,Fentanyl
,2051573,K1),"Two hours following the end of the ketamine infusion, plasma ketamine levels decreased to 14% of the control value (0.81 micrograms.ml-1), while metabolite I (K1) was still about 1.8 micrograms.","[A clinical study on total intravenous anesthesia with droperidol, fentanyl and ketamine--2. Pharmacokinetics following the end of continuous ketamine infusion]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051573/),μg,1.8,54435,DB00813,Fentanyl
,11064622,Maximal median concentrations of plasma,Maximal median concentrations of plasma (0.117-0.247 ng ml-1 for fentanyl and 0.027-0.074 ng ml-1 for sufentanil) were reached approximately 30 and 20 min respectively after the loading doses.,Fentanyl versus sufentanil: plasma concentrations during continuous epidural postoperative infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064622/),[ng] / [ml],0.117-0.247,54451,DB00813,Fentanyl
,11064622,Maximal median concentrations of plasma,Maximal median concentrations of plasma (0.117-0.247 ng ml-1 for fentanyl and 0.027-0.074 ng ml-1 for sufentanil) were reached approximately 30 and 20 min respectively after the loading doses.,Fentanyl versus sufentanil: plasma concentrations during continuous epidural postoperative infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064622/),[ng] / [ml],0.027-0.074,54452,DB00813,Fentanyl
> or =,8602660,train-of-four ratio,All patients were allowed to recover spontaneously to a train-of-four ratio > or = 0.70 after cisatracurium-induced neuromuscular block.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,0.70,54591,DB00813,Fentanyl
,8602660,clearances,The clearances (5.28 +/- 1.23 vs.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,5.28,54592,DB00813,Fentanyl
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,22.4,54593,DB00813,Fentanyl
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,25.5,54594,DB00813,Fentanyl
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],38,54595,DB00813,Fentanyl
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],103,54596,DB00813,Fentanyl
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],101,54597,DB00813,Fentanyl
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],253,54598,DB00813,Fentanyl
,2337359,serum concentration,Five minutes after a single dose of 20 micrograms/kg alfentanil median serum concentration was 66 ng/ml (range: 20-606).,Alfentanil pharmacokinetics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),[ng] / [ml],66,55357,DB00813,Fentanyl
,2337359,clearance,The median clearance was 0.87 ml/kg/min (range: 0.4-9.62) and median elimination half life 321 mins (64-1251).,Alfentanil pharmacokinetics in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),[ml] / [kg·min],0.87,55358,DB00813,Fentanyl
,2337359,elimination half life,The median clearance was 0.87 ml/kg/min (range: 0.4-9.62) and median elimination half life 321 mins (64-1251).,Alfentanil pharmacokinetics in preterm infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),min,321,55359,DB00813,Fentanyl
,2337359,steady state median,In four infants 20 micrograms/kg alfentanil given by infusion over 30 minutes followed by 5 micrograms/kg/hour produced steady state median alfentanil concentrations of 54.5 ng/ml (range: 7-73 ng/ml) with no evidence of drug accumulation.,Alfentanil pharmacokinetics in preterm infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2337359/),[ng] / [ml],54.5,55360,DB00813,Fentanyl
,26381285,apparent clearance,"Fentanyl apparent clearance (between-subject variability [BSV], %) was estimated at 122 L/h/70 kg and 38.5%, respectively.",Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26381285/),[l] / [70·h·kg],122,56055,DB00813,Fentanyl
,26381285,apparent clearance,"Fentanyl apparent clearance (between-subject variability [BSV], %) was estimated at 122 L/h/70 kg and 38.5%, respectively.",Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26381285/),%,38.5,56056,DB00813,Fentanyl
,26381285,absorption rate constant,The absorption rate constant was 0.013 h(-1) .,Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26381285/),1/[h],0.013,56057,DB00813,Fentanyl
,7999650,infusion rates,"Mean infusion rates were 9.3 +/- 2.1 mL/hour and 9.6 +/- 1.7 mL/hour for groups A and B, respectively.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),[ml] / [h],9.3,57278,DB00813,Fentanyl
,7999650,infusion rates,"Mean infusion rates were 9.3 +/- 2.1 mL/hour and 9.6 +/- 1.7 mL/hour for groups A and B, respectively.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),[ml] / [h],9.6,57279,DB00813,Fentanyl
,7999650,study duration,"Mean study duration was 3.7 hours in group A, and 3.0 hours in group B.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),h,3.7,57280,DB00813,Fentanyl
,7999650,study duration,"Mean study duration was 3.7 hours in group A, and 3.0 hours in group B.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),h,3.0,57281,DB00813,Fentanyl
,34077940,central volume of distribution (Vdc),"The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[l] / [kg],4.7,57288,DB00813,Fentanyl
,34077940,clearance (CL),"The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[l] / [h·kg],0.651,57289,DB00813,Fentanyl
,34077940,LD,"Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[μg] / [kg],2.13,57290,DB00813,Fentanyl
,34077940,MD,"Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[μg] / [h·kg],0.29,57291,DB00813,Fentanyl
,1531117,distribution half-life (t1/2 alpha),The distribution half-life (t1/2 alpha) was 5.2 +/- 2.2 (mean +/- SD) min and the elimination half life (t1/2 beta) was 97.0 +/- 42.0 min.,Pharmacokinetics of sufentanil in normal children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),min,5.2,57616,DB00813,Fentanyl
,1531117,elimination half life (t1/2 beta),The distribution half-life (t1/2 alpha) was 5.2 +/- 2.2 (mean +/- SD) min and the elimination half life (t1/2 beta) was 97.0 +/- 42.0 min.,Pharmacokinetics of sufentanil in normal children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),min,97.0,57617,DB00813,Fentanyl
,1531117,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was 2.9 +/- 0.6 L.kg-1 and the clearance was 30.5 +/- 8.8 ml.kg-1.min-1.,Pharmacokinetics of sufentanil in normal children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),[l] / [kg],2.9,57618,DB00813,Fentanyl
,1531117,clearance,The volume of distribution at steady state (Vdss) was 2.9 +/- 0.6 L.kg-1 and the clearance was 30.5 +/- 8.8 ml.kg-1.min-1.,Pharmacokinetics of sufentanil in normal children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),[ml] / [kg·min],30.5,57619,DB00813,Fentanyl
,12621385,time to maximum concentration [T(max)],"Alfentanil was rapidly absorbed (time to maximum concentration [T(max)], 0.7 +/- 0.5 hour).",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,0.7,57943,DB00813,Fentanyl
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],27,57944,DB00813,Fentanyl
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],38,57945,DB00813,Fentanyl
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],57,57946,DB00813,Fentanyl
,12621385,area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )),"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[h·ng] / [ml],105,57947,DB00813,Fentanyl
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],16,57948,DB00813,Fentanyl
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],23,57949,DB00813,Fentanyl
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],31,57950,DB00813,Fentanyl
,12621385,maximum concentration,"Mean values for area under the plasma concentration-time curve extrapolated to infinity (AUC( infinity )) (27 +/- 14, 38 +/- 22, 57 +/- 31, and 105 +/- 59 ng x h x mL(-1)) and maximum concentration (16 +/- 8, 23 +/- 16, 31 +/- 18, and 50 +/- 22 ng/mL) were linear with dose, although there was considerable interindividual variability.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ng] / [ml],50,57951,DB00813,Fentanyl
,12621385,T,"T(max), elimination half-life (1.0 +/- 0.2 hours), total body clearance after oral administration (20 +/- 18 mL x kg(-1) x min(-1)), and dose-normalized AUC(infinity ) were independent of dose.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,1.0,57952,DB00813,Fentanyl
,12621385,elimination half-life,"T(max), elimination half-life (1.0 +/- 0.2 hours), total body clearance after oral administration (20 +/- 18 mL x kg(-1) x min(-1)), and dose-normalized AUC(infinity ) were independent of dose.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,1.0,57953,DB00813,Fentanyl
,12621385,total body clearance,"T(max), elimination half-life (1.0 +/- 0.2 hours), total body clearance after oral administration (20 +/- 18 mL x kg(-1) x min(-1)), and dose-normalized AUC(infinity ) were independent of dose.",Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),[ml] / [kg·min],20,57954,DB00813,Fentanyl
,12621385,Effect half-life,Effect half-life (1.3 +/- 0.9 hours) was similar to plasma half-life.,Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621385/),h,1.3,57955,DB00813,Fentanyl
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],902,58068,DB00813,Fentanyl
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],914,58069,DB00813,Fentanyl
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],4.9,58070,DB00813,Fentanyl
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],11.3,58071,DB00813,Fentanyl
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,250,58072,DB00813,Fentanyl
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,562,58073,DB00813,Fentanyl
,3756054,elimination half-life,The elimination half-life was 7.3-9.7 h.,Pharmacokinetics of fentanyl during constant rate i.v. infusion for the relief of pain after surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756054/),h,7.3-9.7,58986,DB00813,Fentanyl
,10064669,time to reach peak plasma concentration,The time to reach peak plasma concentration ranged from 18 hours to >66 hours in patients receiving the 25 microg/h patch.,"Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10064669/),h,18,59166,DB00813,Fentanyl
>,10064669,time to reach peak plasma concentration,The time to reach peak plasma concentration ranged from 18 hours to >66 hours in patients receiving the 25 microg/h patch.,"Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10064669/),h,66,59167,DB00813,Fentanyl
,8659779,total clearance,"Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min.",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg·min],0.053,59843,DB00813,Fentanyl
,8659779,volume of distribution at steady state,"Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min.",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],9.5,59844,DB00813,Fentanyl
,8659779,residence time,"Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min.",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),min,188,59845,DB00813,Fentanyl
,8659779,systemic clearance,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[kg(-·l] / [min],0.049,59846,DB00813,Fentanyl
,8659779,systemic clearance,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[kg(-·l] / [min],0.048,59847,DB00813,Fentanyl
,8659779,volume of central compartment,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],1.03,59848,DB00813,Fentanyl
,8659779,volume of central compartment,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],0.95,59849,DB00813,Fentanyl
,8659779,volume of steady state,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],8.09,59850,DB00813,Fentanyl
,8659779,volume of steady state,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],8.17,59851,DB00813,Fentanyl
,8214905,PaCO2,"Positive pressure ventilation was begun, maintaining PaCO2 at 49.1 +/- 3.3 mm of Hg and airway pressure at 20 +/- 2 cm of H2O.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),h·mm,49.1,60921,DB00813,Fentanyl
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],94.8,60922,DB00813,Fentanyl
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],170.7,60923,DB00813,Fentanyl
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],390.9,60924,DB00813,Fentanyl
,21917532,flow rate,"The assay procedure involved chromatographic separation using a ZIC-HILIC SeQUANT column (250 mm × 4.6 mm, i.d., 5 μm) and a mobile phase of acetonitrile and acetate buffer (pH 3.4, 20mM) of ratio (=65:35, v/v) at a flow rate of 1.2 mL/min and detection wavelength of 201 nm.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),[ml] / [min],1.2,61099,DB00813,Fentanyl
,21917532,Limit of detection,Limit of detection was 0.8 ng/mL at S/N of 3.,HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),[ng] / [ml],0.8,61100,DB00813,Fentanyl
,21917532,S/N,Limit of detection was 0.8 ng/mL at S/N of 3.,HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),,3,61101,DB00813,Fentanyl
,21917532,T(1/2),"Pharmacokinetic parameters estimated by using moment analysis were T(1/2) 198.3 ± 44.7 min, T(max) 28.3 ± 2.9 min and AUC(0-180) 15.6 ± 2.9(× 10(2))ngmin/mL.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),min,198.3,61102,DB00813,Fentanyl
,21917532,T(max),"Pharmacokinetic parameters estimated by using moment analysis were T(1/2) 198.3 ± 44.7 min, T(max) 28.3 ± 2.9 min and AUC(0-180) 15.6 ± 2.9(× 10(2))ngmin/mL.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),min,28.3,61103,DB00813,Fentanyl
,21917532,AUC(0-180),"Pharmacokinetic parameters estimated by using moment analysis were T(1/2) 198.3 ± 44.7 min, T(max) 28.3 ± 2.9 min and AUC(0-180) 15.6 ± 2.9(× 10(2))ngmin/mL.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),[ngmin] / [ml],15.6,61104,DB00813,Fentanyl
,6110399,maintenance dose,The maintenance dose was on average 0.15 ml/kg-/h-1 +/- 0.03 of alfadione and 2.96 micrograms/kg-1/h-1 +/- 0.58 of fentanyl.,[Plasma concentration of fentanyl administered at a constant flow rate during prolonged anesthesia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6110399/),[ml] / [h·kg-],0.15,61662,DB00813,Fentanyl
,6110399,maintenance dose,The maintenance dose was on average 0.15 ml/kg-/h-1 +/- 0.03 of alfadione and 2.96 micrograms/kg-1/h-1 +/- 0.58 of fentanyl.,[Plasma concentration of fentanyl administered at a constant flow rate during prolonged anesthesia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6110399/),[μg] / [kg],2.96,61663,DB00813,Fentanyl
,6110399,half lives,The study of excretion curves demonstrated the existence of a three compartment system with respective half lives of 12.75 and 510 minutes.,[Plasma concentration of fentanyl administered at a constant flow rate during prolonged anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6110399/),min,12.75,61664,DB00813,Fentanyl
,6110399,half lives,The study of excretion curves demonstrated the existence of a three compartment system with respective half lives of 12.75 and 510 minutes.,[Plasma concentration of fentanyl administered at a constant flow rate during prolonged anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6110399/),min,510,61665,DB00813,Fentanyl
,2882701,elimination half-lives,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,3 to 4,62367,DB00813,Fentanyl
,2882701,steady-state volumes of distribution,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],2 to 4,62368,DB00813,Fentanyl
,2882701,hepatic clearances,"Morphine, pethidine and fentanyl have similar pharmacokinetic profiles with moderately long elimination half-lives (3 to 4 hours), large steady-state volumes of distribution (2 to 4 l/kg), and high hepatic clearances (10 to 20 ml/kg/min).",Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[ml] / [kg·min],10 to 20,62369,DB00813,Fentanyl
,2882701,terminal elimination half-life,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),h,1 1/2,62370,DB00813,Fentanyl
,2882701,steady-state volume of distribution,Alfentanil has a shorter terminal elimination half-life (1 1/2 hours) because of a decreased steady-state volume of distribution (0.5 to 1 l/kg).,Narcotic pharmacokinetics and dynamics: the basis of infusion applications. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882701/),[l] / [kg],0.5 to 1,62371,DB00813,Fentanyl
,7833228,"t1/2,z","Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),h,16,62961,DB00813,Fentanyl
,7833228,CL,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[ml] / [min],1215,62962,DB00813,Fentanyl
,7833228,CLR,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[ml] / [min],7,62963,DB00813,Fentanyl
,7833228,Vss,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[1] / [kg],10.0,62964,DB00813,Fentanyl
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,140,63189,DB00813,Fentanyl
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,15,63190,DB00813,Fentanyl
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,0.92,63191,DB00813,Fentanyl
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,6.8,63192,DB00813,Fentanyl
,1671323,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),[ml] / [kg],1.54,63193,DB00813,Fentanyl
,1671323,clearance from the CSF,"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),μl,27,63194,DB00813,Fentanyl
,26762381,apparent clearance,"The estimated apparent clearance of fentanyl was 49.6 L/h; the absorption rate constant for subcutaneous and transdermal fentanyl was 0.0358 and 0.0135 h(-1), respectively.",Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26762381/),[l] / [h],49.6,63282,DB00813,Fentanyl
,26762381,absorption rate constant,"The estimated apparent clearance of fentanyl was 49.6 L/h; the absorption rate constant for subcutaneous and transdermal fentanyl was 0.0358 and 0.0135 h(-1), respectively.",Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26762381/),1/[h],0.0358,63283,DB00813,Fentanyl
,26762381,absorption rate constant,"The estimated apparent clearance of fentanyl was 49.6 L/h; the absorption rate constant for subcutaneous and transdermal fentanyl was 0.0358 and 0.0135 h(-1), respectively.",Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26762381/),1/[h],0.0135,63284,DB00813,Fentanyl
,9690947,Time-averaged bioavailability,"Time-averaged bioavailability based upon nominal doses averaged approximately 100%, and was > 50% within 5 min of delivery.",Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690947/),%,100,63558,DB00813,Fentanyl
>,9690947,Time-averaged bioavailability,"Time-averaged bioavailability based upon nominal doses averaged approximately 100%, and was > 50% within 5 min of delivery.",Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690947/),%,50,63559,DB00813,Fentanyl
,21831253,T(max),"After FBT administration, fentanyl was rapidly absorbed, with T(max) ranging from 20 minutes to 4 hours postdose.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),min,20,63743,DB00813,Fentanyl
,21831253,T(max),"After FBT administration, fentanyl was rapidly absorbed, with T(max) ranging from 20 minutes to 4 hours postdose.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),h,4,63744,DB00813,Fentanyl
,21831253,AUC(0-∞),"Mean AUC(0-∞) was 1.49 ng•hour/mL, and mean C(max) was 0.237 ng/mL.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),[h·ng] / [ml],1.49,63745,DB00813,Fentanyl
,21831253,C(max),"Mean AUC(0-∞) was 1.49 ng•hour/mL, and mean C(max) was 0.237 ng/mL.",Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831253/),[ng] / [ml],0.237,63746,DB00813,Fentanyl
,6869754,steady state plasma concentration,The steady state plasma concentration associated with the technique which produced the required degree of sedation was found to be 158 micrograms/litre (SEM 36).,Plasma concentrations of etomidate during an intravenous infusion over 48 hours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869754/),[μg] / [l],158,64425,DB00813,Fentanyl
,2569886,elimination half-life (T1/2 beta),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),min,188,65475,DB00813,Fentanyl
,2569886,elimination half-life (T1/2 beta),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),min,195,65476,DB00813,Fentanyl
,2569886,clearance (CI),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),[ml] / [min],1030,65477,DB00813,Fentanyl
,2569886,clearance (CI),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),[ml] / [min],1093,65478,DB00813,Fentanyl
,2569886,apparent volume of distribution at steady state (Vss),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),l,223.0,65479,DB00813,Fentanyl
,2569886,apparent volume of distribution at steady state (Vss),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),l,215.3,65480,DB00813,Fentanyl
,2569886,binding to,Sufentanil binding to plasma proteins was 91.4% in the renal patients and 92.2% in the healthy group (ns).,Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),%,91.4,65481,DB00813,Fentanyl
,2569886,binding to,Sufentanil binding to plasma proteins was 91.4% in the renal patients and 92.2% in the healthy group (ns).,Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),%,92.2,65482,DB00813,Fentanyl
,2569886,T1/2 beta,"The mean absolute differences between methods were: T1/2 beta 2.7 min (95% limits: -26.2 to 31.5), CI 36.5 ml min-1 (-5.5 to 78.4), Vss -18.4 litre (-47.7 to 10.9).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),min,2.7,65483,DB00813,Fentanyl
,2569886,Vss,"The mean absolute differences between methods were: T1/2 beta 2.7 min (95% limits: -26.2 to 31.5), CI 36.5 ml min-1 (-5.5 to 78.4), Vss -18.4 litre (-47.7 to 10.9).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),l,18.4,65484,DB00813,Fentanyl
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],5.3,65594,DB00813,Fentanyl
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],14.6,65595,DB00813,Fentanyl
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.1,65596,DB00813,Fentanyl
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,58,65597,DB00813,Fentanyl
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,35,65598,DB00813,Fentanyl
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,630,65599,DB00813,Fentanyl
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],4.9,65600,DB00813,Fentanyl
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],13.2,65601,DB00813,Fentanyl
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.5,65602,DB00813,Fentanyl
,18641105,Sedation success rates,"Sedation success rates were 88.7% and 27.5%, respectively (p < 0.0001).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),%,88.7,66682,DB00813,Fentanyl
,18641105,Sedation success rates,"Sedation success rates were 88.7% and 27.5%, respectively (p < 0.0001).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),%,27.5,66683,DB00813,Fentanyl
,18641105,time to full alertness,"The median time to full alertness was slightly longer for the 6.5 mg/kg dose (5.5 vs 3.0 min, respectively).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),min,5.5,66684,DB00813,Fentanyl
,18641105,time to full alertness,"The median time to full alertness was slightly longer for the 6.5 mg/kg dose (5.5 vs 3.0 min, respectively).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),min,3.0,66685,DB00813,Fentanyl
,16372825,time to reach maximum serum concentration (tmax),The pharmacokinetics of FEBT were characterised by an absorption phase with a median time to reach maximum serum concentration (tmax) of 0.75-0.99 hours that was consistent irrespective of dose.,Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372825/),h,0.75-0.99,68855,DB00813,Fentanyl
,12932070,elimination half-life,"The elimination half-life of alfentanil was similar in the control and atorvastatin groups (98.8 +/- 12.4 versus 98.3 +/- 11.3 min, respectively).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),min,98.8,69158,DB00813,Fentanyl
,12932070,elimination half-life,"The elimination half-life of alfentanil was similar in the control and atorvastatin groups (98.8 +/- 12.4 versus 98.3 +/- 11.3 min, respectively).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),min,98.3,69159,DB00813,Fentanyl
,12932070,Cl,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [min],0.20,69160,DB00813,Fentanyl
,12932070,Cl,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [min],0.22,69161,DB00813,Fentanyl
,12932070,Vdss,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [kg],0.38,69162,DB00813,Fentanyl
,12932070,Vdss,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[l] / [kg],0.39,69163,DB00813,Fentanyl
,12932070,AUC,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[mg·min] / [ml],0.05,69164,DB00813,Fentanyl
,12932070,AUC,"The clearance (Cl), volume of distribution at steady-state (Vdss) and area under the curve (AUC) were similar in the two groups (Cl = 0.20 (+/- 0.06) and 0.22 (+/- 0.04) L min(-1), Vdss = 0.38 (+/- 0.07) and 0.39 (+/- 0.07) L kg(-1), AUC = 0.05 (+/- 0.02) and 0.04 (+/- 0.01) mg min mL(-1)).",Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12932070/),[mg·min] / [ml],0.04,69165,DB00813,Fentanyl
,9250552,Elimination half-life,Elimination half-life was 382 +/- 205 minutes; volume of distribution for the central compartment 0.74 +/- 0.48 L/kg; volume of distribution at steady state (Vd(ss)) 3.1 +/- 2.0 L/kg; total body clearance 7.5 +/- 5.1 ml x kg(-1) x min(-1).,Fentanyl pharmacokinetics in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250552/),min,382,69176,DB00813,Fentanyl
,9250552,volume of distribution for the central compartment,Elimination half-life was 382 +/- 205 minutes; volume of distribution for the central compartment 0.74 +/- 0.48 L/kg; volume of distribution at steady state (Vd(ss)) 3.1 +/- 2.0 L/kg; total body clearance 7.5 +/- 5.1 ml x kg(-1) x min(-1).,Fentanyl pharmacokinetics in patients undergoing renal transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250552/),[l] / [kg],0.74,69177,DB00813,Fentanyl
,9250552,volume of distribution at steady state (Vd(ss)),Elimination half-life was 382 +/- 205 minutes; volume of distribution for the central compartment 0.74 +/- 0.48 L/kg; volume of distribution at steady state (Vd(ss)) 3.1 +/- 2.0 L/kg; total body clearance 7.5 +/- 5.1 ml x kg(-1) x min(-1).,Fentanyl pharmacokinetics in patients undergoing renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250552/),[l] / [kg],3.1,69178,DB00813,Fentanyl
,9250552,total body clearance,Elimination half-life was 382 +/- 205 minutes; volume of distribution for the central compartment 0.74 +/- 0.48 L/kg; volume of distribution at steady state (Vd(ss)) 3.1 +/- 2.0 L/kg; total body clearance 7.5 +/- 5.1 ml x kg(-1) x min(-1).,Fentanyl pharmacokinetics in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9250552/),[ml] / [kg·min],7.5,69179,DB00813,Fentanyl
,2495860,Central-compartment volume of distribution,"Central-compartment volume of distribution was 0.131 +/- 0.087 L.kg-1 (mean +/- SD) in young healthy volunteers and decreased modestly with increasing age (r = -0.32, P less than 0.05).",Aging and alfentanil disposition in healthy volunteers and surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495860/),[l] / [kg],0.131,69526,DB00813,Fentanyl
,2495860,apparent volume of distribution at steady-state,"However, apparent volume of distribution at steady-state, 0.404 +/- 0.205 L.kg-1 for the whole study cohort, was not age-related.",Aging and alfentanil disposition in healthy volunteers and surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495860/),[l] / [kg],0.404,69527,DB00813,Fentanyl
,2495860,Plasma clearance,"Plasma clearance of alfentanil in young healthy subjects, 9.3 +/- 6.3 ml.kg-1.min-1, also showed an inverse relationship with age (r = -0.54, P less than 0.001), and was not affected by surgical stress in subjects older than 60 years.",Aging and alfentanil disposition in healthy volunteers and surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495860/),[ml] / [kg·min],9.3,69528,DB00813,Fentanyl
,1530165,Cp50(asleep),"The Cp50(asleep) for patients in whom concentrations were maintained within +/- 30% for thiopental alone (n = 17) was 7.32 micrograms/mL (95% confidence interval, 5.53-10.95); for thiopental in the presence of fentanyl (n = 18 with a measured fentanyl concentration of 1.27 +/- 0.5 ng/mL), this was 7.22 micrograms/mL (95% confidence interval, 4.83-10.15).","Fentanyl does not alter the ""sleep"" plasma concentration of thiopental. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530165/),[μg] / [ml],7.32,70137,DB00813,Fentanyl
,1530165,Cp50(asleep),"The Cp50(asleep) for patients in whom concentrations were maintained within +/- 30% for thiopental alone (n = 17) was 7.32 micrograms/mL (95% confidence interval, 5.53-10.95); for thiopental in the presence of fentanyl (n = 18 with a measured fentanyl concentration of 1.27 +/- 0.5 ng/mL), this was 7.22 micrograms/mL (95% confidence interval, 4.83-10.15).","Fentanyl does not alter the ""sleep"" plasma concentration of thiopental. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530165/),[μg] / [ml],7.22,70138,DB00813,Fentanyl
,3840338,plasma concentrations,"Thirty minutes after the injection, fentanyl plasma concentrations were between 7.7 and 13.6 ng X ml-1.",Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),[ng] / [ml],7.7 and 13.6,70248,DB00813,Fentanyl
,3840338,Elimination half-life,"Elimination half-life was 6-32 hr (mean +/- SD, 17.7 +/- 9.3).",Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),h,17.7,70249,DB00813,Fentanyl
,3840338,heart rate,There was a gradual increase in heart rate from 159 +/- 12 min-1 at the time of skin incision to 173 +/- 15 min-1 at the time of skin closure (P less than 0.05).,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),1/[min],159,70250,DB00813,Fentanyl
,3840338,heart rate,There was a gradual increase in heart rate from 159 +/- 12 min-1 at the time of skin incision to 173 +/- 15 min-1 at the time of skin closure (P less than 0.05).,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),1/[min],173,70251,DB00813,Fentanyl
,3840338,plasma concentrations,Fentanyl plasma concentrations remained virtually unchanged between 30 min (10.6 +/- 1.9 ng X ml-1) and 120 min (9.6 +/- 1.6 ng X ml-1); whereas at the end of surgery most infants moved and breathed spontaneously.,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),[ng] / [ml],10.6,70252,DB00813,Fentanyl
,3840338,plasma concentrations,Fentanyl plasma concentrations remained virtually unchanged between 30 min (10.6 +/- 1.9 ng X ml-1) and 120 min (9.6 +/- 1.6 ng X ml-1); whereas at the end of surgery most infants moved and breathed spontaneously.,Fentanyl pharmacokinetics and hemodynamic effects in preterm infants during ligation of patent ductus arteriosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840338/),[ng] / [ml],9.6,70253,DB00813,Fentanyl
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,271.5,70647,DB00813,Fentanyl
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,140.0,70648,DB00813,Fentanyl
,16634542,Onset times,"Onset times for patients receiving 0.3 mg x kg(-1), 0.6 mg x kg(-1) or 0.9 mg x kg(-1) were 271.5 s, 140.0s and 125.4s, respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),s,125.4,70649,DB00813,Fentanyl
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,17.4,70650,DB00813,Fentanyl
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,37.2,70651,DB00813,Fentanyl
,16634542,25% recovery of twitch height,"There was a dose-dependent increase in clinical durations until 25% recovery of twitch height (17.4 min in 0.3 mg x kg(-1) group, 37.2 min in 0.6 mg x kg(-1) and 60.4 min in 0.9 mg x kg(-1) group).","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,60.4,70652,DB00813,Fentanyl
,16634542,elimination half life,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),min,48-76,70653,DB00813,Fentanyl
,16634542,steady state volume of distribution,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),[ml] / [kg],146-181,70654,DB00813,Fentanyl
,16634542,plasma clearance,"Pharmacokinetic study revealed that elimination half life, steady state volume of distribution and plasma clearance of Org 9426 were 48-76 min, 146-181 ml x kg(-1), and 3.8-4.5 ml x min(-1) x kg(-1), respectively.","[Neuromuscular blocking effects, pharmacokinetics and safety of Org 9426 (rocuronium bromide) in Japanese patients]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16634542/),[ml] / [kg·min],3.8-4.5,70655,DB00813,Fentanyl
>,7952116,extraction efficiencies,"The extraction efficiencies for noralfentanil and alfentanil were > 99% and 70%, respectively.",Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952116/),%,99,70774,DB00813,Fentanyl
,7952116,extraction efficiencies,"The extraction efficiencies for noralfentanil and alfentanil were > 99% and 70%, respectively.",Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952116/),%,70,70775,DB00813,Fentanyl
,2878076,duration of action,"Alftentanil reaches its peak effect within 1 min after injection, and its duration of action is very short; at 2 times its MED50, 9r has a duration of action of 11 min.","Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878076/),min,11,70928,DB00813,Fentanyl
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.4,71665,DB00813,Fentanyl
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],2.6,71666,DB00813,Fentanyl
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.7,71667,DB00813,Fentanyl
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],5.5,71668,DB00813,Fentanyl
,10485779,clearance,Ritonavir reduced the clearance of fentanyl by 67% from 15.6+/-8.2 to 5.2+/-2.0 ml x min(-1) x kg(-1) (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ml] / [kg·min],15.6,72309,DB00813,Fentanyl
,10485779,clearance,Ritonavir reduced the clearance of fentanyl by 67% from 15.6+/-8.2 to 5.2+/-2.0 ml x min(-1) x kg(-1) (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ml] / [kg·min],5.2,72310,DB00813,Fentanyl
,10485779,area under the fentanyl plasma concentration-time curve from 0 to 18 h,The area under the fentanyl plasma concentration-time curve from 0 to 18 h was increased from 4.8+/-2.7 to 8.8+/-2.3 ng x ml(-1) x h(-1) by ritonavir (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ng] / [h·ml],4.8,72311,DB00813,Fentanyl
,10485779,area under the fentanyl plasma concentration-time curve from 0 to 18 h,The area under the fentanyl plasma concentration-time curve from 0 to 18 h was increased from 4.8+/-2.7 to 8.8+/-2.3 ng x ml(-1) x h(-1) by ritonavir (P<0.01).,Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10485779/),[ng] / [h·ml],8.8,72312,DB00813,Fentanyl
,30322973,serum fentanyl concentration,"In CI regimen, median (IQR) serum fentanyl concentration was 0.42 (0.35, 0.46) to 0.61 (0.47, 0.89) ng/mL throughout the infusion period.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],0.42,73443,DB00813,Fentanyl
,30322973,serum fentanyl concentration,"In CI regimen, median (IQR) serum fentanyl concentration was 0.42 (0.35, 0.46) to 0.61 (0.47, 0.89) ng/mL throughout the infusion period.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],0.61,73444,DB00813,Fentanyl
,30322973,peak concentration,"In IB regimen, median (IQR) peak concentration ranged from 2.21 (1.82, 3.55) to 3.61 (2.91, 4.51) ng/mL and trough concentration 0.41 (0.33, 0.48) to 0.97 (0.56, 1.25) ng/mL for various doses.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],2.21,73445,DB00813,Fentanyl
,30322973,peak concentration,"In IB regimen, median (IQR) peak concentration ranged from 2.21 (1.82, 3.55) to 3.61 (2.91, 4.51) ng/mL and trough concentration 0.41 (0.33, 0.48) to 0.97 (0.56, 1.25) ng/mL for various doses.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],3.61,73446,DB00813,Fentanyl
,30322973,trough concentration,"In IB regimen, median (IQR) peak concentration ranged from 2.21 (1.82, 3.55) to 3.61 (2.91, 4.51) ng/mL and trough concentration 0.41 (0.33, 0.48) to 0.97 (0.56, 1.25) ng/mL for various doses.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],0.41,73447,DB00813,Fentanyl
,30322973,trough concentration,"In IB regimen, median (IQR) peak concentration ranged from 2.21 (1.82, 3.55) to 3.61 (2.91, 4.51) ng/mL and trough concentration 0.41 (0.33, 0.48) to 0.97 (0.56, 1.25) ng/mL for various doses.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],0.97,73448,DB00813,Fentanyl
,30322973,peak concentration (Cmax,"Median (IQR) peak concentration (Cmax, 3.06 (1.09, 4.50) vs 0.78 (0.49, 1.73) ng/mL; p<0.001) was significantly higher and area under concentration-time curve (AUC0-24, 19.6 (10.4, 33.5) vs 13.2 (10.8, 22.6) µg·hour/L; p=0.12) was higher (though not statistically significant) in IB than CI regimen.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],3.06,73449,DB00813,Fentanyl
,30322973,peak concentration (Cmax,"Median (IQR) peak concentration (Cmax, 3.06 (1.09, 4.50) vs 0.78 (0.49, 1.73) ng/mL; p<0.001) was significantly higher and area under concentration-time curve (AUC0-24, 19.6 (10.4, 33.5) vs 13.2 (10.8, 22.6) µg·hour/L; p=0.12) was higher (though not statistically significant) in IB than CI regimen.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[ng] / [ml],0.78,73450,DB00813,Fentanyl
,30322973,area under concentration-time curve (AUC0-24,"Median (IQR) peak concentration (Cmax, 3.06 (1.09, 4.50) vs 0.78 (0.49, 1.73) ng/mL; p<0.001) was significantly higher and area under concentration-time curve (AUC0-24, 19.6 (10.4, 33.5) vs 13.2 (10.8, 22.6) µg·hour/L; p=0.12) was higher (though not statistically significant) in IB than CI regimen.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[h·μg] / [l],19.6,73451,DB00813,Fentanyl
,30322973,area under concentration-time curve (AUC0-24,"Median (IQR) peak concentration (Cmax, 3.06 (1.09, 4.50) vs 0.78 (0.49, 1.73) ng/mL; p<0.001) was significantly higher and area under concentration-time curve (AUC0-24, 19.6 (10.4, 33.5) vs 13.2 (10.8, 22.6) µg·hour/L; p=0.12) was higher (though not statistically significant) in IB than CI regimen.",Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30322973/),[h·μg] / [l],13.2,73452,DB00813,Fentanyl
,24595018,T,The pulmonary and brain effects of fentanyl were mostly recovered from T = 210 min to the end of experiment.,Evaluation of fentanyl disposition and effects in newborn piglets as an experimental model for human neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24595018/),min,210,73771,DB00813,Fentanyl
,25544247,bioavailability,"In the route of administration study (n = 25), mean Cmax values were highest with IV administration, and bioavailability values were: SL, 59%; BU, 78%; and PO, 9%.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),%,59,74754,DB00813,Fentanyl
,25544247,bioavailability,"In the route of administration study (n = 25), mean Cmax values were highest with IV administration, and bioavailability values were: SL, 59%; BU, 78%; and PO, 9%.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),%,78,74755,DB00813,Fentanyl
,25544247,bioavailability,"In the route of administration study (n = 25), mean Cmax values were highest with IV administration, and bioavailability values were: SL, 59%; BU, 78%; and PO, 9%.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),%,9,74756,DB00813,Fentanyl
,25544247,plasma half-time,The absorption across the oral mucosa was associated with a median plasma half-time (time from Cmax to 50% of Cmax) that was 25-fold longer (2.5 hours) with SL versus IV administration (0.1 hours).,Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,2.5,74757,DB00813,Fentanyl
,25544247,plasma half-time,The absorption across the oral mucosa was associated with a median plasma half-time (time from Cmax to 50% of Cmax) that was 25-fold longer (2.5 hours) with SL versus IV administration (0.1 hours).,Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,0.1,74758,DB00813,Fentanyl
,25544247,AUC0-∞,"In the single- and repeated-dose study (n = 38), mean AUC0-∞ was 125.5 h · pg/mL, and Cmax was 35.0 pg/mL, with a median Tmax of 0.8 hours after the administration of a single sufentanil SL tablet.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),[h·pg] / [ml],125.5,74759,DB00813,Fentanyl
,25544247,Cmax,"In the single- and repeated-dose study (n = 38), mean AUC0-∞ was 125.5 h · pg/mL, and Cmax was 35.0 pg/mL, with a median Tmax of 0.8 hours after the administration of a single sufentanil SL tablet.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),[pg] / [ml],35.0,74760,DB00813,Fentanyl
,25544247,Tmax,"In the single- and repeated-dose study (n = 38), mean AUC0-∞ was 125.5 h · pg/mL, and Cmax was 35.0 pg/mL, with a median Tmax of 0.8 hours after the administration of a single sufentanil SL tablet.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,0.8,74761,DB00813,Fentanyl
,25544247,plasma half-time,"Median plasma half-time after the 40th dose was not statistically longer than that after a single dose (2.7 vs 2.2 hours, respectively), and the median Tmax was 0.3 hours after the last repeated dose.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,2.7,74762,DB00813,Fentanyl
,25544247,plasma half-time,"Median plasma half-time after the 40th dose was not statistically longer than that after a single dose (2.7 vs 2.2 hours, respectively), and the median Tmax was 0.3 hours after the last repeated dose.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,2.2,74763,DB00813,Fentanyl
,25544247,Tmax,"Median plasma half-time after the 40th dose was not statistically longer than that after a single dose (2.7 vs 2.2 hours, respectively), and the median Tmax was 0.3 hours after the last repeated dose.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,0.3,74764,DB00813,Fentanyl
,12358654,bioavailability,"Estimated fentanyl bioavailability (mean +/- SD) was low (36.1 +/- 0.4%), as were peak plasma concentrations (1.03 +/- 0.31 ng.ml-1), suggesting that many children swallowed a large fraction of the dose.",Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358654/),%,36.1,75149,DB00813,Fentanyl
,12358654,peak plasma concentrations,"Estimated fentanyl bioavailability (mean +/- SD) was low (36.1 +/- 0.4%), as were peak plasma concentrations (1.03 +/- 0.31 ng.ml-1), suggesting that many children swallowed a large fraction of the dose.",Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358654/),[ng] / [ml],1.03,75150,DB00813,Fentanyl
,12358654,peak concentration time,This led to a relatively late and variable peak concentration time of 53 +/- 40 min.,Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358654/),min,53,75151,DB00813,Fentanyl
,8557005,Onset time for maximum block,"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),s,61,76032,DB00813,Fentanyl
,8557005,duration of clinical relaxation (DUR25),"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),s,65,76033,DB00813,Fentanyl
,8557005,duration of clinical relaxation (DUR25),"Onset time for maximum block and duration of clinical relaxation (DUR25) were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min, respectively, for patients with and without renal failure.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,42,76034,DB00813,Fentanyl
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,0,76035,DB00813,Fentanyl
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,99,76036,DB00813,Fentanyl
,8557005,time for,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,73,76037,DB00813,Fentanyl
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,0,76038,DB00813,Fentanyl
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,99,76039,DB00813,Fentanyl
,8557005,train-of-four ratio to return spontaneously,"The time for train-of-four ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,73,76040,DB00813,Fentanyl
,8557005,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),[ml] / [kg·min],2.5,76041,DB00813,Fentanyl
,8557005,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),[ml] / [kg·min],3.7,76042,DB00813,Fentanyl
,8557005,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,97.1,76043,DB00813,Fentanyl
,8557005,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) mL kg-1 min-1 and 3.7 (1.4) mL kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) (P < 0.05).",Pharmacokinetics of rocuronium bromide in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557005/),min,58.3,76044,DB00813,Fentanyl
,9687342,half-life,"Fentanyl pharmacokinetics with either E-TRANS (fentanyl) or intravenous infusion were time-invariant over a 24-h application period, with similar mean half-life values (about 15-18 h).",Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9687342/),h,15-18,76399,DB00813,Fentanyl
,16156111,corrected AUC(0-5),"No significant difference existed between the corrected AUC(0-5) of the fentanyl HCl PCTS during the single- and multiple-day treatment periods (0.40 and 0.54 microg x h/L, respectively; p = 0.133).",Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156111/),[h·μg] / [l],0.40,77291,DB00813,Fentanyl
,16156111,corrected AUC(0-5),"No significant difference existed between the corrected AUC(0-5) of the fentanyl HCl PCTS during the single- and multiple-day treatment periods (0.40 and 0.54 microg x h/L, respectively; p = 0.133).",Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156111/),[h·μg] / [l],0.54,77292,DB00813,Fentanyl
,14633756,effect-site concentration,"In the sufentanil group, an effect-site concentration of 0.25 ng x ml(-1) was targeted at extubation.","Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),[ng] / [ml],0.25,77731,DB00813,Fentanyl
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,13,77732,DB00813,Fentanyl
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,14,77733,DB00813,Fentanyl
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,55,77734,DB00813,Fentanyl
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,11,77735,DB00813,Fentanyl
,14633756,effect-site concentration,TCI sufentanil (0.25 ng ml(-1) effect-site concentration at extubation) is more effective than the intraoperative combination of remifentanil TCI infusion with morphine bolus (0.15 mg x kg(-1)) for postoperative pain relief after major abdominal surgery and does not compromise extubation and recovery.,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),,0.25,77736,DB00813,Fentanyl
,28504483,absolute bioavailability,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%,55,78197,DB00813,Fentanyl
,28504483,absolute bioavailability,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%,41,78198,DB00813,Fentanyl
,28504483,mean absorption time,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),min,74,78199,DB00813,Fentanyl
,28504483,mean absorption time,"Relative to i.m. naloxone, geometric mean (90% confidence interval [CI]) absolute bioavailability of i.n. naloxone was modestly lower (55%; 90% CI, 43-70% vs. 41%; 90% CI, 27-62%), whereas average (±SE) mean absorption time was substantially shorter (74 ± 8.8 vs. 6.7 ± 4.9 min).",Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),min,6.7,78200,DB00813,Fentanyl
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,40,78201,DB00813,Fentanyl
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,41,78202,DB00813,Fentanyl
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,49,78203,DB00813,Fentanyl
,28504483,miosis,The i.m. and i.n. naloxone attenuated miosis by similar extents after water (40 ± 15 vs. 41 ± 21 h*%) and grapefruit juice (49 ± 18 vs. 50 ± 22 h*%) pretreatment.,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28504483/),%·h,50,78204,DB00813,Fentanyl
,2889555,steady-state volume,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[l] / [kg],0.21,79728,DB00813,Fentanyl
,2889555,clearance,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[ml] / [kg·min],2.9,79729,DB00813,Fentanyl
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),min,100,79730,DB00813,Fentanyl
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[l] / [kg],0.20,79731,DB00813,Fentanyl
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[ml] / [kg·min],3.2,79732,DB00813,Fentanyl
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),min,84,79733,DB00813,Fentanyl
,2889555,Plasma concentrations,Plasma concentrations associated with 50% blockade averaged 0.2 microgram/ml for both groups.,Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[μg] / [ml],0.2,79734,DB00813,Fentanyl
,8657433,duration,"Onset of pain relief was rapid, and duration was approximately 1.5 h with e.p. and 1 h with i.v. alfentanil.",A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8657433/),h,1.5,79795,DB00813,Fentanyl
,8657433,duration,"Onset of pain relief was rapid, and duration was approximately 1.5 h with e.p. and 1 h with i.v. alfentanil.",A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8657433/),h,1,79796,DB00813,Fentanyl
,10235658,distribution half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,37.24,80580,DB00813,Fentanyl
,10235658,elimination half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,482.69,80581,DB00813,Fentanyl
,10235658,clearance,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ml] / [min],1221.97,80582,DB00813,Fentanyl
,10235658,volume of distribution,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),l,736.46,80583,DB00813,Fentanyl
,10235658,plasma BN concentration,"The mean +/- SEM plasma BN concentration during CPB was 0.51+/-0.03 ng/ml which was adequate for the maintenance of analgesia and anaesthesia, as none of our patients expressed the signs and symptoms of awareness during surgery.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ng] / [ml],0.51,80584,DB00813,Fentanyl
,16037150,arterial Pco(2),The median arterial Pco(2) level was 41 mm Hg and the interquartile range was 39-46 mm Hg.,"Preoperative ""fentanyl challenge"" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16037150/),hg·mm,41,80675,DB00813,Fentanyl
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,2.2,80742,DB00813,Fentanyl
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80743,DB00813,Fentanyl
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.3,80744,DB00813,Fentanyl
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80745,DB00813,Fentanyl
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.8,80746,DB00813,Fentanyl
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],1440,80747,DB00813,Fentanyl
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],499,80748,DB00813,Fentanyl
,9349062,clearance,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],425,80749,DB00813,Fentanyl
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,34.9,80750,DB00813,Fentanyl
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,21.9,80751,DB00813,Fentanyl
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00813,Fentanyl
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00813,Fentanyl
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00813,Fentanyl
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00813,Fentanyl
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00813,Fentanyl
,11942870,steady state plasma concentration,The steady state plasma concentration of ketoprofen was 2.0 microg/mL (range 1.3-2.7 microg/mL).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[μg] / [ml],2.0,80847,DB00813,Fentanyl
,11942870,clearance,The clearance of ketoprofen was 0.09 L x h(-1) x kg(-1) (range 0.06-0.13 L x h(-1) x kg(-1)).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[l] / [h·kg],0.09,80848,DB00813,Fentanyl
,11942870,distribution volume,The distribution volume was 0.16 L/kg (range 0.12-0.21 L/kg).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[l] / [kg],0.16,80849,DB00813,Fentanyl
,11942870,terminal half-life,The terminal half-life was 1.3 h (range 0.8-1.7 h).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),h,1.3,80850,DB00813,Fentanyl
,3094407,Cp50,"Plasma alfentanil concentrations required along with 66% N2O to obtain responses to single episodes of stimulation in 50% of the 37 patients (Cp50 +/- SE) were: 475 +/- 28 ng/ml for tracheal intubation, 279 +/- 20 ng/ml for skin incision, and 150 +/- 23 ng/ml for skin closure.",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],475,80857,DB00813,Fentanyl
,3094407,Cp50,"Plasma alfentanil concentrations required along with 66% N2O to obtain responses to single episodes of stimulation in 50% of the 37 patients (Cp50 +/- SE) were: 475 +/- 28 ng/ml for tracheal intubation, 279 +/- 20 ng/ml for skin incision, and 150 +/- 23 ng/ml for skin closure.",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],279,80858,DB00813,Fentanyl
,3094407,Cp50,"Plasma alfentanil concentrations required along with 66% N2O to obtain responses to single episodes of stimulation in 50% of the 37 patients (Cp50 +/- SE) were: 475 +/- 28 ng/ml for tracheal intubation, 279 +/- 20 ng/ml for skin incision, and 150 +/- 23 ng/ml for skin closure.",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],150,80859,DB00813,Fentanyl
,3094407,Cp50,"The Cp50 (mean +/- SD) for the three surgical procedures were: breast, 270 +/- 63 ng/ml (n = 12); lower abdominal, 309 +/- 44 ng/ml (n = 14); and upper abdominal, 412 +/- 135 ng/ml (n = 11).",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],270,80860,DB00813,Fentanyl
,3094407,Cp50,"The Cp50 (mean +/- SD) for the three surgical procedures were: breast, 270 +/- 63 ng/ml (n = 12); lower abdominal, 309 +/- 44 ng/ml (n = 14); and upper abdominal, 412 +/- 135 ng/ml (n = 11).",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],309,80861,DB00813,Fentanyl
,3094407,Cp50,"The Cp50 (mean +/- SD) for the three surgical procedures were: breast, 270 +/- 63 ng/ml (n = 12); lower abdominal, 309 +/- 44 ng/ml (n = 14); and upper abdominal, 412 +/- 135 ng/ml (n = 11).",Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],412,80862,DB00813,Fentanyl
,3094407,Cp50,The Cp50 for satisfactory spontaneous ventilation after the discontinuation of N2O was 223 +/- 13 ng/ml.,Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094407/),[ng] / [ml],223,80863,DB00813,Fentanyl
,33313887,limit of detection,The limit of detection was 3 pg/mL (S/N > 5) for A-F and B-F.,Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),[pg] / [ml],3,81016,DB00813,Fentanyl
>,33313887,S/N,The limit of detection was 3 pg/mL (S/N > 5) for A-F and B-F.,Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),,5,81017,DB00813,Fentanyl
,33313887,Extraction recoveries,"Extraction recoveries were 91.3%-97.6% with RSD ≤ 11.2% and 90.5%-94.3% with RSD ≤ 10.5% for A-F and B-F, respectively.",Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),%,91.,81018,DB00813,Fentanyl
,33313887,Extraction recoveries,"Extraction recoveries were 91.3%-97.6% with RSD ≤ 11.2% and 90.5%-94.3% with RSD ≤ 10.5% for A-F and B-F, respectively.",Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),%,90.5,81019,DB00813,Fentanyl
,33313887,LOD,"This assay, for which the LOD was 3 pg/mL for A-F and B-F may help the forensic science field to determine fentanyl analogue-related causes of death and identify illicit drug tampering.",Alpha-Methylfentanyl and Beta-Hydroxyfentanyl LC-MS-MS Quantification in Rat Plasma after Long-Term Ethanol Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33313887/),[pg] / [ml],3,81020,DB00813,Fentanyl
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,266,81576,DB00813,Fentanyl
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,168,81577,DB00813,Fentanyl
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1201,81578,DB00813,Fentanyl
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1687,81579,DB00813,Fentanyl
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],726,81580,DB00813,Fentanyl
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1331,81581,DB00813,Fentanyl
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2046,81582,DB00813,Fentanyl
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2665,81583,DB00813,Fentanyl
,2876662,terminal half-life (t1/2 beta),"In the pregnant population terminal half-life (t1/2 beta), volume of distribution at steady state (Vdss), and total plasma clearance (Clp) amounted to 103 +/- 67 min, 541 +/- 155 ml/kg and 6.48 +/- 0.85 ml/kg-1/min-1, respectively (mean +/- SD), and did not differ significantly in nonpregnant patients.",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),min,103,81913,DB00813,Fentanyl
,2876662,volume of distribution at steady state (Vdss),"In the pregnant population terminal half-life (t1/2 beta), volume of distribution at steady state (Vdss), and total plasma clearance (Clp) amounted to 103 +/- 67 min, 541 +/- 155 ml/kg and 6.48 +/- 0.85 ml/kg-1/min-1, respectively (mean +/- SD), and did not differ significantly in nonpregnant patients.",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),[ml] / [kg],541,81914,DB00813,Fentanyl
,2876662,total plasma clearance (Clp),"In the pregnant population terminal half-life (t1/2 beta), volume of distribution at steady state (Vdss), and total plasma clearance (Clp) amounted to 103 +/- 67 min, 541 +/- 155 ml/kg and 6.48 +/- 0.85 ml/kg-1/min-1, respectively (mean +/- SD), and did not differ significantly in nonpregnant patients.",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),[ml] / [kg],6.48,81915,DB00813,Fentanyl
,2876662,protein,"In groups A and B the fetal-maternal ratios indicated a concentration gradient for the total plasma alfentanil content (ratio of total alfentanil concentrations in umbilical venous and maternal blood (Uv/M), 0.31 +/- 0.08 and 0.28 +/- 0.06 (mean +/- SD) in groups A and B respectively) with a larger protein binding capacity in maternal plasma (group A, 85 +/- 3%; group B, 90 +/- 1%) (mean +/- SD).",Pharmacokinetics and placental transfer of intravenous and epidural alfentanil in parturient women. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2876662/),%,85,81916,DB00813,Fentanyl
,7880508,Plasma concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.021 to 0.142,82353,DB00813,Fentanyl
,7880508,maximal peak concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.103,82354,DB00813,Fentanyl
,7880508,plasma concentration,The plasma concentration 48 hours after injection varied from 0.026 to 0.074 ng/ml.,Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.026 to 0.074,82355,DB00813,Fentanyl
,760597,t1/2,"However, the terminal elimination phase was prolonged (t1/2 = 199 +/- 17 min).",Pharmacokinetics of 3H-fentanyl in the dog anesthetized with enflurane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760597/),min,199,82872,DB00813,Fentanyl
,760597,apparent volume of distribution,The apparent volume of distribution was large (9.81/kg) and independent of dose.,Pharmacokinetics of 3H-fentanyl in the dog anesthetized with enflurane. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/760597/),1/[kg],9.81,82873,DB00813,Fentanyl
,22128878,C(max),"Following administration of FBSF doses of 200-1200 μg, mean C(max) values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19 ng/mL, respectively.","Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[ng] / [ml],0.383,82940,DB00813,Fentanyl
,22128878,C(max),"Following administration of FBSF doses of 200-1200 μg, mean C(max) values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19 ng/mL, respectively.","Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[ng] / [ml],2.19,82941,DB00813,Fentanyl
,22128878,AUC(last),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],3.001,82942,DB00813,Fentanyl
,22128878,AUC(last),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],19.17,82943,DB00813,Fentanyl
,22128878,AUC(∞),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],3.456,82944,DB00813,Fentanyl
,22128878,AUC(∞),Mean AUC(last) values increased from 3.001 ng·h/mL to 19.17 ng·h/mL and mean AUC(∞) increased in a linear manner from 3.456 ng·h/mL to 20.43 ng·h/mL.,"Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22128878/),[h·ng] / [ml],20.43,82945,DB00813,Fentanyl
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],876,83299,DB00813,Fentanyl
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],420,83300,DB00813,Fentanyl
,17322146,absolute bioavailability,The transmucosal FBT had the highest absolute bioavailability (0.65) compared with the oral FBT (0.31) or transmucosal OTFC (0.47).,Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322146/),,0.65,83498,DB00813,Fentanyl
,17322146,absolute bioavailability,The transmucosal FBT had the highest absolute bioavailability (0.65) compared with the oral FBT (0.31) or transmucosal OTFC (0.47).,Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322146/),,0.31,83499,DB00813,Fentanyl
,17322146,absolute bioavailability,The transmucosal FBT had the highest absolute bioavailability (0.65) compared with the oral FBT (0.31) or transmucosal OTFC (0.47).,Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322146/),,0.47,83500,DB00813,Fentanyl
,17322146,t(max),Median t(max) values were shorter following the transmucosal FBT (47 minutes) than the oral FBT (90 minutes) or the transmucosal OTFC (91 minutes).,Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322146/),min,47,83501,DB00813,Fentanyl
,17322146,t(max),Median t(max) values were shorter following the transmucosal FBT (47 minutes) than the oral FBT (90 minutes) or the transmucosal OTFC (91 minutes).,Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322146/),min,90,83502,DB00813,Fentanyl
,17322146,t(max),Median t(max) values were shorter following the transmucosal FBT (47 minutes) than the oral FBT (90 minutes) or the transmucosal OTFC (91 minutes).,Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322146/),min,91,83503,DB00813,Fentanyl
,2885190,systemic clearance,"However, there was a greater systemic clearance (P = 0.02) when determined using the post-infusion decay data compared with that calculated during anaesthesia (527 ml min-1 compared with 434 ml min-1).",Alfentanil infusions: relationship between pharmacokinetics and pharmacodynamics in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885190/),[ml] / [min],527,83692,DB00813,Fentanyl
,2885190,systemic clearance,"However, there was a greater systemic clearance (P = 0.02) when determined using the post-infusion decay data compared with that calculated during anaesthesia (527 ml min-1 compared with 434 ml min-1).",Alfentanil infusions: relationship between pharmacokinetics and pharmacodynamics in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885190/),[ml] / [min],434,83693,DB00813,Fentanyl
,8533912,central volume of distribution,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,14.3,83996,DB00813,Fentanyl
,8533912,volume,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,63.1,83997,DB00813,Fentanyl
,8533912,volume,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,261.6,83998,DB00813,Fentanyl
,8533912,steady-state distribution volume,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,339,83999,DB00813,Fentanyl
,8533912,metabolic clearance,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),[l] / [min],0.92,84000,DB00813,Fentanyl
,8533912,distribution clearance,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),[l] / [min],1.55,84001,DB00813,Fentanyl
,8533912,distribution clearance,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),[l] / [min],0.33,84002,DB00813,Fentanyl
,8533912,elimination half-life,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),min,769,84003,DB00813,Fentanyl
,2748192,delay time,There was a mean (S.D.) delay time of 12.7 (9.6) h before minimum effective blood fentanyl concentrations (MEC) were obtained from the systems and pseudo-steady state was reached between 36 and 48 h.,The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748192/),h,12.7,84211,DB00813,Fentanyl
,2748192,decay time,There was a decay time of 16.1 (7.1) h after the systems were removed for the blood fentanyl concentration to decrease to less than the mean MEC for the control of postoperative pain.,The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748192/),h,16.1,84212,DB00813,Fentanyl
,2501060,Elimination half-life,Elimination half-life increased significantly (p less than 0.01) after 7 days from the control value of 84.0 +/- 8.2 minutes to 131.4 +/- 43.5 minutes.,Inhibition of alfentanil metabolism by erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),min,84.0,84269,DB00813,Fentanyl
,2501060,Elimination half-life,Elimination half-life increased significantly (p less than 0.01) after 7 days from the control value of 84.0 +/- 8.2 minutes to 131.4 +/- 43.5 minutes.,Inhibition of alfentanil metabolism by erythromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),min,131.4,84270,DB00813,Fentanyl
,2501060,Clearance,Clearance was decreased significantly (p less than 0.05) from 3.9 +/- 0.8 ml/kg/min to 2.9 +/- 1.2 ml/kg/min after 7 days.,Inhibition of alfentanil metabolism by erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),[ml] / [kg·min],3.9,84271,DB00813,Fentanyl
,2501060,Clearance,Clearance was decreased significantly (p less than 0.05) from 3.9 +/- 0.8 ml/kg/min to 2.9 +/- 1.2 ml/kg/min after 7 days.,Inhibition of alfentanil metabolism by erythromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501060/),[ml] / [kg·min],2.9,84272,DB00813,Fentanyl
,29996718,rate,Median fentanyl rate of 100 µg/h was transitioned to 1 mg/h of hydromorphone.,Transition From Continuous Infusion Fentanyl to Hydromorphone in Critically Ill Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29996718/),[μg] / [h],100,84321,DB00813,Fentanyl
≥,28724494,effective plasma concentrations,"We hypothesized that TFS in rhesus macaques would provide at least 4 d of effective plasma concentrations (assumed to be ≥ 0.2 ng/mL, based on human studies).","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[ng] / [ml],0.2,85804,DB00813,Fentanyl
,28724494,maximal plasma concentration,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[ng] / [ml],1.95,85805,DB00813,Fentanyl
,28724494,maximal plasma concentration,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[ng] / [ml],4.19,85806,DB00813,Fentanyl
,28724494,AUC,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[h] / [ml·ng],227.3,85807,DB00813,Fentanyl
,28724494,AUC,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),[h] / [ml·ng],447.0,85808,DB00813,Fentanyl
,28724494,terminal elimination half-life,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),h,93.7,85809,DB00813,Fentanyl
,28724494,terminal elimination half-life,"For each dose (1.3 and 2.6 mg/kg), respectively, the maximal plasma concentration was 1.95 ± 0.40 and 4.19 ± 0.69 ng/mL, occurring at 21.3 ± 4.1 and 30.7 ± 8.7 h; the AUC was 227.3 ± 31.7 and 447.0 ± 49.1 h/ng/mL, and the terminal elimination half-life was 93.7 ± 7.1 and 98.8 ± 5.4 h.","Pharmacokinetics of a Novel, Transdermal Fentanyl Solution in Rhesus Macaques (Macaca mulatta). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28724494/),h,98.8,85810,DB00813,Fentanyl
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00813,Fentanyl
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00813,Fentanyl
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00813,Fentanyl
,3921471,elimination half-life,The kinetics of the analgesic can be described by a two-compartment model; the elimination half-life has a mean value of 64.8 +/- 38.5 min.,Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921471/),min,64.8,86281,DB00813,Fentanyl
,3921471,elimination half-life,The mean elimination half-life is 29.4 +/- 6.2 min.,Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921471/),min,29.4,86282,DB00813,Fentanyl
,25904383,t1/2 MRT,"Both elimination half-life of fentanyl (t1/2, MRT ) and mean residence time (MRT) were much longer than those observed after single IV bolus dose, and longer in Group I than in Group II (t1/2 MRT 15.9 [3.6-31.5] h vs 8.0 [7.1-13.3] h, P < 0.05, MRTstop-last 22.9 [5.1-45.5] h vs 11.5 [10.2-19.1] h, P < 0.05).",Fentanyl with ropivacaine infusion for postoperative pain relief in infants and children. Kinetics of epidural fentanyl. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25904383/),h,15.9,86705,DB00813,Fentanyl
,25904383,t1/2 MRT,"Both elimination half-life of fentanyl (t1/2, MRT ) and mean residence time (MRT) were much longer than those observed after single IV bolus dose, and longer in Group I than in Group II (t1/2 MRT 15.9 [3.6-31.5] h vs 8.0 [7.1-13.3] h, P < 0.05, MRTstop-last 22.9 [5.1-45.5] h vs 11.5 [10.2-19.1] h, P < 0.05).",Fentanyl with ropivacaine infusion for postoperative pain relief in infants and children. Kinetics of epidural fentanyl. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25904383/),h,8.0,86706,DB00813,Fentanyl
,25904383,MRTstop-last,"Both elimination half-life of fentanyl (t1/2, MRT ) and mean residence time (MRT) were much longer than those observed after single IV bolus dose, and longer in Group I than in Group II (t1/2 MRT 15.9 [3.6-31.5] h vs 8.0 [7.1-13.3] h, P < 0.05, MRTstop-last 22.9 [5.1-45.5] h vs 11.5 [10.2-19.1] h, P < 0.05).",Fentanyl with ropivacaine infusion for postoperative pain relief in infants and children. Kinetics of epidural fentanyl. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25904383/),h,22.9,86707,DB00813,Fentanyl
,25904383,MRTstop-last,"Both elimination half-life of fentanyl (t1/2, MRT ) and mean residence time (MRT) were much longer than those observed after single IV bolus dose, and longer in Group I than in Group II (t1/2 MRT 15.9 [3.6-31.5] h vs 8.0 [7.1-13.3] h, P < 0.05, MRTstop-last 22.9 [5.1-45.5] h vs 11.5 [10.2-19.1] h, P < 0.05).",Fentanyl with ropivacaine infusion for postoperative pain relief in infants and children. Kinetics of epidural fentanyl. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25904383/),h,11.5,86708,DB00813,Fentanyl
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.90,86872,DB00813,Fentanyl
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.24,86873,DB00813,Fentanyl
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],3.19,86874,DB00813,Fentanyl
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],2.84,86875,DB00813,Fentanyl
,1982140,Renal blood flow,"Renal blood flow in rats anaesthetized with the combination alphaxolone/alphadolone (3.90 mL min-1 (g tissue)-1) was significantly (P less than 0.05) greater than in rats anaesthetized with ketamine midazolam (3.24 mL min-1 (g tissue)-1, pentobarbitone (3.19 mL min-1 (g tissue)-1), fentanyl/fluanisone midazolam (2.84 mL min-1 (g tissue)-1) or urethane (1.99 mL min-1 (g tissue)-1).",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [min],1.99,86876,DB00813,Fentanyl
,1982140,blood flow,"Hepatosplanchnic blood flow was highest in the alphaxolone/alphadolone anaesthetized animals (71.7 mL min-1 kg-1), with the urethane anaesthetized animals demonstrating a significantly (P less than 0.05) lower (33.4 mL min-1 kg-1) blood flow.",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [kg·min],71.7,86877,DB00813,Fentanyl
,1982140,blood flow,"Hepatosplanchnic blood flow was highest in the alphaxolone/alphadolone anaesthetized animals (71.7 mL min-1 kg-1), with the urethane anaesthetized animals demonstrating a significantly (P less than 0.05) lower (33.4 mL min-1 kg-1) blood flow.",Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1982140/),[ml] / [kg·min],33.4,86878,DB00813,Fentanyl
,29803320,duration of examination,The average duration of examination were 2.9 ± 1.4 min for EGD and 6.6 ± 2.7 min for colonoscopy.,Plasma concentration based response surface model predict better than effect-site concentration based model for wake-up time during gastrointestinal endoscopy sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803320/),min,2.9,86879,DB00813,Fentanyl
,29803320,duration of examination,The average duration of examination were 2.9 ± 1.4 min for EGD and 6.6 ± 2.7 min for colonoscopy.,Plasma concentration based response surface model predict better than effect-site concentration based model for wake-up time during gastrointestinal endoscopy sedation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29803320/),min,6.6,86880,DB00813,Fentanyl
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],88,88198,DB00813,Fentanyl
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],116,88199,DB00813,Fentanyl
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],130,88200,DB00813,Fentanyl
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.13,88201,DB00813,Fentanyl
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.48,88202,DB00813,Fentanyl
,10951986,Arterial pH,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),units,7.46,88942,DB00813,Fentanyl
,10951986,Paco2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),units,751,88943,DB00813,Fentanyl
,10951986,Paco2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,29.2,88944,DB00813,Fentanyl
,10951986,Pao2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,34.6,88945,DB00813,Fentanyl
,10951986,Pao2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,412.6,88946,DB00813,Fentanyl
,10951986,Pao2,"Arterial pH, Paco2, and Pao2 ranged from 7.46 +/- 0.04 to 751 +/- 0.05 units, 29.2 +/- 3 to 34.6 +/- 4.4 mm Hg, and 412.6 +/- 105.3 to 482.9 +/- 71.2 mm Hg, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),hg·mm,482.9,88947,DB00813,Fentanyl
,10951986,clearance,"The clearance, volume of distribution area, volume of distribution steady state, mean residence time, area under the curve, elimination rate constant, and half-life were 32.5 +/- 2.48 ml/kg/min, 9.04 +/- 1.91 L/kg, 70 +/- 1.2 L/kg, 218.5 +/- 35.5 min, 0.247 +/- 0.019 mg/ml/min, 0.004 + 0.001/min, and 192.0 +/- 33.5 min, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),[ml] / [kg·min],32.5,88948,DB00813,Fentanyl
,10951986,half-life,"The clearance, volume of distribution area, volume of distribution steady state, mean residence time, area under the curve, elimination rate constant, and half-life were 32.5 +/- 2.48 ml/kg/min, 9.04 +/- 1.91 L/kg, 70 +/- 1.2 L/kg, 218.5 +/- 35.5 min, 0.247 +/- 0.019 mg/ml/min, 0.004 + 0.001/min, and 192.0 +/- 33.5 min, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),1/[min],0.004,88949,DB00813,Fentanyl
,10951986,half-life,"The clearance, volume of distribution area, volume of distribution steady state, mean residence time, area under the curve, elimination rate constant, and half-life were 32.5 +/- 2.48 ml/kg/min, 9.04 +/- 1.91 L/kg, 70 +/- 1.2 L/kg, 218.5 +/- 35.5 min, 0.247 +/- 0.019 mg/ml/min, 0.004 + 0.001/min, and 192.0 +/- 33.5 min, respectively.",Pharmacokinetics and cardiopulmonary effects of fentanyl in isoflurane-anesthetized rhesus monkeys (Macaca mulatta). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10951986/),min,192.0,88950,DB00813,Fentanyl
,22584544,absolute bioavailability,The mean absolute bioavailability of the sublingual fentanyl wafer was 78.9% (90% confidence interval [CI] 51.1% to 121.7%).,A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584544/),%,78.9,89004,DB00813,Fentanyl
,22584544,first detectable plasma fentanyl concentration time,"The first detectable plasma fentanyl concentration time ranged from 2 to 10 minutes in all volunteers, and the mean (±SD) time to peak plasma concentration at 0.91 (±0.73) hours after administration.",A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584544/),min,2 to 10,89005,DB00813,Fentanyl
,22584544,time to peak plasma concentration,"The first detectable plasma fentanyl concentration time ranged from 2 to 10 minutes in all volunteers, and the mean (±SD) time to peak plasma concentration at 0.91 (±0.73) hours after administration.",A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584544/),h,0.91,89006,DB00813,Fentanyl
,22584544,absolute bioavailability,The absolute bioavailability of 78.9% indicated a high systemic availability of fentanyl and suggests that further development of this wafer is justified.,A phase I pharmacokinetic and bioavailability study of a sublingual fentanyl wafer in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584544/),%,78.9,89007,DB00813,Fentanyl
,8489055,Cp50,"The Cp50 for fentanyl was 3.26 ng/ml, and the Cp50-BAR was 4.17 ng/ml.","Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489055/),[ng] / [ml],3.26,89419,DB00813,Fentanyl
,8489055,Cp50-BAR,"The Cp50 for fentanyl was 3.26 ng/ml, and the Cp50-BAR was 4.17 ng/ml.","Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489055/),[ng] / [ml],4.17,89420,DB00813,Fentanyl
,20297611,T(max),"Median T(max) values were 15, 12, and 15 minutes for the 50, 100, and 200 microg doses of INFS, respectively.",Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297611/),min,15,89532,DB00813,Fentanyl
,20297611,T(max),"Median T(max) values were 15, 12, and 15 minutes for the 50, 100, and 200 microg doses of INFS, respectively.",Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297611/),min,12,89533,DB00813,Fentanyl
,20297611,C(max),"Mean (SD) values for C(max) were 351 (+/- 226), 595 (+/- 400), and 1195 (+/- 700) pg/mL, respectively, indicating dose-proportionality.",Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297611/),[pg] / [ml],351,89534,DB00813,Fentanyl
,20297611,C(max),"Mean (SD) values for C(max) were 351 (+/- 226), 595 (+/- 400), and 1195 (+/- 700) pg/mL, respectively, indicating dose-proportionality.",Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297611/),[pg] / [ml],595,89535,DB00813,Fentanyl
,20297611,C(max),"Mean (SD) values for C(max) were 351 (+/- 226), 595 (+/- 400), and 1195 (+/- 700) pg/mL, respectively, indicating dose-proportionality.",Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20297611/),[pg] / [ml],1195,89536,DB00813,Fentanyl
,8638836,CLc,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[l] / [min],2.9,90497,DB00813,Fentanyl
,8638836,VDss,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),,21.81,90498,DB00813,Fentanyl
,8638836,terminal half-life,"The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l x min(-1), a VDss of 21.81, and a terminal half-life of 35.1 min.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,35.1,90499,DB00813,Fentanyl
,8638836,T(12)k(e0),"Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,0.75,90500,DB00813,Fentanyl
,8638836,T(12)k(e0),"Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T(12)k(e0) for remifentanil of 0.75 min [corrected] and 0.96 min for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),min,0.96,90501,DB00813,Fentanyl
,8638836,effective concentration for 50% maximal effect,"However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[ng] / [ml],19.9,90502,DB00813,Fentanyl
,8638836,effective concentration for 50% maximal effect,"However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng x ml(-1) versus 375.9 ng x ml(-1) for alfentanil.",Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638836/),[ng] / [ml],375.9,90503,DB00813,Fentanyl
,16616769,t(1/2),"Both the uncompetitive NMDA antagonist ketamine and the glycine(B) antagonist MRZ 2/576 inhibited neuronal responses to iontophoretic NMDA in anaesthetised rats with the time course consistent with their known pharmacokinetics (t(1/2) approximately 10-12min, similar in control and nerve-injured rats).",The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616769/),min,10-12,90636,DB00813,Fentanyl
,3766095,body clearance,"After administration of intravenous morphine the plasma concentration-time curve fitted a 3-compartment model (body clearance = 84 +/- 23 ml/min/kg, mean +/- s.d., N = 5), while after fentanyl the plasma concentration-time curve was best described by a 2-compartment model (body clearance = 3.9-5.8 ml/min/kg, N = 3].","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [kg·min],84,91626,DB00813,Fentanyl
,3766095,body clearance,"After administration of intravenous morphine the plasma concentration-time curve fitted a 3-compartment model (body clearance = 84 +/- 23 ml/min/kg, mean +/- s.d., N = 5), while after fentanyl the plasma concentration-time curve was best described by a 2-compartment model (body clearance = 3.9-5.8 ml/min/kg, N = 3].","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [kg·min],3.9-5.8,91627,DB00813,Fentanyl
,3766095,elimination rates,"After intrathecal injection the elimination rates of the opioids from CSF were 0.3 to 2.0 and 0.6 to 2.4 ml/h/kg for morphine and fentanyl, respectively (N = 3).","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [h·kg],0.3 to 2.0,91628,DB00813,Fentanyl
,3766095,elimination rates,"After intrathecal injection the elimination rates of the opioids from CSF were 0.3 to 2.0 and 0.6 to 2.4 ml/h/kg for morphine and fentanyl, respectively (N = 3).","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),[ml] / [h·kg],0.6 to 2.4,91629,DB00813,Fentanyl
,3766095,time to reach maximum CSF concentration,The time to reach maximum CSF concentration after epidural administration was 0.22 +/- 0.14 h for morphine (N = 6) and 0.22 +/- 0.13 h for fentanyl (N = 8).,"Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),h,0.22,91630,DB00813,Fentanyl
,3766095,time to reach maximum CSF concentration,The time to reach maximum CSF concentration after epidural administration was 0.22 +/- 0.14 h for morphine (N = 6) and 0.22 +/- 0.13 h for fentanyl (N = 8).,"Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),h,0.22,91631,DB00813,Fentanyl
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,2.3,91632,DB00813,Fentanyl
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,11.3,91633,DB00813,Fentanyl
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,0.8,91634,DB00813,Fentanyl
,3766095,CSF availability,"In the same goat the CSF availability was 2.3 and 11.3% for morphine and 0.8 and 3.3% for fentanyl following epidural administration of the low and high doses, respectively.","Pharmacokinetics of intravenous, intrathecal and epidural morphine and fentanyl in the goat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766095/),%,3.3,91635,DB00813,Fentanyl
,2529048,AUC0-120 min,The AUC0-120 min after intranasal dosing was 78 per cent of that after intravenous injection.,Comparison of intravenous and intranasal sufentanil absorption and sedation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529048/),%,78,91638,DB00813,Fentanyl
,3118743,Vdss,"The mean value of Vdss was 0.419 (SE .028) l.kg-1) for the whole group, and elimination t1/2 was 76.3 (SE 6.5) min.",The pharmacokinetics of alfentanil in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118743/),[l] / [kg],0.419,92347,DB00813,Fentanyl
,3118743,elimination t1/2,"The mean value of Vdss was 0.419 (SE .028) l.kg-1) for the whole group, and elimination t1/2 was 76.3 (SE 6.5) min.",The pharmacokinetics of alfentanil in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118743/),min,76.3,92348,DB00813,Fentanyl
,3118743,clearance rate [TBC,The clearance rate [TBC = 7.9 (SE 0.41) ml.kg-1.min-1] was within the range of values previously determined in adult studies.,The pharmacokinetics of alfentanil in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3118743/),[ml] / [kg·min],7.9,92349,DB00813,Fentanyl
,28510304,CL1,The typical values of systemic clearance scaled to a 70-kg patient for the 2 subpopulations were CL1 = 52.6 L/h and CL2 = 158 L/h.,Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),[l] / [h],52.6,92457,DB00813,Fentanyl
,28510304,CL2,The typical values of systemic clearance scaled to a 70-kg patient for the 2 subpopulations were CL1 = 52.6 L/h and CL2 = 158 L/h.,Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),[l] / [h],158,92458,DB00813,Fentanyl
,28510304,Hill coefficient,The parameters of the Hill function were 54.9 weeks for the postmenstrual age of 50% clearance maturation and 0.802 for the Hill coefficient.,Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),,0.802,92459,DB00813,Fentanyl
,28510304,Q,"The typical values of distribution clearance and volumes of the central and peripheral compartments for a patient with a weight of 70 kg were Q = 40.5 L/h, VC = 7.63 L, and VT = 473 L, respectively.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),[l] / [h],40.5,92460,DB00813,Fentanyl
,28510304,VC,"The typical values of distribution clearance and volumes of the central and peripheral compartments for a patient with a weight of 70 kg were Q = 40.5 L/h, VC = 7.63 L, and VT = 473 L, respectively.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),l,7.63,92461,DB00813,Fentanyl
,28510304,VT,"The typical values of distribution clearance and volumes of the central and peripheral compartments for a patient with a weight of 70 kg were Q = 40.5 L/h, VC = 7.63 L, and VT = 473 L, respectively.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),l,473,92462,DB00813,Fentanyl
,28510304,absorption rate constant,"The value of the absorption rate constant from the epidural space was 0.0459/h, which suggests flip-flop pharmacokinetics of sufentanil after epidural administration.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),1/[h],0.0459,92463,DB00813,Fentanyl
,16861093,Total systemic exposure,"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93003,DB00813,Fentanyl
,16861093,Total systemic exposure,"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93004,DB00813,Fentanyl
,16861093,AUC(0-infinity)),"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93005,DB00813,Fentanyl
,16861093,AUC(0-infinity)),"Total systemic exposure (as measured using AUC(0-infinity))) was statistically similar between FEBT 1,080 microg and OTFC 1,600 microg (mean [SD], 18.0 [5.4] vs 18.0 [7.1] ng x h/mL).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],18.0,93006,DB00813,Fentanyl
,16861093,C(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[ng] / [ml],2.7,93007,DB00813,Fentanyl
,16861093,C(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[ng] / [ml],2.2,93008,DB00813,Fentanyl
,16861093,T(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),h,1.0,93009,DB00813,Fentanyl
,16861093,T(max),"However, the mean (SD) C(max) with FEBT 1,080 microg was 2.7 (0.9) ng/mL compared with 2.2 (0.7) ng/mL with OTFC 1,600 microg (P = NS), and the T(max) of 1.0 hour with FEBT was significantly less compared with OTFC (2.0 hours; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),h,2.0,93010,DB00813,Fentanyl
,16861093,AUC(0-Tmax'),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],810,93011,DB00813,Fentanyl
,16861093,AUC(0-Tmax'),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],1.5,93012,DB00813,Fentanyl
,16861093,AUC(0-Tmax'),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],0.8,93013,DB00813,Fentanyl
,16861093,AUC from time 0 to 1 hour,"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],1.5,93014,DB00813,Fentanyl
,16861093,T(max),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],810,93015,DB00813,Fentanyl
,16861093,T(max),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],1.5,93016,DB00813,Fentanyl
,16861093,T(max),"Similarly, mean (SD) early systemic exposure (AUC(0-Tmax'); ie, AUC from time 0 to 1 hour the median T(max) of the reference dose of FEBT [810 microg]) was significantly greater with FEBT compared with OTFC (1.5 [0.5] vs 0.8 [0.4] ng x h/mL; P < 0.001).","Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861093/),[h·ng] / [ml],0.8,93017,DB00813,Fentanyl
,3099603,Total apparent volume of distribution (Vdss),Total apparent volume of distribution (Vdss) was 457 +/- 160 ml/kg in adults and 163 +/- 110 ml/kg in children (P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),[ml] / [kg],457,94559,DB00813,Fentanyl
,3099603,Total apparent volume of distribution (Vdss),Total apparent volume of distribution (Vdss) was 457 +/- 160 ml/kg in adults and 163 +/- 110 ml/kg in children (P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),[ml] / [kg],163,94560,DB00813,Fentanyl
,3099603,Terminal elimination half-life,Terminal elimination half-life was significantly shorter in children (40 +/- 9 min) than in adults (97 +/- 22 min; P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),min,40,94561,DB00813,Fentanyl
,3099603,Terminal elimination half-life,Terminal elimination half-life was significantly shorter in children (40 +/- 9 min) than in adults (97 +/- 22 min; P less than 0.01).,A comparison of alfentanil pharmacokinetics in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099603/),min,97,94562,DB00813,Fentanyl
,27027704,MACBAR,"Mean ± SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 ± 0.28% and 1.79 ± 0.35%, respectively; no significant difference was found between the 2 treatments.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),%,1.70,94698,DB00813,Fentanyl
,27027704,MACBAR,"Mean ± SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 ± 0.28% and 1.79 ± 0.35%, respectively; no significant difference was found between the 2 treatments.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),%,1.79,94699,DB00813,Fentanyl
,27027704,steady-state concentration,"Plasma concentration of fentanyl reached a median steady-state concentration of 1.69 ng/mL (interquartile range [25th to 75th percentile], 1.47 to 1.79 ng/mL), which was maintained throughout the study.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),[ng] / [ml],1.69,94700,DB00813,Fentanyl
,9447861,peak concentrations,"Mean peak concentrations occurred 20-30 min later and ranged from 61-174 ng/ml, related to the dose administered.",Oral transmucosal etomidate in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447861/),[ng] / [ml],61-174,95276,DB00813,Fentanyl
,23895731,volume of distribution at steady-state,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95847,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.25,95848,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,2.18,95849,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,18.6,95850,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95851,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95852,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95853,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95854,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95855,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95856,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95857,DB00813,Fentanyl
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95858,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95859,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95860,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95861,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95862,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95863,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95864,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95865,DB00813,Fentanyl
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95866,DB00813,Fentanyl
,8723888,steady-state concentrations,The transdermal fentanyl patch produced average steady-state concentrations of 1.6 ng/ml.,Disposition of transdermally administered fentanyl in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723888/),[ng] / [ml],1.6,96181,DB00813,Fentanyl
,8723888,rate of delivery,"The actual rate of delivery of transdermal fentanyl was 35.7 (range, 13.7 to 49.8) micrograms/h, which represented 71.48% (range, 27.45 to 99.56%) of the theoretical rate of delivery.",Disposition of transdermally administered fentanyl in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723888/),[μg] / [h],35.7,96182,DB00813,Fentanyl
,8723888,elimination half-life,The mean elimination half-life of fentanyl after patch removal was 1.39 hours.,Disposition of transdermally administered fentanyl in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723888/),h,1.39,96183,DB00813,Fentanyl
,3661922,S-Thiop,Before stopping the infusion after 18/17 min (SD 8/5) (male/female) S-Thiop was (mean (SD) range) 16.0/12.4 (4.6/5.7) 5.9-26.8/5.1-26.6 mg/l; after stop of the infusion 12.8/10.5 (4.5/5.3) 7.6-25.5/4.5-23.4 mg/l. Patients reacted to verbal command after 11.5 (10.3) 11-81 min.,"[Serum thiopental values, spontaneous frontal muscle electromyography activity and compressed EEG amplitudes and frequency values in thiopental infusion anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661922/),[mg] / [l],16,96222,DB00813,Fentanyl
,3661922,S-Thiop,Before stopping the infusion after 18/17 min (SD 8/5) (male/female) S-Thiop was (mean (SD) range) 16.0/12.4 (4.6/5.7) 5.9-26.8/5.1-26.6 mg/l; after stop of the infusion 12.8/10.5 (4.5/5.3) 7.6-25.5/4.5-23.4 mg/l. Patients reacted to verbal command after 11.5 (10.3) 11-81 min.,"[Serum thiopental values, spontaneous frontal muscle electromyography activity and compressed EEG amplitudes and frequency values in thiopental infusion anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661922/),[mg] / [l],12,96223,DB00813,Fentanyl
,17446147,flow-rate,"Chromatographic separation was performed on a BDS HYPERSIL C18 column (250 mmx4.6 mm, 5.0 microm, Thermo electron corporation, USA) with the mobile phase consisting of 30 mM ammonium acetate (0.4% formic acid)-acetonitrile (64:36, v/v) at a flow-rate of 1.2 mL min(-1).",Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446147/),[ml] / [min],1.2,97403,DB00813,Fentanyl
,17446147,total run time,The total run time was 5.8 min for each sample.,Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446147/),min,5.8,97404,DB00813,Fentanyl
,17446147,limit of quantification,The limit of quantification was 1.0 ng mL(-1).,Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446147/),[ng] / [ml],1.0,97405,DB00813,Fentanyl
above,17446147,extraction recovery,The extraction recovery was above 83.3%.,Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446147/),%,83.3,97406,DB00813,Fentanyl
higher,17446147,recovery,The methodology recovery was higher than 93.8%.,Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17446147/),%,93.8,97407,DB00813,Fentanyl
,17228596,elimination half-life,"The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),h,1,97416,DB00813,Fentanyl
,17228596,volume of distribution at steady state,"The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),[l] / [bwt·kg],0.37,97417,DB00813,Fentanyl
,17228596,volume of distribution at steady state,"The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),[l] / [bwt·kg],0.26,97418,DB00813,Fentanyl
,17228596,elimination half-life,"The elimination half-life of PMA was 2 and 1.5 h in awake and anaesthetised horses, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),h,2,97419,DB00813,Fentanyl
,17228596,elimination half-life,"The elimination half-life of PMA was 2 and 1.5 h in awake and anaesthetised horses, respectively.",Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17228596/),h,1.5,97420,DB00813,Fentanyl
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],182,97918,DB00813,Fentanyl
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],48,97919,DB00813,Fentanyl
,8818989,total volume of distribution,"In addition, endotoxin raised the total volume of distribution of alfentanil from 0.70 to 1.4 L/kg.",Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818989/),[l] / [kg],0.70,98093,DB00813,Fentanyl
,8818989,total volume of distribution,"In addition, endotoxin raised the total volume of distribution of alfentanil from 0.70 to 1.4 L/kg.",Influence of Escherichia coli endotoxin on the pharmacokinetics and respiratory depressant effect of alfentanil in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818989/),[l] / [kg],1.4,98094,DB00813,Fentanyl
,23736084,mean absorption,"The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively).",Chronological age affects the permeation of fentanyl through human skin in vitro. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736084/),[ng] / [cm(2],"3,100",98319,DB00813,Fentanyl
,23736084,mean absorption,"The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively).",Chronological age affects the permeation of fentanyl through human skin in vitro. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736084/),[ng] / [cm(2],"2,000",98320,DB00813,Fentanyl
,23736084,mean absorption,"The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively).",Chronological age affects the permeation of fentanyl through human skin in vitro. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736084/),[ng] / [cm(2],"1,475",98321,DB00813,Fentanyl
,23736084,AUC,"The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively).",Chronological age affects the permeation of fentanyl through human skin in vitro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736084/),ng,"9,393",98322,DB00813,Fentanyl
,23736084,AUC,"The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively).",Chronological age affects the permeation of fentanyl through human skin in vitro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736084/),ng,"5,922",98323,DB00813,Fentanyl
,23736084,AUC,"The youngest group had a significantly higher mean absorption (3,100 ng/cm(2)) than the two other groups (2,000 and 1,475 ng/cm(2), respectively) and a significant larger AUC (young age group: 9,393 ng; middle and old age groups: 5,922 and 4,050 ng, respectively).",Chronological age affects the permeation of fentanyl through human skin in vitro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736084/),ng,"4,050",98324,DB00813,Fentanyl
,28358614,elimination half-life,"For all birds, harmonic mean of elimination half-life was 7.2 ± 3.7 hours and showed less individual variation than the other pharmacokinetic parameters.",Plasma Concentrations of Fentanyl Achieved With Transdermal Application in Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28358614/),h,7.2,98332,DB00813,Fentanyl
,16720675,plasma concentrations,"Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1).",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],1,98342,DB00813,Fentanyl
,16720675,plasma concentrations,"Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1).",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],8,98343,DB00813,Fentanyl
,16720675,plasma concentrations,"Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1).",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],16,98344,DB00813,Fentanyl
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],0,98345,DB00813,Fentanyl
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],0.72,98346,DB00813,Fentanyl
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],8.43,98347,DB00813,Fentanyl
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),[ng] / [ml],13.31,98348,DB00813,Fentanyl
,16720675,plasma concentrations,"Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),,8,98349,DB00813,Fentanyl
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.57,98350,DB00813,Fentanyl
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.51,98351,DB00813,Fentanyl
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.41,98352,DB00813,Fentanyl
,16720675,MAC,"The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively.",The effects of i.v. fentanyl administration on the minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720675/),%,1.37,98353,DB00813,Fentanyl
,31498775,Volume of distribution,Volume of distribution changed linearly with bodyweight and was 8.7 L/kg.,Rapidly maturing fentanyl clearance in preterm neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31498775/),[l] / [kg],8.7,98450,DB00813,Fentanyl
,24120713,C(max),"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),[pg] / [ml],"1,748",98599,DB00813,Fentanyl
,24120713,C(max),"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),[pg] / [ml],"1,485",98600,DB00813,Fentanyl
,24120713,C(max),"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),[pg] / [ml],"1,051",98601,DB00813,Fentanyl
,24120713,AUC(0-1h),"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),[h·pg] / [ml],"1,012",98602,DB00813,Fentanyl
,24120713,AUC(0-1h),"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),[h·pg] / [ml],944,98603,DB00813,Fentanyl
,24120713,AUC(0-1h),"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),[h·pg] / [ml],665,98604,DB00813,Fentanyl
,24120713,tmax,"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),h,0.25,98605,DB00813,Fentanyl
,24120713,tmax,"Administration of both 400 μg regimens (4 × 100 μg and 1 × 400 μg) provided greater systemic fentanyl exposure compared with the 200 μg dose (C(max): 1,748 and 1,485 pg/ml vs. 1,051 pg/ml; AUC(0-1h): 1,012 and 944 pg×h/ml vs. 665 pg×h/ml; and tmax: 0.25 hours and 0.50 hours vs. 0.25 hours); fentanyl exposure after 4 × 100 μg and 1 × 400 μg regimens was similar.",A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120713/),h,0.50,98606,DB00813,Fentanyl
,23480028,clearance,"In the clinical trial, fentanyl clearance was 18.8 ± 8.2 mL/min.",Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480028/),[ml] / [min],18.8,99004,DB00813,Fentanyl
,23480028,clearance,"During rifampicin, fentanyl clearance was 15.0 ± 4.4 mL/min/kg in SLCO1B1*1a and 16.7 ± 5.9 mL/min/kg in SLCO1B1*15 carriers (p > 0.5).",Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480028/),[ml] / [kg·min],15.0,99005,DB00813,Fentanyl
,23480028,clearance,"During rifampicin, fentanyl clearance was 15.0 ± 4.4 mL/min/kg in SLCO1B1*1a and 16.7 ± 5.9 mL/min/kg in SLCO1B1*15 carriers (p > 0.5).",Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480028/),[ml] / [kg·min],16.7,99006,DB00813,Fentanyl
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],876,99082,DB00813,Fentanyl
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],420,99083,DB00813,Fentanyl
,6824226,apparent beta-phase half-life,"Plasma concentrations of the drug peaked at 10 micrograms/ml and decreased rapidly at first, and then more slowly, with an apparent beta-phase half-life of 18.2 hours.","Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824226/),h,18.2,101218,DB00813,Fentanyl
,6824226,apparent bioavailability,"After oral administration, caffeine was absorbed poorly with an apparent bioavailability of 39%.","Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824226/),%,39,101219,DB00813,Fentanyl
,6824226,apparent plasma half-life,"Although blood concentrations of caffeine peaked rapidly after oral administration, its apparent plasma half-life by this route was about 42 hours.","Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824226/),h,42,101220,DB00813,Fentanyl
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,6,101227,DB00813,Fentanyl
,9103501,terminal half-life,"Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,19,101228,DB00813,Fentanyl
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101229,DB00813,Fentanyl
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101230,DB00813,Fentanyl
,9103501,blood-brain,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101231,DB00813,Fentanyl
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,2.3 to 5.2,101232,DB00813,Fentanyl
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,0.39 to 0.41,101233,DB00813,Fentanyl
,9103501,half-life,"The blood-brain equilibration half-life was 2.3 to 5.2 min for remifentanil, 0.39 to 0.41 min for GR90291 and 3.1 to 3.7 min for alfentanil.","Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9103501/),min,3.1 to 3.7,101234,DB00813,Fentanyl
,8439023,minimum effective CSF clonidine concentration,Extrapolation of CSF clonidine pharmacokinetics suggests the minimum effective CSF clonidine concentration for postoperative pain relief is 76 +/- 15 ng/ml.,Hemodynamic and analgesic actions of epidurally administered clonidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439023/),[ng] / [ml],76,101547,DB00813,Fentanyl
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],5.9,103159,DB00813,Fentanyl
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],2.2,103160,DB00813,Fentanyl
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],10.4,103161,DB00813,Fentanyl
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],5.8,103162,DB00813,Fentanyl
,15329598,plasma area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),,0.92,103163,DB00813,Fentanyl
,15329598,plasma area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),,3.2,103164,DB00813,Fentanyl
,15329598,plasma area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),,0,103165,DB00813,Fentanyl
,1888048,Onset of analgesia,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,13,103224,DB00813,Fentanyl
,1888048,Onset of analgesia,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,13,103225,DB00813,Fentanyl
,1888048,duration,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,543,103226,DB00813,Fentanyl
,1888048,duration,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,250,103227,DB00813,Fentanyl
,1888048,Peak plasma fentanyl concentrations (Fmax),Peak plasma fentanyl concentrations (Fmax) and the time to reach Cmax (Tmax) were comparable in the two groups (0.29 +/- 0.15 ng.,Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),ng,0.29,103228,DB00813,Fentanyl
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],4.62,103388,DB00813,Fentanyl
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.69,103389,DB00813,Fentanyl
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.29,103390,DB00813,Fentanyl
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,47.4,103391,DB00813,Fentanyl
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,8.6,103392,DB00813,Fentanyl
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,2.8,103393,DB00813,Fentanyl
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,111,103394,DB00813,Fentanyl
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,89,103395,DB00813,Fentanyl
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,104,103396,DB00813,Fentanyl
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,2.8,103397,DB00813,Fentanyl
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,19.1,103398,DB00813,Fentanyl
,8466018,maximal serum concentrations,"The pharmacokinetics of alfentanil from the cerebrospinal fluid to the systemic circulation were linear, i.e., dose-independent with maximal serum concentrations of 0.6, 1.4, and 3.5 ng/mL 10 min after the three respective IT doses.",Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466018/),[ng] / [ml],0.6,103901,DB00813,Fentanyl
,8466018,maximal serum concentrations,"The pharmacokinetics of alfentanil from the cerebrospinal fluid to the systemic circulation were linear, i.e., dose-independent with maximal serum concentrations of 0.6, 1.4, and 3.5 ng/mL 10 min after the three respective IT doses.",Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466018/),[ng] / [ml],1.4,103902,DB00813,Fentanyl
,8466018,maximal serum concentrations,"The pharmacokinetics of alfentanil from the cerebrospinal fluid to the systemic circulation were linear, i.e., dose-independent with maximal serum concentrations of 0.6, 1.4, and 3.5 ng/mL 10 min after the three respective IT doses.",Dose-response effect of intrathecal alfentanil on canine lower urinary tract dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466018/),[ng] / [ml],3.5,103903,DB00813,Fentanyl
,11121932,peak concentration,Mean (SD) peak concentration of fentanyl was 1.7 (0.66) ng.ml-1 and time to reach maximal plasma concentration was 18 (11) h.,Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11121932/),[ng] / [ml],1.7,104215,DB00813,Fentanyl
,11121932,time to reach maximal plasma concentration,Mean (SD) peak concentration of fentanyl was 1.7 (0.66) ng.ml-1 and time to reach maximal plasma concentration was 18 (11) h.,Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11121932/),h,18,104216,DB00813,Fentanyl
,11121932,elimination half-life,"The elimination half-life was 14.5 (6.2) h, and the area under the curve for plasma fentanyl concentration (0-144 h) was 86.8 (27) ng.h.ml-1.",Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11121932/),h,14.5,104217,DB00813,Fentanyl
,11121932,area under the curve for plasma fentanyl concentration (0-144 h),"The elimination half-life was 14.5 (6.2) h, and the area under the curve for plasma fentanyl concentration (0-144 h) was 86.8 (27) ng.h.ml-1.",Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11121932/),[h·ng] / [ml],86.8,104218,DB00813,Fentanyl
less,8010476,half-lives,These isomers differ in potency (the trans-trans and the cis-trans isomers are equipotent and the cis-cis isomer is 1/13th as potent a neuromuscular blocking agent) and in rates of in vitro hydrolysis (in vitro half-lives are less than 2 min for the cis-trans and trans-trans isomers and 276 min for the cis-cis isomer).,The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,2,104337,DB00813,Fentanyl
,8010476,half-lives,These isomers differ in potency (the trans-trans and the cis-trans isomers are equipotent and the cis-cis isomer is 1/13th as potent a neuromuscular blocking agent) and in rates of in vitro hydrolysis (in vitro half-lives are less than 2 min for the cis-trans and trans-trans isomers and 276 min for the cis-cis isomer).,The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,276,104338,DB00813,Fentanyl
,8010476,25-75%,"After discontinuation of the infusion, patients returned to 25% of their baseline muscle strength in 9.3 +/- 3.7 min and had 25-75% and 5-95% recovery indexes of 7.2 +/- 1.8 and 16.8 +/- 3.7 min, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,7.2,104339,DB00813,Fentanyl
,8010476,5-95% recovery indexes,"After discontinuation of the infusion, patients returned to 25% of their baseline muscle strength in 9.3 +/- 3.7 min and had 25-75% and 5-95% recovery indexes of 7.2 +/- 1.8 and 16.8 +/- 3.7 min, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,16.8,104340,DB00813,Fentanyl
,8010476,volumes of distribution (V beta),"The volumes of distribution (V beta) of the cis-trans, trans-trans, and cis-cis isomers were 0.29 +/- 0.24, 0.15 +/- 0.05, and 0.34 +/- 0.08 l/kg, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[l] / [kg],0.29,104341,DB00813,Fentanyl
,8010476,volumes of distribution (V beta),"The volumes of distribution (V beta) of the cis-trans, trans-trans, and cis-cis isomers were 0.29 +/- 0.24, 0.15 +/- 0.05, and 0.34 +/- 0.08 l/kg, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[l] / [kg],0.15,104342,DB00813,Fentanyl
,8010476,volumes of distribution (V beta),"The volumes of distribution (V beta) of the cis-trans, trans-trans, and cis-cis isomers were 0.29 +/- 0.24, 0.15 +/- 0.05, and 0.34 +/- 0.08 l/kg, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[l] / [kg],0.34,104343,DB00813,Fentanyl
,8010476,steady-state clearances,"kg-1.min-1 infusion, the steady-state clearances of the potent cis-trans and trans-trans isomers were 106 +/- 67 and 63 +/- 34 ml.min-1.kg-1, respectively; the clearance of the less potent cis-cis isomer was 4.6 +/- 1.1 ml.min-1.kg-1.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[ml] / [kg·min],106,104344,DB00813,Fentanyl
,8010476,steady-state clearances,"kg-1.min-1 infusion, the steady-state clearances of the potent cis-trans and trans-trans isomers were 106 +/- 67 and 63 +/- 34 ml.min-1.kg-1, respectively; the clearance of the less potent cis-cis isomer was 4.6 +/- 1.1 ml.min-1.kg-1.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[ml] / [kg·min],63,104345,DB00813,Fentanyl
,8010476,clearance,"kg-1.min-1 infusion, the steady-state clearances of the potent cis-trans and trans-trans isomers were 106 +/- 67 and 63 +/- 34 ml.min-1.kg-1, respectively; the clearance of the less potent cis-cis isomer was 4.6 +/- 1.1 ml.min-1.kg-1.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[ml] / [kg·min],4.6,104346,DB00813,Fentanyl
,8010476,elimination half-lives,"The elimination half-lives of the cis-trans and trans-trans isomers were 1.8 +/- 1.1 and 1.9 +/- 0.7 min, respectively, and that of the cis-cis isomer was 52.9 +/- 19.8 min.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,1.8,104347,DB00813,Fentanyl
,8010476,elimination half-lives,"The elimination half-lives of the cis-trans and trans-trans isomers were 1.8 +/- 1.1 and 1.9 +/- 0.7 min, respectively, and that of the cis-cis isomer was 52.9 +/- 19.8 min.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,1.9,104348,DB00813,Fentanyl
,8010476,elimination half-lives,"The elimination half-lives of the cis-trans and trans-trans isomers were 1.8 +/- 1.1 and 1.9 +/- 0.7 min, respectively, and that of the cis-cis isomer was 52.9 +/- 19.8 min.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,52.9,104349,DB00813,Fentanyl
,29679387,elimination half-life,Pharmacokinetic modeling of three timed blood samples identified the elimination half-life as 5.7 hours for carfentanil and 11.8 hours for the norcarfentanil metabolite.,The Pharmacokinetics and Pharmacodynamics of Carfentanil After Recreational Exposure: A Case Report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679387/),h,5.7,104866,DB00813,Fentanyl
,29679387,elimination half-life,Pharmacokinetic modeling of three timed blood samples identified the elimination half-life as 5.7 hours for carfentanil and 11.8 hours for the norcarfentanil metabolite.,The Pharmacokinetics and Pharmacodynamics of Carfentanil After Recreational Exposure: A Case Report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29679387/),h,11.8,104867,DB00813,Fentanyl
,30290794,ED50,The ED50 of hydromorphone in our population was 10.9 μg (95% confidence interval 5.6-16.2 μg).,Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),μg,10.9,105843,DB00813,Fentanyl
,30290794,time to pain relief,"Amongst patients for whom the dose was effective, the median time to pain relief was 24 min.",Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),min,24,105844,DB00813,Fentanyl
,17714055,buccal dwell time,Mean buccal dwell time for FBT across the dose range varied from 14 to 25 minutes (range 3 - 62 minutes).,Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17714055/),min,14 to 25,106499,DB00813,Fentanyl
,17714055,T(max),"There was no evidence of an association between FBT dwell time and values for T(max) (medians 45 - 60 minutes), dose-normalized C(max) (means 0.42-0.66 pg/ml/200 microg) or dose-normalized AUC(0 T(max')) (means 0.24-0.38 pg x h/ml/200 microg) over the range of FBT doses delivered.",Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17714055/),min,45 - 60,106500,DB00813,Fentanyl
,17714055,dose-normalized C(max),"There was no evidence of an association between FBT dwell time and values for T(max) (medians 45 - 60 minutes), dose-normalized C(max) (means 0.42-0.66 pg/ml/200 microg) or dose-normalized AUC(0 T(max')) (means 0.24-0.38 pg x h/ml/200 microg) over the range of FBT doses delivered.",Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17714055/),[pg] / [200·ml·μg],0.42-0.66,106501,DB00813,Fentanyl
,17714055,dose-normalized AUC(0 T(max')),"There was no evidence of an association between FBT dwell time and values for T(max) (medians 45 - 60 minutes), dose-normalized C(max) (means 0.42-0.66 pg/ml/200 microg) or dose-normalized AUC(0 T(max')) (means 0.24-0.38 pg x h/ml/200 microg) over the range of FBT doses delivered.",Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17714055/),[h·pg] / [200·ml·μg],0.24-0.38,106502,DB00813,Fentanyl
,4051149,volume of distribution,"There was wide discrepancy between the reported calculated pharmacokinetic constants from the various studies, such that the volume of distribution ranged from 4.4 to 59.7 litres, estimates of terminal elimination half-life ranged from 141 to 853 minutes while total body clearance values ranged from 160 to 1530 ml/minute.",Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051149/),l,4.4 to 59.7,106829,DB00813,Fentanyl
,4051149,terminal elimination half-life,"There was wide discrepancy between the reported calculated pharmacokinetic constants from the various studies, such that the volume of distribution ranged from 4.4 to 59.7 litres, estimates of terminal elimination half-life ranged from 141 to 853 minutes while total body clearance values ranged from 160 to 1530 ml/minute.",Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051149/),min,141 to 853,106830,DB00813,Fentanyl
,4051149,total body clearance,"There was wide discrepancy between the reported calculated pharmacokinetic constants from the various studies, such that the volume of distribution ranged from 4.4 to 59.7 litres, estimates of terminal elimination half-life ranged from 141 to 853 minutes while total body clearance values ranged from 160 to 1530 ml/minute.",Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051149/),[ml] / [min],160 to 1530,106831,DB00813,Fentanyl
,4051149,peak concentration,The peak concentration following a bolus of 500 micrograms ranged from 8.4-113.6 ng/ml and took from 2.9 to 18.9 hours to fall to 0.5 ng/ml.,Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051149/),[ng] / [ml],8.4-113.6,106832,DB00813,Fentanyl
,4051149,peak concentration,The peak concentration following a bolus of 500 micrograms ranged from 8.4-113.6 ng/ml and took from 2.9 to 18.9 hours to fall to 0.5 ng/ml.,Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051149/),[ng] / [ml],0.5,106833,DB00813,Fentanyl
,4051149,steady state plasma concentration,The steady state plasma concentration reached with an infusion of 0.3 microgram/kg/minute varied from 12.2-119.9 ng/ml and the plateau level attained with a two-rate infusion (2.7 micrograms/kg/minute for 20 minutes then 0.3 micrograms/kg/minute) ranged from 10.6-50.8 ng/ml.,Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051149/),[ng] / [ml],12.2-119.9,106834,DB00813,Fentanyl
,23385102,plasma levels,"Plasma levels of fentanyl were higher in patients with clinical coma (3.7±4.7 vs. 2.0±1.8 ng/mL, p=0.0001) as were midazolam plasma levels (1050±2232 vs. 168±249 ng/mL, p=0.0001).","Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385102/),[ng] / [ml],1050,106990,DB00813,Fentanyl
,23385102,plasma levels,"Plasma levels of fentanyl were higher in patients with clinical coma (3.7±4.7 vs. 2.0±1.8 ng/mL, p=0.0001) as were midazolam plasma levels (1050±2232 vs. 168±249 ng/mL, p=0.0001).","Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385102/),[ng] / [ml],168,106991,DB00813,Fentanyl
,2078976,volume of distribution,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[l] / [kg],0.84,107691,DB00813,Fentanyl
,2078976,volume of distribution,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[l] / [kg],0.82,107692,DB00813,Fentanyl
,2078976,clearance,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[ml] / [kg·min],1.35,107693,DB00813,Fentanyl
,2078976,clearance,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),[ml] / [kg·min],1.7,107694,DB00813,Fentanyl
,2078976,effective half-life,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),min,455,107695,DB00813,Fentanyl
,2078976,effective half-life,"No significant difference was observed in volume of distribution (0.84 +/- 0.48 l/kg vs. 0.82 +/- 0.30 l/kg), clearance (1.35 +/- 0.69 ml.kg-1.min-1 vs. 1.7 +/- 0.47 ml.kg-1.min-1), or effective half-life (455 +/- 111 min vs. 328 +/- 48 min) between the two groups.",Influence of gestational age on pharmacokinetics of alfentanil in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2078976/),min,328,107696,DB00813,Fentanyl
,8745970,Cmax,The Cmax was 859 +/- 503 ng.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),ng,859,108253,DB00813,Fentanyl
,8745970,Tmax,mL-1 after a Tmax to 47 +/- 17 min.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,47,108254,DB00813,Fentanyl
,8745970,elimination half-life,The mean elimination half-life was 87 +/- 19 min (mean +/- SD).,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,87,108255,DB00813,Fentanyl
,8745970,total clearance,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),[ml] / [min],"4,521",108256,DB00813,Fentanyl
,8745970,volume of distribution,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),l,568,108257,DB00813,Fentanyl
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],4,109705,DB00813,Fentanyl
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],6,109706,DB00813,Fentanyl
,19781381,volume of central compartment (V(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,5.4,109707,DB00813,Fentanyl
,19781381,volume of distribution at steady-state (Vdss),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,222.6,109708,DB00813,Fentanyl
,19781381,metabolic clearance (Cl(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[l] / [min],0.84,109709,DB00813,Fentanyl
,19781381,elimination half-life (t(1/2Y)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),min,389,109710,DB00813,Fentanyl
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],33.2,110008,DB00813,Fentanyl
,31353195,Clearance (CL,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg·min],61.3,110009,DB00813,Fentanyl
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],33.6,110010,DB00813,Fentanyl
,31353195,maximum concentration,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ng] / [ml],20.0,110011,DB00813,Fentanyl
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],436,110012,DB00813,Fentanyl
,31353195,apparent volume of the rapid peripheral compartment,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],925,110013,DB00813,Fentanyl
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],4064,110014,DB00813,Fentanyl
,31353195,apparent volume at steady state,"Clearance (CL; mL minute-1 kg-1) was 33.2 (24.0-48.0) and 61.3 (44.5-72.7), maximum concentration (ng mL-1) 33.6 (23.4-36.6) and 20.0 (16.7-28.0), apparent volume of the rapid peripheral compartment (mL kg-1) 436 (352-723) and 925 (499-1887), apparent volume at steady state (mL kg-1) 4064 (3453-6546) and 7195 (5077-8601), cardiac index (CI; mL minute-1 m-2) 2.83 (1.98-3.67) and 4.91 (3.22-6.09) and HR (beats minute-1) 68 (49-72) and 120 (102-129) for LHR and HHR, respectively, with significant differences between treatments.",Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353195/),[ml] / [kg],7195,110015,DB00813,Fentanyl
,1744940,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,21.65,110196,DB00813,Fentanyl
,1744940,clearance (Cl),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14.1,110197,DB00813,Fentanyl
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,55.95,110198,DB00813,Fentanyl
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,68.03,110199,DB00813,Fentanyl
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14,110200,DB00813,Fentanyl
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],13.6,110201,DB00813,Fentanyl
,2922980,sedation score,During infusion the sedation score decreased from 3.8 after ICU arrival to 2.2 at 8 a.m. of the first postoperative day.,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),,3.8,111355,DB00813,Fentanyl
,2922980,sedation score,During infusion the sedation score decreased from 3.8 after ICU arrival to 2.2 at 8 a.m. of the first postoperative day.,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),,2.2,111356,DB00813,Fentanyl
,2922980,T1/2 beta,T1/2 beta of MDZ after cessation was 125 min (range 90-320) and its total body clearance was 10.5 ml/kg/min (s.d. = 3.1).,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),min,125,111357,DB00813,Fentanyl
,2922980,total body clearance,T1/2 beta of MDZ after cessation was 125 min (range 90-320) and its total body clearance was 10.5 ml/kg/min (s.d. = 3.1).,Continuous infusion of midazolam during anaesthesia and postoperative sedation after maxillofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2922980/),[ml] / [kg·min],10.5,111358,DB00813,Fentanyl
,25464106,flow rate,"Separation of analytes was performed with a Hypersil C18 column and a mobile phase with acetonitrile and 0.1% formic acid (60/40, v/v) under isocratic conditions at a flow rate of 280μl/min.","Simultaneous detection of ketamine, lorazepam, midazolam and sufentanil in human serum with liquid chromatography-tandem mass spectrometry for monitoring of analgosedation in critically ill patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25464106/),[μl] / [min],280,112299,DB00813,Fentanyl
,8053579,steady-state volume of distribution,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),1,43.2,112419,DB00813,Fentanyl
,8053579,total plasma clearance,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),[ml] / [min],418,112420,DB00813,Fentanyl
,8053579,total plasma clearance,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),min,119,112421,DB00813,Fentanyl
,8053579,elimination half-life,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),[ml] / [min],418,112422,DB00813,Fentanyl
,8053579,mean residence time,"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43.2 +/- 19.5 1,418 +/- 129 ml/min, 119 +/- 34 min, and 103 +/- 26 min, respectively.",Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),min,103,112423,DB00813,Fentanyl
,8053579,systemic availability,The mean systemic availability and mean absorption time derived from the deconvolution data were 100 +/- 17% and 114 +/- 24 min.,Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),%,100,112424,DB00813,Fentanyl
,8053579,mean absorption time,The mean systemic availability and mean absorption time derived from the deconvolution data were 100 +/- 17% and 114 +/- 24 min.,Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8053579/),min,114,112425,DB00813,Fentanyl
,8280548,requirement,Mean intraoperative alfentanil requirement was greater in patients with Crohn's disease (2.48 micrograms kg-1 min-1) than in control patients (1.35 micrograms kg-1 min-1) (P < 0.01).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[μg] / [kg·min],2.48,112887,DB00813,Fentanyl
,8280548,requirement,Mean intraoperative alfentanil requirement was greater in patients with Crohn's disease (2.48 micrograms kg-1 min-1) than in control patients (1.35 micrograms kg-1 min-1) (P < 0.01).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[μg] / [kg·min],1.35,112888,DB00813,Fentanyl
,8280548,elimination half-life,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),min,80,112889,DB00813,Fentanyl
,8280548,total plasma clearance,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],5.7,112890,DB00813,Fentanyl
,8280548,total plasma clearance,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],6.4,112891,DB00813,Fentanyl
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ml] / [kg·min],6.4,112892,DB00813,Fentanyl
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[l] / [kg],0.70,112893,DB00813,Fentanyl
,8280548,steady state distribution volume,"Mean elimination half-life, total plasma clearance and steady state distribution volume in patients with Crohn's disease were comparable to those in control patients (80 vs 81 min, 5.7 vs 6.4 ml kg-1 min-1 and 0.70 vs 0.68 litre kg-1, respectively).",Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[l] / [kg],0.68,112894,DB00813,Fentanyl
,8280548,plasma concentration,Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml-1) than in the control group (199 ng ml-1) (P < 0.02).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ng] / [ml],359,112895,DB00813,Fentanyl
,8280548,plasma concentration,Mean plasma concentration at which the probability of no response was 50% for the intra-abdominal period of surgery was greater in the Crohn group (359 ng ml-1) than in the control group (199 ng ml-1) (P < 0.02).,Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8280548/),[ng] / [ml],199,112896,DB00813,Fentanyl
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,45,113314,DB00813,Fentanyl
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,4.4,113315,DB00813,Fentanyl
,7741289,times to detectable concentrations,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),min,33,113404,DB00813,Fentanyl
,7741289,times to detectable concentrations,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),min,19,113405,DB00813,Fentanyl
,7741289,times to maximum concentration,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),min,122,113406,DB00813,Fentanyl
,7741289,times to maximum concentration,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),min,119,113407,DB00813,Fentanyl
,7741289,maximum concentrations,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),[ng] / [ml],0.76,113408,DB00813,Fentanyl
,7741289,maximum concentrations,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),[ng] / [ml],1.59,113409,DB00813,Fentanyl
,7741289,areas under the curve,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),ng,233,113410,DB00813,Fentanyl
,7741289,areas under the curve,Mean times to detectable concentrations of plasma fentanyl were 33 and 19 min; mean times to maximum concentration were 122 and 119 min; maximum concentrations were 0.76 and 1.59 ng/ml (P = 0.010); mean areas under the curve of the plasma fentanyl concentration versus time relation were 233 and 474 ng.,The iontophoresis of fentanyl citrate in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),ng,474,113411,DB00813,Fentanyl
,7741289,elimination half-lives,ml-1.min (P = 0.003); and mean elimination half-lives were 354 and 413 min (P = 0.326).,The iontophoresis of fentanyl citrate in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),min,354,113412,DB00813,Fentanyl
,7741289,elimination half-lives,ml-1.min (P = 0.003); and mean elimination half-lives were 354 and 413 min (P = 0.326).,The iontophoresis of fentanyl citrate in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741289/),min,413,113413,DB00813,Fentanyl
,3954090,volume of the central compartment,"The mean +/- SEM values of selected model parameters were volume of the central compartment, 1.45 +/- 0.34 L/kg; volume of distribution at steady state, 5.1 +/- 1 L/kg; clearance, 17.94 +/- 4.38 ml X kg-1 X min-1; and terminal elimination half-life (t 1/2 beta), 317 +/- 70 min.",Pharmacokinetics of fentanyl in neonates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954090/),[l] / [kg],1.45,114547,DB00813,Fentanyl
,3954090,volume of distribution at steady state,"The mean +/- SEM values of selected model parameters were volume of the central compartment, 1.45 +/- 0.34 L/kg; volume of distribution at steady state, 5.1 +/- 1 L/kg; clearance, 17.94 +/- 4.38 ml X kg-1 X min-1; and terminal elimination half-life (t 1/2 beta), 317 +/- 70 min.",Pharmacokinetics of fentanyl in neonates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954090/),[l] / [kg],5.1,114548,DB00813,Fentanyl
,3954090,clearance,"The mean +/- SEM values of selected model parameters were volume of the central compartment, 1.45 +/- 0.34 L/kg; volume of distribution at steady state, 5.1 +/- 1 L/kg; clearance, 17.94 +/- 4.38 ml X kg-1 X min-1; and terminal elimination half-life (t 1/2 beta), 317 +/- 70 min.",Pharmacokinetics of fentanyl in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954090/),[ml] / [kg·min],17.94,114549,DB00813,Fentanyl
,3954090,terminal elimination half-life (t 1/2 beta),"The mean +/- SEM values of selected model parameters were volume of the central compartment, 1.45 +/- 0.34 L/kg; volume of distribution at steady state, 5.1 +/- 1 L/kg; clearance, 17.94 +/- 4.38 ml X kg-1 X min-1; and terminal elimination half-life (t 1/2 beta), 317 +/- 70 min.",Pharmacokinetics of fentanyl in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954090/),min,317,114550,DB00813,Fentanyl
,3584862,half life of distribution through the circulation,The half life of distribution through the circulation has been worked out at 4 minutes and the half for elimination of the drug at 460 minutes.,[Fentanyl in peridural obstetrical analgesia. Evaluation after 4 years' use]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584862/),min,4,114873,DB00813,Fentanyl
,3584862,half for elimination,The half life of distribution through the circulation has been worked out at 4 minutes and the half for elimination of the drug at 460 minutes.,[Fentanyl in peridural obstetrical analgesia. Evaluation after 4 years' use]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584862/),min,460,114874,DB00813,Fentanyl
,16291719,E(max),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),mm,2.5,116660,DB00813,Fentanyl
,16291719,gamma,"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),,2.5,116661,DB00813,Fentanyl
,16291719,EC(50),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),[ng] / [ml],76.8,116662,DB00813,Fentanyl
,16291719,E(max),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),mm,2.8,116663,DB00813,Fentanyl
,16291719,EC(50),"In 6 volunteers, the sigmoid E(max) model was applicable (average E(max) = 2.5 +/- 0.7 mm, gamma = 2.5 +/- 1.6 and EC(50) = 76.8 +/- 22.3 ng/mL), and in 3, the simple E(max) model was applicable (average E(max) = 2.8 +/- 0.3 mm and EC(50) = 19.9 +/- 8.5 ng/mL).",Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291719/),[ng] / [ml],19.9,116664,DB00813,Fentanyl
,3126050,maintenance infusion rate,The maintenance infusion rate of approximately 1 microgram kg-1 min-1 results in steady-state plasma levels in the therapeutic range in most patients.,The pharmacokinetic basis of alfentanil infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126050/),[μg] / [kg·min],1,119070,DB00813,Fentanyl
,21814196,central volume of distribution (V(1)),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),l,113.0,119403,DB00813,Fentanyl
,21814196,central volume of distribution (V(1)),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),l,189.0,119404,DB00813,Fentanyl
,21814196,peripheral volume of distribution (V(2)),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),l,94.3,119405,DB00813,Fentanyl
,21814196,peripheral volume of distribution (V(2)),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),l,412.0,119406,DB00813,Fentanyl
,21814196,peripheral volume of distribution (V(2)),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),l,427.0,119407,DB00813,Fentanyl
,21814196,intercompartmental clearance (Q),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),[l] / [h],22.6,119408,DB00813,Fentanyl
,21814196,intercompartmental clearance (Q),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),[l] / [h],28.2,119409,DB00813,Fentanyl
,21814196,metabolic clearance (Cl),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),[l] / [h],21.7,119410,DB00813,Fentanyl
,21814196,metabolic clearance (Cl),"Estimates were made of the pharmacokinetic parameters during the preanhepatic, anhepatic, and neohepatic phases: central volume of distribution (V(1)) (l): 59.0 + hourly volume infused by rapid infusion system (RIS) × 42.5, 113.0, and 189.0, respectively, × (body weight/69)(1.3); peripheral volume of distribution (V(2)) (l): 94.3, 412.0, and 427.0, respectively; intercompartmental clearance (Q) (l/h): 96.4 × (cardiac output (CO)/6.7)(2.5), 22.6, and 28.2, respectively; metabolic clearance (Cl) (l/h): 21.7 during the preanhepatic and neohepatic phases, and 0 during the anhepatic phase.",The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21814196/),[l] / [h],0,119411,DB00813,Fentanyl
,7669465,T1/T0,"Mivacurium chloride was infused at a rate of 15 micrograms kg-1 min-1 for 10 min, 7.5 micrograms kg-1 min-1 for a further 10 min, and then at a rate adjusted to maintain T1/T0 at 5%.","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),%,5,119905,DB00813,Fentanyl
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.4,119906,DB00813,Fentanyl
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.1,119907,DB00813,Fentanyl
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],3.8,119908,DB00813,Fentanyl
,2905588,isoflurane,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120712,DB00813,Fentanyl
,2905588,concentration,The mean isoflurane concentration in group 1 was 0.8 vol% combined with an average alfentanil bolus of 6.8 mg and three additional doses of 1.1-1.4 mg.,[Clinical experiences with alfentanil for balanced anesthesia in upper abdominal surgery]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905588/),vol%,0.8,120713,DB00813,Fentanyl
,28444856,time to maximum naloxone concentration (Tmax),"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),min,14.5,120716,DB00813,Fentanyl
,28444856,maximum naloxone concentration (Cmax),"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),[ng] / [ml],1.09,120717,DB00813,Fentanyl
,28444856,AUC0-90 min,"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),[min·ng] / [ml],37.1,120718,DB00813,Fentanyl
,28444856,Elimination half-life,Elimination half-life estimated from the median concentration data was 28.2 min.,Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),min,28.2,120719,DB00813,Fentanyl
,30849683,LOD,"The LOD were 0.05 ng/mL for U-47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.",Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),[ng] / [ml],0.05,121138,DB00813,Fentanyl
,30849683,LOD,"The LOD were 0.05 ng/mL for U-47700 and N-desmethyl-U-47700 and 0.1 ng/mL for N,N-didesmethyl-U-47700.",Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),[ng] / [ml],0.1,121139,DB00813,Fentanyl
>,30849683,Extraction recovery,Extraction recovery was >79%.,Quantification of U-47700 and its metabolites in plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30849683/),%,79,121140,DB00813,Fentanyl
,1590573,FiO2,"Anaesthesia was induced with a bolus dose of thiopental 4 mg/kg body wt, fentanyl 7 micrograms/kg and pancuronium 0.1 mg/kg and maintained with a continuous infusion of fentanyl 20 micrograms/min and mechanical ventilation with O2/N2O at an FiO2 of 0.5.",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.,121198,DB00813,Fentanyl
,1590573,Cardiac output,"Cardiac output (HZV) also decreased from 6.17 l/min to 4.76 l/min after induction, but remained unchanged at sternotomy (Table 2).",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],6.17,121199,DB00813,Fentanyl
,1590573,Cardiac output,"Cardiac output (HZV) also decreased from 6.17 l/min to 4.76 l/min after induction, but remained unchanged at sternotomy (Table 2).",[Hepatic elimination of thiopental in heart surgery patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],4.76,121200,DB00813,Fentanyl
,1590573,Hepatic clearance,Hepatic clearance of thiopental as the product of hepatic extraction of thiopental (with a median value of 0.29) and hepatic plasma flow was 0.21 l/min.,[Hepatic elimination of thiopental in heart surgery patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.29,121201,DB00813,Fentanyl
,1590573,hepatic plasma flow,Hepatic clearance of thiopental as the product of hepatic extraction of thiopental (with a median value of 0.29) and hepatic plasma flow was 0.21 l/min.,[Hepatic elimination of thiopental in heart surgery patients]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],0.21,121202,DB00813,Fentanyl
,1590573,hepatic extraction,Thiopental is subject to a relatively low hepatic extraction of 0.29.,[Hepatic elimination of thiopental in heart surgery patients]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),,0.29,121203,DB00813,Fentanyl
,1590573,hepatic clearance,"The hepatic clearance of thiopental found in this study, with an absolute value of 0.21 l/min, is absolutely comparable with the data for total-body clearance reported in the literature.",[Hepatic elimination of thiopental in heart surgery patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1590573/),[l] / [min],0.21,121204,DB00813,Fentanyl
,1990898,peak plasma concentration,Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min.,Plasma concentrations of midazolam in children following intranasal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990898/),[ng] / [ml],72.2,121885,DB00813,Fentanyl
,2812836,maximum lumbar CSF concentration,"The mean maximum lumbar CSF concentration was 19.1 ng/ml, while the time associated with these maximum concentrations was 22.5 min.",Pharmacokinetics of fentanyl in lumbar and cervical CSF following lumbar epidural and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2812836/),[ng] / [ml],19.1,121916,DB00813,Fentanyl
,2812836,time associated with,"The mean maximum lumbar CSF concentration was 19.1 ng/ml, while the time associated with these maximum concentrations was 22.5 min.",Pharmacokinetics of fentanyl in lumbar and cervical CSF following lumbar epidural and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2812836/),min,22.5,121917,DB00813,Fentanyl
,2295106,elimination,"After surgery the times to awakening and extubation, and alfentanil elimination half-life (t1/2B = 0.693/-k) were determined for each patient.",Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),,0.693,122218,DB00813,Fentanyl
,2295106,times to awakening,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,3.2,122219,DB00813,Fentanyl
,2295106,extubation,The times to awakening and extubation for all patients were 3.2 +/- 0.6 and 8.8 +/- 1.2 hr (mean +/- SEM) respectively.,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,8.8,122220,DB00813,Fentanyl
,2295106,elimination half-life,The elimination half-life for all patients was 5.1 +/- 1.0 hr (mean +/- SEM).,Pharmacokinetics of alfentanil and clinical responses during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295106/),h,5.1,122221,DB00813,Fentanyl
,20020418,K(m),"Using non-linear regression, we determined a K(m) value of 577 nM, indicating relatively low threshold enzyme saturation consistent with previous in vivo observation.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),nM,577,122411,DB00813,Fentanyl
,20020418,T(1/2),"The metabolic stability was determined at a concentration of 100 nm (<<K(m)) and the observed T(1/2) was 90 min with a CL(i) of 0.008 mL/min indicating moderately low clearance in dog liver microsomes, also consistent with previous in vivo data.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),min,90,122412,DB00813,Fentanyl
,20020418,CL(i),"The metabolic stability was determined at a concentration of 100 nm (<<K(m)) and the observed T(1/2) was 90 min with a CL(i) of 0.008 mL/min indicating moderately low clearance in dog liver microsomes, also consistent with previous in vivo data.",Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020418/),[ml] / [min],0.008,122413,DB00813,Fentanyl
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.24,124543,DB00813,Fentanyl
,20444024,mean residence time (MRT),Ketoconazole significantly inhibited its own elimination with the mean residence time (MRT) increasing from 6.24 h in Phase 1 to 12.54 h in Phase 3.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,12.54,124544,DB00813,Fentanyl
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,0.81,124545,DB00813,Fentanyl
,20444024,MRT,"Ketoconazole significantly decreased the elimination of midazolam, as expected, with the MRT increasing from 0.81 to 1.49 h.",The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,1.49,124546,DB00813,Fentanyl
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,3.90,124547,DB00813,Fentanyl
,20444024,MRT,The elimination of fentanyl was not significantly altered by co-administration of ketoconazole with the MRT being 3.90 and 6.35 h.,The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444024/),h,6.35,124548,DB00813,Fentanyl
,2875679,steady state plasma concentration (Css),"In a group of seven patients undergoing intracranial surgery under neurolept anesthesia, an alfentanil infusion was initiated with a loading dose of 235 micrograms/kg over 5 min, followed by a maintenance infusion rate of 1.8 microgram X kg-1 X min-1 in order to obtain a steady state plasma concentration (Css) of 400 ng/ml-1 according to an infusion model.",The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875679/),[ng] / [ml],400,124664,DB00813,Fentanyl
,2875679,Css,The mean values of Css (446 +/- 209 ng/ml) were close to the predicted ones.,The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875679/),[ng] / [ml],446,124665,DB00813,Fentanyl
,2875679,hepatic extraction coefficient,Alfentanil plasma clearance did not differ from alfentanil hepatic clearance and alfentanil hepatic extraction coefficient values ranged from 0.32-0.53.,The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875679/),,0.32-0.53,124666,DB00813,Fentanyl
,2053728,first distribution half-life,"In dogs, compared with rabbits and sheep, the first distribution half-life was longer, probably because of pronounced drug-induced bradycardia (mean +/- SD, 48 +/- 21 beats/min).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[beats] / [min],48,125031,DB00813,Fentanyl
,2053728,Elimination half-life,"Elimination half-life was similar in all species (rabbits, 62.4 +/- 11.3 minutes; sheep, 65.1 +/- 27.1 minutes; dogs, 58.3 +/- 10.3 minutes).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),min,62.4,125032,DB00813,Fentanyl
,2053728,Elimination half-life,"Elimination half-life was similar in all species (rabbits, 62.4 +/- 11.3 minutes; sheep, 65.1 +/- 27.1 minutes; dogs, 58.3 +/- 10.3 minutes).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),min,65.1,125033,DB00813,Fentanyl
,2053728,Elimination half-life,"Elimination half-life was similar in all species (rabbits, 62.4 +/- 11.3 minutes; sheep, 65.1 +/- 27.1 minutes; dogs, 58.3 +/- 10.3 minutes).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),min,58.3,125034,DB00813,Fentanyl
,2053728,steady-state volume of distribution,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg],908.3,125035,DB00813,Fentanyl
,2053728,steady-state volume of distribution,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg],720.0,125036,DB00813,Fentanyl
,2053728,steady-state volume of distribution,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg],597.7,125037,DB00813,Fentanyl
,2053728,systemic clearance,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg·min],19.4,125038,DB00813,Fentanyl
,2053728,systemic clearance,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg·min],13.3,125039,DB00813,Fentanyl
,2053728,systemic clearance,"This rapid half-life resulted from a small steady-state volume of distribution (rabbits, 908.3 +/- 269.0 ml/kg; sheep, 720.0 +/- 306.7 ml/kg; dogs, 597.7 +/- 290.2 ml/kg) and rapid systemic clearance (rabbits, 19.4 +/- 5.3 ml/min/kg; sheep, 13.3 +/- 3.0 ml/min/kg; dogs, 18.7 +/- 7.5 ml/min/kg).","Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053728/),[ml] / [kg·min],18.7,125040,DB00813,Fentanyl
,22831891,plasma concentrations,"Anaesthesia was managed with propofol and TCI of sufentanil, using the Gepts model, targeting plasma concentrations of 0.4 (n=18) or 0.8 ng ml(-1) (n=20).",Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831891/),[ng] / [ml],0.4,125739,DB00813,Fentanyl
,22831891,plasma concentrations,"Anaesthesia was managed with propofol and TCI of sufentanil, using the Gepts model, targeting plasma concentrations of 0.4 (n=18) or 0.8 ng ml(-1) (n=20).",Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831891/),[ng] / [ml],0.8,125740,DB00813,Fentanyl
,7171414,elimination half-life (T1/2 beta),"Plasma fentanyl concentrations declined bi-exponentially in the controls with an average elimination half-life (T1/2 beta) of 263 min; total plasma clearance (Cl) as 10.8 ml min-1 kg-1, and total apparent volume of distribution (V beta) 3.81 litre kg-1.",Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171414/),min,263,126136,DB00813,Fentanyl
,7171414,total plasma clearance (Cl),"Plasma fentanyl concentrations declined bi-exponentially in the controls with an average elimination half-life (T1/2 beta) of 263 min; total plasma clearance (Cl) as 10.8 ml min-1 kg-1, and total apparent volume of distribution (V beta) 3.81 litre kg-1.",Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171414/),[ml] / [kg·min],10.8,126137,DB00813,Fentanyl
,7171414,total apparent volume of distribution (V beta),"Plasma fentanyl concentrations declined bi-exponentially in the controls with an average elimination half-life (T1/2 beta) of 263 min; total plasma clearance (Cl) as 10.8 ml min-1 kg-1, and total apparent volume of distribution (V beta) 3.81 litre kg-1.",Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171414/),[l] / [kg],3.81,126138,DB00813,Fentanyl
,7171414,T1/2 beta,"No significant change was observed in patients with cirrhosis: T1/2 beta was 304 min, Cl 11.3 ml min-1 kg-1 and V beta 4.41 litre kg-1.",Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171414/),min,304,126139,DB00813,Fentanyl
,7171414,Cl,"No significant change was observed in patients with cirrhosis: T1/2 beta was 304 min, Cl 11.3 ml min-1 kg-1 and V beta 4.41 litre kg-1.",Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171414/),[ml] / [kg·min],11.3,126140,DB00813,Fentanyl
,7171414,V beta,"No significant change was observed in patients with cirrhosis: T1/2 beta was 304 min, Cl 11.3 ml min-1 kg-1 and V beta 4.41 litre kg-1.",Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7171414/),[l] / [kg],4.41,126141,DB00813,Fentanyl
,25728546,tmax,The median tmax ranged from 23.0 to 23.2 h across the 4 ITS groups.,Pharmacokinetic characteristics of fentanyl iontophoretic trandermal system over a range of applied current. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728546/),h,23.0 to 23.2,126562,DB00813,Fentanyl
,25728546,t1/2,Mean t1/2 values ranged from 11.0 to 13.0 h.,Pharmacokinetic characteristics of fentanyl iontophoretic trandermal system over a range of applied current. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728546/),h,11.0 to 13.0,126563,DB00813,Fentanyl
,30940694,time to reach Cmax (Tmax),"Nalmefene was absorbed slowly following IN administration, with a median time to reach Cmax (Tmax) of 2 hours.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,2,126814,DB00813,Fentanyl
,30940694,Tmax,"Addition of the absorption enhancer dodecyl maltoside (Intravail, Neurelis, Inc., Encinitas, CA) reduced Tmax to 0.25 hour and increased Cmax by ∼2.2-fold.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,0.25,126815,DB00813,Fentanyl
>,30940694,half-life,"The high affinity, very rapid onset, and long half-life (>7 hours) of IN nalmefene present distinct advantages as a rescue medication, particularly against longer-lived synthetic opioids.",Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30940694/),h,7,126816,DB00813,Fentanyl
,8317748,Tmax,A 1.5 h Tmax was observed.,In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317748/),h,1.5,127181,DB00813,Fentanyl
,8317748,maximal plasma levels,The maximal plasma levels after 1.5 h were 29.3 +/- 14 ng/mL for fentanyl and 29.1 +/- 14 ng/mL for sufentanil.,In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317748/),[ng] / [ml],29.3,127182,DB00813,Fentanyl
,8317748,maximal plasma levels,The maximal plasma levels after 1.5 h were 29.3 +/- 14 ng/mL for fentanyl and 29.1 +/- 14 ng/mL for sufentanil.,In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317748/),[ng] / [ml],29.1,127183,DB00813,Fentanyl
,14616320,k(elCO2) (elimination rate constant of CO2,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),1/[min],0.144,127216,DB00813,Fentanyl
,14616320,F,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),,4.0,127217,DB00813,Fentanyl
,14616320,C50,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),[μg] / [l],61.3,127218,DB00813,Fentanyl
,14616320,k,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),1/[min],0.654,127219,DB00813,Fentanyl
,14616320,k,"The following pharmacodynamic parameters were estimated with NONMEM [population means and interindividual variability (CV)]: k(elCO2) (elimination rate constant of CO2) 0.144 (-) min(-1), F (gain of the CO2 response) 4.0 (fixed according to literature values) (28%), C50 (both drugs) 61.3 microg l-1 (41%), k(eo alfentanil) 0.654 (-) min(-1) and k(eo piritramide) 0.023 (-) min(-1).",Piritramide and alfentanil display similar respiratory depressant potency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616320/),1/[min],0.023,127220,DB00813,Fentanyl
,8447206,hepatic clearance,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),[l] / [min],0.57,127626,DB00813,Fentanyl
,8447206,hepatic clearance,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),[l] / [min],0.55,127627,DB00813,Fentanyl
,8447206,hepatic extraction,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),%,92,127628,DB00813,Fentanyl
,8447206,hepatic extraction,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),%,91,127629,DB00813,Fentanyl
,8431572,total body clearance (TBC),"In the VASC group, ME total body clearance (TBC) was 6 +/- 2 mL/kg/min (mean +/- SD), which is less than in previous studies.",Comparison of the pharmacokinetics of methohexital during cardiac surgery with cardiopulmonary bypass and vascular surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431572/),[ml] / [kg·min],6,128144,DB00813,Fentanyl
greater,21382685,recoveries,"Alfentanil and midazolam were extracted from plasma using a mixed-mode cation exchange solid phase extraction method, with recoveries of both compounds greater than 80% at 3 different concentrations (1, 10 and 100ng/ml).",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),%,80,128197,DB00813,Fentanyl
,21382685,flow rate,"Compounds were analyzed on a C(18) column with a water and methanol mobile phase gradient with acetic acid as an additive, at a flow rate of 0.3ml/min.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),[ml] / [min],0.3,128198,DB00813,Fentanyl
,21382685,signal to noise ratio,"The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),,80,128199,DB00813,Fentanyl
,21382685,signal to noise ratio,"The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration.",Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21382685/),,40,128200,DB00813,Fentanyl
,10638903,rate constant,"Decreasing core temperature over 38.0-34.0 degrees C decreases the plasma clearance of vecuronium (11.3% per degrees C), decreases the rate constant for drug equilibration between plasma and effect site (0.023 min(-1) per degrees C), and increases the slope of the concentration-response relationship (0.43 per degrees C).",Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638903/),1/[c·degrees·min],0.023,128475,DB00813,Fentanyl
,9428853,bioavailability,Derived pharmacokinetic parameters were similar to those previously reported in children; bioavailability of the fentanyl in Fentanyl Oralet was 0.33.,Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428853/),,0.33,129923,DB00813,Fentanyl
,9428853,bio-availability,"The bio-availability of the fentanyl in Fentanyl Oralet was estimated to be 33%, which is less than that reported in adults (approximately 50%).",Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428853/),%,33,129924,DB00813,Fentanyl
,9428853,bio-availability,"The bio-availability of the fentanyl in Fentanyl Oralet was estimated to be 33%, which is less than that reported in adults (approximately 50%).",Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428853/),%,50,129925,DB00813,Fentanyl
,1416159,clearance,"Similarly, calculated clearance values for the two groups were not significantly different (group receiving epidural fentanyl infusion: 0.95 +/- 0.26 l.kg-1.h-1; group receiving intravenous fentanyl infusion: 0.87 +/- 0.25 l.kg-1.h-1; P = 0.3).","A randomized, double-blind comparison of lumbar epidural and intravenous fentanyl infusions for postthoracotomy pain relief. Analgesic, pharmacokinetic, and respiratory effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416159/),[l] / [h·kg],0.95,130574,DB00813,Fentanyl
,1416159,clearance,"Similarly, calculated clearance values for the two groups were not significantly different (group receiving epidural fentanyl infusion: 0.95 +/- 0.26 l.kg-1.h-1; group receiving intravenous fentanyl infusion: 0.87 +/- 0.25 l.kg-1.h-1; P = 0.3).","A randomized, double-blind comparison of lumbar epidural and intravenous fentanyl infusions for postthoracotomy pain relief. Analgesic, pharmacokinetic, and respiratory effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1416159/),[l] / [h·kg],0.87,130575,DB00813,Fentanyl
,28317124,zero-time plasma fentanyl concentrations,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[ng] / [ml],6.0,130890,DB00813,Fentanyl
,28317124,total plasma clearance,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [h·kg],1.10,130891,DB00813,Fentanyl
,28317124,volumes of distribution,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [kg],0.30,130892,DB00813,Fentanyl
,28317124,volumes of distribution,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [kg],1.10,130893,DB00813,Fentanyl
,28317124,volumes of distribution,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [kg],1.5,130894,DB00813,Fentanyl
,28317124,V1,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [kg],1.10,130895,DB00813,Fentanyl
,28317124,V1,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [kg],1.5,130896,DB00813,Fentanyl
,28317124,V2,"Extrapolated, zero-time plasma fentanyl concentrations were 6.0 ng/ml (1.7-14.6 ng/ml) after i.v. administration, total plasma clearance was 1.10 L hr-1 kg-1 (0.75-1.40 L hr-1 kg-1 ), volumes of distribution were 0.30 L/kg (0.10-0.99 L/kg), 1.10 L/kg (0.70-2.96 L/kg) and 1.5 L/kg (0.8-3.5 L/kg) for V1 , V2 , and Vss , respectively.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[l] / [kg],1.5,130897,DB00813,Fentanyl
,28317124,Elimination half-life,Elimination half-life was 1.2 hr (0.5-4.3 hr).,Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),h,1.2,130898,DB00813,Fentanyl
,28317124,Mean residence time,Mean residence time (range) after i.v. dosing was 1.30 hr (0.65-4.00 hr).,Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),h,1.30,130899,DB00813,Fentanyl
,28317124,maximum plasma fentanyl concentration,"After t.d. fentanyl administration, maximum plasma fentanyl concentration was 1.20 ng/ml (0.72-3.00 ng/ml), which occurred at 25 hr (8-48 hr) after patch placement.",Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[ng] / [ml],1.20,130900,DB00813,Fentanyl
,28317124,area under the plasma fentanyl concentration-vs-time curve,The area under the plasma fentanyl concentration-vs-time curve (extrapolated to infinity) after t.d. fentanyl was 61 ng*hr/ml (49-93 ng*hr/ml).,Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[h·ng] / [ml],61,130901,DB00813,Fentanyl
,28317124,dose-normalized bioavailability,The dose-normalized bioavailability of fentanyl from t.d. fentanyl in alpacas was 35.5% (27-64%).,Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),%,35.5,130902,DB00813,Fentanyl
,28317124,rate,Fentanyl absorption from the t.d. fentanyl patch into the central compartment occurred at a rate of approximately 50 μg/hr (29-81 μg/hr) between 8 and 72 hr after patch placement.,Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[μg] / [h],50,130903,DB00813,Fentanyl
,28317124,rate,Fentanyl absorption from the t.d. fentanyl patch into the central compartment occurred at a rate of approximately 50 μg/hr (29-81 μg/hr) between 8 and 72 hr after patch placement.,Pharmacokinetics of intravenous and transdermal fentanyl in alpacas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317124/),[μg] / [h],29-81,130904,DB00813,Fentanyl
,22984155,time to maximum concentration,"The time to maximum concentration was slightly shorter for the inhaled than IV fentanyl, 20.5 and 31.5 seconds, respectively.",Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22984155/),seconds,20.5,131692,DB00813,Fentanyl
,22984155,time to maximum concentration,"The time to maximum concentration was slightly shorter for the inhaled than IV fentanyl, 20.5 and 31.5 seconds, respectively.",Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22984155/),seconds,31.5,131693,DB00813,Fentanyl
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,34.2,131865,DB00813,Fentanyl
,7488483,T1/2 beta,"The typical value of T1/2 beta was 4.2 min longer in renal failure than in the healthy patients (34.2 vs 30.0 min, P < 0.005).",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),min,30.0,131866,DB00813,Fentanyl
,7488483,clearance,"In the healthy patients, clearance of 51W89 was greater in males, but it decreased with increasing age by approximately 1.5 ml min-1 yr-1.",Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7488483/),[ml] / [min·yr],1.5,131867,DB00813,Fentanyl
,1545554,temperature coefficient,The median temperature coefficient for man on nonpulsatile cardiopulmonary bypass is 2.8.,The effect of temperature on cerebral metabolism and blood flow in adults during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545554/),,2.8,132760,DB00813,Fentanyl
,17705569,C(max),"Median C(max) values were comparable: 1.14 ng/mL (range 0.26-2.69 ng/mL) in patients with mucositis, and 1.21 ng/mL (range 0.21-2.34 ng/mL) in patients without mucositis.",Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),[ng] / [ml],1.14,133249,DB00813,Fentanyl
,17705569,C(max),"Median C(max) values were comparable: 1.14 ng/mL (range 0.26-2.69 ng/mL) in patients with mucositis, and 1.21 ng/mL (range 0.21-2.34 ng/mL) in patients without mucositis.",Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),[ng] / [ml],1.21,133250,DB00813,Fentanyl
,17705569,t(max),The t(max) was not significantly different in the two groups: median t(max) was 25.0 min (range 15-45 min) in patients with mucositis and 22.5 min (range 10-121 min) in patients without mucositis.,Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),min,25.0,133251,DB00813,Fentanyl
,17705569,t(max),The t(max) was not significantly different in the two groups: median t(max) was 25.0 min (range 15-45 min) in patients with mucositis and 22.5 min (range 10-121 min) in patients without mucositis.,Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),min,22.5,133252,DB00813,Fentanyl
,17705569,AUC(tmax'),"Median AUC(tmax') values were 0.17 ng . h/mL (range 0.04-0.52 ng . h/mL) in patients with mucositis, and 0.20 ng . h/mL (range 0.00-0.65 ng . h/mL) in patients without mucositis.",Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),[h·ng] / [ml],0.17,133253,DB00813,Fentanyl
,17705569,AUC(tmax'),"Median AUC(tmax') values were 0.17 ng . h/mL (range 0.04-0.52 ng . h/mL) in patients with mucositis, and 0.20 ng . h/mL (range 0.00-0.65 ng . h/mL) in patients without mucositis.",Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),[h·ng] / [ml],0.20,133254,DB00813,Fentanyl
,17705569,AUC(8),"The corresponding AUC(8) values were 2.05 ng . h/mL (range 1.16-3.83 ng . h/mL) and 1.55 ng . h/mL (range 0.74-3.07 ng . h/mL), respectively.",Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),[h·ng] / [ml],2.05,133255,DB00813,Fentanyl
,17705569,AUC(8),"The corresponding AUC(8) values were 2.05 ng . h/mL (range 1.16-3.83 ng . h/mL) and 1.55 ng . h/mL (range 0.74-3.07 ng . h/mL), respectively.",Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17705569/),[h·ng] / [ml],1.55,133256,DB00813,Fentanyl
,8363073,MEACs,The MEACs ranged from < 1 to 175 ng/ml and showed substantial interindividual variability.,Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],1 to 175,133512,DB00813,Fentanyl
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],59,133513,DB00813,Fentanyl
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],52,133514,DB00813,Fentanyl
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],65,133515,DB00813,Fentanyl
,8363073,MEACs,"The median MEACs at the four study times were 59, 52, 65, and 43 ng/ml.",Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363073/),[ng] / [ml],43,133516,DB00813,Fentanyl
,3379665,total plasma clearance,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[ml] / [kg·min],31.1,133529,DB00813,Fentanyl
,3379665,total plasma clearance,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[ml] / [kg·min],21.9,133530,DB00813,Fentanyl
,3379665,volume of distribution,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[l] / [kg],3.78,133531,DB00813,Fentanyl
,3379665,volume of distribution,"Although statistically non-significant, fentanyl reduced the total plasma clearance of R 8110 (31.1 +/- 6.9 vs. 21.9 +/- 2.3 ml/kg/min) and decreased the volume of distribution (3.78 +/- 1.83 vs. 2.23 +/- 0.90 l/kg, P less than 0.05).",Hypnoanalgesia with R 8110/fentanyl in the dog: pharmacodynamic and pharmacokinetic interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379665/),[l] / [kg],2.23,133532,DB00813,Fentanyl
,3407970,peak values,"The mean peak values of fluoride ions were 3.8 +/- 1.1, 3.9 +/- 1.4, and 4.2 +/- 0.9 mumole/1 (M +/- SD) in patients in groups I, II, and III, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),mumole,3.8,133954,DB00813,Fentanyl
,3407970,peak values,"The mean peak values of fluoride ions were 3.8 +/- 1.1, 3.9 +/- 1.4, and 4.2 +/- 0.9 mumole/1 (M +/- SD) in patients in groups I, II, and III, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),mumole,3.9,133955,DB00813,Fentanyl
,3407970,peak values,"The mean peak values of fluoride ions were 3.8 +/- 1.1, 3.9 +/- 1.4, and 4.2 +/- 0.9 mumole/1 (M +/- SD) in patients in groups I, II, and III, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),mumole,4.2,133956,DB00813,Fentanyl
,3407970,half-lives,"The half-lives of fluoride ion and of organic fluorine as metabolites of isoflurane, calculated from the amounts excreted in urine, were 36 h and 41 h, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),h,36,133957,DB00813,Fentanyl
,3407970,half-lives,"The half-lives of fluoride ion and of organic fluorine as metabolites of isoflurane, calculated from the amounts excreted in urine, were 36 h and 41 h, respectively.",Biotransformation of isoflurane: urinary and serum fluoride ion and organic fluorine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407970/),h,41,133958,DB00813,Fentanyl
,2505988,apparent volume of distribution,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[l] / [kg],1.0,134355,DB00813,Fentanyl
,2505988,apparent volume of distribution,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[l] / [kg],0.48,134356,DB00813,Fentanyl
,2505988,clearance,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[ml] / [kg·min],2.2,134357,DB00813,Fentanyl
,2505988,clearance,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),[ml] / [kg·min],5.6,134358,DB00813,Fentanyl
,2505988,elimination half-life,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),min,525,134359,DB00813,Fentanyl
,2505988,elimination half-life,"Compared with older children, premature infants demonstrated a significantly larger apparent volume of distribution (1.0 +/- 0.39 vs. 0.48 +/- 0.19 l/kg), a smaller clearance (2.2 +/- 2.4 vs. 5.6 +/- 2.4 ml/kg/min) and a markedly prolonged elimination half-life (525 +/- 305 vs. 60 +/- 11 min).",Pharmacokinetics of alfentanil in newborn premature infants and older children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505988/),min,60,134360,DB00813,Fentanyl
,9620528,end,General anesthesia was induced with thiopental 4-6 mg/kg and fentanyl 2-4 microg/kg and was maintained with 60% nitrous oxide in oxygen and an end-tidal concentration of 1.5%-2% enflurane.,The pharmacokinetics of vecuronium in male and female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),,1,134931,DB00813,Fentanyl
,9620528,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],39.6,134932,DB00813,Fentanyl
,9620528,volume of distribution at steady state,"The volume of the central compartment and the volume of distribution at steady state were 39.6 +/- 8.6 and 164.8 +/- 29.3 mL/kg, respectively, in women.",The pharmacokinetics of vecuronium in male and female patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620528/),[ml] / [kg],164.8,134933,DB00813,Fentanyl
,9671331,plasma elimination half-life,"Unlike intravenous administration, in which peak plasma levels occur within minutes and the plasma elimination half-life is 2 to 3 hours, after initial transdermal fentanyl patch application, peak levels occur within 14 hours and the elimination half-life exceeds 24 hours.",Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9671331/),h,2 to 3,137401,DB00813,Fentanyl
exceeds,9671331,elimination half-life,"Unlike intravenous administration, in which peak plasma levels occur within minutes and the plasma elimination half-life is 2 to 3 hours, after initial transdermal fentanyl patch application, peak levels occur within 14 hours and the elimination half-life exceeds 24 hours.",Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9671331/),h,24,137402,DB00813,Fentanyl
,12502981,target concentration,The effect-site sufentanil target concentration was initially 0.4 ng/ml but was modified during surgery as a function of blood pressure and heart rate.,Performance of target-controlled sufentanil infusion in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.4,137589,DB00813,Fentanyl
,12502981,target concentrations,Applied sufentanil target concentrations ranged from 0.3 to 0.65 ng/ml.,Performance of target-controlled sufentanil infusion in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.3 to 0.65,137590,DB00813,Fentanyl
,12502981,plasma sufentanil concentration,The mean +/- SD plasma sufentanil concentration measured during spontaneous ventilation was 0.13 +/- 0.03 ng/ml.,Performance of target-controlled sufentanil infusion in obese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.13,137591,DB00813,Fentanyl
,12502981,Clearance,"Clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution (coefficient of variation) were 1.27 l/min (23%), 37.1 l (20%), 0.87 l/min (44%), and 92.7 l (22%), respectively.",Performance of target-controlled sufentanil infusion in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[l] / [min],1.27,137592,DB00813,Fentanyl
,12502981,peripheral volume of distribution,"Clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution (coefficient of variation) were 1.27 l/min (23%), 37.1 l (20%), 0.87 l/min (44%), and 92.7 l (22%), respectively.",Performance of target-controlled sufentanil infusion in obese patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),l,92.7,137593,DB00813,Fentanyl
,9374341,Clearance half-times,Clearance half-times from opioid receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.,Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374341/),h,28.7,138023,DB00813,Fentanyl
,9374341,Clearance half-times,Clearance half-times from opioid receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.,Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9374341/),h,2.0,138024,DB00813,Fentanyl
,1755554,apparent plateau phase (steady state),Those measured during the apparent plateau phase (steady state) of infusion protocol B were close to predicted values (0.5 to 0.6 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),μg,0.5 to 0.6,138071,DB00813,Fentanyl
,1755554,time interval to spontaneous recovery,For all the patients the time interval to spontaneous recovery was 41 +/- 27 min; plasma levels were then 0.199 +/- 0.092 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),min,41,138072,DB00813,Fentanyl
,1755554,plasma levels,For all the patients the time interval to spontaneous recovery was 41 +/- 27 min; plasma levels were then 0.199 +/- 0.092 micrograms.,[Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1755554/),μ,0.199,138073,DB00813,Fentanyl
,32375158,half-life,"MCAM plasma concentrations peaked 15-45 min after injection, with a half-life ranging from 13.7 to 199.8 min, and decreased markedly 1 day after injection.","Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32375158/),min,13.7 to 199.8,138215,DB00813,Fentanyl
,2889403,initial rate,"Thirty healthy surgical patients were given an initial 0.1 mg/kg bolus of vecuronium, followed by an infusion of vecuronium at an initial rate of 1.0 microgram .",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),,1,138618,DB00813,Fentanyl
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.28,138619,DB00813,Fentanyl
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.30,138620,DB00813,Fentanyl
,2889403,infusion rates,"Vecuronium infusion rates (mean +/- SD) were similar for patients given enflurane (0.28 +/- 0.13 microgram . kg-1 . min-1) and isoflurane (0.30 +/- 0.13 microgram . kg-1 . min-1), but significantly higher in patients given fentanyl (0.92 +/- 0.37 microgram . kg-1 . min-1).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[μg] / [kg·min],0.92,138621,DB00813,Fentanyl
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],71,138622,DB00813,Fentanyl
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],72,138623,DB00813,Fentanyl
,2889403,Css90,"Values for Css90 in the patients receiving enflurane and isoflurane were similar (71 +/- 34 and 72 +/- 44 ng/ml, respectively), but significantly higher in those receiving fentanyl (165 +/- 48 ng/ml).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ng] / [ml],165,138624,DB00813,Fentanyl
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.4,138625,DB00813,Fentanyl
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],4.6,138626,DB00813,Fentanyl
,2889403,Total plasma clearance,"Total plasma clearance was similar during enflurane, isoflurane, and fentanyl anesthesia (4.4 +/- 2.6, 4.6 +/- 1.2, and 5.6 +/- 1.9 ml X kg-1 min-1, respectively).",Continuous infusion of vecuronium: the effect of anesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889403/),[ml] / [kg·min],5.6,138627,DB00813,Fentanyl
,2897149,Vc,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],82,139625,DB00813,Fentanyl
,2897149,VDSS,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],277,139626,DB00813,Fentanyl
,2897149,clearance,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg·min],2.01,139627,DB00813,Fentanyl
,2897149,t1/2 beta,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),min,117,139628,DB00813,Fentanyl
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,5944,139629,DB00813,Fentanyl
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,1240,139630,DB00813,Fentanyl
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB00813,Fentanyl
,20137766,Bioavailability,"Bioavailability compared with OTFC was significantly greater for all nasal fentanyl formulations (FPNS 132.4%, FChNS 154.1%, FChPNS 122.3%).","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),%,132.4,139717,DB00813,Fentanyl
,20137766,Bioavailability,"Bioavailability compared with OTFC was significantly greater for all nasal fentanyl formulations (FPNS 132.4%, FChNS 154.1%, FChPNS 122.3%).","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),%,154.1,139718,DB00813,Fentanyl
,20137766,Bioavailability,"Bioavailability compared with OTFC was significantly greater for all nasal fentanyl formulations (FPNS 132.4%, FChNS 154.1%, FChPNS 122.3%).","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),%,122.3,139719,DB00813,Fentanyl
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,0.33,139720,DB00813,Fentanyl
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,0.17,139721,DB00813,Fentanyl
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,0.26,139722,DB00813,Fentanyl
,20137766,tmax,"Median tmax (FPNS 0.33 h, FChNS 0.17 h, FChPNS 0.26 h) were significantly (p < 0.001) reduced (OTFC 1.5 h) and mean C(max) significantly increased with all nasal formulations compared with OTFC.","Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137766/),h,1.5,139723,DB00813,Fentanyl
,15190236,Fi O2,After tracheal intubation the lungs were ventilated to achieve normocapnia with an oxygen-air mixture (Fi O2 = 0.33).,Relationships between total and unbound propofol in plasma and CSF during continuous drug infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15190236/),,0.33,139755,DB00813,Fentanyl
,29880278,Maximum plasma fentanyl concentrations,Maximum plasma fentanyl concentrations were variable among calves (0.726-6.923 ng mL-1).,Adverse reactions to fentanyl transdermal patches in calves: a preliminary clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29880278/),[ng] / [ml],0.726-6.923,140378,DB00813,Fentanyl
,11493236,time to patient comfort,The mean (SD) time to patient comfort was 27.6 (20.2) min for the mixture and 41.2 (18.6) min for morphine (p = 0.01).,A mixture of alfentanil and morphine for rapid postoperative loading with opioid: theoretical basis and initial clinical investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493236/),min,27.6,140705,DB00813,Fentanyl
,11493236,time to patient comfort,The mean (SD) time to patient comfort was 27.6 (20.2) min for the mixture and 41.2 (18.6) min for morphine (p = 0.01).,A mixture of alfentanil and morphine for rapid postoperative loading with opioid: theoretical basis and initial clinical investigation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11493236/),min,41.2,140706,DB00813,Fentanyl
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],114.8,140727,DB00813,Fentanyl
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],158.8,140728,DB00813,Fentanyl
,1642933,plasma clearance,Patients with non-alcoholic liver disease had lesser plasma clearance (114.8 (range 66.8-213.5) ml min-1) than the alcoholic group (158.8 (100.0-220.7) ml min-1) or controls (187.4 (125.2-269.5) ml min-1).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),[ml] / [min],187.4,140729,DB00813,Fentanyl
,1642933,Mean residence time,Mean residence time was prolonged in the alcoholic group compared with controls (284.9 (217.8-362.2) min vs 226.8 (201.2-250) min).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),min,284.9,140730,DB00813,Fentanyl
,1642933,Mean residence time,Mean residence time was prolonged in the alcoholic group compared with controls (284.9 (217.8-362.2) min vs 226.8 (201.2-250) min).,Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642933/),min,226.8,140731,DB00813,Fentanyl
,25943714,plasma concentrations,Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia.,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ng] / [ml],1.6-4.5,140789,DB00813,Fentanyl
,25943714,plasma concentrations,Mean fentanyl plasma concentrations were 1.6-4.5 ng mL(-1) during isoflurane anesthesia and 1.6-2.0 ng mL(-1) during recovery from anesthesia.,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ng] / [ml],1.6-2.0,140790,DB00813,Fentanyl
,25943714,volume of the central compartment,Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1).,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],0.80,140791,DB00813,Fentanyl
,25943714,volume of the central compartment,Recovery from isoflurane anesthesia without sedation was associated with an increase in the volume of the central compartment from 0.80 to 1.02 L kg(-1).,Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],1.02,140792,DB00813,Fentanyl
,25943714,systemic clearance,"After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1).",Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[ml] / [kg·minute],31.5 to 40.3,140793,DB00813,Fentanyl
,25943714,volume of the central compartment,"After administration of acepromazine, systemic clearance of fentanyl increased from 31.5 to 40.3 mL minute(-1) kg(-1) and the volume of the central compartment increased from 0.70 to 0.94 L kg(-1).",Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25943714/),[l] / [kg],0,140794,DB00813,Fentanyl
,28947731,clearance (CL),The clearance (CL) of tacrolimus decreased significantly from 1.28 to 0.68 mL/min/kg with concomitant use of fentanyl.,Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947731/),[ml] / [kg·min],1.28,141253,DB00813,Fentanyl
,28947731,clearance (CL),The clearance (CL) of tacrolimus decreased significantly from 1.28 to 0.68 mL/min/kg with concomitant use of fentanyl.,Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947731/),[ml] / [kg·min],0.68,141254,DB00813,Fentanyl
,21144689,flow rate,"The mobile phase (MP) consisted of acetonitrile:water (45:55, v/v) under isocratic conditions at a flow rate of 0.2 ml/min.",Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21144689/),[ml] / [min],0.2,141456,DB00813,Fentanyl
>,21144689,m,"Sufentanil and internal-standard (IS) fentanyl were eluted at 1.47 and 1.16 min, respectively, and their responses were optimized at the transitions m/z 387.2>238.0 and m/z 337.2>188.0, respectively.",Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21144689/),,33,141457,DB00813,Fentanyl
,21144689,recovery,"The accuracy and precision of the method were between 96.49% and 100.37% (RSD<9%), and the mean recovery of sufentanil was 84.08 ± 7.29%.",Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21144689/),%,84.08,141458,DB00813,Fentanyl
,19238656,hepatic,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141867,DB00813,Fentanyl
,19238656,intestinal extraction,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),,0,141868,DB00813,Fentanyl
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,37,141869,DB00813,Fentanyl
,19238656,bioavailability,"Steady-state ritonavir increased the AUC(0-Infinity)/dose ratio for IV and oral ALF 4- and 10-fold, respectively; reduced hepatic extraction (from 0.26 to 0.07) and intestinal extraction (from 0.51 to 0); and increased bioavailability (from 37 to 95%).",Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238656/),%,95,141870,DB00813,Fentanyl
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB00813,Fentanyl
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],4.6,142800,DB00813,Fentanyl
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],4.8,142801,DB00813,Fentanyl
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],3.9,142802,DB00813,Fentanyl
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],7.8,142803,DB00813,Fentanyl
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],7.7,142804,DB00813,Fentanyl
,17554244,systemic clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],6.0,142805,DB00813,Fentanyl
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],11.8,142806,DB00813,Fentanyl
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],13.3,142807,DB00813,Fentanyl
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],12.6,142808,DB00813,Fentanyl
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],35.2,142809,DB00813,Fentanyl
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],36.4,142810,DB00813,Fentanyl
,17554244,apparent oral clearances,"In CYP3A5(*)3/(*)3 (n=62), (*)1/(*)3 (n=28), and (*)1/(*)1 (n=8) genotypes, systemic clearances of ALF were 4.6+/-1.8, 4.8+/-1.7, and 3.9+/-1.7 ml/kg/min and those of MDZ were 7.8+/-2.3, 7.7+/-2.3, and 6.0+/-1.4 ml/kg/min, respectively (not significant), and apparent oral clearances were 11.8+/-7.2, 13.3+/-6.1, and 12.6+/-8.2 ml/kg/min for ALF and 35.2+/-19.0, 36.4+/-15.7, and 29.4+/-9.3 ml/kg/min for MDZ (not significant).",Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554244/),[ml] / [kg·min],29.4,142811,DB00813,Fentanyl
,28238111,AUC0-∞,Mean fentanyl AUC0-∞ was 1.5 ± 0.5 h·ng/mL.,Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238111/),[h·ng] / [ml],1.5,144243,DB00813,Fentanyl
,28238111,Systemic clearance,Systemic clearance of fentanyl was 1522 ± 310 mL/min and 11.2 ± 2.6 mL/min·kg TBW.,Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238111/),[ml] / [min],1522,144244,DB00813,Fentanyl
,28238111,Systemic clearance,Systemic clearance of fentanyl was 1522 ± 310 mL/min and 11.2 ± 2.6 mL/min·kg TBW.,Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238111/),[ml] / [kg·min],11.2,144245,DB00813,Fentanyl
,28238111,Volume of distribution,Volume of distribution was 635 ± 282 L and 4.7 ± 2.1 L/kg TBW.,Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238111/),l,635,144246,DB00813,Fentanyl
,28238111,Volume of distribution,Volume of distribution was 635 ± 282 L and 4.7 ± 2.1 L/kg TBW.,Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238111/),[l] / [kg],4.7,144247,DB00813,Fentanyl
,9197301,half-lives of equilibrium,"The half-lives of equilibrium between blood and brain were 6.3 and 0.8 min for meperidine and alfentanil, respectively: The rate of penetration of both opioids into the brain was rapid and not rate-limiting.",The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197301/),min,6.3,145020,DB00813,Fentanyl
,9197301,half-lives of equilibrium,"The half-lives of equilibrium between blood and brain were 6.3 and 0.8 min for meperidine and alfentanil, respectively: The rate of penetration of both opioids into the brain was rapid and not rate-limiting.",The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9197301/),min,0.8,145021,DB00813,Fentanyl
,23271030,Plasma half-time,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,80 to 90,145134,DB00813,Fentanyl
,23271030,Plasma half-time,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,15,145135,DB00813,Fentanyl
,23271030,time from peak plasma concentration to 50% of peak concentration,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,80 to 90,145136,DB00813,Fentanyl
,23271030,time from peak plasma concentration to 50% of peak concentration,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,15,145137,DB00813,Fentanyl
,620479,half-life (t 1/2),"Thereafter, serum levels fell more slowly with an observed half-life (t 1/2) of approximately 10 to 20 min.",Pharmacokinetics of fentanyl as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/620479/),min,10 to 20,145479,DB00813,Fentanyl
,620479,t 1/2,"By 2 hr serum levels had stabilized at low values (1, 5, and 8 ng/ml) and continued to decrease very slowly thereafter, with an observed t 1/2 of 1 to 2 hr at the low dose (0.1 mg/m2) and greater than 4 hr at 0.5 and 1.0 mg/m2.",Pharmacokinetics of fentanyl as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/620479/),h,1 to 2,145480,DB00813,Fentanyl
greater,620479,t 1/2,"By 2 hr serum levels had stabilized at low values (1, 5, and 8 ng/ml) and continued to decrease very slowly thereafter, with an observed t 1/2 of 1 to 2 hr at the low dose (0.1 mg/m2) and greater than 4 hr at 0.5 and 1.0 mg/m2.",Pharmacokinetics of fentanyl as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/620479/),h,4,145481,DB00813,Fentanyl
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.95,145894,DB00813,Fentanyl
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.75,145895,DB00813,Fentanyl
,21223952,plasma fentanyl,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],12.8,147062,DB00813,Fentanyl
,21223952,plasma fentanyl,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],16.8,147063,DB00813,Fentanyl
,21223952,plasma fentanyl,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],28.1,147064,DB00813,Fentanyl
,21223952,concentration,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],12.8,147065,DB00813,Fentanyl
,21223952,concentration,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],16.8,147066,DB00813,Fentanyl
,21223952,concentration,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],28.1,147067,DB00813,Fentanyl
,17171862,plasma concentrations,"The doses administered gave plasma concentrations of 1.55 microg/mL, which are considered therapeutic.",Compartmental analysis of lidocaine kinetics during extracorporeal circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171862/),,1.55,147178,DB00813,Fentanyl
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],56,147482,DB00813,Fentanyl
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],28,147483,DB00813,Fentanyl
,12631041,concentrations,"The estimated concentrations immediately (t = 0) after injection were 56 mg l(-1) (H), 28 mg l(-1) (I) and 14 mg l(-1) (L).",Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631041/),[mg] / [l],14,147484,DB00813,Fentanyl
,21209242,t(first),"After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.08 to 0.25,147740,DB00813,Fentanyl
,21209242,t(max),"After single doses, median t(first) was 0.08 to 0.25 hours and t(max) 0.50 to 1.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.50 to 1.00,147741,DB00813,Fentanyl
,21209242,"t(max) (t(max,ss))","After repeat dosing, median t(max) (t(max,ss)) was 0.50 to 2.00 hours.","Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209242/),h,0.50 to 2.00,147742,DB00813,Fentanyl
,3120765,free fractions,"The degree of plasma protein binding was also similar in children and adults with mean free fractions of 11.5 +/- 0.9% (+/- SD) and 11.8 +/- 3.9%, respectively.",Pharmacokinetics of alfentanil in children undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),%,11.5,148142,DB00813,Fentanyl
,3120765,free fractions,"The degree of plasma protein binding was also similar in children and adults with mean free fractions of 11.5 +/- 0.9% (+/- SD) and 11.8 +/- 3.9%, respectively.",Pharmacokinetics of alfentanil in children undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),%,11.8,148143,DB00813,Fentanyl
,3120765,elimination half-life,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),min,63,148144,DB00813,Fentanyl
,3120765,elimination half-life,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),min,95,148145,DB00813,Fentanyl
,3120765,plasma clearance,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),[ml] / [kg·min],11.1,148146,DB00813,Fentanyl
,3120765,plasma clearance,There were marked differences in the elimination half-life of alfentanil (63 +/- 24 min in children; 95 +/- 20 min in adults (P less than 0.001] and plasma clearance of alfentanil (11.1 +/- 3.9 ml min-1 kg-1 in children and 5.9 +/- 1.6 ml min-1 kg-1 in adults (P less than 0.001].,Pharmacokinetics of alfentanil in children undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3120765/),[ml] / [kg·min],5.9,148147,DB00813,Fentanyl
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],1228,148719,DB00813,Fentanyl
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],2753,148720,DB00813,Fentanyl
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],201,148721,DB00813,Fentanyl
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],447,148722,DB00813,Fentanyl
,10925135,apparent release flux,"With increasing concentration of copolymer in the cellulose membrane transport, the apparent release flux of fentanyl (200 microgram/ml) decreased to 1. 09+/-0.19 microgram cm(-2) h(-1).",Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10925135/),[μg] / [(cm)^2·h],1. 09,148807,DB00813,Fentanyl
,10925135,apparent permeability coefficient,Assessment of the effect of the copolymer on nude mouse skin also showed a decrease in the apparent permeability coefficient [(P(H(2)O))=2.24+/-0.47x10(-6) cm s(-1) vs. (P(46% block copolymer))=0.93+/-0.23x10(-7) cm s(-1)].,Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10925135/),[cm] / [s],2.24,148808,DB00813,Fentanyl
,10925135,apparent permeability coefficient,Assessment of the effect of the copolymer on nude mouse skin also showed a decrease in the apparent permeability coefficient [(P(H(2)O))=2.24+/-0.47x10(-6) cm s(-1) vs. (P(46% block copolymer))=0.93+/-0.23x10(-7) cm s(-1)].,Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10925135/),[cm] / [s],0.93,148809,DB00813,Fentanyl
,10925135,P,Assessment of the effect of the copolymer on nude mouse skin also showed a decrease in the apparent permeability coefficient [(P(H(2)O))=2.24+/-0.47x10(-6) cm s(-1) vs. (P(46% block copolymer))=0.93+/-0.23x10(-7) cm s(-1)].,Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10925135/),[cm] / [s],0.93,148810,DB00813,Fentanyl
,10925135,elimination half-life (t(1/2)),"The preliminary pharmacokinetics of the fentanyl patch was shown to be in steady state within 24 h, and this was maintained for at least 72 h with an elimination half-life (t(1/2)) of 10.5+/-3.4 h.",Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10925135/),h,10.5,148811,DB00813,Fentanyl
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,3.9,149435,DB00813,Fentanyl
,3140563,elimination half-life,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),h,1.2,149436,DB00813,Fentanyl
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,107,149437,DB00813,Fentanyl
,3140563,apparent volume of distribution,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),l,31,149438,DB00813,Fentanyl
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],20,149439,DB00813,Fentanyl
,3140563,total body clearance,"The following mean pharmacokinetic parameters (mean +/- s.e. mean) were calculated for midazolam and alfentanil, respectively: elimination half-life 3.9 +/- 0.3 h and 1.2 +/- 0.05 h, apparent volume of distribution 107 +/- 61 and 31 +/- 1.5 l, total body clearance 20 +/- 0.7 l/h and 18 +/- 0.8 l/h.","Pharmacokinetics of midazolam and alfentanil in outpatient general anesthesia. A study with concomitant thiopentone, flumazenil or placebo administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3140563/),[l] / [h],18,149440,DB00813,Fentanyl
,6416281,distribution half-life,"The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),min,7.4,149511,DB00813,Fentanyl
,6416281,elimination half-life,"The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),min,86.7,149512,DB00813,Fentanyl
,6416281,"apparent volume of distribution, Varea","The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),[l] / [kg],0.44,149513,DB00813,Fentanyl
,6416281,elimination clearance,"The distribution half-life (mean +/- SD) (7.4 +/- 3.1 min), elimination half-life (86.7 +/- 15.8 min), apparent volume of distribution, Varea (0.44 +/- 0.15 litre kg-1) and elimination clearance (3.33 +/- 0.75 ml kg-1 min-1) were similar to those previously reported for a single bolus of alfentanil.",Pharmacokinetics of the infusion of alfentanil in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),[ml] / [kg·min],3.33,149514,DB00813,Fentanyl
,6416281,steady state plasma concentration,"These values for apparent volume of distribution and clearance can be used to calculate correct bolus and infusion doses to maintain any desired steady state plasma concentration using standard formulae: for example, to maintain a steady state plasma concentration of 400 ng ml-1, a bolus dose of 176 micrograms kg-1 and an infusion of 1.3 micrograms kg-1 min1 would be required.",Pharmacokinetics of the infusion of alfentanil in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6416281/),[ng] / [ml],400,149515,DB00813,Fentanyl
,15320597,peak serum concentration,"Use of the TTS resulted in variable serum concentrations of fentanyl, with a peak serum concentration of 2.2+/-1.1 ng/mL (mean+/-SD) and a time to peak serum concentration of 26+/-13 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),[ng] / [ml],2.2,149699,DB00813,Fentanyl
,15320597,time to peak serum concentration,"Use of the TTS resulted in variable serum concentrations of fentanyl, with a peak serum concentration of 2.2+/-1.1 ng/mL (mean+/-SD) and a time to peak serum concentration of 26+/-13 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),h,26,149700,DB00813,Fentanyl
,15320597,time to reach serum fentanyl concentrations,"After transdermal fentanyl administration, mean time to reach serum fentanyl concentrations consistent with analgesia in other species (1 ng/mL) was 14 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),h,1,149701,DB00813,Fentanyl
,15320597,time to reach serum fentanyl concentrations,"After transdermal fentanyl administration, mean time to reach serum fentanyl concentrations consistent with analgesia in other species (1 ng/mL) was 14 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),h,14,149702,DB00813,Fentanyl
,7661346,terminal half-life,"In subjects wearing the device for 24 h, the terminal half-life of fentanyl after removal of the device was 16 h.",Biopharmaceutics of a new transdermal fentanyl device. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661346/),h,16,150011,DB00813,Fentanyl
,7661346,bioavailability,The bioavailability of transdermally administered fentanyl was 63 +/- 35% coefficient of variation.,Biopharmaceutics of a new transdermal fentanyl device. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661346/),%,63,150012,DB00813,Fentanyl
,7661346,rate of fentanyl absorption,The rate of fentanyl absorption from 12-24 h ranged from 10 to 230 micrograms/h in subjects still wearing the device.,Biopharmaceutics of a new transdermal fentanyl device. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661346/),[μg] / [h],10 to 230,150013,DB00813,Fentanyl
,1610997,steady-state volume of distribution (Vss,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg],258,150037,DB00813,Fentanyl
,1610997,elimination clearance (Cle,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],10.7,150038,DB00813,Fentanyl
,1610997,distribution clearance (Cld,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],6.8,150039,DB00813,Fentanyl
,1610997,Vss,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg],"1,107",150040,DB00813,Fentanyl
,1610997,Cle,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],20.0,150041,DB00813,Fentanyl
,1610997,Cld,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],23.0,150042,DB00813,Fentanyl
,1610997,distribution half-life (t1/2 lambda 1,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,2.8,150043,DB00813,Fentanyl
,1610997,elimination half-life (t1/2 lambda 2,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,36,150044,DB00813,Fentanyl
,1610997,t1/2 lambda 1,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,1.7,150045,DB00813,Fentanyl
,1610997,t1/2 lambda 2,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,68,150046,DB00813,Fentanyl
,24684621,volume of distribution (area),The volume of distribution (area) was larger for fentanyl (7.42 L/kg) compared to buprenorphine (3.54 L/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[l] / [kg],7.42,150329,DB00813,Fentanyl
,24684621,volume of distribution (area),The volume of distribution (area) was larger for fentanyl (7.42 L/kg) compared to buprenorphine (3.54 L/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[l] / [kg],3.54,150330,DB00813,Fentanyl
,24684621,plasma clearance,The plasma clearance of fentanyl (38.6 mL·min/kg) was faster than buprenorphine (10.3 mL·min/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[min·ml] / [kg],38.6,150331,DB00813,Fentanyl
,24684621,plasma clearance,The plasma clearance of fentanyl (38.6 mL·min/kg) was faster than buprenorphine (10.3 mL·min/kg).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),[min·ml] / [kg],10.3,150332,DB00813,Fentanyl
,24684621,terminal half-life,The terminal half-life of fentanyl (2.22 h) was shorter than buprenorphine (3.96 h).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),h,2.22,150333,DB00813,Fentanyl
,24684621,terminal half-life,The terminal half-life of fentanyl (2.22 h) was shorter than buprenorphine (3.96 h).,Comparative pharmacokinetics of intravenous fentanyl and buprenorphine in healthy greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24684621/),h,3.96,150334,DB00813,Fentanyl
,18282254,Peak plasma concentrations,"Peak plasma concentrations were variable (0.1-28.7 ng mL(-1)), were reached after 14.3 +/- 7.6 hours (mean +/- SD), and returned to baseline concentrations 12 hours after FTS removal.",Pharmacokinetics and tolerance of transdermal fentanyl administration in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282254/),[ng] / [ml],0.1-28.7,150454,DB00813,Fentanyl
,19715381,Cmax,"Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03 ng/mL; p<0.05).","Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[ng] / [ml],1.67,151020,DB00813,Fentanyl
,19715381,Cmax,"Compared with OTFC, peak plasma fentanyl concentrations with pH 7.25 FBSF were significantly higher (mean Cmax 1.67 vs 1.03 ng/mL; p<0.05).","Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[ng] / [ml],1.03,151021,DB00813,Fentanyl
,19715381,AUCinfinity,Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUCinfinity 14.5 vs 10.3 ng . h/mL).,"Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[h·ng] / [ml],14.5,151022,DB00813,Fentanyl
,19715381,AUCinfinity,Overall exposure was also greater with pH 7.25 FBSF than with OTFC (mean AUCinfinity 14.5 vs 10.3 ng . h/mL).,"Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715381/),[h·ng] / [ml],10.3,151023,DB00813,Fentanyl
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.1,152189,DB00813,Fentanyl
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.8,152190,DB00813,Fentanyl
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],507.8,152191,DB00813,Fentanyl
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],392.2,152192,DB00813,Fentanyl
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],285.4,152193,DB00813,Fentanyl
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],435.6,152194,DB00813,Fentanyl
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],338.8,152195,DB00813,Fentanyl
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],462.7,152196,DB00813,Fentanyl
,28828532,Peak plasma concentration,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[μg] / [l],3.75,152587,DB00813,Fentanyl
,28828532,area under the curve to infinity,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],2174,152588,DB00813,Fentanyl
,28828532,area under the curve to infinity,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152589,DB00813,Fentanyl
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[μg] / [l],2.54,152590,DB00813,Fentanyl
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],2174,152591,DB00813,Fentanyl
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152592,DB00813,Fentanyl
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,310,152593,DB00813,Fentanyl
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],1594,152594,DB00813,Fentanyl
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152595,DB00813,Fentanyl
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,158,152596,DB00813,Fentanyl
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,310,152597,DB00813,Fentanyl
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,164,152598,DB00813,Fentanyl
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h],58.6,152599,DB00813,Fentanyl
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h],44.9,152600,DB00813,Fentanyl
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h·kg],0.47,152601,DB00813,Fentanyl
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h·kg],0.64,152602,DB00813,Fentanyl
less,12393357,ventilatory frequency,"Respiratory depression was defined as a ventilatory frequency less than10 breaths min(-1) on two occasions or a peripheral oxygen saturation < or =92%, or administration of naloxone.","Remifentanil compared with sufentanil during extra-corporeal shock wave lithotripsy with spontaneous ventilation: a double-blind, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393357/),[breaths] / [min],10,152612,DB00813,Fentanyl
,20150521,C(max),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[ng] / [ml],1.08,152668,DB00813,Fentanyl
,20150521,C(max),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[ng] / [ml],1.01,152669,DB00813,Fentanyl
,20150521,AUC(0-12),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],6.3,152670,DB00813,Fentanyl
,20150521,AUC(0-12),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],6.2,152671,DB00813,Fentanyl
,20150521,AUC(inf),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],9.14,152672,DB00813,Fentanyl
,20150521,AUC(inf),"Peak plasma concentrations (mean C(max) = 1.08 and 1.01 ng/mL) and overall exposure (mean AUC(0-12) = 6.3 and 6.2 h.ng/mL; mean AUC(inf) = 9.14 and 9.60 h.ng/mL) were nearly identical after the 2 single doses (P >or= .1, all comparisons).",Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150521/),[h·ng] / [ml],9.60,152673,DB00813,Fentanyl
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,51.2,152868,DB00813,Fentanyl
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,40.5,152869,DB00813,Fentanyl
,22580527,V(C),"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),l,24.7,153731,DB00813,Fentanyl
,22580527,V(T),"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),l,112,153732,DB00813,Fentanyl
,22580527,Cl,"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),[l] / [min],2.64,153733,DB00813,Fentanyl
,22580527,Q,"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),[l] / [min],0.989,153734,DB00813,Fentanyl
,22580527,rate constant,"Delay of the anesthetic effect, with respect to plasma concentrations, was described by the effect compartment with the rate constant for the distribution to the effector compartment equal to 0.240 min(-1).",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),1/[min],0.240,153735,DB00813,Fentanyl
,22580527,EC(50),The BIS index was linked to the effect site concentrations through a sigmoidal E(max) model with EC(50) = 2.19 mg/l.,Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),[mg] / [l],2.19,153736,DB00813,Fentanyl
,11312475,CPB time,"CPB time was 116 +/- 10 minutes, and ischemic time was 81 +/- 6 minutes.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),min,116,154299,DB00813,Fentanyl
,11312475,ischemic time,"CPB time was 116 +/- 10 minutes, and ischemic time was 81 +/- 6 minutes.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),min,81,154300,DB00813,Fentanyl
,11312475,pump flow,"Mean pump flow was 4.49 +/- 0.03 L/min, and mean arterial pressure was 70.1 +/- 1 mmHg during the study period.",Desflurane pharmacokinetics during cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11312475/),[l] / [min],4.49,154301,DB00813,Fentanyl
,26105145,VC,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),l,7.90,156987,DB00813,Fentanyl
,26105145,VT,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),l,481,156988,DB00813,Fentanyl
,26105145,Cl,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),[l] / [h],5.3,156989,DB00813,Fentanyl
,26105145,Q,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),[l] / [h],38.3,156990,DB00813,Fentanyl
,7902032,central clearance,"The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),[l] / [min],2.8,157088,DB00813,Fentanyl
,7902032,volume of distribution at steady state,"The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),l,32.8,157089,DB00813,Fentanyl
,7902032,terminal half-life,"The NONMEM analysis population pharmacokinetic parameters included a central clearance of 2.8 l/min, a volume of distribution at steady state of 32.8 l, and a terminal half-life of 48 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),min,48,157090,DB00813,Fentanyl
,7902032,clearance,"The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),[l] / [min],2.9,157091,DB00813,Fentanyl
,7902032,volume of distribution at steady state,"The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),l,31.8,157092,DB00813,Fentanyl
,7902032,mean residence time,"The mean results of the nonparametric moment analysis included a clearance of 2.9 l/min, a volume of distribution at steady state of 31.8 l, and a mean residence time of 10.9 min.",The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902032/),min,10.9,157093,DB00813,Fentanyl
,14508316,V1,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,14.4,157827,DB00813,Fentanyl
,14508316,V2,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,36.4,157828,DB00813,Fentanyl
,14508316,V3,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,169,157829,DB00813,Fentanyl
,14508316,Cl1,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],0.82,157830,DB00813,Fentanyl
,14508316,Cl2,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],2.31,157831,DB00813,Fentanyl
,14508316,Cl3,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],1.35,157832,DB00813,Fentanyl
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],4,158541,DB00813,Fentanyl
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],6,158542,DB00813,Fentanyl
,19236806,central volume of distribution (V(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,5.4,158543,DB00813,Fentanyl
,19236806,volume of distribution at steady-state (Vdss),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,195.4,158544,DB00813,Fentanyl
,19236806,systemic clearance (Cl(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[l] / [min],1.10,158545,DB00813,Fentanyl
,19236806,elimination half-life (t(1/2) gamma),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),min,271.8,158546,DB00813,Fentanyl
,17083458,Tcmax,"The initial delay ranged from 0 to 5.1 h (mean, 1.91+/-2.0 h), Tcmax ranged from 8.5 to 14.5 h (mean, 11.4+/-2.7 h) and Cmax ranged from 0.67 to 5.12 ng/mL (mean, 2.77+/-1.92 ng/mL).",Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses--variability among horses and its clinical implications. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083458/),h,8.5 to 14.5,158940,DB00813,Fentanyl
,17083458,Tcmax,"The initial delay ranged from 0 to 5.1 h (mean, 1.91+/-2.0 h), Tcmax ranged from 8.5 to 14.5 h (mean, 11.4+/-2.7 h) and Cmax ranged from 0.67 to 5.12 ng/mL (mean, 2.77+/-1.92 ng/mL).",Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses--variability among horses and its clinical implications. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083458/),h,11.4,158941,DB00813,Fentanyl
,17083458,Cmax,"The initial delay ranged from 0 to 5.1 h (mean, 1.91+/-2.0 h), Tcmax ranged from 8.5 to 14.5 h (mean, 11.4+/-2.7 h) and Cmax ranged from 0.67 to 5.12 ng/mL (mean, 2.77+/-1.92 ng/mL).",Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses--variability among horses and its clinical implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083458/),[ng] / [ml],0.67 to 5.12,158942,DB00813,Fentanyl
,17083458,Cmax,"The initial delay ranged from 0 to 5.1 h (mean, 1.91+/-2.0 h), Tcmax ranged from 8.5 to 14.5 h (mean, 11.4+/-2.7 h) and Cmax ranged from 0.67 to 5.12 ng/mL (mean, 2.77+/-1.92 ng/mL).",Pharmacokinetics of fentanyl delivered transdermally in healthy adult horses--variability among horses and its clinical implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083458/),[ng] / [ml],2.77,158943,DB00813,Fentanyl
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.62,159632,DB00813,Fentanyl
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.81,159633,DB00813,Fentanyl
,9232131,Noncompartmental clearances,"Noncompartmental clearances (mean +/- SD) were 3.62 +/- 0.76, 3.81 +/- 0.96, and 3.60 +/- 0.84 ml/kg/ min, respectively, on days 2, 13, and 21 of the menstrual cycle.",Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232131/),[ml] / [·kg·min],3.60,159634,DB00813,Fentanyl
,2331054,plasma levels,"Maternal fentanyl plasma levels decreased significantly, from 7.84 (3.55-17.24) ng/ml 1 min after injection to 5.92 (2.01-14.15) ng/ml during omphalotomy.",[Use of fentanyl for anesthesia induction in cesarean section. Pharmacokinetics and pharmacodynamics in mother and child]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331054/),[ng] / [ml],7.84,160194,DB00813,Fentanyl
,2331054,plasma levels,"Maternal fentanyl plasma levels decreased significantly, from 7.84 (3.55-17.24) ng/ml 1 min after injection to 5.92 (2.01-14.15) ng/ml during omphalotomy.",[Use of fentanyl for anesthesia induction in cesarean section. Pharmacokinetics and pharmacodynamics in mother and child]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331054/),[ng] / [ml],5.92,160195,DB00813,Fentanyl
,2331054,plasma levels,The corresponding fentanyl plasma levels in the umbilical vein were 2.08 (0.88-3.42) ng/ml.,[Use of fentanyl for anesthesia induction in cesarean section. Pharmacokinetics and pharmacodynamics in mother and child]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331054/),ng,2.08,160196,DB00813,Fentanyl
,2331054,feto-maternal ratio,The feto-maternal ratio was 0.44 (0.08-1.00).,[Use of fentanyl for anesthesia induction in cesarean section. Pharmacokinetics and pharmacodynamics in mother and child]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331054/),,0.44,160197,DB00813,Fentanyl
,2331054,induction-delivery time,The induction-delivery time ranged from 2 to 8 min.,[Use of fentanyl for anesthesia induction in cesarean section. Pharmacokinetics and pharmacodynamics in mother and child]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331054/),min,2 to 8,160198,DB00813,Fentanyl
,9723968,clearance,"The values (mean+/-s.e., n=20) of clearance, volume of distribution at steady-state and terminal half-life were 45+/-3 ml x min(-1) x kg(-1), 0.91+/-0.09 l/kg(-1) and 23+/-1 min, respectively, and independent of the administered dose.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[ml] / [kg·min],45,160328,DB00813,Fentanyl
,9723968,volume of distribution at steady-state,"The values (mean+/-s.e., n=20) of clearance, volume of distribution at steady-state and terminal half-life were 45+/-3 ml x min(-1) x kg(-1), 0.91+/-0.09 l/kg(-1) and 23+/-1 min, respectively, and independent of the administered dose.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[l] / [kg],0.91,160329,DB00813,Fentanyl
,9723968,terminal half-life,"The values (mean+/-s.e., n=20) of clearance, volume of distribution at steady-state and terminal half-life were 45+/-3 ml x min(-1) x kg(-1), 0.91+/-0.09 l/kg(-1) and 23+/-1 min, respectively, and independent of the administered dose.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),min,23,160330,DB00813,Fentanyl
,9723968,E0,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),μv,56,160331,DB00813,Fentanyl
,9723968,Emax,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),μv,93,160332,DB00813,Fentanyl
,9723968,EC50,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[ng] / [ml],235,160333,DB00813,Fentanyl
,9723968,Hill factor,"The averaged values of the pharmacodynamic parameters of alfentanil were (mean+/-s.e., n=20): E0=56+/-3 microV, Emax=93+/-8 microV, EC50=235+/-27 ng x ml(-1) and Hill factor=1.6+/-0.1, respectively.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),,1.6,160334,DB00813,Fentanyl
,9723968,EC50,"For the second of the two consecutive infusions a significantly higher value of the EC50 of 404+/-56 ng x ml(-1) was observed (P < 0.05), while the values of the other pharmacodynamic parameters were unchanged.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723968/),[ng] / [ml],404,160335,DB00813,Fentanyl
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00813,Fentanyl
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00813,Fentanyl
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00813,Fentanyl
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00813,Fentanyl
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00813,Fentanyl
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00813,Fentanyl
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00813,Fentanyl
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,33-36,161929,DB00813,Fentanyl
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,26-30,161930,DB00813,Fentanyl
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,100.1,161931,DB00813,Fentanyl
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161932,DB00813,Fentanyl
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,114.5,161933,DB00813,Fentanyl
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161934,DB00813,Fentanyl
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,108.8,161935,DB00813,Fentanyl
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,164.8,161936,DB00813,Fentanyl
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.20,161937,DB00813,Fentanyl
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.26,161938,DB00813,Fentanyl
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],1.40,161939,DB00813,Fentanyl
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],0.93,161940,DB00813,Fentanyl
,1577053,plasma clearance,"Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h.",Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577053/),[ml] / [min],3.9,162451,DB00813,Fentanyl
,1577053,elimination half-life,"Individual pharmacokinetic parameters were calculated: plasma clearance was 3.9 ml.min-1, elimination half-life was 12.0 h.",Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1577053/),h,12.0,162452,DB00813,Fentanyl
,14622685,C(max),"With heat, the mean C(max) was 0.63 ng/mL compared with a C(max) of 0.24 ng/mL without heat (P =.007).",The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14622685/),[ng] / [ml],0.63,162729,DB00813,Fentanyl
,14622685,C(max),"With heat, the mean C(max) was 0.63 ng/mL compared with a C(max) of 0.24 ng/mL without heat (P =.007).",The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14622685/),[ng] / [ml],0.24,162730,DB00813,Fentanyl
,14622685,AUC,"With early heat, the mean AUC was 1.22 ng/mL.",The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14622685/),[ng] / [ml],1.22,162731,DB00813,Fentanyl
,1989741,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state (Vdss) were 0.44 +/- 0.022 and 0.63 +/- 0.32 L.kg-1, respectively.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[l] / [kg],0.44,163236,DB00813,Fentanyl
,1989741,volume of distribution at steady state (Vdss),"The volume of the central compartment and the volume of distribution at steady state (Vdss) were 0.44 +/- 0.022 and 0.63 +/- 0.32 L.kg-1, respectively.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[l] / [kg],0.63,163237,DB00813,Fentanyl
,1989741,Total drug clearance,Total drug clearance was 6.4 = 1.9 ml.min-1.kg-1.,Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[ml] / [kg·min],6.4,163238,DB00813,Fentanyl
,1989741,elimination half-time,The elimination half-time was 3.7 +/- 2.6 hr.,Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),h,3.7,163239,DB00813,Fentanyl
,1989741,elimination half-time,"In general surgical patients, the elimination half-time of alfentanil has been reported to be 1.2-2.0 hr.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),h,1.2-2.0,163240,DB00813,Fentanyl
,23611571,F1,"The estimated primary PK parameters were F1 = 59%, CL=33.5 l/h, V2 = 68.8 l and KA = 12.8 1/h.",An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611571/),%,59,163351,DB00813,Fentanyl
,23611571,CL,"The estimated primary PK parameters were F1 = 59%, CL=33.5 l/h, V2 = 68.8 l and KA = 12.8 1/h.",An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611571/),[l] / [h],33.5,163352,DB00813,Fentanyl
,23611571,V2,"The estimated primary PK parameters were F1 = 59%, CL=33.5 l/h, V2 = 68.8 l and KA = 12.8 1/h.",An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611571/),l,68.8,163353,DB00813,Fentanyl
,23611571,KA,"The estimated primary PK parameters were F1 = 59%, CL=33.5 l/h, V2 = 68.8 l and KA = 12.8 1/h.",An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611571/),[1] / [h],12.8,163354,DB00813,Fentanyl
,2646620,lag time,A median lag time of 2.25 hours after application of the transdermal system was observed before the appearance of fentanyl in the blood.,Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646620/),h,2.25,164170,DB00813,Fentanyl
,2646620,peak concentration,"Median peak concentration and time to peak were 1.0 ng/ml and 22 hours, respectively.",Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646620/),[ng] / [ml],1.0,164171,DB00813,Fentanyl
,2646620,time to peak,"Median peak concentration and time to peak were 1.0 ng/ml and 22 hours, respectively.",Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646620/),h,22,164172,DB00813,Fentanyl
,8130056,PaCO2,Halothane was maintained at 1.05-1.07% end-tidal concentration with a PaCO2 of 6-7.3 kPa.,Effect of xylazine and ketamine on the pharmacokinetics of alfentanil during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130056/),kpa,6-7.3,164456,DB00813,Fentanyl
,2573385,total volume of distribution,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),[ml] / [kg],5427,164862,DB00813,Fentanyl
,2573385,total volume of distribution,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),[ml] / [kg],3518,164863,DB00813,Fentanyl
,2573385,elimination half-life,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),min,232,164864,DB00813,Fentanyl
,2573385,elimination half-life,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),min,143,164865,DB00813,Fentanyl
,9447475,unbound fraction,The unbound fraction of fentanyl rose from 0.23 to 0.34 after the start of CPB.,Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447475/),,0.23,164971,DB00813,Fentanyl
,9447475,unbound fraction,The unbound fraction of fentanyl rose from 0.23 to 0.34 after the start of CPB.,Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447475/),,0.34,164972,DB00813,Fentanyl
,9447475,elimination half-life,The estimated elimination half-life of fentanyl using the grouped data was 4.7 h.,Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447475/),h,4.7,164973,DB00813,Fentanyl
,9447475,elimination half-life,The estimated elimination half-life of alcuronium using the grouped data was 234 min.,Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447475/),min,234,164974,DB00813,Fentanyl
,3954113,peak arterial plasma lidocaine concentration,"Despite a large total dose of topical lidocaine (5.3 +/- 2.1 mg/kg), the mean peak arterial plasma lidocaine concentration was low (0.6 +/- 2.1 micrograms/ml).",Cardiovascular responses and lidocaine absorption in fiberoptic-assisted awake intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954113/),[μg] / [ml],0.6,164985,DB00813,Fentanyl
,2573716,binding to,"Alfentanil binding to plasma proteins was 87.6% (s.d. 2.0) in the patients with chronic renal failure, and 89.7% (1.2) in patients with normal renal function (P = 0.025).",Disposition of alfentanil in patients receiving a renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),%,87.6,165750,DB00813,Fentanyl
,2573716,binding to,"Alfentanil binding to plasma proteins was 87.6% (s.d. 2.0) in the patients with chronic renal failure, and 89.7% (1.2) in patients with normal renal function (P = 0.025).",Disposition of alfentanil in patients receiving a renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),%,89.7,165751,DB00813,Fentanyl
,2573716,Elimination half life,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,142.4,165752,DB00813,Fentanyl
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,120.2,165753,DB00813,Fentanyl
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,128.5,165754,DB00813,Fentanyl
,2573716,mean residence time,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),min,136.0,165755,DB00813,Fentanyl
,2573716,apparent volume of distribution at steady state,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,40.5,165756,DB00813,Fentanyl
,2573716,apparent volume of distribution at steady state,"Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142.4 and 120.2 min; 128.5 and 136.0 min; and 40.5 and 27.6 L, respectively in chronic renal failure patients and patients with normal renal function).",Disposition of alfentanil in patients receiving a renal transplant. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,27.6,165757,DB00813,Fentanyl
,2573716,Total drug clearance,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),[ml] / [min],341.9,165758,DB00813,Fentanyl
,2573716,Total drug clearance,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),[ml] / [min],211.8,165759,DB00813,Fentanyl
,2573716,Vd area,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,69.3,165760,DB00813,Fentanyl
,2573716,Vd area,Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341.9 vs 211.8 mL min-1; and 69.3 and 35.5 L.,Disposition of alfentanil in patients receiving a renal transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573716/),l,35.5,165761,DB00813,Fentanyl
,17166193,minimum effective concentration,"The minimum effective concentration of fentanyl in serum (0.63 ng/mL) was achieved at 11.3 +/- 4.9 hours after application, and serum concentrations remained above this level until 13 hours after removal.",Pharmacokinetic profile and efficacy of a fentanyl transdermal delivery system for acute postoperative pain after intra-abdominal gynecologic surgery for cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166193/),[ng] / [ml],0.63,166182,DB00813,Fentanyl
,24335580,Maximum serum concentrations (Cmax),"Maximum serum concentrations (Cmax) and area under the curve (AUC)0-72 at 2.1 and 4.2 mg were 0.26 and 0.35 ng/ml, and 11.58 and 15.95 ng·h/ml, respectively.",Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24335580/),[ng] / [ml],0.26,167021,DB00813,Fentanyl
,24335580,area under the curve (AUC)0-72,"Maximum serum concentrations (Cmax) and area under the curve (AUC)0-72 at 2.1 and 4.2 mg were 0.26 and 0.35 ng/ml, and 11.58 and 15.95 ng·h/ml, respectively.",Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24335580/),[h·ng] / [ml],11.58,167022,DB00813,Fentanyl
,24335580,area under the curve (AUC)0-72,"Maximum serum concentrations (Cmax) and area under the curve (AUC)0-72 at 2.1 and 4.2 mg were 0.26 and 0.35 ng/ml, and 11.58 and 15.95 ng·h/ml, respectively.",Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24335580/),[h·ng] / [ml],15.95,167023,DB00813,Fentanyl
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00813,Fentanyl
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00813,Fentanyl
,8694326,elimination half-life,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,9.9,168144,DB00813,Fentanyl
,8694326,Ts,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,8.6,168145,DB00813,Fentanyl
,8694326,Tsb,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,11.7,168146,DB00813,Fentanyl
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],15.2,168147,DB00813,Fentanyl
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],14.8,168148,DB00813,Fentanyl
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],12.9,168149,DB00813,Fentanyl
,8694326,Ts,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],14.8,168150,DB00813,Fentanyl
,8694326,Tsb,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],12.9,168151,DB00813,Fentanyl
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],17.8,168152,DB00813,Fentanyl
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],16.9,168153,DB00813,Fentanyl
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],22.9,168154,DB00813,Fentanyl
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],20.0,168155,DB00813,Fentanyl
,8694326,Ts,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],20.0,168156,DB00813,Fentanyl
,8694326,Tsb,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],22.4,168157,DB00813,Fentanyl
,8694326,Tsb,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],14.5,168158,DB00813,Fentanyl
,8694326,terminal elimination half-life,The terminal elimination half-life of sufentanil in CSF was 7.2 +/- 0.6 h.,The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,7.2,168159,DB00813,Fentanyl
,31538188,population clearance,"The population clearance and intercompartmental clearance were 7.19 and 2.16 L/hour, respectively, and the volume of distribution for the central and peripheral compartments was 4.01 and 25.1 L, respectively.",Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31538188/),[l] / [h],7.19,168901,DB00813,Fentanyl
,31538188,intercompartmental clearance,"The population clearance and intercompartmental clearance were 7.19 and 2.16 L/hour, respectively, and the volume of distribution for the central and peripheral compartments was 4.01 and 25.1 L, respectively.",Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31538188/),[l] / [h],2.16,168902,DB00813,Fentanyl
,31538188,volume of distribution,"The population clearance and intercompartmental clearance were 7.19 and 2.16 L/hour, respectively, and the volume of distribution for the central and peripheral compartments was 4.01 and 25.1 L, respectively.",Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31538188/),l,4.01,168903,DB00813,Fentanyl
,31538188,volume of distribution,"The population clearance and intercompartmental clearance were 7.19 and 2.16 L/hour, respectively, and the volume of distribution for the central and peripheral compartments was 4.01 and 25.1 L, respectively.",Characterizing Fentanyl Variability Using Population Pharmacokinetics in Pediatric Burn Patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31538188/),l,25.1,168904,DB00813,Fentanyl
,22731773,C(max),"The C(max) was 2.34 ± 1.29 (mean ± standard deviation) and 2.02 ± 0.84 ng/mL for the ventral and dorsal application groups, respectively.","Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731773/),[ng] / [ml],2.34,168988,DB00813,Fentanyl
,22731773,C(max),"The C(max) was 2.34 ± 1.29 (mean ± standard deviation) and 2.02 ± 0.84 ng/mL for the ventral and dorsal application groups, respectively.","Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731773/),[ng] / [ml],2.02,168989,DB00813,Fentanyl
,22731773,terminal elimination half-lives (t(1/2)),"The terminal elimination half-lives (t(1/2)) for both groups were similar with values of 137 ± 58.9 and 117 ± 59.6 h for the ventral and dorsal application site groups, respectively.","Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731773/),h,137,168990,DB00813,Fentanyl
,22731773,terminal elimination half-lives (t(1/2)),"The terminal elimination half-lives (t(1/2)) for both groups were similar with values of 137 ± 58.9 and 117 ± 59.6 h for the ventral and dorsal application site groups, respectively.","Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731773/),h,117,168991,DB00813,Fentanyl
≥,22731773,mean absorption rate,A mean absorption rate of ≥ 2 μg · kg/h was maintained from 2 to 144 h following dorsal application and from 2 to 264 h following ventral application.,"Pharmacokinetics and the effect of application site on a novel, long-acting transdermal fentanyl solution in healthy laboratory Beagles. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731773/),[kg·μg] / [h],2,168992,DB00813,Fentanyl
,9560536,Pp,"Fifteen minutes after the cessation of propofol infusion, Pp decreased to 1.5 micrograms.","[Pharmacokinetics of propofol and ketamine during and after total intravenous anesthesia with propofol, fentanyl and ketamine for pediatric patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9560536/),μg,1.5,169344,DB00813,Fentanyl
,9560536,Pk,Pk values at 15 minutes and 120 minutes after the cessation of the infusion were 93 ng.,"[Pharmacokinetics of propofol and ketamine during and after total intravenous anesthesia with propofol, fentanyl and ketamine for pediatric patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9560536/),ng,93,169345,DB00813,Fentanyl
more,8214669,clearance,Five sets from the literature also showed a reliable predictive accuracy but four other sets with a clearance more than 5 mL.kg-1.min-1 and derived from a large bolus injection were inaccurate (MDAPE > 50%) as they underestimated the alfentanil concentrations.,Predictive accuracy of continuous alfentanil infusion in volunteers: variability of different pharmacokinetic sets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214669/),[ml] / [kg·min],5,169393,DB00813,Fentanyl
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.76,170597,DB00813,Fentanyl
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.48,170598,DB00813,Fentanyl
,14576555,maximum concentration,"The plasma concentration of fentanyl also increased steadily, reaching a maximum concentration of 0.37 +/- 0.11 ng/ml by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[ng] / [ml],0.37,170599,DB00813,Fentanyl
,27933600,Cmax,"Following administration of FBSF doses of 200-1200 μg, mean Cmax values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19ng/mL, respectively.","Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[ng] / [ml],0.383,170876,DB00813,Fentanyl
,27933600,Cmax,"Following administration of FBSF doses of 200-1200 μg, mean Cmax values increased in a linear manner with values ranging from 0.383 ng/mL to 2.19ng/mL, respectively.","Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[ng] / [ml],2.19,170877,DB00813,Fentanyl
,27933600,AUClast,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[ng] / [ml],3.001,170878,DB00813,Fentanyl
,27933600,AUClast,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[h·ng] / [ml],19.17,170879,DB00813,Fentanyl
,27933600,AUC∞,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[h·ng] / [ml],3.456,170880,DB00813,Fentanyl
,27933600,AUC∞,Mean AUClast values increased from 3.001 ng ·/mL to 19.17 ng·h/mL and mean AUC∞ increased in a linear manner from 3.456 ng·h/mL to 20.43 ng ·h/mL.,"Dose Proportionality and Pharmacokinetics of Fentanyl Buccal Soluble Film in Healthy Subjects : A Phase I, Open-Label, Three-Period, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27933600/),[h·ng] / [ml],20.43,170881,DB00813,Fentanyl
,20919897,half-life,"Following a dose of 2.5 g/kg administered IV, the half-life was 3.08 hours (range, 2.20 to 3.36 hours), volume of distribution at steady state was 8.86 L/kg (range, 5.55 to 15.04 L/kg), and systemic clearance was 3.62 L/kg/h (range, 2.51 to 5.39 L/kg/h).",Pharmacokinetics of fentanyl administered transdermally and intravenously in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919897/),h,3.08,170886,DB00813,Fentanyl
,20919897,volume of distribution at steady state,"Following a dose of 2.5 g/kg administered IV, the half-life was 3.08 hours (range, 2.20 to 3.36 hours), volume of distribution at steady state was 8.86 L/kg (range, 5.55 to 15.04 L/kg), and systemic clearance was 3.62 L/kg/h (range, 2.51 to 5.39 L/kg/h).",Pharmacokinetics of fentanyl administered transdermally and intravenously in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919897/),[l] / [kg],8.86,170887,DB00813,Fentanyl
,20919897,systemic clearance,"Following a dose of 2.5 g/kg administered IV, the half-life was 3.08 hours (range, 2.20 to 3.36 hours), volume of distribution at steady state was 8.86 L/kg (range, 5.55 to 15.04 L/kg), and systemic clearance was 3.62 L/kg/h (range, 2.51 to 5.39 L/kg/h).",Pharmacokinetics of fentanyl administered transdermally and intravenously in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919897/),[l] / [h·kg],3.62,170888,DB00813,Fentanyl
,20919897,Time to maximum plasma concentration,"Time to maximum plasma concentration and maximal concentration were 12 hours (range, 4 to 24 hours) and 1.30 ng/mL (range, 0.62 to 2.73 ng/mL), respectively.",Pharmacokinetics of fentanyl administered transdermally and intravenously in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919897/),h,12,170889,DB00813,Fentanyl
,20919897,maximal concentration,"Time to maximum plasma concentration and maximal concentration were 12 hours (range, 4 to 24 hours) and 1.30 ng/mL (range, 0.62 to 2.73 ng/mL), respectively.",Pharmacokinetics of fentanyl administered transdermally and intravenously in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919897/),[ng] / [ml],1.30,170890,DB00813,Fentanyl
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,65.5,171206,DB00813,Fentanyl
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,83.6,171207,DB00813,Fentanyl
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,892",171208,DB00813,Fentanyl
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,373",171209,DB00813,Fentanyl
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,6,171264,DB00813,Fentanyl
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,2,171265,DB00813,Fentanyl
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.15,171266,DB00813,Fentanyl
,11038831,fraction (Fd),"After induction of anesthesia and endotracheal intubation, desired fraction (Fd) of desflurane(6%), sevoflurane(2%), isoflurane (1.15%) and enflurane(1.7%) in oxygen and nitrous oxide(1:2) were inhaled in D, S, I and E groups, respectively.","[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),%,1.7,171267,DB00813,Fentanyl
,11038831,fractional end tidal alveolar concentration (Fa),The fractional end tidal alveolar concentration (Fa) was adjusted to 1MAC during the maintenance of anesthsia.,"[The pharmacokinetic study of desflurane, sevoflurane, isoflurane and enflurane in general anesthesia]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038831/),,1,171268,DB00813,Fentanyl
,16491890,effect-site concentration,Fentanyl was injected repeatedly to insure maintenance of the effect-site concentration in the 2.0 to 2.5 ng x ml(-1) range with off line computer similation program.,[Recovery from propofol anesthesia is delayed in hepatectomy patients due to altered pharmacodynamics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16491890/),[ng] / [ml],2.0 to 2.5,171269,DB00813,Fentanyl
,8320806,elimination half-life,The elimination half-life of midazolam was about 3 times longer in hepatectomy group (24.2 hours) than in the group without liver injury (8.4 hours).,[Pharmacokinetics of midazolam in patients with liver damage for hepatectomy]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8320806/),h,24.2,171273,DB00813,Fentanyl
,8320806,elimination half-life,The elimination half-life of midazolam was about 3 times longer in hepatectomy group (24.2 hours) than in the group without liver injury (8.4 hours).,[Pharmacokinetics of midazolam in patients with liver damage for hepatectomy]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8320806/),h,8.4,171274,DB00813,Fentanyl
,17656164,m,"Both fentanyl (analyte) and the internal standard (fentanyl-d5) were determined via multiple reaction monitoring (MRM) and the MS/MS ion transitions monitored were m/z 337.0/188.0 and 342.0/188.0, respectively.",Rapid and sensitive determination of fentanyl in dog plasma by on-line solid-phase extraction integrated with a hydrophilic column coupled to tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656164/),,337.0,171611,DB00813,Fentanyl
,17656164,m,"Both fentanyl (analyte) and the internal standard (fentanyl-d5) were determined via multiple reaction monitoring (MRM) and the MS/MS ion transitions monitored were m/z 337.0/188.0 and 342.0/188.0, respectively.",Rapid and sensitive determination of fentanyl in dog plasma by on-line solid-phase extraction integrated with a hydrophilic column coupled to tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656164/),,342.0,171612,DB00813,Fentanyl
,17656164,recoveries,"The recoveries ranged from 90 to 105% in plasma at the concentrations of 0.04, 0.4, 4 and 40 ng/mL.",Rapid and sensitive determination of fentanyl in dog plasma by on-line solid-phase extraction integrated with a hydrophilic column coupled to tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17656164/),%,90 to 105,171613,DB00813,Fentanyl
,14973303,area under the curve (AUC),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),h·mm,13.6,172187,DB00813,Fentanyl
,14973303,area under the curve (AUC),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),h·mm,8.7,172188,DB00813,Fentanyl
,14973303,k(el),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],0.35,172189,DB00813,Fentanyl
,14973303,k(el),"Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm*h, p< 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05).",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],0.52,172190,DB00813,Fentanyl
,14973303,plasma C(max),Quinidine increased oral fentanyl plasma C(max) (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs.,Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),[ng] / [ml],0.55,172191,DB00813,Fentanyl
,14973303,plasma C(max),Quinidine increased oral fentanyl plasma C(max) (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs.,Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),[ng] / [ml],0.21,172192,DB00813,Fentanyl
,14973303,AUC,Quinidine increased oral fentanyl plasma C(max) (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs.,Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),,1.9,172193,DB00813,Fentanyl
,14973303,maximum miosis,"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),mm,3.4,172194,DB00813,Fentanyl
,14973303,maximum miosis,"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),mm,2.3,172195,DB00813,Fentanyl
,14973303,rate constant for the transfer between plasma and effect compartment (k(e0)),"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],1.9,172196,DB00813,Fentanyl
,14973303,rate constant for the transfer between plasma and effect compartment (k(e0)),"Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p< 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect compartment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different.",Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973303/),1/[h],3.6,172197,DB00813,Fentanyl
,11927479,V1,"The parameters of this three-compartment model are: V1 15.0 l, V2 20.0 l, V3 86.1 l, Cl1 1.08 L x min(-1), Cl2 4.90 L x min(-1), and Cl3 2.60 L x min(-1).",Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927479/),l,15.0,172275,DB00813,Fentanyl
,11927479,V2,"The parameters of this three-compartment model are: V1 15.0 l, V2 20.0 l, V3 86.1 l, Cl1 1.08 L x min(-1), Cl2 4.90 L x min(-1), and Cl3 2.60 L x min(-1).",Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927479/),l,20.0,172276,DB00813,Fentanyl
,11927479,V3,"The parameters of this three-compartment model are: V1 15.0 l, V2 20.0 l, V3 86.1 l, Cl1 1.08 L x min(-1), Cl2 4.90 L x min(-1), and Cl3 2.60 L x min(-1).",Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927479/),l,86.1,172277,DB00813,Fentanyl
,11927479,Cl1,"The parameters of this three-compartment model are: V1 15.0 l, V2 20.0 l, V3 86.1 l, Cl1 1.08 L x min(-1), Cl2 4.90 L x min(-1), and Cl3 2.60 L x min(-1).",Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927479/),[l] / [min],1.08,172278,DB00813,Fentanyl
,11927479,Cl2,"The parameters of this three-compartment model are: V1 15.0 l, V2 20.0 l, V3 86.1 l, Cl1 1.08 L x min(-1), Cl2 4.90 L x min(-1), and Cl3 2.60 L x min(-1).",Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927479/),[l] / [min],4.90,172279,DB00813,Fentanyl
,11927479,Cl3,"The parameters of this three-compartment model are: V1 15.0 l, V2 20.0 l, V3 86.1 l, Cl1 1.08 L x min(-1), Cl2 4.90 L x min(-1), and Cl3 2.60 L x min(-1).",Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927479/),[l] / [min],2.60,172280,DB00813,Fentanyl
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,47,172779,DB00813,Fentanyl
,9209610,half-life of elimination,"The mean half-life of elimination was 47 s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211 s with a 95% confidence range of 139 to 282 s.",Pharmacokinetics and pharmacodynamics of suxamethonium. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209610/),s,211,172780,DB00813,Fentanyl
,7586903,clearance,"Remifentanil undergoes widespread extrahepatic metabolism by blood and tissue nonspecific esterases, resulting in an extremely rapid clearance of approximately 3 L/min (180 L/h).",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),[l] / [min],3,173335,DB00813,Fentanyl
,7586903,steady-state volume of distribution,"Like the other members of this class of drugs, remifentanil is lipophilic and is widely distributed in body tissues with a steady-state volume of distribution of approximately 30L.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),l,30,173336,DB00813,Fentanyl
,7586903,half-time,"Determined by computer simulation, the context-sensitive half-time of remifentanil is approximately 3 minutes, and is independent of infusion duration.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,3,173337,DB00813,Fentanyl
,7586903,t1/2ke0,"Speed of onset of effect is very rapid and is similar to that of alfentanil, which is reflected in a t1/2ke0 (a parameter used to characterise the delay between peak blood drug concentration and peak pharmacodynamic effect utilising a theoretical effect compartment) of approximately 1 to 2 minutes.",Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586903/),min,1 to 2,173338,DB00813,Fentanyl
,28681626,maximum plasma concentrations,Mean maximum plasma concentrations were reached between 0.27-0.60 h post-dose for fentanyl sublingual spray.,Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a single ascending dose study in opioid-naïve healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28681626/),h,0.27-0.60,173359,DB00813,Fentanyl
,18728103,clearance,The pharmacokinetics of intravenous fentanyl reflected a 2-compartment model with a clearance of approximately 1.5 L/min.,Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),[l] / [min],1.5,174334,DB00813,Fentanyl
,18728103,Bioavailability,"Bioavailability of intranasal fentanyl was 89%, following first-order absorption, with a lag of approximately 5 minutes and a half-life of approximately 6.5 minutes.",Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),%,89,174335,DB00813,Fentanyl
,18728103,lag,"Bioavailability of intranasal fentanyl was 89%, following first-order absorption, with a lag of approximately 5 minutes and a half-life of approximately 6.5 minutes.",Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),min,5,174336,DB00813,Fentanyl
,18728103,half-life,"Bioavailability of intranasal fentanyl was 89%, following first-order absorption, with a lag of approximately 5 minutes and a half-life of approximately 6.5 minutes.",Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),min,6.5,174337,DB00813,Fentanyl
,18728103,time to maximum concentration,Intranasal versus intravenous administration led to a delayed mean fentanyl time to maximum concentration (13 vs 6 min) and lower maximum concentration (1.2 vs 2.0 ng/mL).,Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),min,13,174338,DB00813,Fentanyl
,18728103,time to maximum concentration,Intranasal versus intravenous administration led to a delayed mean fentanyl time to maximum concentration (13 vs 6 min) and lower maximum concentration (1.2 vs 2.0 ng/mL).,Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),min,6,174339,DB00813,Fentanyl
,18728103,maximum concentration,Intranasal versus intravenous administration led to a delayed mean fentanyl time to maximum concentration (13 vs 6 min) and lower maximum concentration (1.2 vs 2.0 ng/mL).,Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),[ng] / [ml],1.2,174340,DB00813,Fentanyl
,18728103,maximum concentration,Intranasal versus intravenous administration led to a delayed mean fentanyl time to maximum concentration (13 vs 6 min) and lower maximum concentration (1.2 vs 2.0 ng/mL).,Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),[ng] / [ml],2.0,174341,DB00813,Fentanyl
,18728103,half-life,"Analgesic effect lagged behind the venous fentanyl concentration, with a half-life of approximately 2.5 minutes as described by a fractional sigmoid maximum drug effect dynamic model.",Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),min,2.5,174342,DB00813,Fentanyl
,18728103,50% effective concentration,"The concentration-analgesia relationship was steep, with a 50% effective concentration of 0.46 ng/mL (Hill coefficient 3.5).",Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),[ng] / [ml],0.46,174343,DB00813,Fentanyl
,18728103,Hill coefficient,"The concentration-analgesia relationship was steep, with a 50% effective concentration of 0.46 ng/mL (Hill coefficient 3.5).",Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728103/),,3.5,174344,DB00813,Fentanyl
,28877414,plasma FEN,"Mean plasma FEN concentration (± SD) 2 hours following patch application was 1.06 ± 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours.",Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],1.06,175015,DB00813,Fentanyl
,28877414,concentration,"Mean plasma FEN concentration (± SD) 2 hours following patch application was 1.06 ± 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours.",Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],1.06,175016,DB00813,Fentanyl
,28877414,concentration,"Mean plasma FEN concentration (± SD) 2 hours following patch application was 1.06 ± 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours.",Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],0,175017,DB00813,Fentanyl
,28877414,Maximum mean plasma FEN concentration (Cmax ),Maximum mean plasma FEN concentration (Cmax ) was 1.84 (ranging from 0.81 to 3.35) ng/mL with average time to maximum concentration (Tmax ) of 12 hours after patch application.,Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),[ng] / [ml],1.84,175018,DB00813,Fentanyl
,28877414,time to maximum concentration (Tmax ),Maximum mean plasma FEN concentration (Cmax ) was 1.84 (ranging from 0.81 to 3.35) ng/mL with average time to maximum concentration (Tmax ) of 12 hours after patch application.,Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28877414/),h,12,175019,DB00813,Fentanyl
,2339802,terminal half-life,"However, simulation beyond 24 h after a bolus administration showed a terminal half-life of 20 h for fentanyl, i.e., an elimination phase that has not yet been described in actual pharmacokinetic studies.",Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339802/),h,20,175155,DB00813,Fentanyl
,1959542,Serum midazolam concentrations,Serum midazolam concentrations between 100-400 micrograms/l were sufficient for sedation.,Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959542/),,100-400,175836,DB00813,Fentanyl
,19192980,absorption rate,The average absorption rate was 2.3 microg/h.,Passive absorption of fentanyl from the fentanyl HCl iontophoretic transdermal system. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192980/),[μg] / [h],2.3,176264,DB00813,Fentanyl
,19192980,maximum observed serum fentanyl concentration,The mean maximum observed serum fentanyl concentration was 0.06 ng/mL.,Passive absorption of fentanyl from the fentanyl HCl iontophoretic transdermal system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19192980/),[ng] / [ml],0.06,176265,DB00813,Fentanyl
,12631050,CBF,"In group 1, baseline CBF was 55 +/- 7 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],55,176357,DB00813,Fentanyl
,12631050,CBF,Indomethacin decreased CBF to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176358,DB00813,Fentanyl
,12631050,CBF,"In group 2, baseline CBF was 54 +/- 10 ml/100 cm3/min.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],54,176359,DB00813,Fentanyl
,12631050,CBF,Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm3/min (P < 0.002).,No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[ml] / [100·cm3·min],41,176360,DB00813,Fentanyl
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],3.9,176361,DB00813,Fentanyl
,12631050,Total plasma concentrations,"Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 microg/ml, respectively.",No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12631050/),[μg] / [ml],1.4,176362,DB00813,Fentanyl
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],0.64,176375,DB00813,Fentanyl
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),,9.35,176376,DB00813,Fentanyl
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],5.53,176377,DB00813,Fentanyl
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],15.3,176378,DB00813,Fentanyl
,3377942,clearance,Calculated clearance of fentanyl was 1.05 +/- 0.38 litre min-1 and was not related to weight or age.,Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[l] / [min],1.05,177042,DB00813,Fentanyl
,3377942,serum concentrations,"Mean serum concentrations of fentanyl in these groups were 1.42 +/- 0.14 (SD) and 1.90 +/- 0.30 ng ml-1, respectively.",Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[ng] / [ml],1.42,177043,DB00813,Fentanyl
,3377942,serum concentrations,"Mean serum concentrations of fentanyl in these groups were 1.42 +/- 0.14 (SD) and 1.90 +/- 0.30 ng ml-1, respectively.",Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[ng] / [ml],1.90,177044,DB00813,Fentanyl
,3377942,Steady-state serum concentrations,Steady-state serum concentrations in this group were 2.15 +/- 0.92 (SD) ng ml-1.,Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),[ng] / [ml],2.15,177045,DB00813,Fentanyl
,3377942,apparent half-life,"Serum concentrations of fentanyl increased slowly (15 h to plateau) and decreased slowly (apparent half-life, 21 h).",Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377942/),h,21,177046,DB00813,Fentanyl
,28001306,plasma concentration (Cp),"In the randomized controlled trial, the authors explored the role of the increase in CO by doxapram (plasma concentration (Cp) 1,000-3,500 ng/mL) on the pharmacokinetics (PKs) and pharmacodynamics (PDs) of the potent opioid alfentanil (Cp 100-200 ng/mL).",Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28001306/),[ng] / [ml],"1,000-3,500",177435,DB00813,Fentanyl
,28001306,Cp,"In the randomized controlled trial, the authors explored the role of the increase in CO by doxapram (plasma concentration (Cp) 1,000-3,500 ng/mL) on the pharmacokinetics (PKs) and pharmacodynamics (PDs) of the potent opioid alfentanil (Cp 100-200 ng/mL).",Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28001306/),[ng] / [ml],100-200,177436,DB00813,Fentanyl
,17457124,time to achieve a recovery of train-of-four ratio,The primary endpoint of the study was the time to achieve a recovery of train-of-four ratio to 0.9.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),,0.9,177448,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,0.9,177449,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,52.1,177450,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,51.7,177451,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,35.6,177452,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.8,177453,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.5,177454,DB00813,Fentanyl
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.4,177455,DB00813,Fentanyl
,17457124,cumulative excretion,The median cumulative excretion of rocuronium in the urine over 24 h was 26% in the placebo group and increased to 58-74% after 4-8 mg/kg sugammadex.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),%,26,177456,DB00813,Fentanyl
,17457124,cumulative excretion,The median cumulative excretion of rocuronium in the urine over 24 h was 26% in the placebo group and increased to 58-74% after 4-8 mg/kg sugammadex.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),%,58-74,177457,DB00813,Fentanyl
,17457124,plasma clearances,"The mean plasma clearances of sugammadex and rocuronium were 0.084 and 0.26 l/min, respectively.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),[l] / [min],0.084,177458,DB00813,Fentanyl
,17457124,plasma clearances,"The mean plasma clearances of sugammadex and rocuronium were 0.084 and 0.26 l/min, respectively.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),[l] / [min],0.26,177459,DB00813,Fentanyl
,22943926,Cmax,"The mean fentanyl Cmax and AUC0-∞ values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pg×h/ml, 4,489 pg×h/ml. respectively.",Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943926/),[pg] / [ml],948,177479,DB00813,Fentanyl
,22943926,Cmax,"The mean fentanyl Cmax and AUC0-∞ values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pg×h/ml, 4,489 pg×h/ml. respectively.",Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943926/),[h·pg] / [ml],"4,439",177480,DB00813,Fentanyl
,22943926,AUC0-∞,"The mean fentanyl Cmax and AUC0-∞ values for SDS and MDS were 948 pg/ml, 949 pg/ml and 4,439 pg×h/ml, 4,489 pg×h/ml. respectively.",Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943926/),[h·pg] / [ml],"4,489",177481,DB00813,Fentanyl
,7486182,half-time,The modelled context-sensitive half-time for a 3-h infusion of alfentanil is 50-55 min and is 3 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,50-55,177586,DB00813,Fentanyl
,7486182,half-time,The modelled context-sensitive half-time for a 3-h infusion of alfentanil is 50-55 min and is 3 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,3,177587,DB00813,Fentanyl
,7486182,terminal elimination half-life,The terminal elimination half-life is 111 min for alfentanil and 12-30 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,111,177588,DB00813,Fentanyl
,7486182,terminal elimination half-life,The terminal elimination half-life is 111 min for alfentanil and 12-30 min for remifentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,12-30,177589,DB00813,Fentanyl
,7486182,half-time,"The measured pharmacokinetic context-sensitive half-time for remifentanil after a 3-h infusion was 3.2 +/- 0.9 min, and its pharmacodynamic offset was 5.4 +/- 1.8 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,3.2,177590,DB00813,Fentanyl
,7486182,half-time,"The measured pharmacokinetic context-sensitive half-time for remifentanil after a 3-h infusion was 3.2 +/- 0.9 min, and its pharmacodynamic offset was 5.4 +/- 1.8 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,5.4,177591,DB00813,Fentanyl
,7486182,context-sensitive half-time,"Alfentanil's measured pharmacokinetic context-sensitive half-time was 47.3 +/- 12 min, and its pharmacodynamic offset was 54.0 +/- 48 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,47.3,177592,DB00813,Fentanyl
,7486182,offset,"Alfentanil's measured pharmacokinetic context-sensitive half-time was 47.3 +/- 12 min, and its pharmacodynamic offset was 54.0 +/- 48 min.",Measured context-sensitive half-times of remifentanil and alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,54.0,177593,DB00813,Fentanyl
,7486182,terminal elimination half-life,The terminal elimination half-life modelled from the volunteers was 11.8 +/- 5.1 min for remifentanil and 76.5 +/- 12.6 min for alfentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,11.8,177594,DB00813,Fentanyl
,7486182,terminal elimination half-life,The terminal elimination half-life modelled from the volunteers was 11.8 +/- 5.1 min for remifentanil and 76.5 +/- 12.6 min for alfentanil.,Measured context-sensitive half-times of remifentanil and alfentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486182/),min,76.5,177595,DB00813,Fentanyl
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),[μg] / [l],6.6,178377,DB00813,Fentanyl
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),[μg] / [l],158,178378,DB00813,Fentanyl
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,13.0,178379,DB00813,Fentanyl
,1874209,maximum levels,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,9.7,178380,DB00813,Fentanyl
,1874209,time,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,13.0,178381,DB00813,Fentanyl
,1874209,time,"The maximum levels of plasma hyoscine (6.6 micrograms l-1) and morphine (158 micrograms l-1) and the time they were reached (13.0 and 9.7 min, respectively) were comparable with the values obtained in earlier studies using young healthy subjects.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),min,9.7,178382,DB00813,Fentanyl
,1874209,elimination half-life,"The elimination half-life of hyoscine in the plasma was 2.4 h, which is somewhat greater than obtained in earlier studies with young healthy patients under regional anaesthesia.",Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),h,2.4,178383,DB00813,Fentanyl
,1874209,t1/2el,Elimination of plasma morphine (t1/2el = 3.3 h) was not significantly altered by the procedure.,Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874209/),h,3.3,178384,DB00813,Fentanyl
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],4.2,178518,DB00813,Fentanyl
,27779354,V2,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],130,178519,DB00813,Fentanyl
,27779354,Q,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·h·kg],6.02,178520,DB00813,Fentanyl
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],2.03,178521,DB00813,Fentanyl
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180275,DB00813,Fentanyl
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180276,DB00813,Fentanyl
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.52,180277,DB00813,Fentanyl
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180278,DB00813,Fentanyl
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180279,DB00813,Fentanyl
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.28,180280,DB00813,Fentanyl
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180281,DB00813,Fentanyl
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180282,DB00813,Fentanyl
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180283,DB00813,Fentanyl
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,34.7,180284,DB00813,Fentanyl
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,10.9,180285,DB00813,Fentanyl
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180286,DB00813,Fentanyl
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.99,180287,DB00813,Fentanyl
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180288,DB00813,Fentanyl
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.69,180289,DB00813,Fentanyl
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180290,DB00813,Fentanyl
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180291,DB00813,Fentanyl
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.16,180292,DB00813,Fentanyl
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,1.0,180293,DB00813,Fentanyl
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.85,180294,DB00813,Fentanyl
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,339,180295,DB00813,Fentanyl
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180296,DB00813,Fentanyl
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,6.7,180297,DB00813,Fentanyl
,16707411,area under the curve (AUCtau),"The mean area under the curve (AUCtau) and peak concentrations (C(max)) of the matrix formulation were 84 838 pg.h/mL and 1680 pg/mL, respectively.","Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16707411/),[h·pg] / [ml],84 838,180929,DB00813,Fentanyl
,16707411,peak concentrations (C(max)),"The mean area under the curve (AUCtau) and peak concentrations (C(max)) of the matrix formulation were 84 838 pg.h/mL and 1680 pg/mL, respectively.","Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16707411/),[pg] / [ml],1680,180930,DB00813,Fentanyl
,16707411,Adherence,"Adherence of the matrix formulation was higher than the reservoir formulation (62.5 vs 56.2%, P < .0001), without affecting skin irritation.","Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16707411/),%,62.5,180931,DB00813,Fentanyl
,16707411,Adherence,"Adherence of the matrix formulation was higher than the reservoir formulation (62.5 vs 56.2%, P < .0001), without affecting skin irritation.","Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16707411/),%,56.2,180932,DB00813,Fentanyl
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],0.3 to 97.3,181080,DB00813,Fentanyl
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],6.7,181081,DB00813,Fentanyl
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],402.8,181082,DB00813,Fentanyl
,8541435,total dose,Over a period of 69.2 +/- 39.8 min during resection of the tumor the total dose was 7017 +/- 12433 micrograms.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),μg,7017,181083,DB00813,Fentanyl
,19918182,maximum concentration,"After subcutaneous bolus dose administration, the median maximum concentration of fentanyl was 0.55 ng ml(-1) (range 0.28-0.87 ng ml(-1)), reached at a median time of 15 min (range 10-30 min).",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),[ng] / [ml],0.55,181497,DB00813,Fentanyl
,19918182,terminal half-life,The terminal half-life was 10.00 h (range 5.48-16.37 h).,Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,10.00,181498,DB00813,Fentanyl
,19918182,terminal half-life,"Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer (10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes.",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,10,181499,DB00813,Fentanyl
,19918182,terminal half-life,"Absorption of subcutaneous fentanyl was relatively rapid and similar to the rate of absorption previously reported for subcutaneous morphine; the terminal half-life for fentanyl was substantially longer (10 h) than that of morphine (2.1 h), and blood concentrations were no more variable than that after administration by other nonintravenous routes.",Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19918182/),h,2.1,181500,DB00813,Fentanyl
,23458227,Cmax,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[pg] / [ml],453.0,181662,DB00813,Fentanyl
,23458227,Cmax,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[pg] / [ml],467.8,181663,DB00813,Fentanyl
,23458227,AUCt,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,292.3",181664,DB00813,Fentanyl
,23458227,AUCt,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,325.4",181665,DB00813,Fentanyl
,23458227,AUC0-∞,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,430.6",181666,DB00813,Fentanyl
,23458227,AUC0-∞,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],"1,387",181667,DB00813,Fentanyl
,23458227,tmax,"Measures of fentanyl absorption (mean or median) were similar between Control and Rhinitis conditions: Cmax 453.0 vs. 467.8 pg/ml; AUCt 1,292.3 vs. 1,325.4 pg×h/ml, AUC0-∞ 1,430.6 vs. 1,387 pg×h/ml and tmax 20 vs.",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),,20,181668,DB00813,Fentanyl
,23458227,AUC0-∞,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],1,181669,DB00813,Fentanyl
,23458227,AUC0-∞,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[h·pg] / [ml],362.4,181670,DB00813,Fentanyl
,23458227,rate of absorption (tmax,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),min,53,181671,DB00813,Fentanyl
,23458227,Cmax,"When oxymetazoline was co-administered, overall fentanyl absorption was slightly reduced (AUC0-∞ 1,362.4 pg×h/ml); but, more clinically relevant were the delayed rate of absorption (tmax 53 minutes) and reduced Cmax (235.3 pg/ml).",Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23458227/),[pg] / [ml],235.3,181672,DB00813,Fentanyl
,33330726,plasma concentration,"Ingestion of an FTP was not observed but the fentanyl plasma concentration on the day of intoxication was 20.7 ng/ml, while at its peak after FTP administration it was only 0.492 ng/ml.",Case Report: Intoxication in a Pig (Sus Scrofa Domesticus) After Transdermal Fentanyl Patch Ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33330726/),,20.,182127,DB00813,Fentanyl
,20645689,bioavailability,"Intranasal fentanyl has a bioavailability of 89%, with a short onset of action ( approximately 7 min) and duration times ( approximately 1 h).",Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20645689/),%,89,182162,DB00813,Fentanyl
,6869758,half-life,The postinfusion plasma etomidate concentration was described by a three compartment model with a mean half-life of 540 minutes (SEM 66.9) and volume of distribution of 8.9 litres/kg (SEM 0.6).,Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869758/),min,540,182304,DB00813,Fentanyl
,6869758,volume of distribution,The postinfusion plasma etomidate concentration was described by a three compartment model with a mean half-life of 540 minutes (SEM 66.9) and volume of distribution of 8.9 litres/kg (SEM 0.6).,Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869758/),[l] / [kg],8.9,182305,DB00813,Fentanyl
,6869758,Clearance,Clearance was 12.7 ml/kg/minute (SEM 2.3).,Etomidate anaesthesia in patients with cirrhosis of the liver: pharmacokinetic data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6869758/),[ml] / [kg·min],12.7,182306,DB00813,Fentanyl
,8311274,elimination half-time (t1/2 beta,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),min,180,182815,DB00813,Fentanyl
,8311274,central distribution volume (Vc,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.25,182816,DB00813,Fentanyl
,8311274,total volume of distribution (Vdss,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.63,182817,DB00813,Fentanyl
,8311274,Vd area,"Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound.",Alfentanil pharmacokinetics in cardiac surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311274/),[l] / [kg],0.92,182818,DB00813,Fentanyl
more,28455212,elimination half-life,Plasma concentrations of tramadol rapidly decreased in the first 2 hours for both doses with an elimination half-life of more than 40 minutes.,Cardiovascular effects and intraoperative pharmacokinetics of tramadol in sheep undergoing spinal surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28455212/),min,40,183661,DB00813,Fentanyl
,9914653,rate of excretion,"The rate of excretion of bupivacaine enantiomers' approximated a steady state after approximately 30 hr with values of 1.27 +/- 0.26 and 0.76 +/- 0.13 mg hr-1 for (R)- and (S)-enantiomers, respectively.",Stereoselective urinary excretion of bupivacaine and its metabolites during epidural infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914653/),[mg] / [h],1.27,184281,DB00813,Fentanyl
,9914653,rate of excretion,"The rate of excretion of bupivacaine enantiomers' approximated a steady state after approximately 30 hr with values of 1.27 +/- 0.26 and 0.76 +/- 0.13 mg hr-1 for (R)- and (S)-enantiomers, respectively.",Stereoselective urinary excretion of bupivacaine and its metabolites during epidural infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914653/),[mg] / [h],0.76,184282,DB00813,Fentanyl
,31601999,total clearance,Mean estimated total clearance of fentanyl and mean metabolic clearance of midazolam (as a marker of CYP3A activity) were 75.5 and 36.3 L/h.,Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31601999/),[l] / [h],75.5,184567,DB00813,Fentanyl
,31601999,metabolic clearance,Mean estimated total clearance of fentanyl and mean metabolic clearance of midazolam (as a marker of CYP3A activity) were 75.5 and 36.3 L/h.,Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31601999/),[l] / [h],36.3,184568,DB00813,Fentanyl
,16855177,dissociation (k(off)),"The values of the parameter estimates of the rate constants for biophase distribution (k(eo)), receptor association (k(on)), and dissociation (k(off)) were 0.0348 min(-1) [95% confidence interval (CI), 0.0193-0.0503 min(-1)], 0.57 ml/ng/min (95% CI, 0.38-0.76 ml/ng/min), and 0.0903 min(-1) (95% CI, 0.035-0.196 min(-1)), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855177/),1/[min],0.0903,184681,DB00813,Fentanyl
,16855177,equilibrium dissociation constant,"The values of the equilibrium dissociation constant and intrinsic activity were 0.16 ng/ml and 0.48 (95% CI, 0.45-0.51), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855177/),[ng] / [ml],0.16,184682,DB00813,Fentanyl
,16855177,intrinsic activity,"The values of the equilibrium dissociation constant and intrinsic activity were 0.16 ng/ml and 0.48 (95% CI, 0.45-0.51), respectively.",Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855177/),,0.48,184683,DB00813,Fentanyl
,9403781,clearance,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[min·ml] / [kg],53,184989,DB00813,Fentanyl
,9403781,volume of distribution,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[l] / [kg],1.19,184990,DB00813,Fentanyl
,9403781,terminal half-life,"The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml.min/kg, volume of distribution = 1.19 +/- 0.19 l/kg and terminal half-life = 24.5 +/- 2.3 min.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),min,24.5,184991,DB00813,Fentanyl
,9403781,E0,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),μv,57,184992,DB00813,Fentanyl
,9403781,Emax,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),μv,95,184993,DB00813,Fentanyl
,9403781,EC50,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),[ng] / [ml],202,184994,DB00813,Fentanyl
,9403781,Hill factor,"The values of the pharmacodynamic parameters were (mean +/- SE, n = 7): E0 = 57 +/- 4 microV, Emax = 95 +/- 17 microV, EC50 = 202 +/- 55 ng/ml and Hill factor = 1.53 +/- 0.20.",Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403781/),,1.53,184995,DB00813,Fentanyl
,8703661,rate,Plasma concentrations of fentanyl were measured by g.c. in 20 patients (median age: 75 years and range: 54-86 years; eight females) in palliative care receiving the drug by continuous s.c. infusion (median rate: 1200 micrograms day-1 and range: 100-5000 micrograms day-1).,Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703661/),,1200,185054,DB00813,Fentanyl
,8703661,total steady-state plasma concentrations,"The total steady-state plasma concentrations of fentanyl ranged between 0.1 and 9 ng ml-1, with a median of 1 ng ml-1.",Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703661/),[ng] / [ml],1,185055,DB00813,Fentanyl
,8703661,unbound fraction,"The unbound fraction of fentanyl in the plasma ranged from 17.8 to 44.4%, with a median value of 33.6%.",Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703661/),%,17.8 to 44.4,185056,DB00813,Fentanyl
,8703661,unbound fraction,"The unbound fraction of fentanyl in the plasma ranged from 17.8 to 44.4%, with a median value of 33.6%.",Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703661/),%,33.6,185057,DB00813,Fentanyl
,10850844,elimination half-life,"Plasma concentrations of fentanyl given IV decreased rapidly (mean elimination half-life, 2.35 +/- 0.57 hours).",Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850844/),h,2.35,185252,DB00813,Fentanyl
,10850844,rate of transdermal delivery,Mean +/- SEM calculated rate of transdermal delivery of fentanyl was 8.48 +/- 1.7 mg/h (< 36% of the theoretical 25 mg/h).,Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850844/),[mg] / [h],8.48,185253,DB00813,Fentanyl
,10850844,rate of transdermal delivery,Mean +/- SEM calculated rate of transdermal delivery of fentanyl was 8.48 +/- 1.7 mg/h (< 36% of the theoretical 25 mg/h).,Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850844/),,25,185254,DB00813,Fentanyl
,10850844,steady-state concentration,Median steady-state concentration of fentanyl 12 to 100 hours after application of the transdermal patch was 1.58 ng/ml.,Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850844/),[ng] / [ml],1.58,185255,DB00813,Fentanyl
,30867551,peak occupancies,"Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively.",Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30867551/),%,67,186162,DB00813,Fentanyl
,30867551,peak occupancies,"Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively.",Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30867551/),%,85,186163,DB00813,Fentanyl
,30867551,half-life of occupancy disappearance,The estimated half-life of occupancy disappearance was ~100 min.,Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30867551/),min,100,186164,DB00813,Fentanyl
,15087613,elimination clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.1,186485,DB00813,Fentanyl
,15087613,elimination clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],1.9,186486,DB00813,Fentanyl
,15087613,distribution clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.7,186487,DB00813,Fentanyl
,15087613,distribution clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.0,186488,DB00813,Fentanyl
,15087613,peripheral volume of distribution,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),l,179,186489,DB00813,Fentanyl
,15087613,peripheral volume of distribution,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),l,141,186490,DB00813,Fentanyl
,10069275,Total sufen,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186592,DB00813,Fentanyl
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186593,DB00813,Fentanyl
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μ,610,186594,DB00813,Fentanyl
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,14.4,186595,DB00813,Fentanyl
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,11.2,186596,DB00813,Fentanyl
,10069275,Plasma,Plasma sufentanil concentrations at extubation were similar in both groups (0.5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],0.5,186597,DB00813,Fentanyl
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],17,186598,DB00813,Fentanyl
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],23,186599,DB00813,Fentanyl
,29498947,Bioavailability,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.",Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),%,52,187661,DB00813,Fentanyl
,29498947,Bioavailability,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.",Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),%,35,187662,DB00813,Fentanyl
,29498947,Time for concentrations to decrease 50% from maximal,Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5 ± 0.85 h) and 12 doses (2.5 ± 0.72 h).,Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),h,2.5,187663,DB00813,Fentanyl
,29498947,Time for concentrations to decrease 50% from maximal,Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5 ± 0.85 h) and 12 doses (2.5 ± 0.72 h).,Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),h,2.5,187664,DB00813,Fentanyl
,3954128,Total drug clearance,Total drug clearance was 9.8 +/- 1.8 ml X min-1 X kg-1.,Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954128/),[ml] / [kg·min],9.8,187973,DB00813,Fentanyl
,3954128,volume of distribution at steady-state (Vdss),The volume of distribution at steady-state (Vdss) was 5.4 +/- 1.9 X 1 kg-1.,Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954128/),[1] / [kg],5.4,187974,DB00813,Fentanyl
,3954128,Elimination half-time,Elimination half-time was 8.7 +/- 2.5 h.,Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954128/),h,8.7,187975,DB00813,Fentanyl
,3954128,elimination half-times,"In healthy volunteers or patients undergoing general surgery, other investigators report mean elimination half-times for fentanyl ranging from 1.7 to 4.4 h.",Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954128/),h,1.7 to 4.4,187976,DB00813,Fentanyl
,8424569,limit of detection,A gas chromatographic/mass spectrometry method was used to assay fentanyl (limit of detection 0.2 ng/ml).,Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424569/),[ng] / [ml],0.2,188280,DB00813,Fentanyl
,8424569,maximum concentration,"For the fifth dose, the mean (SD) maximum concentration was 2.6 (1.3) ng/ml and the mean (SD) area under the serum fentanyl concentration-time curve (0-72 h) was 116.9 (59.9).",Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424569/),[ng] / [ml],2.6,188281,DB00813,Fentanyl
,8424569,area under the serum fentanyl concentration-time curve (0-72 h),"For the fifth dose, the mean (SD) maximum concentration was 2.6 (1.3) ng/ml and the mean (SD) area under the serum fentanyl concentration-time curve (0-72 h) was 116.9 (59.9).",Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424569/),,116.9,188282,DB00813,Fentanyl
,8424569,apparent half-life,"Following removal of the system, the mean (SD) apparent half-life was 21.9 (8.9) h.",Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424569/),h,21.9,188283,DB00813,Fentanyl
,17428913,clearance (CL,"Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central compartment volume (V(1), 0.37 vs 0.61 L/kg), and total volume of distribution (V(area), 3.6 vs 5.8 L/kg) were higher in burned patients.",Fentanyl clearance and volume of distribution are increased in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428913/),[ml] / [kg·min],21.0,189683,DB00813,Fentanyl
,17428913,clearance (CL,"Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central compartment volume (V(1), 0.37 vs 0.61 L/kg), and total volume of distribution (V(area), 3.6 vs 5.8 L/kg) were higher in burned patients.",Fentanyl clearance and volume of distribution are increased in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428913/),[ml] / [kg·min],29.4,189684,DB00813,Fentanyl
,17428913,central compartment volume (V(1),"Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central compartment volume (V(1), 0.37 vs 0.61 L/kg), and total volume of distribution (V(area), 3.6 vs 5.8 L/kg) were higher in burned patients.",Fentanyl clearance and volume of distribution are increased in patients with major burns. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428913/),[l] / [kg],0.37,189685,DB00813,Fentanyl
,17428913,central compartment volume (V(1),"Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central compartment volume (V(1), 0.37 vs 0.61 L/kg), and total volume of distribution (V(area), 3.6 vs 5.8 L/kg) were higher in burned patients.",Fentanyl clearance and volume of distribution are increased in patients with major burns. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428913/),[l] / [kg],0.61,189686,DB00813,Fentanyl
,17428913,total volume of distribution (V(area),"Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central compartment volume (V(1), 0.37 vs 0.61 L/kg), and total volume of distribution (V(area), 3.6 vs 5.8 L/kg) were higher in burned patients.",Fentanyl clearance and volume of distribution are increased in patients with major burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428913/),[l] / [kg],3.6,189687,DB00813,Fentanyl
,17428913,total volume of distribution (V(area),"Median fentanyl clearance (CL, 21.0 vs 29.4 mL/kg/min), central compartment volume (V(1), 0.37 vs 0.61 L/kg), and total volume of distribution (V(area), 3.6 vs 5.8 L/kg) were higher in burned patients.",Fentanyl clearance and volume of distribution are increased in patients with major burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17428913/),[l] / [kg],5.8,189688,DB00813,Fentanyl
,15268689,MAC,The baseline isoflurane MAC was 1.51 +/- 0.21% (mean +/- SD).,Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15268689/),%,1.51,189985,DB00813,Fentanyl
,15268689,MAC,Isoflurane MAC determined during administration of fentanyl 25 micro g hour(-1) and naloxone (1.44 +/- 0.16%) and fentanyl 50 micro g hour(-1) and naloxone (1.51 +/- 0.19%) was not significantly different from baseline MAC (1.51 +/- 0.21%).,Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15268689/),%,1,189986,DB00813,Fentanyl
,3148286,infusion rate,The infusion rate was reduced to 0.5 microgram/kg/min after ten minutes.,A comparison of alfentanil requirements in European and Asian patients during general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148286/),[μg] / [kg·min],0.5,189989,DB00813,Fentanyl
,34407992,CLint,Fetal hepatic clearance of fentanyl was predicted from CYP3A7 mediated norfentanyl formation in fetal liver microsomes (CLint = 0.20 {plus minus} 0.05 µL/min/mg protein).,Predicting maternal-fetal disposition of fentanyl following intravenous and epidural administration using physiologically-based pharmacokinetic modeling. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34407992/),[μl] / [mg·min],0.20,190221,DB00813,Fentanyl
,2960465,central compartment concentration,"At that point, an infusion of sufentanil, aimed to reach a central compartment concentration of 5 ng.",Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,5,190294,DB00813,Fentanyl
,2960465,Plasma concentrations,Plasma concentrations of sufentanil reached 3.8 +/- 0.4 ng.,Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,3.8,190295,DB00813,Fentanyl
,28921282,infusion rate,The infusion rate of ketamine was 2 mg·kg-1·hr-1 following a bolus administration of 1.5 mg·kg-1 for the induction of anesthesia.,Pharmacokinetics of ketamine during hypothermic cardiopulmonary bypass in cardiac patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921282/),[mg] / [h·kg],2,190367,DB00813,Fentanyl
,31806432,target plasma concentration (TPC),"Dogs were allocated to group fTCI [target plasma concentration (TPC) 1 ng mL-1] or group PNB (nerve stimulator-guided femoral-sciatic block using 0.2 and 0.1 mL kg-1 of levobupivacaine 0.5%, respectively).",Peripheral nerve block versus systemic analgesia in dogs undergoing tibial plateau levelling osteotomy: Analgesic efficacy and pharmacoeconomics comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806432/),[ng] / [ml],1,190829,DB00813,Fentanyl
,30793320,clearance,"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ml] / [kg·min],20.1,190898,DB00813,Fentanyl
,30793320,clearance,"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ml] / [kg·min],13.2,190899,DB00813,Fentanyl
,30793320,area under the plasma concentration curve (AUC),"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ng] / [min·ml],150,190900,DB00813,Fentanyl
,30793320,area under the plasma concentration curve (AUC),"Fentanyl clearance was significantly higher in the carbamazepine group compared to controls (mean ± SD: 20.1 ± 6.8 vs 13.2 ± 4.8 ml/min per kg, P < 0.05), and area under the plasma concentration curve (AUC) was significantly lower (150 ± 65 vs 233 ± 70 ng/ml × min, P < 0.02).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[ng] / [min·ml],233,190901,DB00813,Fentanyl
,30793320,Volume of distribution,"Volume of distribution was larger in the carbamazepine group, but the difference was not statistically significant (5.4 ± 3.1 vs 3.6 ± 1.2 l/kg, P > 0.15).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[l] / [kg],5.4,190902,DB00813,Fentanyl
,30793320,Volume of distribution,"Volume of distribution was larger in the carbamazepine group, but the difference was not statistically significant (5.4 ± 3.1 vs 3.6 ± 1.2 l/kg, P > 0.15).",Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30793320/),[l] / [kg],3.6,190903,DB00813,Fentanyl
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],136,191220,DB00813,Fentanyl
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],157,191221,DB00813,Fentanyl
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],209,191222,DB00813,Fentanyl
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0675,191223,DB00813,Fentanyl
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0568,191224,DB00813,Fentanyl
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0478,191225,DB00813,Fentanyl
,7426257,initial half-life,Before cardiopulmonary bypass the kinetics can be described by a biexponential decay curve with an initial half-life of 1.7 +/- 0.85 min and a half-life during the tissue uptake phase of 69 +/- 8.2 min.,Pharmacokinetics of high-dose fentanyl. A study in patients undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426257/),min,1.7,191662,DB00813,Fentanyl
,7426257,half-life during the tissue uptake phase,Before cardiopulmonary bypass the kinetics can be described by a biexponential decay curve with an initial half-life of 1.7 +/- 0.85 min and a half-life during the tissue uptake phase of 69 +/- 8.2 min.,Pharmacokinetics of high-dose fentanyl. A study in patients undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426257/),min,69,191663,DB00813,Fentanyl
,7426257,half-life,The half-life in the post-bypass elimination phase was 423 +/- 36.9 min.,Pharmacokinetics of high-dose fentanyl. A study in patients undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7426257/),min,423,191664,DB00813,Fentanyl
,3134933,total plasma clearance,The total plasma clearance ranged between 93 and 431 ml min-1 (mean 249 ml min-1).,Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[ml] / [min],249,191911,DB00813,Fentanyl
,3134933,apparent volume of distribution at steady-state,The apparent volume of distribution at steady-state ranged between 0.27 and 0.64 litre kg-1 (mean 0.44 litre kg-1).,Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[l] / [kg],0.44,191912,DB00813,Fentanyl
,3134933,apparent volume of distribution (Vd beta),"The apparent volume of distribution (Vd beta) was 0.58 litre kg-1, resulting in a terminal half-life of 112 min.",Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),[l] / [kg],0.58,191913,DB00813,Fentanyl
,3134933,terminal half-life,"The apparent volume of distribution (Vd beta) was 0.58 litre kg-1, resulting in a terminal half-life of 112 min.",Pharmacokinetics of alfentanil in total i.v. anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134933/),min,112,191914,DB00813,Fentanyl
,6650910,terminal elimination half-time (t 1/2 beta,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),min,211,192168,DB00813,Fentanyl
,6650910,apparent volume of distribution,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),[l] / [kg],9.5,192169,DB00813,Fentanyl
,6650910,volume of the central compartment,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),[l] / [kg],1.14,192170,DB00813,Fentanyl
,6650910,clearance,"The terminal elimination half-time (t 1/2 beta = 211 min), the apparent volume of distribution (9.5 l X kg-1), the volume of the central compartment (1.14 l X kg-1), and the clearance (37 ml X kg-1 X min-1) of fentanyl were independent of dose over the 6.4-640 micrograms X kg-1 dose range.",Dose-independent pharmacokinetics of fentanyl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650910/),[ml] / [kg·min],37,192171,DB00813,Fentanyl
,18081355,AUC from time 0 to t(max'),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),[h·ng] / [ml],0.35,192212,DB00813,Fentanyl
,18081355,time to C(max),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),[h·ng] / [ml],0.35,192213,DB00813,Fentanyl
,18081355,time to C(max),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),h,0.75,192214,DB00813,Fentanyl
,18081355,time to C(max),"Buccal and sublingual placement resulted in similar values for both AUC from time 0 to t(max') (AUC(tmax')), where t(max') is the median time to C(max) of a single 400-microg dose of FBT administered buccally (mean [SD]: 0.35 [0.16] ng . h/mL buccal; 0.35 [0.16] ng . h/mL sublingual) and for time to C(max) (median [range]: 0.75 [0.33-3.13] hours buccal; 0.78 [0.17-3.00] hours sublingual).",Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18081355/),h,0.78,192215,DB00813,Fentanyl
,10969297,plasma target concentrations,The range of plasma target concentrations was 2-5 microgram/ml for propofol and 0.2-1 ng/ml for sufentanil.,Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),[μg] / [ml],2-5,192254,DB00813,Fentanyl
,10969297,plasma target concentrations,The range of plasma target concentrations was 2-5 microgram/ml for propofol and 0.2-1 ng/ml for sufentanil.,Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),[ng] / [ml],0.2-1,192255,DB00813,Fentanyl
,10969297,wobble,"The wobble values were 11.6% and 22.3% for propofol and sufentanil, respectively.",Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),%,11.6,192256,DB00813,Fentanyl
,10969297,wobble,"The wobble values were 11.6% and 22.3% for propofol and sufentanil, respectively.",Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),%,22.3,192257,DB00813,Fentanyl
,15956985,t(1/2),The mean t(1/2) of nalmefene was 13.4 h after single and repeated dosing.,Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956985/),h,13.4,193356,DB00813,Fentanyl
,15956985,occupancy,High nalmefene occupancy (83-100%) persisted at 26 h after the dosings.,Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956985/),%,83-100,193357,DB00813,Fentanyl
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],11.1,195168,DB00813,Fentanyl
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],8.3,195169,DB00813,Fentanyl
,21388844,peak concentration (C(MAX)),Fentanyl was rapidly absorbed with a mean peak concentration (C(MAX)) of 3.56ng/mL at 0.24h.,Pharmacokinetics of subcutaneous fentanyl in Greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21388844/),[ng] / [ml],3.56,195524,DB00813,Fentanyl
,21388844,terminal half-life,"The mean terminal half-life, volume of distribution per bioavailability, and clearance per bioavailability were 2.97h, 7.09L/kg, 27.60mL/min/kg, respectively.",Pharmacokinetics of subcutaneous fentanyl in Greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21388844/),h,2.97,195525,DB00813,Fentanyl
,21388844,volume of distribution per bioavailability,"The mean terminal half-life, volume of distribution per bioavailability, and clearance per bioavailability were 2.97h, 7.09L/kg, 27.60mL/min/kg, respectively.",Pharmacokinetics of subcutaneous fentanyl in Greyhounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21388844/),[l] / [kg],7.09,195526,DB00813,Fentanyl
,21388844,clearance per bioavailability,"The mean terminal half-life, volume of distribution per bioavailability, and clearance per bioavailability were 2.97h, 7.09L/kg, 27.60mL/min/kg, respectively.",Pharmacokinetics of subcutaneous fentanyl in Greyhounds. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21388844/),[ml] / [kg·min],27.60,195527,DB00813,Fentanyl
,1317685,Onset time,"Onset time in the elderly was prolonged (6.9 +/- 2.6 vs 4.3 +/- 1.5 min, P less than 0.02).",Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317685/),min,6.9,195672,DB00813,Fentanyl
,1317685,Onset time,"Onset time in the elderly was prolonged (6.9 +/- 2.6 vs 4.3 +/- 1.5 min, P less than 0.02).",Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317685/),min,4.3,195673,DB00813,Fentanyl
,32533977,Ki,"Using radioligand binding assays, U-47700 displayed high affinity for μ-opioid receptors (Ki = 11.1 nM) whereas metabolites were more than 18-fold weaker.","Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32533977/),nM,11.1,196033,DB00813,Fentanyl
,17185999,half-time,"The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,16.4,196163,DB00813,Fentanyl
,17185999,half-time,"The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,75.3,196164,DB00813,Fentanyl
,17185999,"t(1/2, k(eo))","The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,16.4,196165,DB00813,Fentanyl
,17185999,"t(1/2, k(eo))","The half-time values of biophase equilibration (t(1/2, k(eo))) were 16.4 and 75.3 min for fentanyl and buprenorphine, respectively.",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),min,75.3,196166,DB00813,Fentanyl
,17185999,k(on),"In addition, for buprenorphine, the value of k(on) was 0.246 ml/ng/min and the value of k(off) was 0.0102 min(-1).",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),[ml] / [min·ng],0.246,196167,DB00813,Fentanyl
,17185999,k(off),"In addition, for buprenorphine, the value of k(on) was 0.246 ml/ng/min and the value of k(off) was 0.0102 min(-1).",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),1/[min],0.0102,196168,DB00813,Fentanyl
,17185999,intrinsic activity alpha,"The concentration-effect relationship of buprenorphine was characterized by a ceiling effect at higher concentrations (intrinsic activity alpha=0.56, 95% confidence interval (CI): 0.50-0.62), whereas fentanyl displayed full respiratory depressant effect (alpha=0.91, 95% CI: 0.19-1.62).",Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17185999/),,0.56,196169,DB00813,Fentanyl
,8518376,plasma midazolam,"The plasma midazolam level for induction was 196 +/- 139 ng/mL in the CACI group and 300 +/- 128 ng/mL in the MCI group, and the fentanyl level was similar in both groups, 6.7 +/- 1.9 ng/mL in CACI and 6.3 +/- 4.6 ng/mL in the MCI group.",Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8518376/),[ng] / [ml],196,196314,DB00813,Fentanyl
,8518376,plasma midazolam,"The plasma midazolam level for induction was 196 +/- 139 ng/mL in the CACI group and 300 +/- 128 ng/mL in the MCI group, and the fentanyl level was similar in both groups, 6.7 +/- 1.9 ng/mL in CACI and 6.3 +/- 4.6 ng/mL in the MCI group.",Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8518376/),[ng] / [ml],300,196315,DB00813,Fentanyl
,8518376,duration,"In the MCI group, the average duration of anesthesia was 246.5 +/- 35.0 minutes, with a mean total fentanyl dose of 30.27 +/- 11.14 micrograms/kg.",Midazolam and fentanyl continuous infusion anesthesia for cardiac surgery: a comparison of computer-assisted versus manual infusion systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8518376/),min,246,196316,DB00813,Fentanyl
,1829656,Onset time until maximum block,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.7,197004,DB00813,Fentanyl
,1829656,duration until,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,53,197005,DB00813,Fentanyl
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.8,197006,DB00813,Fentanyl
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,19,197007,DB00813,Fentanyl
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,131,197008,DB00813,Fentanyl
,1829656,distribution volume at steady-state,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[l] / [kg],0.264,197009,DB00813,Fentanyl
,1829656,plasma clearance,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[ml] / [kg·min],4.0,197010,DB00813,Fentanyl
,1829656,Plasma concentration at 25% recovery of the twitch height,Plasma concentration at 25% recovery of the twitch height was 1.0 mg.L-1.,"The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[mg] / [l],1.0,197011,DB00813,Fentanyl
,24982551,plasma concentrations,Mean fentanyl plasma concentrations did not differ (P ≥ 0.05) between T1 (3.70 ± 0.56 ng/mL) and T3 (3.50 ± 0.56 ng/mL).,The interaction of nitrous oxide and fentanyl on the minimum alveolar concentration of sevoflurane blocking motor movement (MACNM) in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24982551/),[ng] / [ml],3.70,197770,DB00813,Fentanyl
,24982551,plasma concentrations,Mean fentanyl plasma concentrations did not differ (P ≥ 0.05) between T1 (3.70 ± 0.56 ng/mL) and T3 (3.50 ± 0.56 ng/mL).,The interaction of nitrous oxide and fentanyl on the minimum alveolar concentration of sevoflurane blocking motor movement (MACNM) in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24982551/),[ng] / [ml],3.50,197771,DB00813,Fentanyl
,1467073,protein binding,The mean protein binding of alfentanil was 94.2 (SEM 0.05)% in the burns group and 90.7 (0.4)% in the control group (P = 0.004).,Disposition of alfentanil in burns patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467073/),%,94.2,197958,DB00813,Fentanyl
,1467073,protein binding,The mean protein binding of alfentanil was 94.2 (SEM 0.05)% in the burns group and 90.7 (0.4)% in the control group (P = 0.004).,Disposition of alfentanil in burns patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467073/),%,90.7,197959,DB00813,Fentanyl
,29603262,Terminal elimination half-life,"Terminal elimination half-life was estimated at 12.7 and 3.6 hr for fentanyl and norfentanyl, respectively.",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),h,12.7,198068,DB00813,Fentanyl
,29603262,Terminal elimination half-life,"Terminal elimination half-life was estimated at 12.7 and 3.6 hr for fentanyl and norfentanyl, respectively.",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),h,3.6,198069,DB00813,Fentanyl
,29603262,systemic clearance,"For fentanyl, systemic clearance was estimated at 2.0 L hr-1 kg-1 , volume of distribution at steady-state was 24.8 L/kg and extraction ratio was 0.42.",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),[l] / [h·kg],2.0,198070,DB00813,Fentanyl
,29603262,volume of distribution at steady-state,"For fentanyl, systemic clearance was estimated at 2.0 L hr-1 kg-1 , volume of distribution at steady-state was 24.8 L/kg and extraction ratio was 0.42.",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),[l] / [kg],24.8,198071,DB00813,Fentanyl
,29603262,extraction ratio,"For fentanyl, systemic clearance was estimated at 2.0 L hr-1 kg-1 , volume of distribution at steady-state was 24.8 L/kg and extraction ratio was 0.42.",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),,0.42,198072,DB00813,Fentanyl
,29603262,half-life,"At a hypothetical LLOQ of 0.05 ng/ml fentanyl half-life, volume of distribution at steady-state and clearance were, respectively, of 3.0 hr, 8.8 L/kg and 3.4 L kg-1 hr-1 .",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),h,3.0,198073,DB00813,Fentanyl
,29603262,volume of distribution at steady-state,"At a hypothetical LLOQ of 0.05 ng/ml fentanyl half-life, volume of distribution at steady-state and clearance were, respectively, of 3.0 hr, 8.8 L/kg and 3.4 L kg-1 hr-1 .",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),[l] / [kg],8.8,198074,DB00813,Fentanyl
,29603262,clearance,"At a hypothetical LLOQ of 0.05 ng/ml fentanyl half-life, volume of distribution at steady-state and clearance were, respectively, of 3.0 hr, 8.8 L/kg and 3.4 L kg-1 hr-1 .",Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29603262/),[l] / [h·kg],3.4,198075,DB00813,Fentanyl
,12923616,duration of sedation,The mean duration of sedation was 12+/-7 days.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),d,12,198213,DB00813,Fentanyl
,12923616,initial half-life t(1/2alpha),The initial half-life t(1/2alpha) was 1.33+/-1.15 h.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,1.33,198214,DB00813,Fentanyl
,12923616,elimination half-life (t(1/2beta),The observed prolonged elimination half-life (t(1/2beta)=25.5+/-9.4 h) was related to the large volume of distribution (Vdbeta=22.6+/-9.4 l/kg).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,25.5,198215,DB00813,Fentanyl
,12923616,volume of distribution (Vdbeta,The observed prolonged elimination half-life (t(1/2beta)=25.5+/-9.4 h) was related to the large volume of distribution (Vdbeta=22.6+/-9.4 l/kg).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),[l] / [kg],22.6,198216,DB00813,Fentanyl
,12923616,total clearance,The mean total clearance was 13.4+/-7.0 ml/kg per minute.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),[ml] / [kg·min],13.4,198217,DB00813,Fentanyl
,12923616,tcp(0/2,The mean time required to obtain a 50% decrease in plasma concentration was short (tcp(0/2=)4.7+/-3.7 h).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,4.7,198218,DB00813,Fentanyl
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,11.63,199186,DB00813,Fentanyl
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,13.23,199187,DB00813,Fentanyl
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,16.97,199188,DB00813,Fentanyl
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,22.3,199189,DB00813,Fentanyl
,24424109,Cmax,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),[ng] / [ml],0.789,199361,DB00813,Fentanyl
,24424109,Cmax,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),[ng] / [ml],0.821,199362,DB00813,Fentanyl
,24424109,tmax,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),h,45.3,199363,DB00813,Fentanyl
,24424109,tmax,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),h,41.2,199364,DB00813,Fentanyl
,24424109,t1/2,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),h,21.5,199365,DB00813,Fentanyl
,24424109,t1/2,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),h,22.6,199366,DB00813,Fentanyl
,24424109,AUC0-T,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),[ng] / [h·ml],52.5,199367,DB00813,Fentanyl
,24424109,AUC0-T,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),[ng] / [h·ml],55.7,199368,DB00813,Fentanyl
,24424109,AUC0-∞,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),[ng] / [h·ml],54.6,199369,DB00813,Fentanyl
,24424109,AUC0-∞,"The value of two formulations was as follows: Cmax, 0.789 (0.256) and 0.821 (0.278) ng/mL; tmax, 45.3 and 41.2 h; t1/2, 21.5 (8.8) and 22.6 (7.2) h; AUC0-T, 52.5 (18.6) and 55.7 (19.7) ng/mL×h; and AUC0-∞, 54.6 (19.3) and 57.5 (21.1) ng/mL×h, respectively.",Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24424109/),[ng] / [h·ml],57.5,199370,DB00813,Fentanyl
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],4.48,199576,DB00813,Fentanyl
,7739943,Plasma clearance,Plasma clearance was greater during isoflurane than during balanced anesthesia (4.48 vs 3.49 ml/kg/min).,The effect of isoflurane versus balanced anesthesia on rocuronium's pharmacokinetics and infusion requirement. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7739943/),[ml] / [kg·min],3.49,199577,DB00813,Fentanyl
,15907650,half-lives,Alfentanil and remifentanil are very fast equilibrating opioids with equilibration half-lives between plasma and effect site of about 1 minute.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,1,199979,DB00813,Fentanyl
,15907650,half-lives,"They are followed by fentanyl and sufentanil, each with equilibration half-lives of about 6 min.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,6,199980,DB00813,Fentanyl
,15907650,half-life,Methadone equilibrates with a half-life of about 8 min.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,8,199981,DB00813,Fentanyl
,15907650,half-life,"Morphine, in contrast, equilibrates with a half-life of 2-3 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,2-3,199982,DB00813,Fentanyl
,15907650,half-life,"The slowest opioid with respect to plasma-effect site transfer is M6G, with an equilibration half-life of about 7 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,7,199983,DB00813,Fentanyl
,26861166,clearance,"Fentanyl clearance for a 6.4 kg child, the median weight in our cohort, is 5.7 l h(-1) (2.2-9.2 l h(-1) ), similar to values found in prior formal PK studies.",Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861166/),[l] / [h],5.7,200068,DB00813,Fentanyl
,18027600,half-time,"For this reason the context-sensitive half-time of remifentanil is only 3-5 min, irrespective of the duration of infusion; it is thus context-INsensitive.",[Remifentanil--could it open a new era in our anesthesia practice in Japan?]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027600/),min,3-5,200144,DB00813,Fentanyl
,21502953,effective concentration 50,GSK1521498 had high affinity for human brain ORs (GSK1521498 effective concentration 50 = 7.10 ng ml(-1)) and there was a direct relationship between receptor occupancy (RO) and plasma concentrations of GSK1521498.,Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502953/),[ng] / [ml],7.10,200324,DB00813,Fentanyl
,12906959,maximum concentration produced,The maximum concentration produced for each dosage group (Cmax) was 1.09 ng/ml for two 400 microg dose and 1.10 ng/ml for one 800 microg dose.,A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906959/),[ng] / [ml],1.09,204168,DB00813,Fentanyl
,12906959,maximum concentration produced,The maximum concentration produced for each dosage group (Cmax) was 1.09 ng/ml for two 400 microg dose and 1.10 ng/ml for one 800 microg dose.,A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906959/),[ng] / [ml],1.10,204169,DB00813,Fentanyl
,12906959,Area under the curve (AUC),Area under the curve (AUC) was 8.2 ng/ml.hr (SE=1.1) and 7.2 ng/ml.hr (SE=1.0).,A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906959/),[ng] / [h·ml],8.2,204170,DB00813,Fentanyl
,12906959,Area under the curve (AUC),Area under the curve (AUC) was 8.2 ng/ml.hr (SE=1.1) and 7.2 ng/ml.hr (SE=1.0).,A pharmacokinetic study to compare two simultaneous 400 microg doses with a single 800 microg dose of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906959/),[ng] / [h·ml],7.2,204171,DB00813,Fentanyl
,9661572,clearance,Alfentanil clearance was decreased from 3.1 +/- 1.1 mL.min-1.kg-1 to 1.3 +/- 0.3 mL.min-1.,The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661572/),[ml] / [kg·min],3.1,204213,DB00813,Fentanyl
,9661572,clearance,Alfentanil clearance was decreased from 3.1 +/- 1.1 mL.min-1.kg-1 to 1.3 +/- 0.3 mL.min-1.,The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661572/),[ml] / [min],1.3,204214,DB00813,Fentanyl
,32486875,plasma elimination half-life,Mean plasma elimination half-life is 13 hours and bioavailability 47-57% after the first sublingual sufentanil tablet.,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486875/),h,13,204667,DB00813,Fentanyl
,32486875,bioavailability,Mean plasma elimination half-life is 13 hours and bioavailability 47-57% after the first sublingual sufentanil tablet.,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486875/),%,47-57,204668,DB00813,Fentanyl
,2903758,T1/2fast,"During the following 14 min, fentanyl was released, apparently from two binding sites (T1/2fast: 0.22 (0.16-0.27) min; T1/2slow: 5.78 (3.65-13.86) min).",Pulmonary kinetics of fentanyl and alfentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903758/),min,0.22,204687,DB00813,Fentanyl
,2903758,T1/2slow,"During the following 14 min, fentanyl was released, apparently from two binding sites (T1/2fast: 0.22 (0.16-0.27) min; T1/2slow: 5.78 (3.65-13.86) min).",Pulmonary kinetics of fentanyl and alfentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903758/),min,5.78,204688,DB00813,Fentanyl
,2903758,T1/2,"Initially, there was a rapid release of alfentanil (T1/2: 0.28 (0.08-0.51) min).",Pulmonary kinetics of fentanyl and alfentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903758/),min,0.28,204689,DB00813,Fentanyl
,15200183,elimination half-life,The elimination half-life of ropivacaine was significantly less than that of bupivacaine (5.2 +/- 0.7 h vs. 10.8 +/- 1.06 h).,[Clinical effects and pharmacokinetics of ropivacaine and bupivacaine for epidural analgesia during labor]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200183/),h,5.2,205076,DB00813,Fentanyl
,15200183,elimination half-life,The elimination half-life of ropivacaine was significantly less than that of bupivacaine (5.2 +/- 0.7 h vs. 10.8 +/- 1.06 h).,[Clinical effects and pharmacokinetics of ropivacaine and bupivacaine for epidural analgesia during labor]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200183/),h,10.8,205077,DB00813,Fentanyl
,8310787,clearance,"Propofol clearance (1.53 [1.02-2.10] L.min-1 x kg-1 versus 1.65 [1.39-1.78] L.min-1 x kg-1 in normal patients), and half-lives elimination were not modified by renal failure.",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg·min],1.53,205318,DB00813,Fentanyl
,8310787,clearance,"Propofol clearance (1.53 [1.02-2.10] L.min-1 x kg-1 versus 1.65 [1.39-1.78] L.min-1 x kg-1 in normal patients), and half-lives elimination were not modified by renal failure.",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg·min],1.65,205319,DB00813,Fentanyl
,8310787,volume of distribution at steady state,"Renal failure patients exhibited a higher volume of distribution at steady state as compared to normal patients (19.28 [11.71-76.81] L.kg-1 versus 8.60 [6.58-9.81] L.kg-1, p < 0.05).",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg],19.28,205320,DB00813,Fentanyl
,8310787,volume of distribution at steady state,"Renal failure patients exhibited a higher volume of distribution at steady state as compared to normal patients (19.28 [11.71-76.81] L.kg-1 versus 8.60 [6.58-9.81] L.kg-1, p < 0.05).",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg],8.60,205321,DB00813,Fentanyl
,2729633,terminal half-life,"The decline in serum fentanyl concentrations after removal of the transdermal system had a terminal half-life of 17.0 +/- 2.3 h (mean +/- SD), considerably longer than the terminal elimination half-life seen after intravenous administration of fentanyl in the same patients (6.1 +/- 2.0 h).",Absorption characteristics of transdermally administered fentanyl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729633/),h,17.0,205807,DB00813,Fentanyl
,2729633,terminal elimination half-life,"The decline in serum fentanyl concentrations after removal of the transdermal system had a terminal half-life of 17.0 +/- 2.3 h (mean +/- SD), considerably longer than the terminal elimination half-life seen after intravenous administration of fentanyl in the same patients (6.1 +/- 2.0 h).",Absorption characteristics of transdermally administered fentanyl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729633/),h,6.1,205808,DB00813,Fentanyl
,2729633,rate of absorption,The rate of absorption during this period was 91.7 +/- 25.7 micrograms/h.,Absorption characteristics of transdermally administered fentanyl. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729633/),[μg] / [h],91.7,205809,DB00813,Fentanyl
,2729633,bioavailability,"Systemic fentanyl bioavailability was found to be 0.92 +/- 0.33, with no evidence of significant cutaneous metabolism or degradation by the skin's bacterial flora.",Absorption characteristics of transdermally administered fentanyl. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729633/),,0.92,205810,DB00813,Fentanyl
,18679666,Cmax,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],879.11,206161,DB00813,Fentanyl
,18679666,Cmax,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],"1,145.58",206162,DB00813,Fentanyl
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],256.01,206163,DB00813,Fentanyl
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],455.95,206164,DB00813,Fentanyl
,18679666,Cl/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ml] / [kg·min],10.61,206165,DB00813,Fentanyl
,18679666,Cl/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ml] / [kg·min],5.64,206166,DB00813,Fentanyl
,18679666,Vd/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[l] / [kg],3.26,206167,DB00813,Fentanyl
,18679666,Vd/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[l] / [kg],2.19,206168,DB00813,Fentanyl
,18679666,Cmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],82.71,206169,DB00813,Fentanyl
,18679666,Cmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],141.38,206170,DB00813,Fentanyl
,18679666,Tmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,44.71,206171,DB00813,Fentanyl
,18679666,Tmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,193.14,206172,DB00813,Fentanyl
,18679666,t(1/2)alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,7.64,206173,DB00813,Fentanyl
,18679666,t(1/2)alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,59.77,206174,DB00813,Fentanyl
,18679666,alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),1/[min],0.097,206175,DB00813,Fentanyl
,18679666,alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),1/[min],0.012,206176,DB00813,Fentanyl
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],29.91,206177,DB00813,Fentanyl
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],108.23,206178,DB00813,Fentanyl
,7978186,peak plasma concentrations,The peak plasma concentrations were P 10.6 +/- 1.5 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,10.6,207603,DB00813,Fentanyl
,7978186,M,ml-1 and M 12.4 +/- 2.6 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,12.4,207604,DB00813,Fentanyl
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,15,207605,DB00813,Fentanyl
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,50,207606,DB00813,Fentanyl
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,25,207607,DB00813,Fentanyl
,6122384,plasma half-life,"The plasma half-life of alfentanyl in the alpha-phase was about 4 min, the elimination half-life was 70 min.",[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),min,4,208264,DB00813,Fentanyl
,6122384,elimination half-life,"The plasma half-life of alfentanyl in the alpha-phase was about 4 min, the elimination half-life was 70 min.",[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),min,70,208265,DB00813,Fentanyl
,6122384,total volume of distribution,The total volume of distribution was calculated to 33 1.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),1,33,208266,DB00813,Fentanyl
,6122384,total plasma clearance,The total plasma clearance amounted to 336 ml/min.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),[ml] / [min],336,208267,DB00813,Fentanyl
,6122384,Plasma protein binding,Plasma protein binding of alfentanyl was about 92%; binding to human erythrocytes showed values less than 0.1%.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),%,92,208268,DB00813,Fentanyl
less,6122384,Plasma protein binding,Plasma protein binding of alfentanyl was about 92%; binding to human erythrocytes showed values less than 0.1%.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),%,0.1,208269,DB00813,Fentanyl
,6122384,renal excretion,The renal excretion of unchanged alfentanyl amounted to only 0.4% of the total dose in a time period of 24h.,[Clinical pharmacokinetics of alfentanyl (author's transl)]. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6122384/),%,0.4,208270,DB00813,Fentanyl
,9685889,maximal plasma concentration,"Immediately after the 5 min pulsing, fentanyl plasma levels reached one third of the maximal plasma concentration of approximately 30 ng/ml, the peak occurring 30 min after the electroporation.",Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9685889/),[ng] / [ml],30,208294,DB00813,Fentanyl
,9813514,half-time,The mean half-time (time for plasma concentrations to double after patch application) was 4.2 h in the younger group and 11.1 h in the elderly group (P < 0.005).,Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9813514/),h,4.2,208343,DB00813,Fentanyl
,9813514,half-time,The mean half-time (time for plasma concentrations to double after patch application) was 4.2 h in the younger group and 11.1 h in the elderly group (P < 0.005).,Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9813514/),h,11.1,208344,DB00813,Fentanyl
,9813514,maximum plasma concentrations,Mean maximum plasma concentrations were 1.9 ng ml-1 and 1.5 ng ml-1 in the younger and elderly groups respectively (ns).,Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9813514/),[ng] / [ml],1.9,208345,DB00813,Fentanyl
,9813514,maximum plasma concentrations,Mean maximum plasma concentrations were 1.9 ng ml-1 and 1.5 ng ml-1 in the younger and elderly groups respectively (ns).,Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9813514/),[ng] / [ml],1.5,208346,DB00813,Fentanyl
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1,208483,DB00813,Fentanyl
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.4,208484,DB00813,Fentanyl
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.0,208485,DB00813,Fentanyl
,16172184,Area under the plasma concentration-time curve (AUC) ratios,"Area under the plasma concentration-time curve (AUC) ratios (fluconazole/control) after 100, 200, and 400 mg fluconazole were (geometric mean) 1.3*, 1.4*, and 2.0* for intravenous midazolam and 1.2*, 1.6*, and 2.2* for intravenous alfentanil (*significantly different from control), indicating 16% to 21%, 31% to 36%, and 43% to 53% inhibition of hepatic CYP3A.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2,208486,DB00813,Fentanyl
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,0.9,208487,DB00813,Fentanyl
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.0,208488,DB00813,Fentanyl
,16172184,AUC ratios,"Pupil miosis AUC ratios were 0.9, 1.0, and 1.2*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.2,208489,DB00813,Fentanyl
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.3,208490,DB00813,Fentanyl
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,3.6,208491,DB00813,Fentanyl
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,5.3,208492,DB00813,Fentanyl
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.8,208493,DB00813,Fentanyl
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.9,208494,DB00813,Fentanyl
,16172184,plasma AUC ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.9,208495,DB00813,Fentanyl
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.4,208496,DB00813,Fentanyl
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.5,208497,DB00813,Fentanyl
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,6.9,208498,DB00813,Fentanyl
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,1.8,208499,DB00813,Fentanyl
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,2.9,208500,DB00813,Fentanyl
,16172184,ratios,"After oral dosing, plasma AUC ratios were 2.3*, 3.6*, and 5.3* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil; plasma single-point ratios were 2.4*, 4.5*, and 6.9* for midazolam and 1.8*, 2.9*, and 4.9* for alfentanil, and alfentanil miosis ratios were 1.1, 1.9*, and 2.7*.",Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16172184/),,4.9,208501,DB00813,Fentanyl
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,1.455,208515,DB00813,Fentanyl
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,2.344,208516,DB00813,Fentanyl
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],10.997,208517,DB00813,Fentanyl
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],7.014,208518,DB00813,Fentanyl
,10225075,"noncompartmental clearance (Cl, 1/min)","No difference between groups with respect to the primary outcome variable noncompartmental clearance (Cl, 1/min) 1.7 vs 1.6, was found.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),,1.7,208640,DB00813,Fentanyl
,10225075,"noncompartmental clearance (Cl, 1/min)","No difference between groups with respect to the primary outcome variable noncompartmental clearance (Cl, 1/min) 1.7 vs 1.6, was found.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),,1.6,208641,DB00813,Fentanyl
,10225075,"volume of distribution at steady state (Vss,","However, the volume of distribution at steady state (Vss, 1/kg) was larger in women (3.1) compared to men (1.3).",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[1] / [kg],3.1,208642,DB00813,Fentanyl
,10225075,"volume of distribution at steady state (Vss,","However, the volume of distribution at steady state (Vss, 1/kg) was larger in women (3.1) compared to men (1.3).",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[1] / [kg],1.3,208643,DB00813,Fentanyl
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,1.5,208644,DB00813,Fentanyl
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,2.2,208645,DB00813,Fentanyl
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,42,208646,DB00813,Fentanyl
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,40,208647,DB00813,Fentanyl
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,222,208648,DB00813,Fentanyl
,10225075,half-lives,"The half-lives (min) of the alpha, beta and gamma phases (men vs women, medians) were 1.5 vs 2.2, 42 vs 40 and 222 vs 360, respectively.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),min,360,208649,DB00813,Fentanyl
,10225075,Area under the curve (AUC,"Area under the curve (AUC, min microgram/l) was 39,810 vs 34,905.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[min·μg] / [l],"39,810",208650,DB00813,Fentanyl
,10225075,Area under the curve (AUC,"Area under the curve (AUC, min microgram/l) was 39,810 vs 34,905.",Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10225075/),[min·μg] / [l],"34,905",208651,DB00813,Fentanyl
,23732079,F,"For aerosolized pulmonary Fentanyl, F=1 and t90<1 min indicating complete and rapid absorption.",Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732079/),,1,209550,DB00813,Fentanyl
<,23732079,t90,"For aerosolized pulmonary Fentanyl, F=1 and t90<1 min indicating complete and rapid absorption.",Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732079/),min,1,209551,DB00813,Fentanyl
,23732079,F,The F value ranged from 0.35 to 0.74 for oral and various transmucosal routes.,Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732079/),,0.35 to 0.74,209552,DB00813,Fentanyl
,23732079,t90,Oral Fentanyl was absorbed the slowest (t90~300 min); the absorption of intranasal Fentanyl was relatively rapid (t90~20-40 min); and the various oral transmucosal routes had intermediate absorption rates (t90~160-300 min).,Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732079/),min,300,209553,DB00813,Fentanyl
,23732079,t90,Oral Fentanyl was absorbed the slowest (t90~300 min); the absorption of intranasal Fentanyl was relatively rapid (t90~20-40 min); and the various oral transmucosal routes had intermediate absorption rates (t90~160-300 min).,Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732079/),min,20-40,209554,DB00813,Fentanyl
,23732079,t90,Oral Fentanyl was absorbed the slowest (t90~300 min); the absorption of intranasal Fentanyl was relatively rapid (t90~20-40 min); and the various oral transmucosal routes had intermediate absorption rates (t90~160-300 min).,Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23732079/),min,160-300,209555,DB00813,Fentanyl
,2932983,detection limit,The detection limit for sufentanil and its metabolites is 30-50 pg/ml with minimal interfering substances in the chromatograms.,Detection of picogram levels of sufentanil by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932983/),[pg] / [ml],30-50,209664,DB00813,Fentanyl
,8531080,peak alfentanil concentrations,"Alfentanil was administered by use of three different drug infusion strategies in order to develop a pharmacokinetic-pharmacodynamic model for acute tolerance: I) intravenous infusion of 0.5 mg/kg in 10 min, achieving peak alfentanil concentrations of 750 ng/ml; II) computer-controlled infusion to rapidly achieve and maintain a constant drug level of 750 ng/ml, followed by washout; III) computer-controlled infusion to step through multiple constant drug levels (up to 1500 ng/ml), followed by washout.",Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),[ng] / [ml],750,210233,DB00813,Fentanyl
,8531080,Clearance,Clearance values ranged from (S.E.) 49.7 (2.8) ml/min/kg at low alfentanil concentrations to a minimum value of 29.3 (0.8) ml/min/kg at high concentrations.,Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),[ml] / [kg·min],49.7,210234,DB00813,Fentanyl
,8531080,minimum value,Clearance values ranged from (S.E.) 49.7 (2.8) ml/min/kg at low alfentanil concentrations to a minimum value of 29.3 (0.8) ml/min/kg at high concentrations.,Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),[ml] / [kg·min],29.3,210235,DB00813,Fentanyl
,8531080,half-life,Maximum tolerance diminished alfentanil's effect by 46% and was achieved with a half-life of 7.0 min.,Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531080/),min,7.0,210236,DB00813,Fentanyl
,6499894,elimination half-life,"Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),h,1.30,210351,DB00813,Fentanyl
,6499894,total plasma clearance,"Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),[ml] / [kg·min],13.8,210352,DB00813,Fentanyl
,6499894,volume of distribution,"Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),[l] / [kg],1.52,210353,DB00813,Fentanyl
,6499894,"volume of distribution, steady-state,","Plasma papaverine concentrations declined biexponentially in the control patients with a mean elimination half-life of 1.30 +/- 0.25 h, total plasma clearance of 13.8 +/- 3.75 ml/min/kg, volume of distribution of 1.52 +/- 0.45 l/kg and volume of distribution, steady-state, of 0.992 +/- 0.530 l/kg.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),[l] / [kg],0.992,210354,DB00813,Fentanyl
,6499894,half-life,"For the CPB group, only half-life was estimated, and averaged 2.77 +/- 0.28 h, significantly greater (p less than 0.01) than that in the controls.",Papaverine disposition in cardiac surgery patients and the effect of cardiopulmonary bypass. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6499894/),h,2.77,210355,DB00813,Fentanyl
,7165072,Minimum analgesic blood concentrations,"Minimum analgesic blood concentrations were found to be approximately log-normally distributed (mean 2.89 ng/ml, c.v. 77.56%).","[""Analgesic"" fentanyl blood concentrations during neuroleptanalgesia]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7165072/),[ng] / [ml],2.89,210836,DB00813,Fentanyl
,15717705,k(ip),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.374,211082,DB00813,Fentanyl
,15717705,k(ei),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.151,211083,DB00813,Fentanyl
,15717705,EC50,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),[μg] / [l],98,211084,DB00813,Fentanyl
,15717705,gamma,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),,3.7,211085,DB00813,Fentanyl
,17461710,serum concentrations,"When comparing fentanyl ITS with intravenously administered fentanyl, serum concentrations differ significantly at 10 minutes after the initial dose is administered: 0.1 ng/ml for fentanyl ITS versus 0.7 ng/ml for intravenous fentanyl.",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),ng,0.1,211555,DB00813,Fentanyl
,17461710,serum concentrations,"When comparing fentanyl ITS with intravenously administered fentanyl, serum concentrations differ significantly at 10 minutes after the initial dose is administered: 0.1 ng/ml for fentanyl ITS versus 0.7 ng/ml for intravenous fentanyl.",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[ng] / [ml],0.7,211556,DB00813,Fentanyl
,17461710,maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[μg] / [ml],1.37,211557,DB00813,Fentanyl
,17461710,maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[μg] / [ml],1.82,211558,DB00813,Fentanyl
,17461710,time to maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),h,0.65,211559,DB00813,Fentanyl
,17461710,time to maximum concentration,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),h,0.58,211560,DB00813,Fentanyl
,17461710,area under the concentration-time curve at 23-24 hrs,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[h·μg] / [ml],1.23,211561,DB00813,Fentanyl
,17461710,area under the concentration-time curve at 23-24 hrs,"Other pharmacokinetic parameters of fentanyl ITS are comparable to those of intravenous fentanyl after 24 hours (maximum concentration 1.37 and 1.82 microg/ml, time to maximum concentration 0.65 and 0.58 hr, and area under the concentration-time curve at 23-24 hrs 1.23 and 1.34 microg x hr/ml for fentanyl ITS and intravenous fentanyl, respectively,).",Iontophoretic drug delivery system: focus on fentanyl. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17461710/),[h·μg] / [ml],1.34,211562,DB00813,Fentanyl
,16021436,t(1/2)alpha,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,13.5,211876,DB00813,Fentanyl
,16021436,t(1/2)beta,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,192.5,211877,DB00813,Fentanyl
,16021436,t(1/2)gamma,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,620,211878,DB00813,Fentanyl
,16021436,AUC(0-infinity),"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[min·ng] / [milliliter],137.404,211879,DB00813,Fentanyl
,16021436,C(l)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [min],464.984,211880,DB00813,Fentanyl
,16021436,V(d)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),l,299.974,211881,DB00813,Fentanyl
,16021436,C(l)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [kg·min],6.875,211882,DB00813,Fentanyl
,16021436,V(d)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[l] / [kg],4.441,211883,DB00813,Fentanyl
,16021436,latency,"The latency between drug administration and birth was 28.5 min, with a maternal and fetal plasma concentration of 0.310 and 0.245 ng/ml, respectively, at a median fetal/maternal ratio of 0.892.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,28.5,211884,DB00813,Fentanyl
,25263971,volume of distribution,"The average volume of distribution was 3.55, 1.53 and 1.82 l/kg bwt and clearance 50.2, 40.7 and 35.7 ml/min/kg bwt when foals were 6–8, 20–22 and 41–42 days of age, respectively.",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),[l] / [bwt·kg],3.55,212811,DB00813,Fentanyl
,25263971,volume of distribution,"The average volume of distribution was 3.55, 1.53 and 1.82 l/kg bwt and clearance 50.2, 40.7 and 35.7 ml/min/kg bwt when foals were 6–8, 20–22 and 41–42 days of age, respectively.",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),[l] / [bwt·kg],1.53,212812,DB00813,Fentanyl
,25263971,volume of distribution,"The average volume of distribution was 3.55, 1.53 and 1.82 l/kg bwt and clearance 50.2, 40.7 and 35.7 ml/min/kg bwt when foals were 6–8, 20–22 and 41–42 days of age, respectively.",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),[l] / [bwt·kg],1.82,212813,DB00813,Fentanyl
,25263971,clearance,"The average volume of distribution was 3.55, 1.53 and 1.82 l/kg bwt and clearance 50.2, 40.7 and 35.7 ml/min/kg bwt when foals were 6–8, 20–22 and 41–42 days of age, respectively.",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),[ml] / [bwt·kg·min],50.2,212814,DB00813,Fentanyl
,25263971,clearance,"The average volume of distribution was 3.55, 1.53 and 1.82 l/kg bwt and clearance 50.2, 40.7 and 35.7 ml/min/kg bwt when foals were 6–8, 20–22 and 41–42 days of age, respectively.",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),[ml] / [bwt·kg·min],40.7,212815,DB00813,Fentanyl
,25263971,clearance,"The average volume of distribution was 3.55, 1.53 and 1.82 l/kg bwt and clearance 50.2, 40.7 and 35.7 ml/min/kg bwt when foals were 6–8, 20–22 and 41–42 days of age, respectively.",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),[ml] / [bwt·kg·min],35.7,212816,DB00813,Fentanyl
,25263971,elimination half-life,"The elimination half-life was slightly prolonged (49.3 min) at 6–8 days relative to 20–22 and 41–42 days of age (25.8 and 33.7 min, respectively).",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),min,49.3,212817,DB00813,Fentanyl
,25263971,elimination half-life,"The elimination half-life was slightly prolonged (49.3 min) at 6–8 days relative to 20–22 and 41–42 days of age (25.8 and 33.7 min, respectively).",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),min,25.8,212818,DB00813,Fentanyl
,25263971,elimination half-life,"The elimination half-life was slightly prolonged (49.3 min) at 6–8 days relative to 20–22 and 41–42 days of age (25.8 and 33.7 min, respectively).",Effects of age on the pharmacokinetics and selected pharmacodynamics of intravenously administered fentanyl in foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25263971/),min,33.7,212819,DB00813,Fentanyl
,8010470,onset of neuromuscular blockade,The onset of neuromuscular blockade was longer (P < 0.01) in patients with cirrhosis (158 +/- 56 s) than in normal patients (108 +/- 33 s).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),s,158,213175,DB00813,Fentanyl
,8010470,onset of neuromuscular blockade,The onset of neuromuscular blockade was longer (P < 0.01) in patients with cirrhosis (158 +/- 56 s) than in normal patients (108 +/- 33 s).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),s,108,213176,DB00813,Fentanyl
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,77,213177,DB00813,Fentanyl
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,88,213178,DB00813,Fentanyl
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,57,213179,DB00813,Fentanyl
,8010470,Recovery of the,"Recovery of the thumb twitch to 75 and 90% of its control value was 77 +/- 25 and 88 +/- 29 min in cirrhotic patients versus 57 +/- 11 and 64 +/- 13 min, respectively, in normal patients (P < 0.05).",Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,64,213180,DB00813,Fentanyl
,8010470,central volume of distribution,The central volume of distribution of rocuronium was 104 +/- 21 in cirrhotic patients and 78 +/- 24 ml.kg-1 in normal patients (P < 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),[ml] / [kg],104,213181,DB00813,Fentanyl
,8010470,central volume of distribution,The central volume of distribution of rocuronium was 104 +/- 21 in cirrhotic patients and 78 +/- 24 ml.kg-1 in normal patients (P < 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),[ml] / [kg],78,213182,DB00813,Fentanyl
,8010470,elimination half-life,The elimination half-life was 87.5 +/- 17.5 min in normal patients and 96.0 +/- 36.8 min in cirrhotic patients (difference not significant).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,87.5,213183,DB00813,Fentanyl
,8010470,elimination half-life,The elimination half-life was 87.5 +/- 17.5 min in normal patients and 96.0 +/- 36.8 min in cirrhotic patients (difference not significant).,Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010470/),min,96.0,213184,DB00813,Fentanyl
,26491862,total clearance,"For a patient population with a mean weight of 92 kg and no history of severe liver disease or congestive heart failure, the final model, which performed well in repeated 10-fold cross-validation, estimated total clearance, intercompartmental clearance (Q), and volumes of distribution for the central (V1) and peripheral compartments (V2) to be 35 L/hr (95% CI, 32-39 L/hr), 55 L/hr (95% CI, 42-68 L/hr), 203 L (95% CI, 140-266 L), and 523 L (95% CI, 428-618 L), respectively.",Population Pharmacokinetics of Fentanyl in the Critically Ill. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491862/),[l] / [h],35,213205,DB00813,Fentanyl
,26491862,intercompartmental clearance (Q),"For a patient population with a mean weight of 92 kg and no history of severe liver disease or congestive heart failure, the final model, which performed well in repeated 10-fold cross-validation, estimated total clearance, intercompartmental clearance (Q), and volumes of distribution for the central (V1) and peripheral compartments (V2) to be 35 L/hr (95% CI, 32-39 L/hr), 55 L/hr (95% CI, 42-68 L/hr), 203 L (95% CI, 140-266 L), and 523 L (95% CI, 428-618 L), respectively.",Population Pharmacokinetics of Fentanyl in the Critically Ill. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491862/),[l] / [h],55,213206,DB00813,Fentanyl
,26491862,peripheral compartments (V2),"For a patient population with a mean weight of 92 kg and no history of severe liver disease or congestive heart failure, the final model, which performed well in repeated 10-fold cross-validation, estimated total clearance, intercompartmental clearance (Q), and volumes of distribution for the central (V1) and peripheral compartments (V2) to be 35 L/hr (95% CI, 32-39 L/hr), 55 L/hr (95% CI, 42-68 L/hr), 203 L (95% CI, 140-266 L), and 523 L (95% CI, 428-618 L), respectively.",Population Pharmacokinetics of Fentanyl in the Critically Ill. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26491862/),l,523,213207,DB00813,Fentanyl
,29494402,cardiac outputs,"The cardiac outputs (means ± SD) were 2.9 ± 0.7, 5.4 ± 0.7, and 9.6 ± 1.6 l/min in the low, control, and high cardiac output groups, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],2.9,213441,DB00813,Fentanyl
,29494402,cardiac outputs,"The cardiac outputs (means ± SD) were 2.9 ± 0.7, 5.4 ± 0.7, and 9.6 ± 1.6 l/min in the low, control, and high cardiac output groups, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],5.4,213442,DB00813,Fentanyl
,29494402,cardiac outputs,"The cardiac outputs (means ± SD) were 2.9 ± 0.7, 5.4 ± 0.7, and 9.6 ± 1.6 l/min in the low, control, and high cardiac output groups, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],9.6,213443,DB00813,Fentanyl
,29494402,CL1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],0.9,213444,DB00813,Fentanyl
,29494402,CL1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],1.2,213445,DB00813,Fentanyl
,29494402,CL1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],1.7,213446,DB00813,Fentanyl
,29494402,CL2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],0.9,213447,DB00813,Fentanyl
,29494402,CL2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],3.1,213448,DB00813,Fentanyl
,29494402,CL2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],6.9,213449,DB00813,Fentanyl
,29494402,V1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,1.6,213450,DB00813,Fentanyl
,29494402,V1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,2.9,213451,DB00813,Fentanyl
,29494402,V1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,5.2,213452,DB00813,Fentanyl
,29494402,V2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,27.5,213453,DB00813,Fentanyl
,29494402,V2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,47.0,213454,DB00813,Fentanyl
,29494402,V2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,79.8,213455,DB00813,Fentanyl
,29494402,target plasma concentration,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[ng] / [ml],0,213456,DB00813,Fentanyl
,29494402,target plasma concentration,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),,128.6,213457,DB00813,Fentanyl
,29494402,target plasma concentration,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),,157,213458,DB00813,Fentanyl
,29494402,cardiac outputs,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],3,213459,DB00813,Fentanyl
,29494402,cardiac outputs,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],5,213460,DB00813,Fentanyl
,29494402,cardiac outputs,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],7,213461,DB00813,Fentanyl
,29494402,half-times,"The context-sensitive half-times for these cardiac outputs increased from 3.1 to 19.9 and 25.9 min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),min,3.1,213462,DB00813,Fentanyl
,29494402,half-times,"The context-sensitive half-times for these cardiac outputs increased from 3.1 to 19.9 and 25.9 min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),min,19.9,213463,DB00813,Fentanyl
,29494402,half-times,"The context-sensitive half-times for these cardiac outputs increased from 3.1 to 19.9 and 25.9 min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),min,25.9,213464,DB00813,Fentanyl
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,72 to 108,214228,DB00813,Fentanyl
,2839637,half-time of blockade,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,4-12,214229,DB00813,Fentanyl
,2839637,half-time of the terminal phase,"The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr).",Duration of occupancy of opiate receptors by naltrexone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2839637/),h,96,214230,DB00813,Fentanyl
,7616387,extraction,Fentanyl extraction was 16.5 +/- 3.0% (mean +/- S.E.) at 0 mm Hg of IAP.,Effect of increased intra-abdominal pressure on hepatic extraction and clearance of fentanyl in neonatal lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7616387/),%,16.5,214680,DB00813,Fentanyl
,1610996,Total sampling time,"Total sampling time before CPB (45 to 75 minutes) was too short to allow full characterization of the pharmacokinetics of alfentanil, but allowed estimation of the initial volume of distribution.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),min,45 to 75,214806,DB00813,Fentanyl
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214807,DB00813,Fentanyl
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214808,DB00813,Fentanyl
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214809,DB00813,Fentanyl
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],80,214810,DB00813,Fentanyl
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214811,DB00813,Fentanyl
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],179,214812,DB00813,Fentanyl
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],17.9,214813,DB00813,Fentanyl
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],18.3,214814,DB00813,Fentanyl
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],11.1,214815,DB00813,Fentanyl
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],12.9,214816,DB00813,Fentanyl
,2132132,infusion rate,The average infusion rate postoperatively was 1.47 +/- 0.08 micrograms/kg/h (114.3 +/- 8.3 micrograms/h).,"Lumbar epidural fentanyl infusions for post-thoracotomy patients: analgesic, respiratory, and pharmacokinetic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2132132/),[μg] / [h·kg],1.47,215253,DB00813,Fentanyl
,2132132,infusion rate,The average infusion rate postoperatively was 1.47 +/- 0.08 micrograms/kg/h (114.3 +/- 8.3 micrograms/h).,"Lumbar epidural fentanyl infusions for post-thoracotomy patients: analgesic, respiratory, and pharmacokinetic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2132132/),[μg] / [h],114.3,215254,DB00813,Fentanyl
,2132132,steady state CONC,A steady state CONC of approximately 2.0 ng/mL was reached after 9 hours.,"Lumbar epidural fentanyl infusions for post-thoracotomy patients: analgesic, respiratory, and pharmacokinetic effects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2132132/),[ng] / [ml],2.0,215255,DB00813,Fentanyl
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.96,215622,DB00813,Fentanyl
,8250313,Total plasma clearance,"Total plasma clearance did not differ between controls (2.96 +/- 1.05 mL.min-1.kg-1, mean +/- SD) and cirrhotics (2.61 +/- 1.16 mL.min-1.kg-1).",Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg·min],2.61,215623,DB00813,Fentanyl
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,111,215624,DB00813,Fentanyl
,8250313,Terminal elimination half-life,Terminal elimination half-life was 111 +/- 46 min in controls and 143 +/- 25 min in cirrhotics.,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),min,143,215625,DB00813,Fentanyl
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],350,215626,DB00813,Fentanyl
,8250313,total apparent volume of distribution at steady state,The total apparent volume of distribution at steady state did not differ between controls (350 +/- 81 mL/kg) and cirrhotics (452 +/- 222 mL/kg).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),[ml] / [kg],452,215627,DB00813,Fentanyl
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,233,215628,DB00813,Fentanyl
,8250313,onset of neuromuscular blocking effect,The onset of neuromuscular blocking effect was longer in cirrhotics (233 +/- 112 s) (P < 0.05) than in controls (170 +/- 33 s).,Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250313/),s,170,215629,DB00813,Fentanyl
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],2.3,215709,DB00813,Fentanyl
,2875678,clearance rate,"The alfentanil clearance rate was significantly lower in patients with liver dysfunction (2.3 +/- 1.3 vs 4.2 +/- 2.0 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.2,215710,DB00813,Fentanyl
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],1.5,215711,DB00813,Fentanyl
,2875678,clearance rates,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ml] / [kg·min],4.1,215712,DB00813,Fentanyl
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,406,215713,DB00813,Fentanyl
,2875678,elimination half-life,"In addition, the patients who required opioid antagonists to reverse postoperative respiratory depression had lower clearance rates (1.5 +/- 0.7 vs 4.1 +/- 1.9 ml X kg-1 X min-1) and longer elimination half-life values (406 +/- 304 vs 87 +/- 53 min).",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),min,87,215714,DB00813,Fentanyl
exceeding,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],300,215715,DB00813,Fentanyl
,2875678,ED95,"For maintenance of hemodynamic stability during superficial and intraabdominal operations, alfentanil serum concentration-response curves revealed ED95 values exceeding 300 ng/ml and 400 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2875678/),[ng] / [ml],400,215716,DB00813,Fentanyl
,7997393,clearance,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),[ml] / [kg·min],6.94,215860,DB00813,Fentanyl
,7997393,clearance,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),[ml] / [kg·min],3.47,215861,DB00813,Fentanyl
,7997393,elimination half-life,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),min,50.6,215862,DB00813,Fentanyl
,7997393,elimination half-life,"However, clearance was significantly higher and elimination half-life lower in the group taking long-term drugs: clearance 6.94 +/- 4.64 versus 3.47 +/- 0.16 ml.kg-1.min-1, and elimination half-life 50.6 +/- 13.9 versus 90.7 +/- 22.4 minutes, respectively (p < 0.05).",Effects of long-term drugs on alfentanil clearance in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7997393/),min,90.7,215863,DB00813,Fentanyl
,2979128,maximum inspired concentration,"After intubation, anesthesia was maintained with nitrous oxide-oxygen and halothane to a maximum inspired concentration of 0.6%.",Alfentanil in infants and children with congenital heart defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),%,0.6,216495,DB00813,Fentanyl
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],8.2,216496,DB00813,Fentanyl
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],6.3,216497,DB00813,Fentanyl
,7793651,Apparent renal fluoride,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),[ml] / [min],51.8,216581,DB00813,Fentanyl
,7793651,clearances,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),[ml] / [min],52.6,216582,DB00813,Fentanyl
,7793651,apparent elimination half-lives,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),h,21.4,216583,DB00813,Fentanyl
,7793651,apparent elimination half-lives,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),h,20.1,216584,DB00813,Fentanyl
,7793651,Renal,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"4,300",216585,DB00813,Fentanyl
,7793651,HFIP,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"4,300",216586,DB00813,Fentanyl
,7793651,net fluoride excretion,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"3,300",216587,DB00813,Fentanyl
,7283113,half-life,"While duration and half-life of the alpha-phase are prolonged, the half-life of the beta-phase (150 min) remains almost unchanged.",[Prevention of fentanyl rebound by administration of cimetidine (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7283113/),min,150,216975,DB00813,Fentanyl
,14872546,run time,"The chromatographic run time was 2.0 min per injection, with retention times of 1.1 and 1.2 min for paroxetine and IS, respectively.",Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872546/),[min] / [injection],2.0,217809,DB00813,Fentanyl
,14872546,retention times,"The chromatographic run time was 2.0 min per injection, with retention times of 1.1 and 1.2 min for paroxetine and IS, respectively.",Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872546/),min,1.1,217810,DB00813,Fentanyl
,14872546,retention times,"The chromatographic run time was 2.0 min per injection, with retention times of 1.1 and 1.2 min for paroxetine and IS, respectively.",Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14872546/),min,1.2,217811,DB00813,Fentanyl
,22731777,terminal half-life,The PKs were primarily characterized by a rapid initial increase in plasma fentanyl concentrations and a long terminal half-life of 74.0 (95% C.I. [54.7-113]) h governed by flip-flop kinetics for the typical subject.,Population pharmacokinetics of transdermal fentanyl solution following a single dose administered prior to soft tissue and orthopedic surgery in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22731777/),h,74.0,218392,DB00813,Fentanyl
,1879253,volume of distribution,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),[l] / [kg],0.46,219671,DB00813,Fentanyl
,1879253,volume of distribution,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),[l] / [kg],0.61,219672,DB00813,Fentanyl
,1879253,mean residence time,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,68.8,219673,DB00813,Fentanyl
,1879253,mean residence time,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,62.3,219674,DB00813,Fentanyl
,1879253,elimination half-life,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,47.7,219675,DB00813,Fentanyl
,1879253,elimination half-life,"Increased IAP appears to have no significant effect on the volume of distribution (0.46 +/- 0.06 vs. 0.61 +/- 0.23 liter/kg), mean residence time (68.8 +/- 27.8 vs. 62.3 +/- 27.8 min) and elimination half-life (47.7 +/- 19.0 vs. 43.2 +/- 19.3 min).",Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1879253/),min,43.2,219676,DB00813,Fentanyl
,30698833,Tmax,The addition of the absorption enhancer dodecyl maltoside (Intravail) increased Cmax by ∼3-fold and reduced the Tmax from 0.5 to 0.17 hours.,Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,0.5,219742,DB00813,Fentanyl
,30698833,Tmax,The addition of the absorption enhancer dodecyl maltoside (Intravail) increased Cmax by ∼3-fold and reduced the Tmax from 0.5 to 0.17 hours.,Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,0.17,219743,DB00813,Fentanyl
,30698833,half-life,"Despite these very rapid increases in plasma concentrations of naltrexone, its short half-life following intranasal administration (∼2.2 hours) could limit its usefulness as a rescue medication, particularly against longer-lived synthetic opioids.",Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30698833/),h,∼2.2,219744,DB00813,Fentanyl
,21084042,tmax,Median tmax values for FPNS ranged from 15 to 21 min post-dose and were dose-independent.,Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084042/),min,15 to 21,219894,DB00813,Fentanyl
,21084042,relative bioavailability,Mean relative bioavailability of FPNS to OTFC ranged from 103% to 163%.,Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084042/),%,103,219895,DB00813,Fentanyl
,21084042,relative bioavailability,Mean relative bioavailability of FPNS to OTFC ranged from 103% to 163%.,Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21084042/),%,163,219896,DB00813,Fentanyl
,17580185,total gas flow,"Anesthesia was maintained with sevoflurane (2%), O(2), and N(2)O at a total gas flow of 6 L . min(-1) using a semiclosed circle system with a sodalime canister.",Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),[l] / [min],6,221315,DB00813,Fentanyl
,17580185,duration of surgery,Mean duration of surgery was 9:06 +/- 0:09 hours.,Renal safety and extrahepatic defluorination of sevoflurane in hepatic transplantations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17580185/),h,9:06,221316,DB00813,Fentanyl
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.97,221407,DB00813,Fentanyl
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.98,221408,DB00813,Fentanyl
,31288863,CL,"The parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature - 36.9)) L h-1, central volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance (Q) = 41 L h-1.",Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288863/),[l] / [h],37.8,222287,DB00813,Fentanyl
,31288863,central volume of distribution (V1),"The parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature - 36.9)) L h-1, central volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance (Q) = 41 L h-1.",Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288863/),l,229,222288,DB00813,Fentanyl
,31288863,intercompartmental clearance (Q),"The parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature - 36.9)) L h-1, central volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance (Q) = 41 L h-1.",Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288863/),[l] / [h],41,222289,DB00813,Fentanyl
,17178769,"steady-state brain-to-serum concentration ratio (K(p,brain","However, the steady-state brain-to-serum concentration ratio (K(p,brain,ss)) was approximately 3-fold lower in mdr1a(+/+) mice compared with mdr1a(-/-) mice (0.19 +/- 0.01 versus 0.54 +/- 0.04, respectively).",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),,0.19,222342,DB00813,Fentanyl
,17178769,"steady-state brain-to-serum concentration ratio (K(p,brain","However, the steady-state brain-to-serum concentration ratio (K(p,brain,ss)) was approximately 3-fold lower in mdr1a(+/+) mice compared with mdr1a(-/-) mice (0.19 +/- 0.01 versus 0.54 +/- 0.04, respectively).",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),,0.54,222343,DB00813,Fentanyl
,17178769,EC(50),"However, there was no difference in the antinociception versus brain concentration relationship, or in the brain tissue EC(50) (11 +/- 1.8 versus 9.2 +/- 1.7 ng/g), between mdr1a(+/+) and mdr1a(-/-) mice.",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),[ng] / [g],11,222344,DB00813,Fentanyl
,17178769,EC(50),"However, there was no difference in the antinociception versus brain concentration relationship, or in the brain tissue EC(50) (11 +/- 1.8 versus 9.2 +/- 1.7 ng/g), between mdr1a(+/+) and mdr1a(-/-) mice.",Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178769/),[ng] / [g],9.2,222345,DB00813,Fentanyl
,8317689,serum half-life,Serum peak levels are obtained 8-16 h after application; the serum half-life is about 16-21 h because of the dermal depot.,[Fentanyl-TTS for postoperative pain therapy. A new alternative?]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317689/),h,16-21,223211,DB00813,Fentanyl
,3709338,Distribution T1/2,Distribution T1/2 (10.2 +/- 2.4 min) and total body clearance (13.3 +/- 6.5 ml/kg/min) were similar to adult values.,Unexpected alterations in fentanyl pharmacokinetics in children undergoing cardiac surgery: age related or disease related? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709338/),min,10.2,223346,DB00813,Fentanyl
,3709338,total body clearance,Distribution T1/2 (10.2 +/- 2.4 min) and total body clearance (13.3 +/- 6.5 ml/kg/min) were similar to adult values.,Unexpected alterations in fentanyl pharmacokinetics in children undergoing cardiac surgery: age related or disease related? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709338/),[ml] / [kg·min],13.3,223347,DB00813,Fentanyl
,3709338,elimination t1/2,"An elimination t1/2 (102 +/- 85 min) shorter than in adults is readily explained by the significantly smaller distribution volume of the drug (1,203 +/- 777 ml/kg).",Unexpected alterations in fentanyl pharmacokinetics in children undergoing cardiac surgery: age related or disease related? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709338/),min,102,223348,DB00813,Fentanyl
,3709338,distribution volume,"An elimination t1/2 (102 +/- 85 min) shorter than in adults is readily explained by the significantly smaller distribution volume of the drug (1,203 +/- 777 ml/kg).",Unexpected alterations in fentanyl pharmacokinetics in children undergoing cardiac surgery: age related or disease related? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709338/),[ml] / [kg],"1,203",223349,DB00813,Fentanyl
,18180911,C(max) (maximum serum concentration),"The arterial C(max) (maximum serum concentration) of 0.83 ng/ml was nearly twofold higher than the venous C(max) of 0.47 ng/ml, and the arterial T(max) (time to maximum serum concentration) of 7.0 min was about 5 min shorter than the venous T(max) of 11.6 min.",Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),[ng] / [ml],0.83,223553,DB00813,Fentanyl
,18180911,C(max),"The arterial C(max) (maximum serum concentration) of 0.83 ng/ml was nearly twofold higher than the venous C(max) of 0.47 ng/ml, and the arterial T(max) (time to maximum serum concentration) of 7.0 min was about 5 min shorter than the venous T(max) of 11.6 min.",Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),[ng] / [ml],0.47,223554,DB00813,Fentanyl
,18180911,T(max) (time to maximum serum concentration),"The arterial C(max) (maximum serum concentration) of 0.83 ng/ml was nearly twofold higher than the venous C(max) of 0.47 ng/ml, and the arterial T(max) (time to maximum serum concentration) of 7.0 min was about 5 min shorter than the venous T(max) of 11.6 min.",Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),min,7.0,223555,DB00813,Fentanyl
,18180911,T(max),"The arterial C(max) (maximum serum concentration) of 0.83 ng/ml was nearly twofold higher than the venous C(max) of 0.47 ng/ml, and the arterial T(max) (time to maximum serum concentration) of 7.0 min was about 5 min shorter than the venous T(max) of 11.6 min.",Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),min,11.6,223556,DB00813,Fentanyl
,18180911,AUC(0-60) (,The arterial AUC(0-60) (area under the curve from 0 to 60 min after administration) of 21 min*ng/ml was approximately 30% larger than the venous AUC(0-60) of 15 min*ng/ml (all p values < or = 0.005).,Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),[min·ng] / [ml],21,223557,DB00813,Fentanyl
,18180911,area under the curve from 0 to 60 min after administration),The arterial AUC(0-60) (area under the curve from 0 to 60 min after administration) of 21 min*ng/ml was approximately 30% larger than the venous AUC(0-60) of 15 min*ng/ml (all p values < or = 0.005).,Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),[min·ng] / [ml],21,223558,DB00813,Fentanyl
,18180911,AUC(0-60),The arterial AUC(0-60) (area under the curve from 0 to 60 min after administration) of 21 min*ng/ml was approximately 30% larger than the venous AUC(0-60) of 15 min*ng/ml (all p values < or = 0.005).,Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18180911/),[min·ng] / [ml],15,223559,DB00813,Fentanyl
,2529072,maximal length of effective analgesia,"The mean maximal length of effective analgesia was 4.69 +/- 0.32 hours (mean +/- SEM), whereas the length of effective analgesia with the last dose was only 3.34 +/- 0.46 hours (p less than 0.0005).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),h,4.69,224177,DB00813,Fentanyl
,2529072,length of effective analgesia,"The mean maximal length of effective analgesia was 4.69 +/- 0.32 hours (mean +/- SEM), whereas the length of effective analgesia with the last dose was only 3.34 +/- 0.46 hours (p less than 0.0005).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),h,3.34,224178,DB00813,Fentanyl
,2529072,serum concentration,"Mean serum concentration of sufentanil during periods of slow respiratory rate (0.47 +/- 0.05 ng/ml) was significantly higher than during episodes without adverse respiratory effects (0.37 +/- 0.05 ng/ml, p less than 0.05).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),[ng] / [ml],0.47,224179,DB00813,Fentanyl
,2529072,serum concentration,"Mean serum concentration of sufentanil during periods of slow respiratory rate (0.47 +/- 0.05 ng/ml) was significantly higher than during episodes without adverse respiratory effects (0.37 +/- 0.05 ng/ml, p less than 0.05).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),[ng] / [ml],0.37,224180,DB00813,Fentanyl
,8424499,CP50,"The CP50 of sufentanil to suppress responses to intubation, incision, and sternotomy was 7.1 ng/mL and for mediastinal dissection it was 12.7 ng/mL.",Evaluation of sufentanil anesthesia obtained by a computer-controlled infusion for cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424499/),[ng] / [ml],7.1,224338,DB00813,Fentanyl
,8424499,CP50,"The CP50 of sufentanil to suppress responses to intubation, incision, and sternotomy was 7.1 ng/mL and for mediastinal dissection it was 12.7 ng/mL.",Evaluation of sufentanil anesthesia obtained by a computer-controlled infusion for cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424499/),[ng] / [ml],12.7,224339,DB00813,Fentanyl
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,17.6,224536,DB00813,Fentanyl
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,14.7,224537,DB00813,Fentanyl
,25901479,tmax,Median tmax was 10-15 minutes across five regimens.,Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25901479/),min,10-15,224665,DB00813,Fentanyl
,4025866,concentrations,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),[ng] / [ml],25.4,225103,DB00813,Fentanyl
,4025866,concentrations,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),[ng] / [ml],12.7,225104,DB00813,Fentanyl
,4025866,concentrations,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),[ng] / [ml],7.9,225105,DB00813,Fentanyl
,4025866,elimination phase half-life,"Mean plasma fentanyl concentrations were 25.4, 12.7, and 7.9 ng/ml at 5, 15, and 30 min postbolus, respectively, with an elimination phase half-life of 35.8 min.",Cardiovascular and pharmacodynamic effects of high-dose fentanyl in newborn piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025866/),min,35.8,225106,DB00813,Fentanyl
,7639354,Metabolic clearance,Metabolic clearance was 361 +/- 97 mL/min.,Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),[ml] / [min],361,225826,DB00813,Fentanyl
,7639354,intercompartmental clearance,"Rapid intercompartmental clearance was 2197 +/- 997 mL/min and slow intercompartmental clearance, 481 +/- 225 mL/min.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),[ml] / [min],2197,225827,DB00813,Fentanyl
,7639354,intercompartmental clearance,"Rapid intercompartmental clearance was 2197 +/- 997 mL/min and slow intercompartmental clearance, 481 +/- 225 mL/min.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),[ml] / [min],481,225828,DB00813,Fentanyl
,7639354,volume of the central compartment (Vc),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vdss) were 5.8 +/- 5.3 L and 118.2 +/- 70.4 L, respectively.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),l,5.8,225829,DB00813,Fentanyl
,7639354,volume of distribution at steady state (Vdss),"The volume of the central compartment (Vc) and the volume of distribution at steady state (Vdss) were 5.8 +/- 5.3 L and 118.2 +/- 70.4 L, respectively.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),l,118.2,225830,DB00813,Fentanyl
,7639354,elimination half-life,"The elimination half-life was 6.3 +/- 3.6 h, 1.5- to 3-fold longer than has been previously reported in patients undergoing surgery.",Midazolam pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639354/),h,6.3,225831,DB00813,Fentanyl
,11296436,time for extubation,The average time for extubation was 18 minutes after discontinuation of propofol infusion.,[Evaluation of emergence from total intravenous anesthesia with propofol for long neurosurgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296436/),min,18,226357,DB00813,Fentanyl
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],24.84,226435,DB00813,Fentanyl
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],14.52,226436,DB00813,Fentanyl
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],19.44,226437,DB00813,Fentanyl
,2268988,CL,"There was a significant negative correlation (r = -0.79, p less than 0.001) between plasma alfentanil clearance (CL) and age in women (less than 50y, median CL 24.84 L/h; greater than 50y, median CL 14.52 L/h), but not in men (less than 50y, median CL 19.44 L/h; greater than 50y, median CL 16.2 L/h).",Influence of age on the pharmacokinetics of alfentanil. Gender dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2268988/),[l] / [h],16.2,226438,DB00813,Fentanyl
,18415415,Serum half-life time,Serum half-life time is prolonged (16-21 h) because of the intradermal depot of fentanyl.,[Transdermal fentanyl for the treatment of cancer pain.]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18415415/),h,16-21,226576,DB00813,Fentanyl
<,18415415,respiratory rate,"During therapy of cancer pain with Fentanyl-TTS, 3 of 246 patients developed a bradypnea (respiratory rate <10/min).",[Transdermal fentanyl for the treatment of cancer pain.]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18415415/),1/[min],10,226577,DB00813,Fentanyl
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,15,227254,DB00813,Fentanyl
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,30,227255,DB00813,Fentanyl
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,60,227256,DB00813,Fentanyl
,19574865,area under the concentration-time curve,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,30,227257,DB00813,Fentanyl
,19574865,area under the concentration-time curve,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,60,227258,DB00813,Fentanyl
,20678689,therapeutic window,The reported therapeutic window of fentanyl is between 0.2 and 1.2 ng/mL.,"Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),[ng] / [ml],0.2 and 1.2,227917,DB00813,Fentanyl
,20678689,VAS scores,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,14.8,227918,DB00813,Fentanyl
,20678689,VAS scores,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,6.0,227919,DB00813,Fentanyl
,20678689,VAS,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,31.0,227920,DB00813,Fentanyl
,20678689,VAS,"Mean VAS scores at baseline were 14.8 (17.8) for the fentanyl group and 6.0 (9.7) for the placebo group (P = NS); at the time of drain removal, the corresponding VAS scores were 31.0 (20.6) and 33.8 (25.7) (P = NS).","Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),,33.8,227921,DB00813,Fentanyl
,20678689,C(max),A mean estimated C(max) of 0.184 (0.069) ng/mL was reached at 13.76 (3.56) minutes after administration of intranasal fentanyl.,"Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),[ng] / [ml],0.184,227922,DB00813,Fentanyl
,20678689,C(max),The mean measured C(max) was 0.22 (0.088) ng/mL.,"Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678689/),[ng] / [ml],0.22,227923,DB00813,Fentanyl
,32977559,fraction excreted in urine,The adult PBPK model predicted a fraction of fentanyl dose metabolized to norfentanyl of ~33% and a fraction excreted in urine of ~7%.,Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32977559/),%,7,228314,DB00813,Fentanyl
,19915709,AUC(0-infinity),"Regimens A and B had bioequivalent systemic exposure parameters (B/A [90% CI]: AUC(0-infinity)108.4 [103.4, 113.7], AUC(0-last) 106.1 [100.7, 111.7], and C(max) 92.3 [83.2, 102.4]).",Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),,108.4,229124,DB00813,Fentanyl
,19915709,AUC(0-last),"Regimens A and B had bioequivalent systemic exposure parameters (B/A [90% CI]: AUC(0-infinity)108.4 [103.4, 113.7], AUC(0-last) 106.1 [100.7, 111.7], and C(max) 92.3 [83.2, 102.4]).",Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),,106.1,229125,DB00813,Fentanyl
,19915709,C(max),"Regimens A and B had bioequivalent systemic exposure parameters (B/A [90% CI]: AUC(0-infinity)108.4 [103.4, 113.7], AUC(0-last) 106.1 [100.7, 111.7], and C(max) 92.3 [83.2, 102.4]).",Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),,92.3,229126,DB00813,Fentanyl
,19915709,time to C(max),Median time to C(max) was 45 minutes for regimen A and 60 minutes for regimens B and C.,Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),min,45,229127,DB00813,Fentanyl
,19915709,time to C(max),Median time to C(max) was 45 minutes for regimen A and 60 minutes for regimens B and C.,Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915709/),min,60,229128,DB00813,Fentanyl
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,1.4,229332,DB00813,Fentanyl
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,0.45,229333,DB00813,Fentanyl
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,1.15,229334,DB00813,Fentanyl
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.2,229335,DB00813,Fentanyl
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.6,229336,DB00813,Fentanyl
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.5,229337,DB00813,Fentanyl
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,8.6,229338,DB00813,Fentanyl
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,22.0,229339,DB00813,Fentanyl
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,8.9,229340,DB00813,Fentanyl
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],6.9,229341,DB00813,Fentanyl
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],5.8,229342,DB00813,Fentanyl
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],11.1,229343,DB00813,Fentanyl
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,26,229344,DB00813,Fentanyl
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,79,229345,DB00813,Fentanyl
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,41,229346,DB00813,Fentanyl
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,5,229347,DB00813,Fentanyl
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,11.3,229348,DB00813,Fentanyl
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,12.2,229349,DB00813,Fentanyl
,1677546,50% recovery time,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,97.1,229394,DB00813,Fentanyl
,1677546,50% recovery time,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,39.8,229395,DB00813,Fentanyl
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,25,229396,DB00813,Fentanyl
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,75,229397,DB00813,Fentanyl
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,49.4,229398,DB00813,Fentanyl
,1677546,recovery index,"Spontaneous recovery was significantly longer in elderly patients than in younger patients (50% recovery time, 97.1 +/- 29 vs 39.8 +/- 14 min, mean +/- SD; recovery index [25%-75%], 49.4 +/- 11 vs 15.0 +/- 8 min).","Distribution, elimination, and action of vecuronium in the elderly. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,15.0,229399,DB00813,Fentanyl
,1677546,elimination half-life,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,125,229400,DB00813,Fentanyl
,1677546,elimination half-life,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),min,78,229401,DB00813,Fentanyl
,1677546,plasma clearance,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),[ml] / [kg·min],2.6,229402,DB00813,Fentanyl
,1677546,plasma clearance,"In addition, in elderly patients elimination half-life of vecuronium was significantly prolonged (125 +/- 55 vs 78 +/- 21 min, P = 0.04) and plasma clearance reduced (2.6 +/- 0.6 vs 5.6 +/- 3.2 mL.kg-1.min-1, P = 0.049).","Distribution, elimination, and action of vecuronium in the elderly. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1677546/),[ml] / [kg·min],5.6,229403,DB00813,Fentanyl
,25628234,C e50,The C e50 and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L.,Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25628234/),[mg] / [l],1.40,229510,DB00813,Fentanyl
,25628234,biophase concentration,The C e50 and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L.,Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25628234/),[mg] / [l],1.13,229511,DB00813,Fentanyl
,24118506,bioavailability,"The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively.",Intranasal sufentanil/ketamine analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),%,24.6,229514,DB00813,Fentanyl
,24118506,bioavailability,"The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively.",Intranasal sufentanil/ketamine analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),%,35.8,229515,DB00813,Fentanyl
,24118506,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) of sufentanil was 0.042 mcg·l(-1) (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (Tmax).,Intranasal sufentanil/ketamine analgesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),[mcg] / [l],0.042,229516,DB00813,Fentanyl
,24118506,T,Maximum plasma concentration (Cmax) of sufentanil was 0.042 mcg·l(-1) (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (Tmax).,Intranasal sufentanil/ketamine analgesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),,13,229517,DB00813,Fentanyl
,24118506,Cmax,"Cmax for ketamine was 0.102 mg·l(-1) (CV 10.8%), and Tmax was 8.5 min (CV 17.3%).",Intranasal sufentanil/ketamine analgesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),[mg] / [l],0.102,229518,DB00813,Fentanyl
,24118506,Tmax,"Cmax for ketamine was 0.102 mg·l(-1) (CV 10.8%), and Tmax was 8.5 min (CV 17.3%).",Intranasal sufentanil/ketamine analgesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),min,8.5,229519,DB00813,Fentanyl
,6128948,t 1/2 pi,"The combined mean (+/- SEM) half-lives for the 11 patients for the rapid and slow distribution phases were short (t 1/2 pi = 1.2 +/- 0.26 min, t 1/2 alpha = 11.6 +/- 1.63 min).",The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),min,1.2,229931,DB00813,Fentanyl
,6128948,t 1/2 alpha,"The combined mean (+/- SEM) half-lives for the 11 patients for the rapid and slow distribution phases were short (t 1/2 pi = 1.2 +/- 0.26 min, t 1/2 alpha = 11.6 +/- 1.63 min).",The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),min,11.6,229932,DB00813,Fentanyl
,6128948,"elimination half-life, t 1/2 beta","The elimination half-life, t 1/2 beta was 94 +/- 5.87 min which is considerably shorter than that of other opioids.",The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),min,94,229933,DB00813,Fentanyl
,6128948,total body clearance,The mean (+/- SEM) total body clearance was 6.4 +/- 1.39 ml . kg-1 . min-1 and the volume of distribution (Vd) was 0.86 +/- 0.194 l/kg.,The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),[ml] / [kg·min],6.4,229934,DB00813,Fentanyl
,6128948,volume of distribution (Vd),The mean (+/- SEM) total body clearance was 6.4 +/- 1.39 ml . kg-1 . min-1 and the volume of distribution (Vd) was 0.86 +/- 0.194 l/kg.,The pharmacokinetics of alfentanil (R39209): a new opioid analgesic. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128948/),[l] / [kg],0.86,229935,DB00813,Fentanyl
,6124179,t 1/2 pi,"The disappearance of the drug from plasma was rapid (t 1/2 pi = 3.5 +/- 1.3 minutes, t 1/2 alpha = 16.8 +/- 6.4 minutes) with 96.4% of the drug eliminated from plasma in 1 hour, indicating extensive transfer to the remote peripheral compartment.",Pharmacokinetics of alfentanil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),min,3.5,230095,DB00813,Fentanyl
,6124179,t 1/2 alpha,"The disappearance of the drug from plasma was rapid (t 1/2 pi = 3.5 +/- 1.3 minutes, t 1/2 alpha = 16.8 +/- 6.4 minutes) with 96.4% of the drug eliminated from plasma in 1 hour, indicating extensive transfer to the remote peripheral compartment.",Pharmacokinetics of alfentanil in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),min,16.8,230096,DB00813,Fentanyl
,6124179,t 1/2 beta,This was followed by a slower elimination phase with a t 1/2 beta of 94 +/- 38 minutes.,Pharmacokinetics of alfentanil in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),min,94,230097,DB00813,Fentanyl
,6124179,Total volume of distribution,Total volume of distribution was 1.03 +/- 0.50 L/kg.,Pharmacokinetics of alfentanil in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),[l] / [kg],1.03,230098,DB00813,Fentanyl
,6124179,Total plasma clearance,Total plasma clearance was 456 +/- 155 ml/min.,Pharmacokinetics of alfentanil in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124179/),[ml] / [min],456,230099,DB00813,Fentanyl
,1835321,volume of distribution,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],9098,230270,DB00813,Fentanyl
,1835321,volume of distribution,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],5073,230271,DB00813,Fentanyl
,1835321,elimination half-life,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),min,208,230272,DB00813,Fentanyl
,1835321,elimination half-life,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),min,135,230273,DB00813,Fentanyl
,1835321,plasma clearance,"In contrast, plasma clearance was similar in both obese and control groups (32.9 +/- 12.5 vs 26.4 +/- 5.7 mL/kg ideal body weight).",Pharmacokinetics of sufentanil in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],32.9,230274,DB00813,Fentanyl
,1835321,plasma clearance,"In contrast, plasma clearance was similar in both obese and control groups (32.9 +/- 12.5 vs 26.4 +/- 5.7 mL/kg ideal body weight).",Pharmacokinetics of sufentanil in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],26.4,230275,DB00813,Fentanyl
,6135368,plasma concentrations,Alfentanil plasma concentrations of 0.45 microgram/ml were maintained by the same infusion scheme beginning with skin incision until 20 minutes prior to the end of surgery.,Pharmacokinetics as applied to total intravenous anaesthesia. Practical implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135368/),[μg] / [ml],0.45,230377,DB00813,Fentanyl
,15720520,Cmax,"After oral and nasal dosing, Cmax values were 0.96 and 1.48 ng/mL at 5 and 2 min, respectively.",Relationship between plasma concentrations and analgesia after intravenous fentanyl and disposition after other routes of administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720520/),[ng] / [ml],0.96,230935,DB00813,Fentanyl
,15720520,Cmax,"After oral and nasal dosing, Cmax values were 0.96 and 1.48 ng/mL at 5 and 2 min, respectively.",Relationship between plasma concentrations and analgesia after intravenous fentanyl and disposition after other routes of administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720520/),[ng] / [ml],1.48,230936,DB00813,Fentanyl
,16861092,T,Median T was between 35 and 45 minutes after FEBT administration.,"Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861092/),min,35 and 45,231486,DB00813,Fentanyl
,16861092,AUC(0-Tmax'),AUC(0-Tmax') ranged from 0.09 ng x h/mL with the 100-microg dose to 0.52 ng x h/mL with the 800-microg dose.,"Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861092/),[h·ng] / [ml],0.09,231487,DB00813,Fentanyl
,16861092,AUC(0-Tmax'),AUC(0-Tmax') ranged from 0.09 ng x h/mL with the 100-microg dose to 0.52 ng x h/mL with the 800-microg dose.,"Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16861092/),[h·ng] / [ml],0.52,231488,DB00813,Fentanyl
,17350525,maximum plasma concentration (Cpmax),There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.51,231928,DB00813,Fentanyl
,17350525,time to maximum concentration tCpmax,There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231929,DB00813,Fentanyl
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.62,231930,DB00813,Fentanyl
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.79,231931,DB00813,Fentanyl
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231932,DB00813,Fentanyl
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,22.5,231933,DB00813,Fentanyl
,17350525,Cpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.47,231934,DB00813,Fentanyl
,17350525,tCpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),h,24,231935,DB00813,Fentanyl
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.72,231936,DB00813,Fentanyl
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],1.74,231937,DB00813,Fentanyl
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.14,231938,DB00813,Fentanyl
,22417021,maximum venous concentration,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [ml],0.05,231939,DB00813,Fentanyl
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],19.50,231940,DB00813,Fentanyl
,22417021,area under the concentration curve,"Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the patient group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14 ± 0.06 vs 0.05 ± 0.02 µg/ml (P <0.0001); area under the concentration curve 19.50 ± 9.15 vs 9.72 ± 2.71 µg/ml/minute (P <0.001) respectively.",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),[μg] / [min·ml],9.72,231941,DB00813,Fentanyl
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,22.10,231942,DB00813,Fentanyl
,22417021,time to maximum venous concentration,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,20.50,231943,DB00813,Fentanyl
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,353,231944,DB00813,Fentanyl
,22417021,mean residence time,"However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10 ± 18.0 vs 20.50 ± 16.10 minutes (P=0.81); mean residence time 353 ± 191 vs 291 ± 80 minutes (P=0.26).",Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417021/),min,291,231945,DB00813,Fentanyl
,17319131,peak plasma concentration (C(max)),"Carfentanil was rapidly absorbed following administration, with the peak plasma concentration (C(max)) at 13.8 min.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),min,13,232829,DB00813,Fentanyl
,17319131,C(max),Naltrexone was readily absorbed and reached C(max) at 23.4 +/- 16.8 min after administration.,Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),min,23.4,232830,DB00813,Fentanyl
,17319131,half-life,"Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),h,7.7,232831,DB00813,Fentanyl
,17319131,half-life,"Carfentanil has a half-life of 7.7 hr, whereas naltrexone has a much shorter half-life of 3.7 hr.",Pharmacokinetics and pharmacodynamics of carfentanil and naltrexone in female common eland (Taurotragus oryx). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17319131/),h,3.7,232832,DB00813,Fentanyl
,17112806,plasma clearance,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),[ml] / [kg·min],4.4,232835,DB00813,Fentanyl
,17112806,plasma clearance,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),[ml] / [kg·min],0.67,232836,DB00813,Fentanyl
,17112806,elimination half-life,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),h,1.5,232837,DB00813,Fentanyl
,17112806,elimination half-life,"Voriconazole decreased the mean plasma clearance of intravenous alfentanil by 85%, from the control value of 4.4+/-2.4 mL.min-1.kg-1 to 0.67+/-0.27 mL.min-1.kg-1 (P<.001), and prolonged its elimination half-life from 1.5+/-0.49 hours to 6.6+/-1.8 hours (P<.001).","Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112806/),h,6.6,232838,DB00813,Fentanyl
,6489427,Concentrations,Concentrations across the membrane fall from 120 ng/ml to 10 ng/ml.,Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489427/),[ng] / [ml],120,232885,DB00813,Fentanyl
,6489427,Concentrations,Concentrations across the membrane fall from 120 ng/ml to 10 ng/ml.,Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489427/),[ng] / [ml],10,232886,DB00813,Fentanyl
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,60,233049,DB00813,Fentanyl
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,300,233050,DB00813,Fentanyl
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,1.5 to 6,233051,DB00813,Fentanyl
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,15,233052,DB00813,Fentanyl
,6226471,total body clearance,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),[l] / [min],0.4 to over 1.5,233053,DB00813,Fentanyl
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],25,234545,DB00813,Fentanyl
,16044107,delivery rate,"For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],50,234546,DB00813,Fentanyl
,16044107,initial delivery rate,"For 6 patients, the initial delivery rate was 75-150 microg/h.",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[μg] / [h],75-150,234547,DB00813,Fentanyl
,16044107,bioavailability,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),%,78,234548,DB00813,Fentanyl
,16044107,total clearance,A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h.,Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],41,234549,DB00813,Fentanyl
>,16044107,total clearance,"At the 2 highest doses, an increase of total clearance was observed (>60 L/h).",Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044107/),[l] / [h],60,234550,DB00813,Fentanyl
,23958818,CL1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.01,234602,DB00813,Fentanyl
,23958818,V1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,3.35,234603,DB00813,Fentanyl
,23958818,CL2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.47,234604,DB00813,Fentanyl
,23958818,V2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,13.9,234605,DB00813,Fentanyl
,23958818,CL3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.41,234606,DB00813,Fentanyl
,23958818,V3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,145,234607,DB00813,Fentanyl
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,26,234608,DB00813,Fentanyl
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,84,234609,DB00813,Fentanyl
,31231918,ED50,"The ED50 of propofol was 1.651 mg/kg (95% CI, 1.561-1.722 mg/kg) in Group A and 1.991 mg/kg (95% CI, 1.902-2.081 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.651,235173,DB00813,Fentanyl
,31231918,ED50,"The ED50 of propofol was 1.651 mg/kg (95% CI, 1.561-1.722 mg/kg) in Group A and 1.991 mg/kg (95% CI, 1.902-2.081 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.991,235174,DB00813,Fentanyl
,31231918,ED95,"The ED95 of propofol was 1.827 mg/kg (95% CI, 1.746-2.236 mg/kg) in Group A and 2.153 mg/kg (95% CI, 2.070-2.73 7 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.827,235175,DB00813,Fentanyl
,31231918,ED95,"The ED95 of propofol was 1.827 mg/kg (95% CI, 1.746-2.236 mg/kg) in Group A and 2.153 mg/kg (95% CI, 2.070-2.73 7 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],2.153,235176,DB00813,Fentanyl
,31231918,ED50,"The ED50 values for propofol when co-administered with low-dose sufentanil for intravenous anaesthesia in hysteroscopy were 1.651 mg/kg (sufentanil 0.2 μg/kg) and 1.991 mg/kg (sufentanil 0.1 μg/kg). (www.chictr.org.cn, registration number: ChiCTR1900021224).",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.651,235177,DB00813,Fentanyl
,31231918,ED50,"The ED50 values for propofol when co-administered with low-dose sufentanil for intravenous anaesthesia in hysteroscopy were 1.651 mg/kg (sufentanil 0.2 μg/kg) and 1.991 mg/kg (sufentanil 0.1 μg/kg). (www.chictr.org.cn, registration number: ChiCTR1900021224).",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.991,235178,DB00813,Fentanyl
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],131,237005,DB00813,Fentanyl
,10551581,central volume of distribution,"The central volume of distribution was increased to 131 (104-141) ml/kg in patients with cirrhosis (P < 0.01), compared with 75 (47-146) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],75,237006,DB00813,Fentanyl
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],331,237007,DB00813,Fentanyl
,10551581,total apparent volume of distribution,"The total apparent volume of distribution was also increased (P < 0.05) to 331 (284-488) ml/kg in patients with cirrhosis, compared with 221 (124-285) ml/kg in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg],221,237008,DB00813,Fentanyl
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,88,237009,DB00813,Fentanyl
,10551581,elimination half-life,The elimination half-life was 88 (77-102) min in controls and 90 (76-117) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,90,237010,DB00813,Fentanyl
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],6.9,237011,DB00813,Fentanyl
,10551581,Plasma clearance,"Plasma clearance was increased (P < 0.05) to 6.9 (6.1-8.9) ml x min(-1) x kg(-1) in patients with cirrhosis, compared with 5.3 (4.2-8.4) ml x min(-1) x kg(-1) in controls.",Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),[ml] / [kg·min],5.3,237012,DB00813,Fentanyl
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,65,237013,DB00813,Fentanyl
,10551581,Onset time,Onset time was 65 (40-110) s in controls and of 60 (52-240) s in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),s,60,237014,DB00813,Fentanyl
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,49,237015,DB00813,Fentanyl
,10551581,Time to return to 90%,Time to return to 90% of thumb adduction force control value was of 49 (28-80) min in controls and 47 (28-71) min in patients with cirrhosis.,Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551581/),min,47,237016,DB00813,Fentanyl
,6731878,t1/2 alpha,"The calculated values for t1/2 alpha (12 +/- 9 min) (mean +/- SD), t1/2 beta (141 +/- 98 min) and total body clearance (12.8 +/- 7.3 ml X min-1 X kg-1) were similar to adult values.",Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731878/),min,12,237138,DB00813,Fentanyl
,6731878,t1/2 beta,"The calculated values for t1/2 alpha (12 +/- 9 min) (mean +/- SD), t1/2 beta (141 +/- 98 min) and total body clearance (12.8 +/- 7.3 ml X min-1 X kg-1) were similar to adult values.",Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731878/),min,141,237139,DB00813,Fentanyl
,6731878,total body clearance,"The calculated values for t1/2 alpha (12 +/- 9 min) (mean +/- SD), t1/2 beta (141 +/- 98 min) and total body clearance (12.8 +/- 7.3 ml X min-1 X kg-1) were similar to adult values.",Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731878/),[ml] / [kg·min],12.8,237140,DB00813,Fentanyl
,6731878,steady-state volume of distribution,The significantly lower steady-state volume of distribution observed in children with intracardiac shunts (1385 +/- 875 ml X kg-1) compared to reported values for adults (3200-6000 ml X kg-1) explains the higher F plasma concentrations achieved in these children.,Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731878/),[ml] / [kg],1385,237141,DB00813,Fentanyl
,6731878,steady-state volume of distribution,The significantly lower steady-state volume of distribution observed in children with intracardiac shunts (1385 +/- 875 ml X kg-1) compared to reported values for adults (3200-6000 ml X kg-1) explains the higher F plasma concentrations achieved in these children.,Pediatric fentanyl dosing based on pharmacokinetics during cardiac surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6731878/),[ml] / [kg],3200-6000,237142,DB00813,Fentanyl
,10451210,Terminal elimination half-life,"Terminal elimination half-life after IV administration was 1.20+/-0.78 h, volume of distribution at steady state was 1.51+/-0.39 L/kg, and systemic clearance was 2.09+/-0.62 L/kg/h.",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),h,1.20,237919,DB00813,Fentanyl
,10451210,volume of distribution at steady state,"Terminal elimination half-life after IV administration was 1.20+/-0.78 h, volume of distribution at steady state was 1.51+/-0.39 L/kg, and systemic clearance was 2.09+/-0.62 L/kg/h.",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),[l] / [kg],1.51,237920,DB00813,Fentanyl
,10451210,systemic clearance,"Terminal elimination half-life after IV administration was 1.20+/-0.78 h, volume of distribution at steady state was 1.51+/-0.39 L/kg, and systemic clearance was 2.09+/-0.62 L/kg/h.",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),[l] / [h·kg],2.09,237921,DB00813,Fentanyl
,10451210,peak plasma concentrations,"Transdermal administration of fentanyl resulted in variable plasma concentrations, with peak plasma concentrations ranging from 1.12 to 16.69 ng/ml (mean+/-SD, 6.99+/-6.03 ng/ml) and time to peak concentration ranging from 8 to 18 hours (mean+/-SD, 13+/-4.5 hours).",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),[ng] / [ml],1.12 to 16.69,237922,DB00813,Fentanyl
,10451210,peak plasma concentrations,"Transdermal administration of fentanyl resulted in variable plasma concentrations, with peak plasma concentrations ranging from 1.12 to 16.69 ng/ml (mean+/-SD, 6.99+/-6.03 ng/ml) and time to peak concentration ranging from 8 to 18 hours (mean+/-SD, 13+/-4.5 hours).",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),[ng] / [ml],6.99,237923,DB00813,Fentanyl
,10451210,time to peak concentration,"Transdermal administration of fentanyl resulted in variable plasma concentrations, with peak plasma concentrations ranging from 1.12 to 16.69 ng/ml (mean+/-SD, 6.99+/-6.03 ng/ml) and time to peak concentration ranging from 8 to 18 hours (mean+/-SD, 13+/-4.5 hours).",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),h,8 to 18,237924,DB00813,Fentanyl
,10451210,time to peak concentration,"Transdermal administration of fentanyl resulted in variable plasma concentrations, with peak plasma concentrations ranging from 1.12 to 16.69 ng/ml (mean+/-SD, 6.99+/-6.03 ng/ml) and time to peak concentration ranging from 8 to 18 hours (mean+/-SD, 13+/-4.5 hours).",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),h,13,237925,DB00813,Fentanyl
,10451210,terminal elimination half-life,"After removal of the transdermal patch, mean+/-SD terminal elimination half-life was 5.34+/-5.34 hours.",Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10451210/),h,5.34,237926,DB00813,Fentanyl
,1672049,tissue distribution time,Esmolol has a tissue distribution time of 2 minutes and an elimination half-life of 9 minutes.,Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672049/),min,2,238270,DB00813,Fentanyl
,1672049,elimination half-life,Esmolol has a tissue distribution time of 2 minutes and an elimination half-life of 9 minutes.,Evaluation of esmolol and fentanyl in controlling increases in heart rate and blood pressure during endotracheal intubation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672049/),min,9,238271,DB00813,Fentanyl
,6824149,recovery times,"The basic dose schedule provided adequate surgical anaesthesia for 76% of patients (although dose adjustments were used in the remainder), with recovery times of 10 minutes or less in 57% of patients.",Total intravenous anaesthesia with etomidate-fentanyl. Use in general and gynaecological surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824149/),min,10,238660,DB00813,Fentanyl
,10839874,steady-state fentanyl concentration,"The mean (+/-SD) steady-state fentanyl concentration of 2.5 (+/-1) ng/mL achieved between 24 and 48 hours of infusion correlated significantly with the concomitant pain score (r = -0.57, P <.01).",Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839874/),[ng] / [ml],2.5,239798,DB00813,Fentanyl
,10839874,clearance,"The clearance, 11.5 (+/-4.0) mL/min/kg, correlated significantly with the gestational age (r = 0.46, P <.01) and birth weight (r = 0. 48, P <.01).",Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839874/),[ml] / [kg·min],11.5,239799,DB00813,Fentanyl
,8447208,elimination half-life,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),min,182,240009,DB00813,Fentanyl
,8447208,Vdss,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),l,169,240010,DB00813,Fentanyl
,8447208,plasma clearance,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),[ml] / [min],910,240011,DB00813,Fentanyl
,7914736,blood clearance,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[ml] / [kg·min],29.8,240059,DB00813,Fentanyl
,7914736,volume of distribution,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[l] / [kg],3.60,240060,DB00813,Fentanyl
,7914736,blood elimination half-life,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),min,144,240061,DB00813,Fentanyl
,8250312,plasma clearance,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg·min],3.67,240566,DB00813,Fentanyl
,8250312,plasma clearance,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg·min],5.03,240567,DB00813,Fentanyl
,8250312,volume of distribution,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg],399,240568,DB00813,Fentanyl
,8250312,volume of distribution,"Elderly patients, when compared with the younger, also exhibited a significant decrease in plasma clearance (3.67 +/- 1.0 vs 5.03 +/- 1.5 mL.kg-1.min-1, mean +/- SD) and volume of distribution (399 +/- 122 vs 553 +/- 279 mL/kg, mean +/- SD).",Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250312/),[ml] / [kg],553,240569,DB00813,Fentanyl
,22732112,initial effect-site target concentration,The initial effect-site target concentration was 100 ng ml(-1).,Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22732112/),[ng] / [ml],100,241120,DB00813,Fentanyl
,3920934,plasma clearance,Patients with cirrhosis had a significantly lower (P less than 0.01) plasma clearance of alfentanil of 1.6 +/- 1.0 ml . min-1 . kg-1 (mean +/- SD) instead of 3.1 +/- 1.6 ml . min-1 . kg-1 in the controls.,Alfentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),[ml] / [kg·min],1.6,241168,DB00813,Fentanyl
,3920934,plasma clearance,Patients with cirrhosis had a significantly lower (P less than 0.01) plasma clearance of alfentanil of 1.6 +/- 1.0 ml . min-1 . kg-1 (mean +/- SD) instead of 3.1 +/- 1.6 ml . min-1 . kg-1 in the controls.,Alfentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),[ml] / [kg·min],3.1,241169,DB00813,Fentanyl
,3920934,elimination half-life,The elimination half-life was prolonged from 90 +/- 18 min in the controls to 219 +/- 128 min in the cirrhotics (P less than 0.01).,Alfentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),min,90,241170,DB00813,Fentanyl
,3920934,elimination half-life,The elimination half-life was prolonged from 90 +/- 18 min in the controls to 219 +/- 128 min in the cirrhotics (P less than 0.01).,Alfentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),min,219,241171,DB00813,Fentanyl
,3920934,plasma-free fraction,Patients with cirrhosis had a higher (P less than 0.01) alfentanil plasma-free fraction (18.6 +/- 9.4%) compared with the control patients (11.5 +/- 3.9%).,Alfentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),%,18.6,241172,DB00813,Fentanyl
,3920934,plasma-free fraction,Patients with cirrhosis had a higher (P less than 0.01) alfentanil plasma-free fraction (18.6 +/- 9.4%) compared with the control patients (11.5 +/- 3.9%).,Alfentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920934/),%,11.5,241173,DB00813,Fentanyl
,24469018,Delivery rate-adjusted serum fentanyl concentrations,Delivery rate-adjusted serum fentanyl concentrations (0.0012-1.1 nmol/l/μg.h) and MRs (0.08-499) varied widely.,"Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469018/),[nM] / [h·l·μg],0.0012-1.1,241408,DB00813,Fentanyl
,24469018,MRs,Delivery rate-adjusted serum fentanyl concentrations (0.0012-1.1 nmol/l/μg.h) and MRs (0.08-499) varied widely.,"Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469018/),,0.08-499,241409,DB00813,Fentanyl
,10702452,drug,The drug infusion rates (range of means: 5.4-5. 9 mL/h) were similar in all patients.,What concentration of sufentanil should be combined with ropivacaine 0.2% wt/vol for postoperative patient-controlled epidural analgesia? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702452/),[ml] / [h],5.4-5. 9,243262,DB00813,Fentanyl
,10702452,infusion rates,The drug infusion rates (range of means: 5.4-5. 9 mL/h) were similar in all patients.,What concentration of sufentanil should be combined with ropivacaine 0.2% wt/vol for postoperative patient-controlled epidural analgesia? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702452/),[ml] / [h],5.4-5. 9,243263,DB00813,Fentanyl
,16764592,distribution half-time (t1/2alpha,"Pharmacokinetic variables for IV injection were characterized by a short distribution half-time (t1/2alpha was 4.5 minutes), a relatively long elimination half time (t1/2beta was 45.7 minutes), a large volume of distribution (approximately 5 L kg(-1)) and high total body clearance (77.9 mL minute(-1) kg(-1)).",Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764592/),min,4.5,244155,DB00813,Fentanyl
,16764592,elimination half time (t1/2beta,"Pharmacokinetic variables for IV injection were characterized by a short distribution half-time (t1/2alpha was 4.5 minutes), a relatively long elimination half time (t1/2beta was 45.7 minutes), a large volume of distribution (approximately 5 L kg(-1)) and high total body clearance (77.9 mL minute(-1) kg(-1)).",Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764592/),min,45.7,244156,DB00813,Fentanyl
,16764592,volume of distribution,"Pharmacokinetic variables for IV injection were characterized by a short distribution half-time (t1/2alpha was 4.5 minutes), a relatively long elimination half time (t1/2beta was 45.7 minutes), a large volume of distribution (approximately 5 L kg(-1)) and high total body clearance (77.9 mL minute(-1) kg(-1)).",Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764592/),[l] / [kg],5,244157,DB00813,Fentanyl
,16764592,total body clearance,"Pharmacokinetic variables for IV injection were characterized by a short distribution half-time (t1/2alpha was 4.5 minutes), a relatively long elimination half time (t1/2beta was 45.7 minutes), a large volume of distribution (approximately 5 L kg(-1)) and high total body clearance (77.9 mL minute(-1) kg(-1)).",Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16764592/),[ml] / [kg·minute],77.9,244158,DB00813,Fentanyl
,19282712,basal rate,"The PCEA regimen was prepared as 0.15% ropivacaine and fentanyl 2 microg/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min).",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),[ml] / [h],6,244767,DB00813,Fentanyl
,19282712,demand dose,"The PCEA regimen was prepared as 0.15% ropivacaine and fentanyl 2 microg/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min).",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),-1·ml,4,244768,DB00813,Fentanyl
,19282712,milk-plasma ratios,"Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean +/- SD) of 0.25 +/- 0.08 and 0.23 +/- 0.07, respectively.",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),,0.25,244769,DB00813,Fentanyl
,19282712,milk-plasma ratios,"Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean +/- SD) of 0.25 +/- 0.08 and 0.23 +/- 0.07, respectively.",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),,0.23,244770,DB00813,Fentanyl
,7924121,Elimination clearance,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[l] / [min],0.444,244907,DB00813,Fentanyl
,7924121,Elimination clearance,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[l] / [min],0.184,244908,DB00813,Fentanyl
,7924121,steady-state distribution volume,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),l,37,244909,DB00813,Fentanyl
,7924121,steady-state distribution volume,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),l,23,244910,DB00813,Fentanyl
,7924121,elimination half-life,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,127,244911,DB00813,Fentanyl
,7924121,elimination half-life,"Trefentanil versus alfentanil pharmacokinetic parameters were as follows: Elimination clearance, 0.444 +/- 0.073 versus 0.184 +/- 0.031 L/min; steady-state distribution volume, 37 +/- 7 versus 23 +/- 3 L; and elimination half-life, 127 +/- 24 versus 114 +/- 19 minutes.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,114,244912,DB00813,Fentanyl
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,1.2,244913,DB00813,Fentanyl
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),min,0.6,244914,DB00813,Fentanyl
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],429,244915,DB00813,Fentanyl
,7924121,half-time,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],577,244916,DB00813,Fentanyl
,7924121,maximal,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],429,244917,DB00813,Fentanyl
,7924121,maximal,"Trefentanil versus alfentanil pharmacodynamics were as follows: the equilibration half-time between EEG effect and arterial drug concentration, 1.2 +/- 0.5 versus 0.6 +/- 0.4 minutes; and the concentration resulting in 50% of maximal EEG effect, 429 +/- 313 versus 577 +/- 273 ng/ml.",Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924121/),[ng] / [ml],577,244918,DB00813,Fentanyl
,30085862,target plasma concentrations,"In phase 2, pharmacokinetic values for individual birds were used for administration of fentanyl to achieve target plasma concentrations of 8, 16, and 32 ng/mL.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],8,245487,DB00813,Fentanyl
,30085862,target plasma concentrations,"In phase 2, pharmacokinetic values for individual birds were used for administration of fentanyl to achieve target plasma concentrations of 8, 16, and 32 ng/mL.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],16,245488,DB00813,Fentanyl
,30085862,target plasma concentrations,"In phase 2, pharmacokinetic values for individual birds were used for administration of fentanyl to achieve target plasma concentrations of 8, 16, and 32 ng/mL.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],32,245489,DB00813,Fentanyl
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],0,245490,DB00813,Fentanyl
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],5.01,245491,DB00813,Fentanyl
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],12.12,245492,DB00813,Fentanyl
,30085862,plasma concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],24.93,245493,DB00813,Fentanyl
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,2.09,245494,DB00813,Fentanyl
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,1.45,245495,DB00813,Fentanyl
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,1.34,245496,DB00813,Fentanyl
,30085862,MACiso,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),%,0.95,245497,DB00813,Fentanyl
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],0,245498,DB00813,Fentanyl
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],8,245499,DB00813,Fentanyl
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],16,245500,DB00813,Fentanyl
,30085862,target concentrations,"RESULTS Mean ± SD fentanyl plasma concentrations were 0 ng/mL, 5.01 ± 1.53 ng/mL, 12.12 ± 3.58 ng/mL, and 24.93 ± 4.13 ng/mL, and MACiso values were 2.09 ± 0.17%, 1.45 ± 0.32%, 1.34 ± 0.31%, and 0.95 ± 0.14% for fentanyl target concentrations of 0, 8, 16, and 32 ng/mL, respectively.",Effects of three fentanyl plasma concentrations on the minimum alveolar concentration of isoflurane in Hispaniolan Amazon parrots (Amazona ventralis). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30085862/),[ng] / [ml],32,245501,DB00813,Fentanyl
,1859010,clearance,"After intravenous (iv) administration of fentanyl, clearance (mean +/- standard deviation) was 0.67 +/- 0.15 l/min; volume of distribution at steady state was 287 +/- 79 l; and the terminal elimination half-life was 425 +/- 102 min.",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),[l] / [min],0.67,245796,DB00813,Fentanyl
,1859010,volume of distribution at steady state,"After intravenous (iv) administration of fentanyl, clearance (mean +/- standard deviation) was 0.67 +/- 0.15 l/min; volume of distribution at steady state was 287 +/- 79 l; and the terminal elimination half-life was 425 +/- 102 min.",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),l,287,245797,DB00813,Fentanyl
,1859010,terminal elimination half-life,"After intravenous (iv) administration of fentanyl, clearance (mean +/- standard deviation) was 0.67 +/- 0.15 l/min; volume of distribution at steady state was 287 +/- 79 l; and the terminal elimination half-life was 425 +/- 102 min.",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),min,425,245798,DB00813,Fentanyl
,1859010,Peak plasma concentrations,"Peak plasma concentrations of fentanyl were higher (3.0 +/- 1.0 vs. 1.6 +/- 0.6 ng/ml, P = 0.01) and occurred sooner (22 +/- 2.5 vs. 101 +/- 48.8 min, P = 0.003) after OTFC than after oral solution administration.",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),[ng] / [ml],3.0,245799,DB00813,Fentanyl
,1859010,Peak plasma concentrations,"Peak plasma concentrations of fentanyl were higher (3.0 +/- 1.0 vs. 1.6 +/- 0.6 ng/ml, P = 0.01) and occurred sooner (22 +/- 2.5 vs. 101 +/- 48.8 min, P = 0.003) after OTFC than after oral solution administration.",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),[ng] / [ml],1.6,245800,DB00813,Fentanyl
,1859010,Peak plasma concentrations,"Peak plasma concentrations of fentanyl were higher (3.0 +/- 1.0 vs. 1.6 +/- 0.6 ng/ml, P = 0.01) and occurred sooner (22 +/- 2.5 vs. 101 +/- 48.8 min, P = 0.003) after OTFC than after oral solution administration.",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),,101,245801,DB00813,Fentanyl
,1859010,Peak absorption rate,"Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001).",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),[μg] / [min],11.1,245802,DB00813,Fentanyl
,1859010,Peak absorption rate,"Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001).",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),[μg] / [min],3.6,245803,DB00813,Fentanyl
,1859010,Peak absorption rate,"Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001).",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),min,19,245804,DB00813,Fentanyl
,1859010,Peak absorption rate,"Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001).",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),min,87.5,245805,DB00813,Fentanyl
,1859010,Systemic bioavailability,"Systemic bioavailability was greater after OTFC administration than after the oral solution (0.52 +/- 0.1 vs. 0.32 +/- 0.1, P = 0.01).",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),,0.52,245806,DB00813,Fentanyl
,1859010,Systemic bioavailability,"Systemic bioavailability was greater after OTFC administration than after the oral solution (0.52 +/- 0.1 vs. 0.32 +/- 0.1, P = 0.01).",Absorption and bioavailability of oral transmucosal fentanyl citrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859010/),,0.32,245807,DB00813,Fentanyl
,8512110,first-pass uptake,"The first-pass uptake of propofol (mean +/- SEM) was 61.3 +/- 4.9% and 60 +/- 3.7% of the injected dose in control cats and in cats whose lungs were mechanically ventilated, respectively.",Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512110/),%,61.3,246044,DB00813,Fentanyl
,8512110,first-pass uptake,"The first-pass uptake of propofol (mean +/- SEM) was 61.3 +/- 4.9% and 60 +/- 3.7% of the injected dose in control cats and in cats whose lungs were mechanically ventilated, respectively.",Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512110/),%,60,246045,DB00813,Fentanyl
,8123396,Onset time for maximum block,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),s,61,246879,DB00813,Fentanyl
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),s,65,246880,DB00813,Fentanyl
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,55,246881,DB00813,Fentanyl
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,42,246882,DB00813,Fentanyl
,8123396,duration of clinical relaxation (T1(25)),"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,28,246883,DB00813,Fentanyl
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,55,246884,DB00813,Fentanyl
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,42,246885,DB00813,Fentanyl
,8123396,recovery index,"Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,19,246886,DB00813,Fentanyl
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,0,246887,DB00813,Fentanyl
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,99,246888,DB00813,Fentanyl
,8123396,time for TOF ratio to,"The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups.",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,73,246889,DB00813,Fentanyl
,8123396,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),[ml] / [kg·min],2.5,246890,DB00813,Fentanyl
,8123396,rates of clearance,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),[ml] / [kg·min],3.7,246891,DB00813,Fentanyl
,8123396,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,97.1,246892,DB00813,Fentanyl
,8123396,mean residence times,"There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05).",Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8123396/),min,58.3,246893,DB00813,Fentanyl
,31168770,clearance,"The typical fentanyl clearance for 70 kg (reference weight) and 20.1 kg (median weight) patients were 34.6 and 13.6 L/h, respectively.",Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168770/),[l] / [h],34.6,247080,DB00813,Fentanyl
,31168770,clearance,"The typical fentanyl clearance for 70 kg (reference weight) and 20.1 kg (median weight) patients were 34.6 and 13.6 L/h, respectively.",Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31168770/),[l] / [h],13.6,247081,DB00813,Fentanyl
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],68,247242,DB00813,Fentanyl
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],101,247243,DB00813,Fentanyl
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],208,247244,DB00813,Fentanyl
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],304,247245,DB00813,Fentanyl
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],375,247246,DB00813,Fentanyl
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],34,247247,DB00813,Fentanyl
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],51,247248,DB00813,Fentanyl
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],104,247249,DB00813,Fentanyl
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],152,247250,DB00813,Fentanyl
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],188,247251,DB00813,Fentanyl
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,3.6,247252,DB00813,Fentanyl
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,14.9,247253,DB00813,Fentanyl
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,11.9,247254,DB00813,Fentanyl
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,31.1,247255,DB00813,Fentanyl
,7879944,terminal elimination half-life,"There was no difference in terminal elimination half-life after intravenous fentanyl (244 +/- 68 min) or buccal fentanyl administration (pH 7.7, 205 +/- 89 min; pH 7.2, 205 +/- 65 min; pH 6.6, 196 +/- 48 min).",Buccal absorption of fentanyl is pH-dependent in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879944/),min,244,249824,DB00813,Fentanyl
,7879944,terminal elimination half-life,"There was no difference in terminal elimination half-life after intravenous fentanyl (244 +/- 68 min) or buccal fentanyl administration (pH 7.7, 205 +/- 89 min; pH 7.2, 205 +/- 65 min; pH 6.6, 196 +/- 48 min).",Buccal absorption of fentanyl is pH-dependent in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879944/),min,205,249825,DB00813,Fentanyl
,7879944,terminal elimination half-life,"There was no difference in terminal elimination half-life after intravenous fentanyl (244 +/- 68 min) or buccal fentanyl administration (pH 7.7, 205 +/- 89 min; pH 7.2, 205 +/- 65 min; pH 6.6, 196 +/- 48 min).",Buccal absorption of fentanyl is pH-dependent in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879944/),min,205,249826,DB00813,Fentanyl
,7879944,terminal elimination half-life,"There was no difference in terminal elimination half-life after intravenous fentanyl (244 +/- 68 min) or buccal fentanyl administration (pH 7.7, 205 +/- 89 min; pH 7.2, 205 +/- 65 min; pH 6.6, 196 +/- 48 min).",Buccal absorption of fentanyl is pH-dependent in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7879944/),min,196,249827,DB00813,Fentanyl
,9141924,hepatic extraction coefficient,The hepatic extraction coefficient was 0.14 for alfentanil and 0.35 for sufentanil.,Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9141924/),,0.14,249908,DB00813,Fentanyl
,9141924,hepatic extraction coefficient,The hepatic extraction coefficient was 0.14 for alfentanil and 0.35 for sufentanil.,Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9141924/),,0.35,249909,DB00813,Fentanyl
,19915714,C(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[ng] / [ml],1.70,250435,DB00813,Fentanyl
,19915714,C(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[ng] / [ml],1.97,250436,DB00813,Fentanyl
,19915714,AUC(0-6),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[h·ng] / [ml],4.46,250437,DB00813,Fentanyl
,19915714,AUC(0-6),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),[h·ng] / [ml],6.81,250438,DB00813,Fentanyl
,19915714,t(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),min,50,250439,DB00813,Fentanyl
,19915714,t(max),"After doses 1 and 10, respectively, mean (SD) C(max) was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC(0-6) was 4.46 (1.14) ng.h/mL and 6.81 (0.90) ng.h/mL, and median (range) t(max) was 50 (30-110) minutes and 30 (15-120) minutes.",Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915714/),min,30,250440,DB00813,Fentanyl
,3609115,plasma concentration,Fentanyl plasma concentration remained essentially unchanged during hypothermia (6.45 ng/ml 5 min into hypothermia and 5.26 ng/ml 100-140 min later; p greater than 0.1).,The influence of hypothermia on the disposition of fentanyl--human and animal studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609115/),[ng] / [ml],6.45,251057,DB00813,Fentanyl
,3609115,plasma concentration,Fentanyl plasma concentration remained essentially unchanged during hypothermia (6.45 ng/ml 5 min into hypothermia and 5.26 ng/ml 100-140 min later; p greater than 0.1).,The influence of hypothermia on the disposition of fentanyl--human and animal studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609115/),[ng] / [ml],5.26,251058,DB00813,Fentanyl
,7604992,effect-site concentration,The effect-site concentration associated with 50% paralysis of twitch increased after 3 weeks from approximately 250 to 750 ng/ml.,The changing pharmacodynamics of metocurine identify the onset and offset of canine gastrocnemius disuse atrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7604992/),ng,250,251686,DB00813,Fentanyl
,18027597,alpha,"Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively.",[Pharmacokinetic simulations of remifentanil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027597/),min,2,252357,DB00813,Fentanyl
,18027597,beta decay,"Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively.",[Pharmacokinetic simulations of remifentanil]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027597/),min,15,252358,DB00813,Fentanyl
,16879519,Clearance,"Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml x min(-1) x kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65).",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[ml] / [kg·min],3.91,252905,DB00813,Fentanyl
,16879519,Clearance,"Clearance was 3.91 +/- 2.07 and 3.62 +/- 0.80 ml x min(-1) x kg(-1) in sevoflurane and fentanyl groups, respectively (P < 0.65).",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[ml] / [kg·min],3.62,252906,DB00813,Fentanyl
,16879519,Effect compartment concentrations corresponding,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[μg] / [ml],1.41,252907,DB00813,Fentanyl
,16879519,Effect compartment concentrations corresponding,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),[μg] / [ml],2.32,252908,DB00813,Fentanyl
,16879519,rate constants,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),1/[min],0.10,252909,DB00813,Fentanyl
,16879519,rate constants,"Effect compartment concentrations corresponding to 50% inhibition of T1 (EC50) were 1.41 +/- 0.45 and 2.32 +/- 1.00 microg x ml(-1) (P < 0.02), and rate constants for equilibration between plasma and effect compartment (k(e0)) values were 0.10 +/- 0.04 and 0.24 +/- 0.14 min(-1) (P < 0.009) in sevoflurane and fentanyl groups, respectively.",Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16879519/),1/[min],0.24,252910,DB00813,Fentanyl
,22956531,ECe(50),"The ECe(50) of propofol was 3.4 μg/mL (95% CI: 2.9, 3.7 μg/mL) with the Marsh model and 4.5 μg/mL (95% CI: 4.1, 4.8 μg/mL) with the Schnider model (P < 0.001).",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],3.4,252953,DB00813,Fentanyl
,22956531,ECe(50),"The ECe(50) of propofol was 3.4 μg/mL (95% CI: 2.9, 3.7 μg/mL) with the Marsh model and 4.5 μg/mL (95% CI: 4.1, 4.8 μg/mL) with the Schnider model (P < 0.001).",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],4.5,252954,DB00813,Fentanyl
,22956531,ECe(95),"The ECe(95) values were 4.2 μg/mL (95% CI: 3.8, 6.2 μg/mL) and 5.5 μg/mL (95% CI: 5.0, 7.2 μg/mL) with Marsh and Schnider models, respectively.",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],4.2,252955,DB00813,Fentanyl
,22956531,ECe(95),"The ECe(95) values were 4.2 μg/mL (95% CI: 3.8, 6.2 μg/mL) and 5.5 μg/mL (95% CI: 5.0, 7.2 μg/mL) with Marsh and Schnider models, respectively.",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],5.5,252956,DB00813,Fentanyl
,19795933,plasma concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],13.9,253465,DB00813,Fentanyl
,19795933,plasma concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],20.1,253466,DB00813,Fentanyl
,19795933,plasma concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],24.1,253467,DB00813,Fentanyl
,19795933,target concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],16,253468,DB00813,Fentanyl
,19795933,target concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],24,253469,DB00813,Fentanyl
,19795933,target concentrations,"Mean + or - SD fentanyl plasma concentrations were 13.9 + or - 2.6 ng/mL, 20.1 + or - 3.6 ng/mL, and 24.1 + or - 2.4 ng/mL for target concentrations of 16, 24, and 32 ng/mL, respectively.",Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],32,253470,DB00813,Fentanyl
,19795933,plasma target concentration,Results of the study did not verify an isoflurane-sparing effect of fentanyl at a plasma target concentration of 16 ng/mL.,Effects of high plasma fentanyl concentrations on minimum alveolar concentration of isoflurane in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19795933/),[ng] / [ml],16,253471,DB00813,Fentanyl
,7389247,t1/2 beta,Fentanyl concentrations fell rapidly and 98.6% of the dose was eliminated from plasma in 60 min but the terminal elimination phase of fentanyl from the body was slow (t1/2 beta = 219 min) due to the slow return of the unchanged drug from a peripheral compartment to the central compartment where elimination occurred primarily by biotransformation.,Intravenous fentanyl kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389247/),min,219,253520,DB00813,Fentanyl
,25649313,CSHTs at steady-state,"The CSHTs at steady-state were 31.3 and 69.2 min in dogs, and 306.5 min in humans.",Context-sensitive half-time of fentanyl in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649313/),min,31.3,253524,DB00813,Fentanyl
,25649313,CSHTs at steady-state,"The CSHTs at steady-state were 31.3 and 69.2 min in dogs, and 306.5 min in humans.",Context-sensitive half-time of fentanyl in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649313/),min,69.2,253525,DB00813,Fentanyl
,25649313,CSHTs at steady-state,"The CSHTs at steady-state were 31.3 and 69.2 min in dogs, and 306.5 min in humans.",Context-sensitive half-time of fentanyl in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649313/),min,306.5,253526,DB00813,Fentanyl
,9525032,total area under the concentration versus time curve (0 hours to infinity),"The following results were obtained (mean +/- SD): average plasma fentanyl concentration from 24 to 72 hours, 0.7 +/- 0.2 ng/mL (P50), 1.4 +/- 0.5 ng/mL (P75), 1.2 +/- 0.5 ng/mL (P100); the total area under the concentration versus time curve (0 hours to infinity), 46 +/- 12.2 ng/h/mL (P50), 101.2 +/- 41.4 ng/h/mL (P75), 80.4 +/- 38.3 ng/h/mL (P100); and the apparent elimination half-life, 3.6 +/- 1.2 hours (P50), 3.4 +/- 2.7 hours (P75), and 2.5 +/- 2.0 hours (P100).",Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9525032/),[ng] / [h·ml],46,253585,DB00813,Fentanyl
,9525032,total area under the concentration versus time curve (0 hours to infinity),"The following results were obtained (mean +/- SD): average plasma fentanyl concentration from 24 to 72 hours, 0.7 +/- 0.2 ng/mL (P50), 1.4 +/- 0.5 ng/mL (P75), 1.2 +/- 0.5 ng/mL (P100); the total area under the concentration versus time curve (0 hours to infinity), 46 +/- 12.2 ng/h/mL (P50), 101.2 +/- 41.4 ng/h/mL (P75), 80.4 +/- 38.3 ng/h/mL (P100); and the apparent elimination half-life, 3.6 +/- 1.2 hours (P50), 3.4 +/- 2.7 hours (P75), and 2.5 +/- 2.0 hours (P100).",Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9525032/),[ng] / [h·ml],101.2,253586,DB00813,Fentanyl
,9525032,total area under the concentration versus time curve (0 hours to infinity),"The following results were obtained (mean +/- SD): average plasma fentanyl concentration from 24 to 72 hours, 0.7 +/- 0.2 ng/mL (P50), 1.4 +/- 0.5 ng/mL (P75), 1.2 +/- 0.5 ng/mL (P100); the total area under the concentration versus time curve (0 hours to infinity), 46 +/- 12.2 ng/h/mL (P50), 101.2 +/- 41.4 ng/h/mL (P75), 80.4 +/- 38.3 ng/h/mL (P100); and the apparent elimination half-life, 3.6 +/- 1.2 hours (P50), 3.4 +/- 2.7 hours (P75), and 2.5 +/- 2.0 hours (P100).",Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9525032/),[ng] / [h·ml],80.4,253587,DB00813,Fentanyl
,9525032,apparent elimination half-life,"The following results were obtained (mean +/- SD): average plasma fentanyl concentration from 24 to 72 hours, 0.7 +/- 0.2 ng/mL (P50), 1.4 +/- 0.5 ng/mL (P75), 1.2 +/- 0.5 ng/mL (P100); the total area under the concentration versus time curve (0 hours to infinity), 46 +/- 12.2 ng/h/mL (P50), 101.2 +/- 41.4 ng/h/mL (P75), 80.4 +/- 38.3 ng/h/mL (P100); and the apparent elimination half-life, 3.6 +/- 1.2 hours (P50), 3.4 +/- 2.7 hours (P75), and 2.5 +/- 2.0 hours (P100).",Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9525032/),h,3.6,253588,DB00813,Fentanyl
,9525032,apparent elimination half-life,"The following results were obtained (mean +/- SD): average plasma fentanyl concentration from 24 to 72 hours, 0.7 +/- 0.2 ng/mL (P50), 1.4 +/- 0.5 ng/mL (P75), 1.2 +/- 0.5 ng/mL (P100); the total area under the concentration versus time curve (0 hours to infinity), 46 +/- 12.2 ng/h/mL (P50), 101.2 +/- 41.4 ng/h/mL (P75), 80.4 +/- 38.3 ng/h/mL (P100); and the apparent elimination half-life, 3.6 +/- 1.2 hours (P50), 3.4 +/- 2.7 hours (P75), and 2.5 +/- 2.0 hours (P100).",Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9525032/),h,3.4,253589,DB00813,Fentanyl
,9525032,apparent elimination half-life,"The following results were obtained (mean +/- SD): average plasma fentanyl concentration from 24 to 72 hours, 0.7 +/- 0.2 ng/mL (P50), 1.4 +/- 0.5 ng/mL (P75), 1.2 +/- 0.5 ng/mL (P100); the total area under the concentration versus time curve (0 hours to infinity), 46 +/- 12.2 ng/h/mL (P50), 101.2 +/- 41.4 ng/h/mL (P75), 80.4 +/- 38.3 ng/h/mL (P100); and the apparent elimination half-life, 3.6 +/- 1.2 hours (P50), 3.4 +/- 2.7 hours (P75), and 2.5 +/- 2.0 hours (P100).",Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9525032/),h,2.5,253590,DB00813,Fentanyl
,23497761,Cmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),[ng] / [ml],0.81,254914,DB00813,Fentanyl
,23497761,Cmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),[ng] / [ml],0.61,254915,DB00813,Fentanyl
,23497761,Tmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),h,1.5,254916,DB00813,Fentanyl
,23497761,Tmax,Mean Cmax values of fentanyl were higher with FSS versus OTFC (0.81 ng/mL vs 0.61 ng/mL) and were attained more quickly; the median Tmax was 1.5 hours with FSS and 2.0 hours with OTFC (P < 0.05).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),h,2.0,254917,DB00813,Fentanyl
,23497761,Systemic bioavailability,Systemic bioavailability was also greater with FSS than with OTFC (approximately 76% vs 51%).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),%,76,254918,DB00813,Fentanyl
,23497761,Systemic bioavailability,Systemic bioavailability was also greater with FSS than with OTFC (approximately 76% vs 51%).,Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497761/),%,51,254919,DB00813,Fentanyl
,2265045,T1/2 alpha,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,3.1,255342,DB00813,Fentanyl
,2265045,T1/2 beta,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,44,255343,DB00813,Fentanyl
,2265045,T1/2 gamma,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,520,255344,DB00813,Fentanyl
,2265045,clearance,The clearance of propofol was rapid (mean 1.6 (0.24) litre min-1).,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),[l] / [min],1.6,255345,DB00813,Fentanyl
,2265045,Vss,Propofol was distributed initially into a relatively large central compartment (mean 23.7 (6.6) litre) and was extensively redistributed (mean Vss 593 (157) litre).,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),l,593,255346,DB00813,Fentanyl
,15502029,time to reach peak concentration,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),h,1.7,257659,DB00813,Fentanyl
,15502029,peak concentration,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[ng] / [ml],1.83,257660,DB00813,Fentanyl
,15502029,half-life,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),h,4.7,257661,DB00813,Fentanyl
,15502029,area under the plasma concentration time curve,"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[h] / [ml·ng],6.46,257662,DB00813,Fentanyl
,15502029,apparent oral volume of distribution (V/F),"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[l] / [kg],17.5,257663,DB00813,Fentanyl
,15502029,apparent oral clearance (CL/F),"Pharmacokinetic variables for the orally administered IV fentanyl formulation were as follows: time to reach peak concentration = 1.7 +/- 1.6 h, peak concentration = 1.83 +/- 1.19 ng/mL, half-life = 4.7 +/- 2.8 h, area under the plasma concentration time curve = 6.46 +/- 3.96 h . ng(-1) . mL(-1), apparent oral volume of distribution (V/F) = 17.5 +/- 7.2 L/kg, apparent oral clearance (CL/F) = 3.33 +/- 2.25 L . kg(-1) . h(-1).",The pharmacokinetics of the intravenous formulation of fentanyl citrate administered orally in children undergoing general anesthesia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502029/),[l] / [h·kg],3.33,257664,DB00813,Fentanyl
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,53.7,258187,DB00813,Fentanyl
,9278198,25% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,42.3,258188,DB00813,Fentanyl
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,73.9,258189,DB00813,Fentanyl
,9278198,50% recovery T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,52.6,258190,DB00813,Fentanyl
,9278198,75% recovery,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258191,DB00813,Fentanyl
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,84.2,258192,DB00813,Fentanyl
,9278198,T1:T0,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,66.8,258193,DB00813,Fentanyl
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,114.9,258194,DB00813,Fentanyl
,9278198,recovery of T4:T1,"The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,76.1,258195,DB00813,Fentanyl
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],2.66,258196,DB00813,Fentanyl
,9278198,Plasma clearance,Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005).,The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),[-1·min·ml] / [kg],3.70,258197,DB00813,Fentanyl
,9278198,redistribution (,"The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258198,DB00813,Fentanyl
,9278198,"t1/2,lambda1","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,28.3,258199,DB00813,Fentanyl
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,16.8,258200,DB00813,Fentanyl
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,143,258201,DB00813,Fentanyl
,9278198,"elimination (t1/2,z) half-lives","The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively).",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),min,92,258202,DB00813,Fentanyl
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.25,258203,DB00813,Fentanyl
,9278198,exit rate constant for,"The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.",The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278198/),1/[min],0.16,258204,DB00813,Fentanyl
,7946365,target concentrations,Patients were anesthetized using a variable-rate infusion of alfentanil combined with midazolam in an attempt to achieve and maintain target concentrations of 100 ng/ml or 500 ng/ml.,Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ng] / [ml],100,258250,DB00813,Fentanyl
,7946365,target concentrations,Patients were anesthetized using a variable-rate infusion of alfentanil combined with midazolam in an attempt to achieve and maintain target concentrations of 100 ng/ml or 500 ng/ml.,Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ng] / [ml],500,258251,DB00813,Fentanyl
lower,7946365,clearance,"Two of the selected data sets of midazolam, with a clearance lower than 5 ml/kg/min, were very accurate (MDAPE less than 20%) in predicting low or high prebypass concentrations of midazolam in adult patients with good left ventricular function.",Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7946365/),[ml] / [kg·min],5,258252,DB00813,Fentanyl
,3099604,CL,"The mean CL and Vc for alfentanil in a 70-kg male, aged less than 40 yr, were estimated as 0.356 l/min and 7.77 l, respectively.",Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099604/),[l] / [min],0.356,258637,DB00813,Fentanyl
,3099604,Vc,"The mean CL and Vc for alfentanil in a 70-kg male, aged less than 40 yr, were estimated as 0.356 l/min and 7.77 l, respectively.",Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099604/),l,7.77,258638,DB00813,Fentanyl
,7893025,time to peak CSF sufentanil concentration,The time to peak CSF sufentanil concentration differed (P < 0.01) after epidural administration in the lumbar (0.76 +/- 0.50 h) and thoracic (2.1 +/- 1.4 h) region.,The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),h,0.76,259456,DB00813,Fentanyl
,7893025,time to peak CSF sufentanil concentration,The time to peak CSF sufentanil concentration differed (P < 0.01) after epidural administration in the lumbar (0.76 +/- 0.50 h) and thoracic (2.1 +/- 1.4 h) region.,The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),h,2.1,259457,DB00813,Fentanyl
,7893025,CSF/plasma concentration-ratio,"The decline in sufentanil concentration was more rapid in CSF than plasma; in the lumbar group the CSF/plasma concentration-ratio was eight and five at 6 and 10 h, respectively, after sufentanil administration.",The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),,eight,259458,DB00813,Fentanyl
,7893025,CSF/plasma concentration-ratio,"The decline in sufentanil concentration was more rapid in CSF than plasma; in the lumbar group the CSF/plasma concentration-ratio was eight and five at 6 and 10 h, respectively, after sufentanil administration.",The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),,five,259459,DB00813,Fentanyl
,31814149,clearance,Estimated typical clearance was 32.5 L/h (scaled to 70 kg).,Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814149/),[l] / [h],32.5,260364,DB00813,Fentanyl
>,31814149,Css,"A fixed dose rate infusion of 1 µg/kg/h was associated with probabilities between 49% and 58% for achieving Css within target; however, the risk of achieving Css > 3 ng/mL increased with increasing body weight (15% at 16 kg vs 43% at 164 kg).",Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31814149/),[ng] / [ml],3,260365,DB00813,Fentanyl
,20492573,absolute bioavailability,The two buccal film treatments were bioequivalent and both had an absolute bioavailability of 71%.,Single-dose pharmacokinetics of fentanyl buccal soluble film. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20492573/),%,71,260418,DB00813,Fentanyl
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,20,260546,DB00813,Fentanyl
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,39,260547,DB00813,Fentanyl
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260548,DB00813,Fentanyl
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260549,DB00813,Fentanyl
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260550,DB00813,Fentanyl
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260551,DB00813,Fentanyl
,15676050,t(max),"t(max) increased from 39.7 +/- 17.4 to 48.7 +/- 26.3 and 56.7 +/- 24.6 min for the 100, 200 and 400 microg doses, respectively.",Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676050/),min,39.7,260798,DB00813,Fentanyl
,15676050,t(max),"t(max) increased from 39.7 +/- 17.4 to 48.7 +/- 26.3 and 56.7 +/- 24.6 min for the 100, 200 and 400 microg doses, respectively.",Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676050/),min,48.7,260799,DB00813,Fentanyl
,15676050,t(max),"t(max) increased from 39.7 +/- 17.4 to 48.7 +/- 26.3 and 56.7 +/- 24.6 min for the 100, 200 and 400 microg doses, respectively.",Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15676050/),min,56.7,260800,DB00813,Fentanyl
,16156113,maximum serum concentrations (Cmax,"Application of the system to the upper outer arm or chest resulted in similar maximum serum concentrations (Cmax; 1.193 and 1.176 microg/L, respectively) and areas under the serum concentration-time curve (AUC24-25; 1.033 and 1.015 microg h/L).",Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156113/),[μg] / [l],1.193,261314,DB00813,Fentanyl
,16156113,maximum serum concentrations (Cmax,"Application of the system to the upper outer arm or chest resulted in similar maximum serum concentrations (Cmax; 1.193 and 1.176 microg/L, respectively) and areas under the serum concentration-time curve (AUC24-25; 1.033 and 1.015 microg h/L).",Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156113/),[μg] / [l],1.176,261315,DB00813,Fentanyl
,16156113,areas under the serum concentration-time curve (AUC24-25,"Application of the system to the upper outer arm or chest resulted in similar maximum serum concentrations (Cmax; 1.193 and 1.176 microg/L, respectively) and areas under the serum concentration-time curve (AUC24-25; 1.033 and 1.015 microg h/L).",Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156113/),[h·μg] / [l],1.033,261316,DB00813,Fentanyl
,16156113,areas under the serum concentration-time curve (AUC24-25,"Application of the system to the upper outer arm or chest resulted in similar maximum serum concentrations (Cmax; 1.193 and 1.176 microg/L, respectively) and areas under the serum concentration-time curve (AUC24-25; 1.033 and 1.015 microg h/L).",Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156113/),[h·μg] / [l],1.015,261317,DB00813,Fentanyl
,16156113,Cmax,"However, both Cmax and AUC24-25 were less when the system was applied to the lower inner arm (0.859 microg/L and 0.757 microg x h/L).",Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156113/),[μg] / [l],0.859,261318,DB00813,Fentanyl
,16156113,AUC24-25,"However, both Cmax and AUC24-25 were less when the system was applied to the lower inner arm (0.859 microg/L and 0.757 microg x h/L).",Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16156113/),[h·μg] / [l],0.757,261319,DB00813,Fentanyl
,8273922,Time to extubation,Time to extubation was the same in both groups (301 +/- 141 and 307 +/- 148 min).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,301,262732,DB00813,Fentanyl
,8273922,Time to extubation,Time to extubation was the same in both groups (301 +/- 141 and 307 +/- 148 min).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,307,262733,DB00813,Fentanyl
,8273922,plasma concentrations,"At the time, plasma concentrations of F and S were 1.35 +/- 0.9 ng.",[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),ng,1.35,262734,DB00813,Fentanyl
,8273922,elimination half-life,No similar peaks occurred in group S. Mean elimination half-life was shorter with sufentanil (457 +/- 130 min) than with fentanyl (325 +/- 132 min) (not significant).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,457,262735,DB00813,Fentanyl
,8273922,elimination half-life,No similar peaks occurred in group S. Mean elimination half-life was shorter with sufentanil (457 +/- 130 min) than with fentanyl (325 +/- 132 min) (not significant).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,325,262736,DB00813,Fentanyl
,25748562,tmax,"After low-dose CBD, tmax occurred at 3 and 1.5 hours in sessions 1 and 2, respectively.",Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25748562/),h,3,263090,DB00813,Fentanyl
,25748562,tmax,"After low-dose CBD, tmax occurred at 3 and 1.5 hours in sessions 1 and 2, respectively.",Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25748562/),h,1.5,263091,DB00813,Fentanyl
,25748562,tmax,"After high-dose CBD, tmax occurred at 3 and 4 hours in sessions 1 and 2, respectively.",Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25748562/),h,3,263092,DB00813,Fentanyl
,25748562,tmax,"After high-dose CBD, tmax occurred at 3 and 4 hours in sessions 1 and 2, respectively.",Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25748562/),h,4,263093,DB00813,Fentanyl
,7598917,Maximal plasma concentrations,Maximal plasma concentrations were 20.1 ng/ml +/- 7.3 ng/ml after 9 minutes in the intranasal group.,Pharmacokinetics of intranasal alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),[ng] / [ml],20.1,263517,DB00813,Fentanyl
,7598917,concentrations,"At this measurement point, the intranasal alfentanil concentrations were 64.7% (18.7 ng/ml +/- 6.8 ng/ml) of the IV concentrations (28.9 ng/ml +/- 7.9 ng/ml).",Pharmacokinetics of intranasal alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),[ng] / [ml],18.7,263518,DB00813,Fentanyl
,7598917,concentrations,"At this measurement point, the intranasal alfentanil concentrations were 64.7% (18.7 ng/ml +/- 6.8 ng/ml) of the IV concentrations (28.9 ng/ml +/- 7.9 ng/ml).",Pharmacokinetics of intranasal alfentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),[ng] / [ml],28.9,263519,DB00813,Fentanyl
,7598917,bioavailability,The calculated bioavailability after intranasal administration was 64.96% +/- 26.3%.,Pharmacokinetics of intranasal alfentanil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7598917/),%,64.96,263520,DB00813,Fentanyl
,15329599,Maximum pupil diameter change,Maximum pupil diameter change from baseline was significantly less in older (3.1 +/- 0.7 mm) compared with younger (4.5 +/- 1.1 mm) subjects (P < 0.05).,Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329599/),mm,3.1,263886,DB00813,Fentanyl
,15329599,Maximum pupil diameter change,Maximum pupil diameter change from baseline was significantly less in older (3.1 +/- 0.7 mm) compared with younger (4.5 +/- 1.1 mm) subjects (P < 0.05).,Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329599/),mm,4.5,263887,DB00813,Fentanyl
,2841891,PD20,"Although pre-anesthesia PD20 and anes + CPB/AXC PD20 values were not affected by ejection fraction, significant differences in PD20 (P less than 0.05) between groups occurred during fentanyl anesthesia (group I = 2.28 +/- 1.60 micrograms.kg-1, group II 1.57 +/- 0.98 micrograms.kg-1; mean +/- SD).",alpha 1-Adrenergic responsiveness during coronary artery bypass surgery: effect of preoperative ejection fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2841891/),[μg] / [kg],2.28,263948,DB00813,Fentanyl
,2841891,PD20,"Although pre-anesthesia PD20 and anes + CPB/AXC PD20 values were not affected by ejection fraction, significant differences in PD20 (P less than 0.05) between groups occurred during fentanyl anesthesia (group I = 2.28 +/- 1.60 micrograms.kg-1, group II 1.57 +/- 0.98 micrograms.kg-1; mean +/- SD).",alpha 1-Adrenergic responsiveness during coronary artery bypass surgery: effect of preoperative ejection fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2841891/),[μg] / [kg],1.57,263949,DB00813,Fentanyl
,3129956,constant target plasma alfentanil concentration,Alfentanil was administered as an exponentially decreasing infusion using a computer-assisted infusion device with a constant target plasma alfentanil concentration of 300 ng/ml.,Disposition kinetics of propofol during alfentanil anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129956/),[ng] / [ml],300,265999,DB00813,Fentanyl
,3129956,elimination half-life,The elimination half-life of alfentanil was approximately 75 minutes (SD 21).,Disposition kinetics of propofol during alfentanil anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129956/),min,75,266000,DB00813,Fentanyl
,7902033,Total clearance,Total clearance (250-300 l/h) of remifentanil was independent of dose and was approximately three to four times greater than the normal hepatic blood flow.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),[l] / [h],250-300,266515,DB00813,Fentanyl
,7902033,Volume of distribution at steady state,Volume of distribution at steady state (25-40 l) also was independent of dose.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),l,25-40,266516,DB00813,Fentanyl
,7902033,terminal half-life,The terminal half-life of remifentanil ranged from 10 to 21 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,10 to 21,266517,DB00813,Fentanyl
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,3.65,266518,DB00813,Fentanyl
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,33.9,266519,DB00813,Fentanyl
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,58.5,266520,DB00813,Fentanyl
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,262,266521,DB00813,Fentanyl
,7902033,terminal half-life,The mean terminal half-life of GI90291 ranged from 88 to 137 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,88 to 137,266522,DB00813,Fentanyl
,16571960,median recovery time,Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg sugammadex.,Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16571960/),min,21.0,266635,DB00813,Fentanyl
,16571960,median recovery time,Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg sugammadex.,Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16571960/),min,1.1,266636,DB00813,Fentanyl
,6238552,half-lives,"In 9 of the 10 patients, a tri-exponential equation optimally described the sufentanil concentration decay curve, with average (+/-SEM) half-lives for the rapid (pi) and slow (alpha) distribution phases of 1.4 +/- 0.3 min and 17.7 +/- 2.6 min, respectively.",The pharmacokinetics of sufentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,1.4,266688,DB00813,Fentanyl
,6238552,half-lives,"In 9 of the 10 patients, a tri-exponential equation optimally described the sufentanil concentration decay curve, with average (+/-SEM) half-lives for the rapid (pi) and slow (alpha) distribution phases of 1.4 +/- 0.3 min and 17.7 +/- 2.6 min, respectively.",The pharmacokinetics of sufentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,17.7,266689,DB00813,Fentanyl
,6238552,terminal elimination (beta) half-life,The average terminal elimination (beta) half-life was 164 +/- 22 min.,The pharmacokinetics of sufentanil in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,164,266690,DB00813,Fentanyl
,6238552,Vd beta,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[1] / [kg],2.9,266691,DB00813,Fentanyl
,6238552,Vdss,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[1] / [kg],1.7,266692,DB00813,Fentanyl
,6238552,total plasma clearance,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[ml] / [kg·min],12.7,266693,DB00813,Fentanyl
,6238552,total plasma clearance,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[ml] / [min],935,266694,DB00813,Fentanyl
,6238552,distribution half-life,"In one patient, a bi-exponential equation was sufficient to describe the concentration-time data, yielding a distribution half-life of 4.7 min and an elimination half-life of 117 min.",The pharmacokinetics of sufentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,4.7,266695,DB00813,Fentanyl
,6238552,elimination half-life,"In one patient, a bi-exponential equation was sufficient to describe the concentration-time data, yielding a distribution half-life of 4.7 min and an elimination half-life of 117 min.",The pharmacokinetics of sufentanil in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,117,266696,DB00813,Fentanyl
,3512140,elimination half-life,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,149,268206,DB00813,Fentanyl
,3512140,clearance,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.3,268207,DB00813,Fentanyl
,3512140,elimination half-life,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,83 to 137,268208,DB00813,Fentanyl
,3512140,clearance,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],4.37 to 6.47,268209,DB00813,Fentanyl
,3512140,distribution,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,28,268210,DB00813,Fentanyl
,3512140,terminal elimination half-lives,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,273 to 330,268211,DB00813,Fentanyl
,3512140,clearance,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.6 to 25,268212,DB00813,Fentanyl
,3512140,half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,2.1,268213,DB00813,Fentanyl
,3512140,elimination half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,47,268214,DB00813,Fentanyl
,28526486,Cmax,"Fentanyl: Cmax was observed at different time points: for the first TP application: 30 hours for 50 μg hour-1, 6 hours for 75 μg hour-1 and 100 μg hour-1 patches; and for the second TP application: 30 hours for 50 μg hour-1 and 36 hours for 75 μg hour-1 patches.",Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526486/),h,30,268503,DB00813,Fentanyl
,28526486,Cmax,"Fentanyl: Cmax was observed at different time points: for the first TP application: 30 hours for 50 μg hour-1, 6 hours for 75 μg hour-1 and 100 μg hour-1 patches; and for the second TP application: 30 hours for 50 μg hour-1 and 36 hours for 75 μg hour-1 patches.",Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526486/),h,6,268504,DB00813,Fentanyl
,28526486,Cmax,"Fentanyl: Cmax was observed at different time points: for the first TP application: 30 hours for 50 μg hour-1, 6 hours for 75 μg hour-1 and 100 μg hour-1 patches; and for the second TP application: 30 hours for 50 μg hour-1 and 36 hours for 75 μg hour-1 patches.",Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526486/),h,36,268505,DB00813,Fentanyl
,15448532,duration of analgesia (mesor),Rhythm analysis revealed a mean ( +/- SD) duration of analgesia (mesor) of 93.0 +/- 3.8 min.,Chronopharmacology of intrathecal sufentanil for labor analgesia: daily variations in duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448532/),min,93.0,268775,DB00813,Fentanyl
,15448532,amplitude,The amplitude of this 12-h component was 16.1 +/- 5.5 min.,Chronopharmacology of intrathecal sufentanil for labor analgesia: daily variations in duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448532/),min,16.1,268776,DB00813,Fentanyl
,32064536,Limits of detection,Limits of detection were 0.0125 ng/mL (FuF and 4-ANPP) and 0.25 ng/mL (FuNorF).,Quantification of Furanylfentanyl and its Metabolites in Human and Rat Plasma Using LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32064536/),[ng] / [ml],0.0125,270275,DB00813,Fentanyl
,32064536,Limits of detection,Limits of detection were 0.0125 ng/mL (FuF and 4-ANPP) and 0.25 ng/mL (FuNorF).,Quantification of Furanylfentanyl and its Metabolites in Human and Rat Plasma Using LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32064536/),[ng] / [ml],0.25,270276,DB00813,Fentanyl
,32064536,Extraction recoveries,Extraction recoveries ranged from 84.5 to 98.1%.,Quantification of Furanylfentanyl and its Metabolites in Human and Rat Plasma Using LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32064536/),%,84.5 to 98.1,270277,DB00813,Fentanyl
,24978306,maximal plasma concentration,"Foals mostly appeared to be unaffected following 2 μg/kg bwt (1.09 ± 0.41 μg/l; average maximal plasma concentration) of fentanyl, but 6 of the 8 foals appeared to be sedated following 4 μg/kg bwt (3.07 ± 1.11 μg/l).","Disposition, behavioural and physiological effects of escalating doses of intravenously administered fentanyl to young foals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978306/),[μg] / [l],1.09,270689,DB00813,Fentanyl
,24978306,terminal half-life,The average (± s.d.) terminal half-life following administration of the final dose was 44.2 ± 9.85 min.,"Disposition, behavioural and physiological effects of escalating doses of intravenously administered fentanyl to young foals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978306/),min,44.2,270690,DB00813,Fentanyl
,2502166,Cl,"There was no significant decrease in Cl with age, although the lower values for Cl (100-200 ml min-1) were generally found in subjects older than 60 yr.",Pharmacokinetics of alfentanil during and after a fixed rate infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2502166/),[ml] / [min],100-200,271175,DB00813,Fentanyl
,8330593,distribution half-life,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),min,6,271699,DB00813,Fentanyl
,8330593,elimination half-life,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),min,87,271700,DB00813,Fentanyl
,8330593,initial volume of distribution,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),l,10,271701,DB00813,Fentanyl
,8330593,steady state volume of distribution,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),l,31,271702,DB00813,Fentanyl
,8330593,total body clearance,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),[ml] / [min],308,271703,DB00813,Fentanyl
,8330593,distribution clearance,"Mean distribution half-life (6 min), elimination half-life (87 min), initial volume of distribution (10 litres), steady state volume of distribution (31 litres), total body clearance (308 ml min-1), and distribution clearance (656 ml min-1) did not vary with the type of surgery.",Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330593/),[ml] / [min],656,271704,DB00813,Fentanyl
,12847388,Total body clearance,"Total body clearance, apparent volume distribution in terminal phase, and plasma elimination half-life were (mean +/- sd, n = 18): 5.0 +/- 3.9 mL/kg/min, 1.7 +/- 1.1 L/kg, and 5.5 +/- 3.5 hrs, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),[ml] / [kg·min],5.0,272118,DB00813,Fentanyl
,12847388,apparent volume distribution in terminal phase,"Total body clearance, apparent volume distribution in terminal phase, and plasma elimination half-life were (mean +/- sd, n = 18): 5.0 +/- 3.9 mL/kg/min, 1.7 +/- 1.1 L/kg, and 5.5 +/- 3.5 hrs, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),[l] / [kg],1.7,272119,DB00813,Fentanyl
,12847388,plasma elimination half-life,"Total body clearance, apparent volume distribution in terminal phase, and plasma elimination half-life were (mean +/- sd, n = 18): 5.0 +/- 3.9 mL/kg/min, 1.7 +/- 1.1 L/kg, and 5.5 +/- 3.5 hrs, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),h,5.5,272120,DB00813,Fentanyl
,12847388,ratio,"The mean 1-OH-midazolam/midazolam ratio and (1-OH-midazolam + 1-OH-midazolam-glucuronide)/midazolam ratio were 0.14 +/- 0.21 and 1.4 +/- 1.1, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),,0.14,272121,DB00813,Fentanyl
,12847388,ratio,"The mean 1-OH-midazolam/midazolam ratio and (1-OH-midazolam + 1-OH-midazolam-glucuronide)/midazolam ratio were 0.14 +/- 0.21 and 1.4 +/- 1.1, respectively.",Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12847388/),,1.4,272122,DB00813,Fentanyl
,30632944,volume of distribution,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [kg],11.6,273409,DB00813,Fentanyl
,30632944,volume of distribution,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [kg],5.6,273410,DB00813,Fentanyl
,30632944,clearance,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [h·kg],0.535,273411,DB00813,Fentanyl
,30632944,clearance,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [h·kg],0.746,273412,DB00813,Fentanyl
